_unit_id,_created_at,_id,_started_at,_tainted,_channel,_trust,_worker_id,_country,_region,_city,_ip,relations,step_1_select_the_valid_relations,step_2a_copy__paste_only_the_words_from_the_sentence_that_express_the_relation_you_selected_in_step1,step_2b_if_you_selected_none_in_step_1_explain_why,b1,b2,baselinedec,e1,e2,rel-type,sent_id,sentence,term1,term2
790085233,9/17/2015 11:05:50,1740386680,9/17/2015 11:05:33,false,elite,1,33453990,USA,VA,Manassas,207.244.89.75,[LOCATION],[LOCATION],be,N/A,74,15,80,79,34,RO-may_prevent,820369-FS1,"In the future, NON FLUORIDE AGENTS which modify the production of acid in PLAQUE  either antimicrobially, biochemically, or directly  appear to have the most promise for use in topical products and may prove to be effective anticaries systems.",PLAQUE,NON FLUORIDE AGENTS
790085233,9/17/2015 11:17:52,1740389065,9/17/2015 11:16:52,false,points4rewards,1,20113482,USA,PA,Philadelphia,162.208.49.45,[OTHER],[OTHER],modify the production of acid in,N/A,74,15,80,79,34,RO-may_prevent,820369-FS1,"In the future, NON FLUORIDE AGENTS which modify the production of acid in PLAQUE  either antimicrobially, biochemically, or directly  appear to have the most promise for use in topical products and may prove to be effective anticaries systems.",PLAQUE,NON FLUORIDE AGENTS
790085233,9/17/2015 11:19:14,1740389349,9/17/2015 11:18:53,false,neodev,1,32695853,USA,NV,Las Vegas,192.30.80.172,[PART_OF] [DIAGNOSE_BY_TEST_OR_DRUG] [SIDE_EFFECT],"[DIAGNOSE_BY_TEST_OR_DRUG]
[SIDE_EFFECT]
[PART_OF]",of or effective,N/A,74,15,80,79,34,RO-may_prevent,820369-FS1,"In the future, NON FLUORIDE AGENTS which modify the production of acid in PLAQUE  either antimicrobially, biochemically, or directly  appear to have the most promise for use in topical products and may prove to be effective anticaries systems.",PLAQUE,NON FLUORIDE AGENTS
790085233,9/17/2015 11:24:33,1740390135,9/17/2015 11:22:10,false,neodev,1,30581619,USA,CA,San Jose,50.118.162.56,[NONE],[NONE],good,good,74,15,80,79,34,RO-may_prevent,820369-FS1,"In the future, NON FLUORIDE AGENTS which modify the production of acid in PLAQUE  either antimicrobially, biochemically, or directly  appear to have the most promise for use in topical products and may prove to be effective anticaries systems.",PLAQUE,NON FLUORIDE AGENTS
790085233,9/17/2015 11:31:18,1740391408,9/17/2015 11:30:55,false,neodev,1,30941227,USA,NV,Las Vegas,192.30.80.166,[PART_OF] [DIAGNOSE_BY_TEST_OR_DRUG] [SIDE_EFFECT],"[DIAGNOSE_BY_TEST_OR_DRUG]
[SIDE_EFFECT]
[PART_OF]",of or effective,N/A,74,15,80,79,34,RO-may_prevent,820369-FS1,"In the future, NON FLUORIDE AGENTS which modify the production of acid in PLAQUE  either antimicrobially, biochemically, or directly  appear to have the most promise for use in topical products and may prove to be effective anticaries systems.",PLAQUE,NON FLUORIDE AGENTS
790085233,9/17/2015 11:41:50,1740393454,9/17/2015 11:41:38,false,neodev,1,33701549,USA,CA,Torrance,66.171.228.66,[LOCATION] [CAUSES] [IS_A] [NONE],"[CAUSES]
[LOCATION]
[IS_A]
[NONE]",[IS_A],N/A,74,15,80,79,34,RO-may_prevent,820369-FS1,"In the future, NON FLUORIDE AGENTS which modify the production of acid in PLAQUE  either antimicrobially, biochemically, or directly  appear to have the most promise for use in topical products and may prove to be effective anticaries systems.",PLAQUE,NON FLUORIDE AGENTS
790085233,9/17/2015 12:06:11,1740398348,9/17/2015 12:05:52,false,elite,1,30659551,USA,VA,Manassas,207.244.89.77,[SIDE_EFFECT],[SIDE_EFFECT],effective,N/A,74,15,80,79,34,RO-may_prevent,820369-FS1,"In the future, NON FLUORIDE AGENTS which modify the production of acid in PLAQUE  either antimicrobially, biochemically, or directly  appear to have the most promise for use in topical products and may prove to be effective anticaries systems.",PLAQUE,NON FLUORIDE AGENTS
790085233,9/17/2015 12:30:16,1740403636,9/17/2015 12:28:46,false,neodev,1,30588889,NLD,07,Amsterdam,77.248.175.222,[ASSOCIATED_WITH] [OTHER],"[ASSOCIATED_WITH]
[OTHER]",which modify the production,N/A,74,15,80,79,34,RO-may_prevent,820369-FS1,"In the future, NON FLUORIDE AGENTS which modify the production of acid in PLAQUE  either antimicrobially, biochemically, or directly  appear to have the most promise for use in topical products and may prove to be effective anticaries systems.",PLAQUE,NON FLUORIDE AGENTS
790085233,9/17/2015 12:38:33,1740405709,9/17/2015 12:37:47,false,prodege,1,2145087,USA,NY,New York,107.107.57.52,[PREVENTS],[PREVENTS],modify the production of acid in,N/A,74,15,80,79,34,RO-may_prevent,820369-FS1,"In the future, NON FLUORIDE AGENTS which modify the production of acid in PLAQUE  either antimicrobially, biochemically, or directly  appear to have the most promise for use in topical products and may prove to be effective anticaries systems.",PLAQUE,NON FLUORIDE AGENTS
790085233,9/17/2015 12:38:49,1740405762,9/17/2015 12:38:30,false,neodev,1,18881135,CAN,ON,Ajax,99.243.87.224,[TREATS],[TREATS],NON FLUORIDE AGENTS modify production of acid in PLAQUE,na,74,15,80,79,34,RO-may_prevent,820369-FS1,"In the future, NON FLUORIDE AGENTS which modify the production of acid in PLAQUE  either antimicrobially, biochemically, or directly  appear to have the most promise for use in topical products and may prove to be effective anticaries systems.",PLAQUE,NON FLUORIDE AGENTS
790085233,9/17/2015 12:42:58,1740406862,9/17/2015 12:42:33,false,instagc,1,22981457,CAN,ON,Welland,76.67.127.43,[PREVENTS],[PREVENTS],effective anticaries systems.,N/A,74,15,80,79,34,RO-may_prevent,820369-FS1,"In the future, NON FLUORIDE AGENTS which modify the production of acid in PLAQUE  either antimicrobially, biochemically, or directly  appear to have the most promise for use in topical products and may prove to be effective anticaries systems.",PLAQUE,NON FLUORIDE AGENTS
790085233,9/17/2015 13:14:05,1740415667,9/17/2015 13:13:45,false,elite,1,31883685,GBR,"","",79.66.244.188,[TREATS],[TREATS],modify,n/a,74,15,80,79,34,RO-may_prevent,820369-FS1,"In the future, NON FLUORIDE AGENTS which modify the production of acid in PLAQUE  either antimicrobially, biochemically, or directly  appear to have the most promise for use in topical products and may prove to be effective anticaries systems.",PLAQUE,NON FLUORIDE AGENTS
790085233,9/17/2015 13:14:15,1740415710,9/17/2015 13:13:49,false,prodege,1,33854929,USA,CT,Wallingford,24.2.218.232,[PREVENTS],[PREVENTS],modify,n/a,74,15,80,79,34,RO-may_prevent,820369-FS1,"In the future, NON FLUORIDE AGENTS which modify the production of acid in PLAQUE  either antimicrobially, biochemically, or directly  appear to have the most promise for use in topical products and may prove to be effective anticaries systems.",PLAQUE,NON FLUORIDE AGENTS
790085233,9/17/2015 13:14:40,1740415808,9/17/2015 13:14:22,false,neodev,1,33228343,USA,"","",38.95.108.251,[DIAGNOSE_BY_TEST_OR_DRUG] [PREVENTS] [TREATS] [CAUSES] [MANIFESTATION] [ASSOCIATED_WITH] [IS_A] [PART_OF] [NONE],"[TREATS]
[PREVENTS]
[DIAGNOSE_BY_TEST_OR_DRUG]
[CAUSES]
[MANIFESTATION]
[ASSOCIATED_WITH]
[IS_A]
[PART_OF]
[NONE]","In the future, NON FLUORIDE AGENTS which modify the production of acid in PLAQUE either antimicrobially, biochemically, or directly appear to have the most promise for use in topical produ","In the future, NON FLUORIDE AGENTS which modify the production of acid in PLAQUE either antimicrobially, biochemically, or directly appear to have the most promise for use in topical produ",74,15,80,79,34,RO-may_prevent,820369-FS1,"In the future, NON FLUORIDE AGENTS which modify the production of acid in PLAQUE  either antimicrobially, biochemically, or directly  appear to have the most promise for use in topical products and may prove to be effective anticaries systems.",PLAQUE,NON FLUORIDE AGENTS
790085233,9/17/2015 13:16:33,1740416395,9/17/2015 13:15:40,false,neodev,1,12115558,USA,OH,Twinsburg,98.27.164.131,[PREVENTS] [TREATS],"[TREATS]
[PREVENTS]",modify the production of acid,N/A,74,15,80,79,34,RO-may_prevent,820369-FS1,"In the future, NON FLUORIDE AGENTS which modify the production of acid in PLAQUE  either antimicrobially, biochemically, or directly  appear to have the most promise for use in topical products and may prove to be effective anticaries systems.",PLAQUE,NON FLUORIDE AGENTS
790085234,9/17/2015 13:20:58,1740417808,9/17/2015 13:20:45,false,neodev,1.0,33228343,USA,"","",38.95.108.251,[PREVENTS] [TREATS] [SIDE_EFFECT] [LOCATION] [CAUSES] [MANIFESTATION] [IS_A] [OTHER] [NONE],"[TREATS]
[PREVENTS]
[CAUSES]
[LOCATION]
[MANIFESTATION]
[SIDE_EFFECT]
[IS_A]
[OTHER]
[NONE]",In patients with new detected TUBERCULOSIS 23.5% MBT resistant to isoniazid and RIFAMPICIN (MDR) and sensitive to fluor,In patients with new detected TUBERCULOSIS 23.5% MBT resistant to isoniazid and RIFAMPICIN (MDR) and sensitive to fluor,30,80,42,41,90,RO-may_prevent,820205-FS1,In patients with new detected TUBERCULOSIS 23.5% MBT resistant to isoniazid and RIFAMPICIN (MDR) and sensitive to fluoroquinolones were revealed.,TUBERCULOSIS,RIFAMPICIN
790085234,9/17/2015 13:21:57,1740418086,9/17/2015 13:21:36,false,elite,1.0,31883685,GBR,"","",79.66.244.188,[TREATS],[TREATS],resistant to,n/a,30,80,42,41,90,RO-may_prevent,820205-FS1,In patients with new detected TUBERCULOSIS 23.5% MBT resistant to isoniazid and RIFAMPICIN (MDR) and sensitive to fluoroquinolones were revealed.,TUBERCULOSIS,RIFAMPICIN
790085234,9/17/2015 13:30:37,1740420677,9/17/2015 13:30:15,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,[TREATS],[TREATS],resistant to,n/a,30,80,42,41,90,RO-may_prevent,820205-FS1,In patients with new detected TUBERCULOSIS 23.5% MBT resistant to isoniazid and RIFAMPICIN (MDR) and sensitive to fluoroquinolones were revealed.,TUBERCULOSIS,RIFAMPICIN
790085234,9/17/2015 13:33:45,1740421698,9/17/2015 13:33:00,false,prodege,1.0,27934334,GBR,C8,Croydon,81.159.60.206,[TREATS],[TREATS],patients 23.5% resistant,N/A,30,80,42,41,90,RO-may_prevent,820205-FS1,In patients with new detected TUBERCULOSIS 23.5% MBT resistant to isoniazid and RIFAMPICIN (MDR) and sensitive to fluoroquinolones were revealed.,TUBERCULOSIS,RIFAMPICIN
790085234,9/17/2015 14:05:40,1740434358,9/17/2015 14:05:17,false,gifthunterclub,1.0,30901412,GBR,H9,London,77.89.149.62,[TREATS],[TREATS],TUBERCULOSIS 23.5% MBT resistant RIFAMPICIN (MDR),N/A,30,80,42,41,90,RO-may_prevent,820205-FS1,In patients with new detected TUBERCULOSIS 23.5% MBT resistant to isoniazid and RIFAMPICIN (MDR) and sensitive to fluoroquinolones were revealed.,TUBERCULOSIS,RIFAMPICIN
790085234,9/17/2015 14:12:17,1740436782,9/17/2015 14:11:46,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.124.79,[CONTRAINDICATES],[CONTRAINDICATES],resistant to,N/A,30,80,42,41,90,RO-may_prevent,820205-FS1,In patients with new detected TUBERCULOSIS 23.5% MBT resistant to isoniazid and RIFAMPICIN (MDR) and sensitive to fluoroquinolones were revealed.,TUBERCULOSIS,RIFAMPICIN
790085234,9/17/2015 14:13:41,1740437293,9/17/2015 14:12:20,false,zoombucks,1.0,6744840,CAN,BC,Kelowna,174.4.58.160,[TREATS],[TREATS],resistant to,N/A,30,80,42,41,90,RO-may_prevent,820205-FS1,In patients with new detected TUBERCULOSIS 23.5% MBT resistant to isoniazid and RIFAMPICIN (MDR) and sensitive to fluoroquinolones were revealed.,TUBERCULOSIS,RIFAMPICIN
790085234,9/17/2015 14:15:50,1740438124,9/17/2015 14:15:29,false,neodev,1.0,31329809,USA,DE,Wilmington,162.223.93.194,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,N/A,30,80,42,41,90,RO-may_prevent,820205-FS1,In patients with new detected TUBERCULOSIS 23.5% MBT resistant to isoniazid and RIFAMPICIN (MDR) and sensitive to fluoroquinolones were revealed.,TUBERCULOSIS,RIFAMPICIN
790085234,9/17/2015 14:32:19,1740444144,9/17/2015 14:32:02,false,bitcoinget,1.0,32306192,USA,MA,Amherst,72.19.88.245,[TREATS],[TREATS],RIFAMPICIN,N/a,30,80,42,41,90,RO-may_prevent,820205-FS1,In patients with new detected TUBERCULOSIS 23.5% MBT resistant to isoniazid and RIFAMPICIN (MDR) and sensitive to fluoroquinolones were revealed.,TUBERCULOSIS,RIFAMPICIN
790085234,9/17/2015 14:33:08,1740444447,9/17/2015 14:31:54,false,prodege,1,34497719,GBR,N5,Haverhill,151.230.78.163,[OTHER],[OTHER],resistant to,n/a,30,80,42,41,90,RO-may_prevent,820205-FS1,In patients with new detected TUBERCULOSIS 23.5% MBT resistant to isoniazid and RIFAMPICIN (MDR) and sensitive to fluoroquinolones were revealed.,TUBERCULOSIS,RIFAMPICIN
790085234,9/17/2015 14:40:30,1740447376,9/17/2015 14:38:48,false,clixsense,1.0,32049531,USA,"","",38.95.108.252,[NONE],[NONE],none,none,30,80,42,41,90,RO-may_prevent,820205-FS1,In patients with new detected TUBERCULOSIS 23.5% MBT resistant to isoniazid and RIFAMPICIN (MDR) and sensitive to fluoroquinolones were revealed.,TUBERCULOSIS,RIFAMPICIN
790085234,9/17/2015 14:45:59,1740449672,9/17/2015 14:45:16,false,instagc,1.0,22981457,CAN,ON,Ottawa,67.69.8.122,[SIDE_EFFECT],[SIDE_EFFECT],sensitive to fluoroquinolones,N/A,30,80,42,41,90,RO-may_prevent,820205-FS1,In patients with new detected TUBERCULOSIS 23.5% MBT resistant to isoniazid and RIFAMPICIN (MDR) and sensitive to fluoroquinolones were revealed.,TUBERCULOSIS,RIFAMPICIN
790085234,9/17/2015 14:55:55,1740453404,9/17/2015 14:55:09,false,clixsense,1.0,33115750,GBR,I3,Rochester,90.222.106.192,[PREVENTS],[PREVENTS],resistant to,N/A,30,80,42,41,90,RO-may_prevent,820205-FS1,In patients with new detected TUBERCULOSIS 23.5% MBT resistant to isoniazid and RIFAMPICIN (MDR) and sensitive to fluoroquinolones were revealed.,TUBERCULOSIS,RIFAMPICIN
790085234,9/17/2015 15:10:51,1740458550,9/17/2015 15:10:40,false,neodev,1.0,34431172,USA,CA,Torrance,66.171.228.183,[CAUSES] [NONE],"[CAUSES]
[NONE]",no,no,30,80,42,41,90,RO-may_prevent,820205-FS1,In patients with new detected TUBERCULOSIS 23.5% MBT resistant to isoniazid and RIFAMPICIN (MDR) and sensitive to fluoroquinolones were revealed.,TUBERCULOSIS,RIFAMPICIN
790085234,9/17/2015 15:12:04,1740458926,9/17/2015 15:11:49,false,neodev,1.0,30321275,USA,NV,Las Vegas,192.30.80.4,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,N/A,30,80,42,41,90,RO-may_prevent,820205-FS1,In patients with new detected TUBERCULOSIS 23.5% MBT resistant to isoniazid and RIFAMPICIN (MDR) and sensitive to fluoroquinolones were revealed.,TUBERCULOSIS,RIFAMPICIN
790085235,9/17/2015 13:32:59,1740421499,9/17/2015 13:32:38,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],high levels of,n/a,3,38,18,17,43,RO-may_prevent,820327-FS1,"In SERUM HEPATITIS the high levels of HBSAG and HBcAb were observed during the acute period of the disease, while the content of HBsAb did not exceed the normal level.",SERUM HEPATITIS,HBSAG
790085235,9/17/2015 13:39:22,1740425642,9/17/2015 13:38:31,false,prodege,1.0,27934334,GBR,C8,Croydon,81.159.60.206,[DIAGNOSE_BY_TEST_OR_DRUG] [MANIFESTATION],"[DIAGNOSE_BY_TEST_OR_DRUG]
[MANIFESTATION]",high levels observed,N/A,3,38,18,17,43,RO-may_prevent,820327-FS1,"In SERUM HEPATITIS the high levels of HBSAG and HBcAb were observed during the acute period of the disease, while the content of HBsAb did not exceed the normal level.",SERUM HEPATITIS,HBSAG
790085235,9/17/2015 14:08:24,1740435400,9/17/2015 14:08:00,false,gifthunterclub,1.0,30901412,GBR,H9,London,77.89.149.62,[SYMPTOM],[SYMPTOM],SERUM HEPATITIS high levels of HBSAG,N/A,3,38,18,17,43,RO-may_prevent,820327-FS1,"In SERUM HEPATITIS the high levels of HBSAG and HBcAb were observed during the acute period of the disease, while the content of HBsAb did not exceed the normal level.",SERUM HEPATITIS,HBSAG
790085235,9/17/2015 14:14:53,1740437750,9/17/2015 14:14:30,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.124.79,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],high levels of observed,N/A,3,38,18,17,43,RO-may_prevent,820327-FS1,"In SERUM HEPATITIS the high levels of HBSAG and HBcAb were observed during the acute period of the disease, while the content of HBsAb did not exceed the normal level.",SERUM HEPATITIS,HBSAG
790085235,9/17/2015 14:20:24,1740439701,9/17/2015 14:19:10,false,zoombucks,1.0,6744840,CAN,BC,Kelowna,174.4.58.160,[MANIFESTATION],[MANIFESTATION],were observed during the acute period,N/A,3,38,18,17,43,RO-may_prevent,820327-FS1,"In SERUM HEPATITIS the high levels of HBSAG and HBcAb were observed during the acute period of the disease, while the content of HBsAb did not exceed the normal level.",SERUM HEPATITIS,HBSAG
790085235,9/17/2015 14:33:59,1740444751,9/17/2015 14:33:38,false,bitcoinget,1.0,32306192,USA,MA,Amherst,72.19.88.245,[TREATS],[TREATS],SERUM HEPATITIS,N/a,3,38,18,17,43,RO-may_prevent,820327-FS1,"In SERUM HEPATITIS the high levels of HBSAG and HBcAb were observed during the acute period of the disease, while the content of HBsAb did not exceed the normal level.",SERUM HEPATITIS,HBSAG
790085235,9/17/2015 14:48:15,1740450632,9/17/2015 14:46:49,false,clixsense,1.0,32049531,USA,"","",38.95.108.252,[NONE],[NONE],none,none,3,38,18,17,43,RO-may_prevent,820327-FS1,"In SERUM HEPATITIS the high levels of HBSAG and HBcAb were observed during the acute period of the disease, while the content of HBsAb did not exceed the normal level.",SERUM HEPATITIS,HBSAG
790085235,9/17/2015 14:52:03,1740452061,9/17/2015 14:51:36,false,instagc,1.0,22981457,CAN,ON,Ottawa,67.69.8.122,[SYMPTOM],[SYMPTOM],high levels of,N/A,3,38,18,17,43,RO-may_prevent,820327-FS1,"In SERUM HEPATITIS the high levels of HBSAG and HBcAb were observed during the acute period of the disease, while the content of HBsAb did not exceed the normal level.",SERUM HEPATITIS,HBSAG
790085235,9/17/2015 15:00:16,1740454953,9/17/2015 14:58:37,false,clixsense,1.0,33115750,GBR,I3,Rochester,90.222.106.192,[MANIFESTATION],[MANIFESTATION],were observed,N/A,3,38,18,17,43,RO-may_prevent,820327-FS1,"In SERUM HEPATITIS the high levels of HBSAG and HBcAb were observed during the acute period of the disease, while the content of HBsAb did not exceed the normal level.",SERUM HEPATITIS,HBSAG
790085235,9/17/2015 15:02:19,1740455850,9/17/2015 15:01:33,false,neodev,1.0,31329809,USA,DE,Wilmington,162.223.93.194,[PART_OF],[PART_OF],of of of,N/A,3,38,18,17,43,RO-may_prevent,820327-FS1,"In SERUM HEPATITIS the high levels of HBSAG and HBcAb were observed during the acute period of the disease, while the content of HBsAb did not exceed the normal level.",SERUM HEPATITIS,HBSAG
790085235,9/17/2015 15:12:11,1740458975,9/17/2015 15:12:00,false,neodev,1.0,34431172,USA,CA,Torrance,66.171.228.183,[CAUSES] [LOCATION] [NONE],"[CAUSES]
[LOCATION]
[NONE]",no,no,3,38,18,17,43,RO-may_prevent,820327-FS1,"In SERUM HEPATITIS the high levels of HBSAG and HBcAb were observed during the acute period of the disease, while the content of HBsAb did not exceed the normal level.",SERUM HEPATITIS,HBSAG
790085235,9/17/2015 15:13:41,1740459354,9/17/2015 15:13:27,false,neodev,1.0,30321275,USA,NV,Las Vegas,192.30.80.4,[PART_OF],[PART_OF],of of of,N/A,3,38,18,17,43,RO-may_prevent,820327-FS1,"In SERUM HEPATITIS the high levels of HBSAG and HBcAb were observed during the acute period of the disease, while the content of HBsAb did not exceed the normal level.",SERUM HEPATITIS,HBSAG
790085235,9/17/2015 15:19:05,1740461426,9/17/2015 15:18:50,false,neodev,1.0,29363385,USA,DE,Wilmington,162.223.93.162,[PART_OF],[PART_OF],of of,N/A,3,38,18,17,43,RO-may_prevent,820327-FS1,"In SERUM HEPATITIS the high levels of HBSAG and HBcAb were observed during the acute period of the disease, while the content of HBsAb did not exceed the normal level.",SERUM HEPATITIS,HBSAG
790085235,9/17/2015 15:21:21,1740462367,9/17/2015 15:20:44,false,neodev,1.0,12115558,USA,OH,Twinsburg,98.27.164.131,[SYMPTOM],[SYMPTOM],In SERUM HEPATITIS high levels of HBSAG were observed,N/A,3,38,18,17,43,RO-may_prevent,820327-FS1,"In SERUM HEPATITIS the high levels of HBSAG and HBcAb were observed during the acute period of the disease, while the content of HBsAb did not exceed the normal level.",SERUM HEPATITIS,HBSAG
790085235,9/17/2015 15:26:05,1740463974,9/17/2015 15:25:50,false,neodev,1.0,33435788,USA,DE,Wilmington,162.223.93.179,[PART_OF],[PART_OF],of of of,N/A,3,38,18,17,43,RO-may_prevent,820327-FS1,"In SERUM HEPATITIS the high levels of HBSAG and HBcAb were observed during the acute period of the disease, while the content of HBsAb did not exceed the normal level.",SERUM HEPATITIS,HBSAG
790085236,9/17/2015 11:07:07,1740386990,9/17/2015 11:06:47,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],"glycaemia,",N/A,577,391,444,591,408,RO-may_treat,820094-FS1,"placebo controlled, multicentre trial  Voglibose for prevention of type 2 diabetes mellitus: a randomised, double blind trial in Japanese individuals with impaired glucose tolerance  Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial  Trajectories of glycaemia, insulin sensitivity, and INSULIN SECRETION before diagnosis of type 2 diabetes: an analysis from the Whitehall II study  Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for TYPE 2 DIABETES (RECORD): a multicentre.",TYPE 2 DIABETES,INSULIN SECRETION
790085236,9/17/2015 11:21:02,1740389596,9/17/2015 11:20:02,false,neodev,1.0,32695853,USA,NV,Las Vegas,192.30.80.172,[PART_OF] [IS_A] [SIDE_EFFECT] [ASSOCIATED_WITH],"[ASSOCIATED_WITH]
[SIDE_EFFECT]
[IS_A]
[PART_OF]",of a with Effect of a of a of of an a,N/A,577,391,444,591,408,RO-may_treat,820094-FS1,"placebo controlled, multicentre trial  Voglibose for prevention of type 2 diabetes mellitus: a randomised, double blind trial in Japanese individuals with impaired glucose tolerance  Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial  Trajectories of glycaemia, insulin sensitivity, and INSULIN SECRETION before diagnosis of type 2 diabetes: an analysis from the Whitehall II study  Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for TYPE 2 DIABETES (RECORD): a multicentre.",TYPE 2 DIABETES,INSULIN SECRETION
790085236,9/17/2015 11:22:26,1740389801,9/17/2015 11:20:43,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[NONE],[NONE],N/A,There is no relation between the terms.,577,391,444,591,408,RO-may_treat,820094-FS1,"placebo controlled, multicentre trial  Voglibose for prevention of type 2 diabetes mellitus: a randomised, double blind trial in Japanese individuals with impaired glucose tolerance  Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial  Trajectories of glycaemia, insulin sensitivity, and INSULIN SECRETION before diagnosis of type 2 diabetes: an analysis from the Whitehall II study  Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for TYPE 2 DIABETES (RECORD): a multicentre.",TYPE 2 DIABETES,INSULIN SECRETION
790085236,9/17/2015 11:28:20,1740390892,9/17/2015 11:27:14,false,neodev,1.0,30581619,USA,CA,San Jose,50.118.162.56,[NONE],[NONE],good,good,577,391,444,591,408,RO-may_treat,820094-FS1,"placebo controlled, multicentre trial  Voglibose for prevention of type 2 diabetes mellitus: a randomised, double blind trial in Japanese individuals with impaired glucose tolerance  Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial  Trajectories of glycaemia, insulin sensitivity, and INSULIN SECRETION before diagnosis of type 2 diabetes: an analysis from the Whitehall II study  Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for TYPE 2 DIABETES (RECORD): a multicentre.",TYPE 2 DIABETES,INSULIN SECRETION
790085236,9/17/2015 11:32:39,1740391695,9/17/2015 11:32:03,false,neodev,1.0,30941227,USA,NV,Las Vegas,192.30.80.166,[PART_OF] [IS_A] [ASSOCIATED_WITH] [SIDE_EFFECT],"[ASSOCIATED_WITH]
[SIDE_EFFECT]
[IS_A]
[PART_OF]",of a with Effect of of a,N/A,577,391,444,591,408,RO-may_treat,820094-FS1,"placebo controlled, multicentre trial  Voglibose for prevention of type 2 diabetes mellitus: a randomised, double blind trial in Japanese individuals with impaired glucose tolerance  Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial  Trajectories of glycaemia, insulin sensitivity, and INSULIN SECRETION before diagnosis of type 2 diabetes: an analysis from the Whitehall II study  Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for TYPE 2 DIABETES (RECORD): a multicentre.",TYPE 2 DIABETES,INSULIN SECRETION
790085236,9/17/2015 11:42:38,1740393550,9/17/2015 11:42:23,false,neodev,1.0,33701549,USA,CA,Torrance,66.171.228.66,[PREVENTS] [PART_OF] [IS_A] [NONE],"[PREVENTS]
[IS_A]
[PART_OF]
[NONE]",[IS_A],N/A,577,391,444,591,408,RO-may_treat,820094-FS1,"placebo controlled, multicentre trial  Voglibose for prevention of type 2 diabetes mellitus: a randomised, double blind trial in Japanese individuals with impaired glucose tolerance  Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial  Trajectories of glycaemia, insulin sensitivity, and INSULIN SECRETION before diagnosis of type 2 diabetes: an analysis from the Whitehall II study  Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for TYPE 2 DIABETES (RECORD): a multicentre.",TYPE 2 DIABETES,INSULIN SECRETION
790085236,9/17/2015 12:07:07,1740398589,9/17/2015 12:06:50,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[TREATS],[TREATS],therapy,N/A,577,391,444,591,408,RO-may_treat,820094-FS1,"placebo controlled, multicentre trial  Voglibose for prevention of type 2 diabetes mellitus: a randomised, double blind trial in Japanese individuals with impaired glucose tolerance  Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial  Trajectories of glycaemia, insulin sensitivity, and INSULIN SECRETION before diagnosis of type 2 diabetes: an analysis from the Whitehall II study  Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for TYPE 2 DIABETES (RECORD): a multicentre.",TYPE 2 DIABETES,INSULIN SECRETION
790085236,9/17/2015 12:32:32,1740404187,9/17/2015 12:31:21,false,neodev,1.0,30588889,NLD,07,Amsterdam,77.248.175.222,[IS_A],[IS_A],in combination therapy for,N/A,577,391,444,591,408,RO-may_treat,820094-FS1,"placebo controlled, multicentre trial  Voglibose for prevention of type 2 diabetes mellitus: a randomised, double blind trial in Japanese individuals with impaired glucose tolerance  Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial  Trajectories of glycaemia, insulin sensitivity, and INSULIN SECRETION before diagnosis of type 2 diabetes: an analysis from the Whitehall II study  Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for TYPE 2 DIABETES (RECORD): a multicentre.",TYPE 2 DIABETES,INSULIN SECRETION
790085236,9/17/2015 12:40:46,1740406282,9/17/2015 12:39:46,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],INSULIN SECRETION before diagnosis TYPE 2 DIABETES,na,577,391,444,591,408,RO-may_treat,820094-FS1,"placebo controlled, multicentre trial  Voglibose for prevention of type 2 diabetes mellitus: a randomised, double blind trial in Japanese individuals with impaired glucose tolerance  Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial  Trajectories of glycaemia, insulin sensitivity, and INSULIN SECRETION before diagnosis of type 2 diabetes: an analysis from the Whitehall II study  Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for TYPE 2 DIABETES (RECORD): a multicentre.",TYPE 2 DIABETES,INSULIN SECRETION
790085236,9/17/2015 12:41:28,1740406416,9/17/2015 12:40:07,false,prodege,1.0,2145087,USA,NY,New York,107.107.57.52,[SYMPTOM],[SYMPTOM],before diagnosis of,N/A,577,391,444,591,408,RO-may_treat,820094-FS1,"placebo controlled, multicentre trial  Voglibose for prevention of type 2 diabetes mellitus: a randomised, double blind trial in Japanese individuals with impaired glucose tolerance  Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial  Trajectories of glycaemia, insulin sensitivity, and INSULIN SECRETION before diagnosis of type 2 diabetes: an analysis from the Whitehall II study  Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for TYPE 2 DIABETES (RECORD): a multicentre.",TYPE 2 DIABETES,INSULIN SECRETION
790085236,9/17/2015 13:15:08,1740415946,9/17/2015 13:14:48,false,elite,1.0,31883685,GBR,"","",79.66.244.188,[SYMPTOM],[SYMPTOM],before diagnosis,n/a,577,391,444,591,408,RO-may_treat,820094-FS1,"placebo controlled, multicentre trial  Voglibose for prevention of type 2 diabetes mellitus: a randomised, double blind trial in Japanese individuals with impaired glucose tolerance  Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial  Trajectories of glycaemia, insulin sensitivity, and INSULIN SECRETION before diagnosis of type 2 diabetes: an analysis from the Whitehall II study  Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for TYPE 2 DIABETES (RECORD): a multicentre.",TYPE 2 DIABETES,INSULIN SECRETION
790085236,9/17/2015 13:15:30,1740416106,9/17/2015 13:15:18,false,neodev,1.0,33228343,USA,"","",38.95.108.251,[TREATS] [CAUSES] [LOCATION] [CONTRAINDICATES] [SIDE_EFFECT] [PART_OF] [NONE],"[TREATS]
[CAUSES]
[LOCATION]
[CONTRAINDICATES]
[SIDE_EFFECT]
[PART_OF]
[NONE]","placebo controlled, multicentre trial Voglibose for prevention of type 2 diabetes mellitus: a randomised, double blind trial in Japanese individuals with impaired glucose tolerance Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial Trajectories of glycae","placebo controlled, multicentre trial Voglibose for prevention of type 2 diabetes mellitus: a randomised, double blind trial in Japanese individuals with impaired glucose tolerance Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial Trajectories of glycae",577,391,444,591,408,RO-may_treat,820094-FS1,"placebo controlled, multicentre trial  Voglibose for prevention of type 2 diabetes mellitus: a randomised, double blind trial in Japanese individuals with impaired glucose tolerance  Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial  Trajectories of glycaemia, insulin sensitivity, and INSULIN SECRETION before diagnosis of type 2 diabetes: an analysis from the Whitehall II study  Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for TYPE 2 DIABETES (RECORD): a multicentre.",TYPE 2 DIABETES,INSULIN SECRETION
790085236,9/17/2015 13:15:39,1740416132,9/17/2015 13:15:10,false,prodege,1.0,33854929,USA,CT,Wallingford,24.2.218.232,[TREATS],[TREATS],outcomes,n/a,577,391,444,591,408,RO-may_treat,820094-FS1,"placebo controlled, multicentre trial  Voglibose for prevention of type 2 diabetes mellitus: a randomised, double blind trial in Japanese individuals with impaired glucose tolerance  Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial  Trajectories of glycaemia, insulin sensitivity, and INSULIN SECRETION before diagnosis of type 2 diabetes: an analysis from the Whitehall II study  Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for TYPE 2 DIABETES (RECORD): a multicentre.",TYPE 2 DIABETES,INSULIN SECRETION
790085236,9/17/2015 13:19:21,1740417168,9/17/2015 13:17:46,false,neodev,1.0,12115558,USA,OH,Twinsburg,98.27.164.131,[SYMPTOM] [MANIFESTATION],"[SYMPTOM]
[MANIFESTATION]",INSULIN SECRETION before diagnosis of type 2 diabetes:,N/A,577,391,444,591,408,RO-may_treat,820094-FS1,"placebo controlled, multicentre trial  Voglibose for prevention of type 2 diabetes mellitus: a randomised, double blind trial in Japanese individuals with impaired glucose tolerance  Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial  Trajectories of glycaemia, insulin sensitivity, and INSULIN SECRETION before diagnosis of type 2 diabetes: an analysis from the Whitehall II study  Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for TYPE 2 DIABETES (RECORD): a multicentre.",TYPE 2 DIABETES,INSULIN SECRETION
790085236,9/17/2015 13:20:19,1740417578,9/17/2015 13:19:05,false,prodege,1.0,27934334,GBR,C8,Croydon,81.159.60.206,[ASSOCIATED_WITH],[ASSOCIATED_WITH],Trajectories of before diagnosis,N/A,577,391,444,591,408,RO-may_treat,820094-FS1,"placebo controlled, multicentre trial  Voglibose for prevention of type 2 diabetes mellitus: a randomised, double blind trial in Japanese individuals with impaired glucose tolerance  Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial  Trajectories of glycaemia, insulin sensitivity, and INSULIN SECRETION before diagnosis of type 2 diabetes: an analysis from the Whitehall II study  Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for TYPE 2 DIABETES (RECORD): a multicentre.",TYPE 2 DIABETES,INSULIN SECRETION
790085237,9/17/2015 11:03:21,1740386166,9/17/2015 11:02:23,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],receive,N/A,42,165,56,55,175,RO-may_prevent,820293-FS1,"In a double blind study, 35 patients with DUODENAL ULCER diagnosed by endoscopy were randomly assigned to receive cimetidine 800 mg daily and 38 patients to receive CIMETIDINE 800 mg plus sulpiride 200 mg daily.",DUODENAL ULCER,CIMETIDINE
790085237,9/17/2015 11:08:54,1740387398,9/17/2015 11:07:18,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[OTHER],[OTHER],38 patients to receive,N/A,42,165,56,55,175,RO-may_prevent,820293-FS1,"In a double blind study, 35 patients with DUODENAL ULCER diagnosed by endoscopy were randomly assigned to receive cimetidine 800 mg daily and 38 patients to receive CIMETIDINE 800 mg plus sulpiride 200 mg daily.",DUODENAL ULCER,CIMETIDINE
790085237,9/17/2015 11:09:11,1740387448,9/17/2015 11:07:05,false,neodev,1.0,30941227,USA,NV,Las Vegas,192.30.80.166,[ASSOCIATED_WITH] [DIAGNOSE_BY_TEST_OR_DRUG],"[DIAGNOSE_BY_TEST_OR_DRUG]
[ASSOCIATED_WITH]",with by,N/A,42,165,56,55,175,RO-may_prevent,820293-FS1,"In a double blind study, 35 patients with DUODENAL ULCER diagnosed by endoscopy were randomly assigned to receive cimetidine 800 mg daily and 38 patients to receive CIMETIDINE 800 mg plus sulpiride 200 mg daily.",DUODENAL ULCER,CIMETIDINE
790085237,9/17/2015 11:15:49,1740388717,9/17/2015 11:12:56,false,neodev,1.0,30581619,USA,CA,San Jose,50.118.162.56,[NONE],[NONE],good,good,42,165,56,55,175,RO-may_prevent,820293-FS1,"In a double blind study, 35 patients with DUODENAL ULCER diagnosed by endoscopy were randomly assigned to receive cimetidine 800 mg daily and 38 patients to receive CIMETIDINE 800 mg plus sulpiride 200 mg daily.",DUODENAL ULCER,CIMETIDINE
790085237,9/17/2015 11:16:51,1740388872,9/17/2015 11:16:30,false,neodev,1.0,32695853,USA,NV,Las Vegas,192.30.80.172,[IS_A] [DIAGNOSE_BY_TEST_OR_DRUG] [ASSOCIATED_WITH],"[DIAGNOSE_BY_TEST_OR_DRUG]
[ASSOCIATED_WITH]
[IS_A]",a with by,N/A,42,165,56,55,175,RO-may_prevent,820293-FS1,"In a double blind study, 35 patients with DUODENAL ULCER diagnosed by endoscopy were randomly assigned to receive cimetidine 800 mg daily and 38 patients to receive CIMETIDINE 800 mg plus sulpiride 200 mg daily.",DUODENAL ULCER,CIMETIDINE
790085237,9/17/2015 11:21:45,1740389720,9/17/2015 11:20:52,false,gifthulk,1.0,18666417,USA,PA,Meadville,24.101.32.13,[DIAGNOSE_BY_TEST_OR_DRUG] [TREATS],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]",double blind patients with DUODENAL ULCER randomly assigned to,n/a,42,165,56,55,175,RO-may_prevent,820293-FS1,"In a double blind study, 35 patients with DUODENAL ULCER diagnosed by endoscopy were randomly assigned to receive cimetidine 800 mg daily and 38 patients to receive CIMETIDINE 800 mg plus sulpiride 200 mg daily.",DUODENAL ULCER,CIMETIDINE
790085237,9/17/2015 11:39:58,1740393134,9/17/2015 11:39:45,false,neodev,1.0,33701549,USA,CA,Torrance,66.171.228.66,[ASSOCIATED_WITH] [MANIFESTATION] [LOCATION] [NONE],"[LOCATION]
[MANIFESTATION]
[ASSOCIATED_WITH]
[NONE]",[IS_A],N/A,42,165,56,55,175,RO-may_prevent,820293-FS1,"In a double blind study, 35 patients with DUODENAL ULCER diagnosed by endoscopy were randomly assigned to receive cimetidine 800 mg daily and 38 patients to receive CIMETIDINE 800 mg plus sulpiride 200 mg daily.",DUODENAL ULCER,CIMETIDINE
790085237,9/17/2015 11:59:25,1740396968,9/17/2015 11:58:57,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],endoscopy,N/A,42,165,56,55,175,RO-may_prevent,820293-FS1,"In a double blind study, 35 patients with DUODENAL ULCER diagnosed by endoscopy were randomly assigned to receive cimetidine 800 mg daily and 38 patients to receive CIMETIDINE 800 mg plus sulpiride 200 mg daily.",DUODENAL ULCER,CIMETIDINE
790085237,9/17/2015 12:02:13,1740397507,9/17/2015 12:01:53,false,prodege,1.0,14848125,GBR,V8,Airdrie,86.151.77.161,[TREATS],[TREATS],assigned to receive cimetidine,n/a,42,165,56,55,175,RO-may_prevent,820293-FS1,"In a double blind study, 35 patients with DUODENAL ULCER diagnosed by endoscopy were randomly assigned to receive cimetidine 800 mg daily and 38 patients to receive CIMETIDINE 800 mg plus sulpiride 200 mg daily.",DUODENAL ULCER,CIMETIDINE
790085237,9/17/2015 12:23:37,1740402126,9/17/2015 12:22:49,false,neodev,1.0,30588889,NLD,07,Amsterdam,77.248.175.222,[TREATS],[TREATS],receive,N/A,42,165,56,55,175,RO-may_prevent,820293-FS1,"In a double blind study, 35 patients with DUODENAL ULCER diagnosed by endoscopy were randomly assigned to receive cimetidine 800 mg daily and 38 patients to receive CIMETIDINE 800 mg plus sulpiride 200 mg daily.",DUODENAL ULCER,CIMETIDINE
790085237,9/17/2015 12:34:37,1740404713,9/17/2015 12:34:13,false,prodege,1.0,2145087,USA,NY,New York,107.107.57.52,[TREATS],[TREATS],assigned to receive,N/A,42,165,56,55,175,RO-may_prevent,820293-FS1,"In a double blind study, 35 patients with DUODENAL ULCER diagnosed by endoscopy were randomly assigned to receive cimetidine 800 mg daily and 38 patients to receive CIMETIDINE 800 mg plus sulpiride 200 mg daily.",DUODENAL ULCER,CIMETIDINE
790085237,9/17/2015 12:35:29,1740404888,9/17/2015 12:35:09,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,[TREATS],[TREATS],patients with DUODENAL ULCER receive CIMETIDINE,na,42,165,56,55,175,RO-may_prevent,820293-FS1,"In a double blind study, 35 patients with DUODENAL ULCER diagnosed by endoscopy were randomly assigned to receive cimetidine 800 mg daily and 38 patients to receive CIMETIDINE 800 mg plus sulpiride 200 mg daily.",DUODENAL ULCER,CIMETIDINE
790085237,9/17/2015 12:36:45,1740405287,9/17/2015 12:35:51,false,instagc,1.0,22981457,CAN,ON,Welland,76.67.127.43,[NONE],[NONE],N/A,Just says they were taking the product but not that there was any result,42,165,56,55,175,RO-may_prevent,820293-FS1,"In a double blind study, 35 patients with DUODENAL ULCER diagnosed by endoscopy were randomly assigned to receive cimetidine 800 mg daily and 38 patients to receive CIMETIDINE 800 mg plus sulpiride 200 mg daily.",DUODENAL ULCER,CIMETIDINE
790085237,9/17/2015 12:38:02,1740405551,9/17/2015 12:36:40,false,neodev,1.0,34215189,GBR,I2,Manchester,82.8.21.5,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],35 patients with DUODENAL ULCER diagnosed,N/A,42,165,56,55,175,RO-may_prevent,820293-FS1,"In a double blind study, 35 patients with DUODENAL ULCER diagnosed by endoscopy were randomly assigned to receive cimetidine 800 mg daily and 38 patients to receive CIMETIDINE 800 mg plus sulpiride 200 mg daily.",DUODENAL ULCER,CIMETIDINE
790085237,9/17/2015 13:09:34,1740414309,9/17/2015 13:08:14,false,prodege,1.0,33854929,USA,CT,Wallingford,24.2.218.232,[TREATS],[TREATS],receive,n/a,42,165,56,55,175,RO-may_prevent,820293-FS1,"In a double blind study, 35 patients with DUODENAL ULCER diagnosed by endoscopy were randomly assigned to receive cimetidine 800 mg daily and 38 patients to receive CIMETIDINE 800 mg plus sulpiride 200 mg daily.",DUODENAL ULCER,CIMETIDINE
790085238,9/17/2015 11:04:51,1740386483,9/17/2015 11:04:34,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[SYMPTOM],[SYMPTOM],efficacious,N/A,68,31,87,86,44,RO-may_treat,820096-FS1,Frequently Asked Questions  Is ACETAMINOPHEN really efficacious for OSTEOARTHRITIS PAIN,OSTEOARTHRITIS PAIN,ACETAMINOPHEN
790085238,9/17/2015 11:13:55,1740388328,9/17/2015 11:12:29,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",efficacious for,N/A,68,31,87,86,44,RO-may_treat,820096-FS1,Frequently Asked Questions  Is ACETAMINOPHEN really efficacious for OSTEOARTHRITIS PAIN,OSTEOARTHRITIS PAIN,ACETAMINOPHEN
790085238,9/17/2015 11:18:14,1740389143,9/17/2015 11:18:02,false,neodev,1.0,32695853,USA,NV,Las Vegas,192.30.80.172,[IS_A],[IS_A],Is,N/A,68,31,87,86,44,RO-may_treat,820096-FS1,Frequently Asked Questions  Is ACETAMINOPHEN really efficacious for OSTEOARTHRITIS PAIN,OSTEOARTHRITIS PAIN,ACETAMINOPHEN
790085238,9/17/2015 11:20:25,1740389511,9/17/2015 11:18:53,false,neodev,1.0,30581619,USA,CA,San Jose,50.118.162.56,[NONE],[NONE],good,good,68,31,87,86,44,RO-may_treat,820096-FS1,Frequently Asked Questions  Is ACETAMINOPHEN really efficacious for OSTEOARTHRITIS PAIN,OSTEOARTHRITIS PAIN,ACETAMINOPHEN
790085238,9/17/2015 11:30:15,1740391241,9/17/2015 11:30:04,false,neodev,1.0,30941227,USA,NV,Las Vegas,192.30.80.166,[IS_A],[IS_A],Is,N/A,68,31,87,86,44,RO-may_treat,820096-FS1,Frequently Asked Questions  Is ACETAMINOPHEN really efficacious for OSTEOARTHRITIS PAIN,OSTEOARTHRITIS PAIN,ACETAMINOPHEN
790085238,9/17/2015 11:41:09,1740393369,9/17/2015 11:40:55,false,neodev,1.0,33701549,USA,CA,Torrance,66.171.228.66,[CONTRAINDICATES] [LOCATION] [DIAGNOSE_BY_TEST_OR_DRUG] [NONE],"[DIAGNOSE_BY_TEST_OR_DRUG]
[LOCATION]
[CONTRAINDICATES]
[NONE]",[IS_A],N/A,68,31,87,86,44,RO-may_treat,820096-FS1,Frequently Asked Questions  Is ACETAMINOPHEN really efficacious for OSTEOARTHRITIS PAIN,OSTEOARTHRITIS PAIN,ACETAMINOPHEN
790085238,9/17/2015 12:02:01,1740397448,9/17/2015 12:01:46,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[LOCATION],[LOCATION],efficacious,N/A,68,31,87,86,44,RO-may_treat,820096-FS1,Frequently Asked Questions  Is ACETAMINOPHEN really efficacious for OSTEOARTHRITIS PAIN,OSTEOARTHRITIS PAIN,ACETAMINOPHEN
790085238,9/17/2015 12:26:17,1740402765,9/17/2015 12:25:46,false,neodev,1.0,30588889,NLD,07,Amsterdam,77.248.175.222,[TREATS],[TREATS],efficacious,N/A,68,31,87,86,44,RO-may_treat,820096-FS1,Frequently Asked Questions  Is ACETAMINOPHEN really efficacious for OSTEOARTHRITIS PAIN,OSTEOARTHRITIS PAIN,ACETAMINOPHEN
790085238,9/17/2015 12:37:00,1740405374,9/17/2015 12:36:44,false,prodege,1.0,2145087,USA,NY,New York,107.107.57.52,[TREATS],[TREATS],efficacious for,N/A,68,31,87,86,44,RO-may_treat,820096-FS1,Frequently Asked Questions  Is ACETAMINOPHEN really efficacious for OSTEOARTHRITIS PAIN,OSTEOARTHRITIS PAIN,ACETAMINOPHEN
790085238,9/17/2015 12:37:23,1740405449,9/17/2015 12:36:53,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,[TREATS],[TREATS],ACETAMINOPHEN efficacious for OSTEOARTHRITIS PAIN,na,68,31,87,86,44,RO-may_treat,820096-FS1,Frequently Asked Questions  Is ACETAMINOPHEN really efficacious for OSTEOARTHRITIS PAIN,OSTEOARTHRITIS PAIN,ACETAMINOPHEN
790085238,9/17/2015 12:41:40,1740406460,9/17/2015 12:41:01,false,instagc,1.0,22981457,CAN,ON,Welland,76.67.127.43,[NONE],[NONE],N/A,It's a question with no answer about relationships,68,31,87,86,44,RO-may_treat,820096-FS1,Frequently Asked Questions  Is ACETAMINOPHEN really efficacious for OSTEOARTHRITIS PAIN,OSTEOARTHRITIS PAIN,ACETAMINOPHEN
790085238,9/17/2015 12:49:58,1740409045,9/17/2015 12:47:22,false,neodev,1.0,34215189,GBR,I2,Manchester,82.8.21.5,[TREATS],[TREATS],Is ACETAMINOPHEN really efficacious for OSTEOARTHRITIS PAIN,N/A,68,31,87,86,44,RO-may_treat,820096-FS1,Frequently Asked Questions  Is ACETAMINOPHEN really efficacious for OSTEOARTHRITIS PAIN,OSTEOARTHRITIS PAIN,ACETAMINOPHEN
790085238,9/17/2015 13:12:47,1740415270,9/17/2015 13:12:28,false,elite,1.0,31883685,GBR,"","",79.66.244.188,[TREATS],[TREATS],efficacious for,N/A,68,31,87,86,44,RO-may_treat,820096-FS1,Frequently Asked Questions  Is ACETAMINOPHEN really efficacious for OSTEOARTHRITIS PAIN,OSTEOARTHRITIS PAIN,ACETAMINOPHEN
790085238,9/17/2015 13:13:02,1740415320,9/17/2015 13:12:26,false,prodege,1.0,33854929,USA,CT,Wallingford,24.2.218.232,[OTHER],[OTHER],Frequently Asked Questions,n/a,68,31,87,86,44,RO-may_treat,820096-FS1,Frequently Asked Questions  Is ACETAMINOPHEN really efficacious for OSTEOARTHRITIS PAIN,OSTEOARTHRITIS PAIN,ACETAMINOPHEN
790085238,9/17/2015 13:13:25,1740415465,9/17/2015 13:13:10,false,neodev,1.0,33228343,USA,"","",38.95.108.251,[LOCATION] [PREVENTS] [SIDE_EFFECT] [NONE],"[PREVENTS]
[LOCATION]
[SIDE_EFFECT]
[NONE]",requently Asked Questions Is ACETAMINOPHEN really efficacious for OSTEOARTHR,requently Asked Questions Is ACETAMINOPHEN really efficacious for OSTEOARTHR,68,31,87,86,44,RO-may_treat,820096-FS1,Frequently Asked Questions  Is ACETAMINOPHEN really efficacious for OSTEOARTHRITIS PAIN,OSTEOARTHRITIS PAIN,ACETAMINOPHEN
790085239,9/17/2015 09:19:32,1740363876,9/17/2015 09:19:09,false,neodev,1.0,32053642,GBR,I7,Newcastle Upon Tyne,92.23.136.205,[SIDE_EFFECT],[SIDE_EFFECT],may occur,N/A,19,40,32,31,58,RO-may_treat,820052-FS1,Hyperlipidemia and HYPERGLYCEMIA due to INSULIN RESISTANCE and nonalcoholic steatohepatitis may occur with lipodystrophy.,HYPERGLYCEMIA,INSULIN RESISTANCE
790085239,9/17/2015 09:19:51,1740363950,9/17/2015 09:19:33,false,elite,1.0,30659754,USA,"","",162.250.145.204,[CAUSES],[CAUSES],due to,N/A,19,40,32,31,58,RO-may_treat,820052-FS1,Hyperlipidemia and HYPERGLYCEMIA due to INSULIN RESISTANCE and nonalcoholic steatohepatitis may occur with lipodystrophy.,HYPERGLYCEMIA,INSULIN RESISTANCE
790085239,9/17/2015 09:26:51,1740365320,9/17/2015 09:26:36,false,instagc,1.0,18960682,GBR,U2,Annan,92.18.213.181,[CAUSES],[CAUSES],due to,N/A,19,40,32,31,58,RO-may_treat,820052-FS1,Hyperlipidemia and HYPERGLYCEMIA due to INSULIN RESISTANCE and nonalcoholic steatohepatitis may occur with lipodystrophy.,HYPERGLYCEMIA,INSULIN RESISTANCE
790085239,9/17/2015 09:30:45,1740366234,9/17/2015 09:30:25,false,neodev,1.0,15848372,AUS,02,Jannali,14.200.59.55,[MANIFESTATION] [ASSOCIATED_WITH],"[MANIFESTATION]
[ASSOCIATED_WITH]",due to,n/a,19,40,32,31,58,RO-may_treat,820052-FS1,Hyperlipidemia and HYPERGLYCEMIA due to INSULIN RESISTANCE and nonalcoholic steatohepatitis may occur with lipodystrophy.,HYPERGLYCEMIA,INSULIN RESISTANCE
790085239,9/17/2015 09:31:18,1740366359,9/17/2015 09:30:57,false,neodev,1.0,33644825,USA,FL,Fort Lauderdale,65.111.173.161,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],HYPERGLYCEMIA INSULIN RESISTANCE,causes,19,40,32,31,58,RO-may_treat,820052-FS1,Hyperlipidemia and HYPERGLYCEMIA due to INSULIN RESISTANCE and nonalcoholic steatohepatitis may occur with lipodystrophy.,HYPERGLYCEMIA,INSULIN RESISTANCE
790085239,9/17/2015 09:37:51,1740367883,9/17/2015 09:37:37,false,elite,1.0,30659615,USA,"","",162.250.145.234,[CAUSES],[CAUSES],due to,N/A,19,40,32,31,58,RO-may_treat,820052-FS1,Hyperlipidemia and HYPERGLYCEMIA due to INSULIN RESISTANCE and nonalcoholic steatohepatitis may occur with lipodystrophy.,HYPERGLYCEMIA,INSULIN RESISTANCE
790085239,9/17/2015 09:46:25,1740369944,9/17/2015 09:46:01,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[CAUSES],[CAUSES],due to,N/A,19,40,32,31,58,RO-may_treat,820052-FS1,Hyperlipidemia and HYPERGLYCEMIA due to INSULIN RESISTANCE and nonalcoholic steatohepatitis may occur with lipodystrophy.,HYPERGLYCEMIA,INSULIN RESISTANCE
790085239,9/17/2015 09:47:00,1740370102,9/17/2015 09:46:10,false,pocketmoneygpt,1.0,21432964,GBR,F8,Borehamwood,81.159.185.70,[CAUSES],[CAUSES],due to,N/A,19,40,32,31,58,RO-may_treat,820052-FS1,Hyperlipidemia and HYPERGLYCEMIA due to INSULIN RESISTANCE and nonalcoholic steatohepatitis may occur with lipodystrophy.,HYPERGLYCEMIA,INSULIN RESISTANCE
790085239,9/17/2015 09:47:10,1740370128,9/17/2015 09:46:41,false,neodev,1.0,21515166,NLD,11,Nieuwkoop,83.84.200.25,[SYMPTOM],[SYMPTOM],may occur with,n/a,19,40,32,31,58,RO-may_treat,820052-FS1,Hyperlipidemia and HYPERGLYCEMIA due to INSULIN RESISTANCE and nonalcoholic steatohepatitis may occur with lipodystrophy.,HYPERGLYCEMIA,INSULIN RESISTANCE
790085239,9/17/2015 09:53:44,1740371712,9/17/2015 09:53:30,false,elite,1.0,30659677,USA,"","",162.252.172.126,[CAUSES],[CAUSES],due to,N/A,19,40,32,31,58,RO-may_treat,820052-FS1,Hyperlipidemia and HYPERGLYCEMIA due to INSULIN RESISTANCE and nonalcoholic steatohepatitis may occur with lipodystrophy.,HYPERGLYCEMIA,INSULIN RESISTANCE
790085239,9/17/2015 10:14:01,1740376742,9/17/2015 10:12:42,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[SYMPTOM],[SYMPTOM],HYPERGLYCEMIA due to INSULIN RESISTANCE,N/A,19,40,32,31,58,RO-may_treat,820052-FS1,Hyperlipidemia and HYPERGLYCEMIA due to INSULIN RESISTANCE and nonalcoholic steatohepatitis may occur with lipodystrophy.,HYPERGLYCEMIA,INSULIN RESISTANCE
790085239,9/17/2015 10:32:01,1740380206,9/17/2015 10:31:46,false,pocketmoneygpt,1.0,28884030,USA,WI,Minocqua,75.143.134.247,[SYMPTOM],[SYMPTOM],occur,n/a,19,40,32,31,58,RO-may_treat,820052-FS1,Hyperlipidemia and HYPERGLYCEMIA due to INSULIN RESISTANCE and nonalcoholic steatohepatitis may occur with lipodystrophy.,HYPERGLYCEMIA,INSULIN RESISTANCE
790085239,9/17/2015 10:43:05,1740382514,9/17/2015 10:42:13,false,clixsense,1.0,17950689,GBR,L9,Sheffield,146.200.192.103,[TREATS],[TREATS],HYPERGLYCEMIA,NONE,19,40,32,31,58,RO-may_treat,820052-FS1,Hyperlipidemia and HYPERGLYCEMIA due to INSULIN RESISTANCE and nonalcoholic steatohepatitis may occur with lipodystrophy.,HYPERGLYCEMIA,INSULIN RESISTANCE
790085239,9/17/2015 10:56:01,1740384810,9/17/2015 10:54:57,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[CAUSES] [SIDE_EFFECT],"[CAUSES]
[SIDE_EFFECT]",due to,N/A,19,40,32,31,58,RO-may_treat,820052-FS1,Hyperlipidemia and HYPERGLYCEMIA due to INSULIN RESISTANCE and nonalcoholic steatohepatitis may occur with lipodystrophy.,HYPERGLYCEMIA,INSULIN RESISTANCE
790085239,9/17/2015 11:01:39,1740385868,9/17/2015 11:01:25,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[CAUSES],[CAUSES],due to,N/A,19,40,32,31,58,RO-may_treat,820052-FS1,Hyperlipidemia and HYPERGLYCEMIA due to INSULIN RESISTANCE and nonalcoholic steatohepatitis may occur with lipodystrophy.,HYPERGLYCEMIA,INSULIN RESISTANCE
790085240,9/17/2015 09:14:00,1740362737,9/17/2015 09:13:40,false,neodev,1.0,32053642,GBR,I7,Newcastle Upon Tyne,92.23.136.205,[TREATS],[TREATS],reduction in,N/A,145,65,151,150,84,RO-may_prevent,820175-FS1,"Both verapamil and propranolol caused a significant reduction in GLYCERYL TRINITRATE tablet consumption, days with angina pectoris and in severe ANGINA attacks compared to placebo.",ANGINA,GLYCERYL TRINITRATE
790085240,9/17/2015 09:15:42,1740363096,9/17/2015 09:15:29,false,elite,1.0,30659754,USA,"","",162.250.145.204,[CAUSES],[CAUSES],caused,N/A,145,65,151,150,84,RO-may_prevent,820175-FS1,"Both verapamil and propranolol caused a significant reduction in GLYCERYL TRINITRATE tablet consumption, days with angina pectoris and in severe ANGINA attacks compared to placebo.",ANGINA,GLYCERYL TRINITRATE
790085240,9/17/2015 09:21:22,1740364307,9/17/2015 09:21:01,false,instagc,1.0,18960682,GBR,U2,Annan,92.18.213.181,[TREATS],[TREATS],"GLYCERYL TRINITRATE tablet consumption,",N/A,145,65,151,150,84,RO-may_prevent,820175-FS1,"Both verapamil and propranolol caused a significant reduction in GLYCERYL TRINITRATE tablet consumption, days with angina pectoris and in severe ANGINA attacks compared to placebo.",ANGINA,GLYCERYL TRINITRATE
790085240,9/17/2015 09:22:37,1740364528,9/17/2015 09:22:12,false,neodev,1.0,33644825,USA,FL,Fort Lauderdale,65.111.173.161,[PREVENTS],[PREVENTS],GLYCERYL TRINITRATE ANGINA,prevents,145,65,151,150,84,RO-may_prevent,820175-FS1,"Both verapamil and propranolol caused a significant reduction in GLYCERYL TRINITRATE tablet consumption, days with angina pectoris and in severe ANGINA attacks compared to placebo.",ANGINA,GLYCERYL TRINITRATE
790085240,9/17/2015 09:23:03,1740364625,9/17/2015 09:22:26,false,neodev,1.0,15848372,AUS,02,Jannali,14.200.59.55,[PART_OF],[PART_OF],and,n/a,145,65,151,150,84,RO-may_prevent,820175-FS1,"Both verapamil and propranolol caused a significant reduction in GLYCERYL TRINITRATE tablet consumption, days with angina pectoris and in severe ANGINA attacks compared to placebo.",ANGINA,GLYCERYL TRINITRATE
790085240,9/17/2015 09:26:54,1740365323,9/17/2015 09:25:37,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[OTHER],[OTHER],Both verapamil and propranolol caused a significant reduction in,N/A,145,65,151,150,84,RO-may_prevent,820175-FS1,"Both verapamil and propranolol caused a significant reduction in GLYCERYL TRINITRATE tablet consumption, days with angina pectoris and in severe ANGINA attacks compared to placebo.",ANGINA,GLYCERYL TRINITRATE
790085240,9/17/2015 09:34:06,1740367095,9/17/2015 09:33:51,false,elite,1.0,30659615,USA,"","",162.250.145.234,[PREVENTS],[PREVENTS],reduction,N/A,145,65,151,150,84,RO-may_prevent,820175-FS1,"Both verapamil and propranolol caused a significant reduction in GLYCERYL TRINITRATE tablet consumption, days with angina pectoris and in severe ANGINA attacks compared to placebo.",ANGINA,GLYCERYL TRINITRATE
790085240,9/17/2015 09:34:37,1740367167,9/17/2015 09:33:41,false,pocketmoneygpt,1.0,21432964,GBR,F8,Borehamwood,81.159.185.70,[TREATS],[TREATS],"tablet consumption,",N/A,145,65,151,150,84,RO-may_prevent,820175-FS1,"Both verapamil and propranolol caused a significant reduction in GLYCERYL TRINITRATE tablet consumption, days with angina pectoris and in severe ANGINA attacks compared to placebo.",ANGINA,GLYCERYL TRINITRATE
790085240,9/17/2015 09:38:27,1740368073,9/17/2015 09:38:03,false,neodev,1.0,21515166,NLD,11,Nieuwkoop,83.84.200.25,[CAUSES],[CAUSES],caused,n/a,145,65,151,150,84,RO-may_prevent,820175-FS1,"Both verapamil and propranolol caused a significant reduction in GLYCERYL TRINITRATE tablet consumption, days with angina pectoris and in severe ANGINA attacks compared to placebo.",ANGINA,GLYCERYL TRINITRATE
790085240,9/17/2015 09:49:46,1740370716,9/17/2015 09:49:28,false,elite,1.0,30659677,USA,"","",162.252.172.126,[CAUSES],[CAUSES],caused,N/A,145,65,151,150,84,RO-may_prevent,820175-FS1,"Both verapamil and propranolol caused a significant reduction in GLYCERYL TRINITRATE tablet consumption, days with angina pectoris and in severe ANGINA attacks compared to placebo.",ANGINA,GLYCERYL TRINITRATE
790085240,9/17/2015 09:55:13,1740372026,9/17/2015 09:53:05,false,neodev,1.0,34081836,USA,CA,San Jose,23.27.248.146,[CAUSES] [MANIFESTATION],"[CAUSES]
[MANIFESTATION]",caused a significant reduction in GLYCERYL TRINITRATE days with angina pectoris,N/A,145,65,151,150,84,RO-may_prevent,820175-FS1,"Both verapamil and propranolol caused a significant reduction in GLYCERYL TRINITRATE tablet consumption, days with angina pectoris and in severe ANGINA attacks compared to placebo.",ANGINA,GLYCERYL TRINITRATE
790085240,9/17/2015 09:57:51,1740372644,9/17/2015 09:56:26,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[TREATS],[TREATS],significant reduction,N/A,145,65,151,150,84,RO-may_prevent,820175-FS1,"Both verapamil and propranolol caused a significant reduction in GLYCERYL TRINITRATE tablet consumption, days with angina pectoris and in severe ANGINA attacks compared to placebo.",ANGINA,GLYCERYL TRINITRATE
790085240,9/17/2015 10:26:34,1740379174,9/17/2015 10:26:14,false,pocketmoneygpt,1.0,28884030,USA,WI,Minocqua,75.143.134.247,[PREVENTS],[PREVENTS],in,n/a,145,65,151,150,84,RO-may_prevent,820175-FS1,"Both verapamil and propranolol caused a significant reduction in GLYCERYL TRINITRATE tablet consumption, days with angina pectoris and in severe ANGINA attacks compared to placebo.",ANGINA,GLYCERYL TRINITRATE
790085240,9/17/2015 10:32:18,1740380287,9/17/2015 10:31:02,false,clixsense,1.0,17950689,GBR,L9,Sheffield,146.200.192.103,[TREATS],[TREATS],ANGINA,NONE,145,65,151,150,84,RO-may_prevent,820175-FS1,"Both verapamil and propranolol caused a significant reduction in GLYCERYL TRINITRATE tablet consumption, days with angina pectoris and in severe ANGINA attacks compared to placebo.",ANGINA,GLYCERYL TRINITRATE
790085240,9/17/2015 10:52:06,1740384119,9/17/2015 10:49:34,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[OTHER],[OTHER],reduction in and in,N/A,145,65,151,150,84,RO-may_prevent,820175-FS1,"Both verapamil and propranolol caused a significant reduction in GLYCERYL TRINITRATE tablet consumption, days with angina pectoris and in severe ANGINA attacks compared to placebo.",ANGINA,GLYCERYL TRINITRATE
790085241,9/17/2015 09:10:39,1740361868,9/17/2015 09:10:15,false,neodev,1.0,32053642,GBR,I7,Newcastle Upon Tyne,92.23.136.205,[TREATS],[TREATS],induced by,N/A,44,118,71,70,130,RO-may_prevent,820374-FS1,We report a 76 year old woman who developed TDP VENTRICULAR TACHYCARDIA induced by combined use of clarithromycin and DISOPYRAMIDE,TDP VENTRICULAR TACHYCARDIA,DISOPYRAMIDE
790085241,9/17/2015 09:13:44,1740362627,9/17/2015 09:13:27,false,elite,1.0,30659754,USA,"","",162.250.145.204,[ASSOCIATED_WITH],[ASSOCIATED_WITH],combined,N/A,44,118,71,70,130,RO-may_prevent,820374-FS1,We report a 76 year old woman who developed TDP VENTRICULAR TACHYCARDIA induced by combined use of clarithromycin and DISOPYRAMIDE,TDP VENTRICULAR TACHYCARDIA,DISOPYRAMIDE
790085241,9/17/2015 09:15:06,1740362972,9/17/2015 09:13:36,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[CAUSES],[CAUSES],induced,N/A,44,118,71,70,130,RO-may_prevent,820374-FS1,We report a 76 year old woman who developed TDP VENTRICULAR TACHYCARDIA induced by combined use of clarithromycin and DISOPYRAMIDE,TDP VENTRICULAR TACHYCARDIA,DISOPYRAMIDE
790085241,9/17/2015 09:18:20,1740363663,9/17/2015 09:18:02,false,instagc,1.0,18960682,GBR,U2,Annan,92.18.213.181,[CAUSES],[CAUSES],induced by,N/A,44,118,71,70,130,RO-may_prevent,820374-FS1,We report a 76 year old woman who developed TDP VENTRICULAR TACHYCARDIA induced by combined use of clarithromycin and DISOPYRAMIDE,TDP VENTRICULAR TACHYCARDIA,DISOPYRAMIDE
790085241,9/17/2015 09:19:03,1740363779,9/17/2015 09:18:05,false,neodev,1.0,33644825,USA,FL,Fort Lauderdale,65.111.173.161,[PREVENTS],[PREVENTS],TDP VENTRICULAR TACHYCARDIA DISOPYRAMIDE,treats,44,118,71,70,130,RO-may_prevent,820374-FS1,We report a 76 year old woman who developed TDP VENTRICULAR TACHYCARDIA induced by combined use of clarithromycin and DISOPYRAMIDE,TDP VENTRICULAR TACHYCARDIA,DISOPYRAMIDE
790085241,9/17/2015 09:19:34,1740363910,9/17/2015 09:18:37,false,neodev,1.0,15848372,AUS,02,Jannali,14.200.59.55,[CAUSES],[CAUSES],induced by combined use,n/a,44,118,71,70,130,RO-may_prevent,820374-FS1,We report a 76 year old woman who developed TDP VENTRICULAR TACHYCARDIA induced by combined use of clarithromycin and DISOPYRAMIDE,TDP VENTRICULAR TACHYCARDIA,DISOPYRAMIDE
790085241,9/17/2015 09:21:13,1740364299,9/17/2015 09:20:08,false,neodev,1.0,30627835,GBR,D8,Bishop Auckland,217.44.84.223,[MANIFESTATION],[MANIFESTATION],induced by use of,N/A,44,118,71,70,130,RO-may_prevent,820374-FS1,We report a 76 year old woman who developed TDP VENTRICULAR TACHYCARDIA induced by combined use of clarithromycin and DISOPYRAMIDE,TDP VENTRICULAR TACHYCARDIA,DISOPYRAMIDE
790085241,9/17/2015 09:28:05,1740365654,9/17/2015 09:26:29,false,pocketmoneygpt,1.0,21432964,GBR,F8,Borehamwood,81.159.185.70,[ASSOCIATED_WITH],[ASSOCIATED_WITH],induced by combined use,N/A,44,118,71,70,130,RO-may_prevent,820374-FS1,We report a 76 year old woman who developed TDP VENTRICULAR TACHYCARDIA induced by combined use of clarithromycin and DISOPYRAMIDE,TDP VENTRICULAR TACHYCARDIA,DISOPYRAMIDE
790085241,9/17/2015 09:28:06,1740365655,9/17/2015 09:27:53,false,elite,1.0,30659615,USA,"","",162.250.145.234,[CAUSES],[CAUSES],developed,N/A,44,118,71,70,130,RO-may_prevent,820374-FS1,We report a 76 year old woman who developed TDP VENTRICULAR TACHYCARDIA induced by combined use of clarithromycin and DISOPYRAMIDE,TDP VENTRICULAR TACHYCARDIA,DISOPYRAMIDE
790085241,9/17/2015 09:34:47,1740367241,9/17/2015 09:34:15,false,neodev,1.0,21515166,NLD,11,Nieuwkoop,83.84.200.25,[SYMPTOM],[SYMPTOM],developed by combined use,n/a,44,118,71,70,130,RO-may_prevent,820374-FS1,We report a 76 year old woman who developed TDP VENTRICULAR TACHYCARDIA induced by combined use of clarithromycin and DISOPYRAMIDE,TDP VENTRICULAR TACHYCARDIA,DISOPYRAMIDE
790085241,9/17/2015 09:46:44,1740370024,9/17/2015 09:46:08,false,neodev,1.0,34081836,USA,CA,San Jose,23.27.248.146,[CAUSES] [DIAGNOSE_BY_TEST_OR_DRUG],"[DIAGNOSE_BY_TEST_OR_DRUG]
[CAUSES]",TDP VENTRICULAR TACHYCARDIA induced by combined of clarithromycin,N/A,44,118,71,70,130,RO-may_prevent,820374-FS1,We report a 76 year old woman who developed TDP VENTRICULAR TACHYCARDIA induced by combined use of clarithromycin and DISOPYRAMIDE,TDP VENTRICULAR TACHYCARDIA,DISOPYRAMIDE
790085241,9/17/2015 09:47:39,1740370199,9/17/2015 09:47:25,false,elite,1.0,30659677,USA,"","",162.252.172.126,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],combined use,N/A,44,118,71,70,130,RO-may_prevent,820374-FS1,We report a 76 year old woman who developed TDP VENTRICULAR TACHYCARDIA induced by combined use of clarithromycin and DISOPYRAMIDE,TDP VENTRICULAR TACHYCARDIA,DISOPYRAMIDE
790085241,9/17/2015 09:51:17,1740371095,9/17/2015 09:50:40,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[CAUSES],[CAUSES],who developed TDP VENTRICULAR TACHYCARDIA induced by combined use of clarithromycin and DISOPYRAMIDE,N/A,44,118,71,70,130,RO-may_prevent,820374-FS1,We report a 76 year old woman who developed TDP VENTRICULAR TACHYCARDIA induced by combined use of clarithromycin and DISOPYRAMIDE,TDP VENTRICULAR TACHYCARDIA,DISOPYRAMIDE
790085241,9/17/2015 10:23:35,1740378502,9/17/2015 10:23:12,false,clixsense,1.0,31482589,NLD,11,Gouda,77.167.232.121,[CAUSES],[CAUSES],induced,n/a,44,118,71,70,130,RO-may_prevent,820374-FS1,We report a 76 year old woman who developed TDP VENTRICULAR TACHYCARDIA induced by combined use of clarithromycin and DISOPYRAMIDE,TDP VENTRICULAR TACHYCARDIA,DISOPYRAMIDE
790085241,9/17/2015 10:23:36,1740378511,9/17/2015 10:23:14,false,pocketmoneygpt,1.0,28884030,USA,WI,Minocqua,75.143.134.247,[CAUSES],[CAUSES],induced,n/a,44,118,71,70,130,RO-may_prevent,820374-FS1,We report a 76 year old woman who developed TDP VENTRICULAR TACHYCARDIA induced by combined use of clarithromycin and DISOPYRAMIDE,TDP VENTRICULAR TACHYCARDIA,DISOPYRAMIDE
790085242,9/17/2015 12:48:23,1740408589,9/17/2015 12:47:55,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,[CAUSES],[CAUSES],METOPROLOL leads to VENTRICULAR TACHYCARDIA,na,124,51,147,146,61,RO-may_treat,820132-FS1,"The patient took in 120 mgs prajmaline and 600 mgs METOPROLOL during the day of the case, which leads to cardiogenic shock, VENTRICULAR TACHYCARDIA and ventricular fibrillation.",VENTRICULAR TACHYCARDIA,METOPROLOL
790085242,9/17/2015 12:52:17,1740409571,9/17/2015 12:51:58,false,prodege,1.0,2145087,USA,NY,New York,107.107.57.52,[CAUSES],[CAUSES],which leads to,N/A,124,51,147,146,61,RO-may_treat,820132-FS1,"The patient took in 120 mgs prajmaline and 600 mgs METOPROLOL during the day of the case, which leads to cardiogenic shock, VENTRICULAR TACHYCARDIA and ventricular fibrillation.",VENTRICULAR TACHYCARDIA,METOPROLOL
790085242,9/17/2015 13:19:35,1740417233,9/17/2015 13:19:21,false,neodev,1.0,33228343,USA,"","",38.95.108.251,[PREVENTS] [TREATS] [ASSOCIATED_WITH] [SIDE_EFFECT] [OTHER] [NONE],"[TREATS]
[PREVENTS]
[ASSOCIATED_WITH]
[SIDE_EFFECT]
[OTHER]
[NONE]","The patient took in 120 mgs prajmaline and 600 mgs METOPROLOL during the day of the case, which leads to cardiogenic shock, VENTRICULAR TACHYCARDIA and ventricular fibrillation.","The patient took in 120 mgs prajmaline and 600 mgs METOPROLOL during the day of the case, which leads to cardiogenic shock, VENTRICULAR TACHYCARDIA and ventricular fibrillation.",124,51,147,146,61,RO-may_treat,820132-FS1,"The patient took in 120 mgs prajmaline and 600 mgs METOPROLOL during the day of the case, which leads to cardiogenic shock, VENTRICULAR TACHYCARDIA and ventricular fibrillation.",VENTRICULAR TACHYCARDIA,METOPROLOL
790085242,9/17/2015 13:20:26,1740417624,9/17/2015 13:20:04,false,elite,1.0,31883685,GBR,"","",79.66.244.188,[CAUSES],[CAUSES],leads to,n/a,124,51,147,146,61,RO-may_treat,820132-FS1,"The patient took in 120 mgs prajmaline and 600 mgs METOPROLOL during the day of the case, which leads to cardiogenic shock, VENTRICULAR TACHYCARDIA and ventricular fibrillation.",VENTRICULAR TACHYCARDIA,METOPROLOL
790085242,9/17/2015 13:21:34,1740417976,9/17/2015 13:21:16,false,prodege,1.0,33854929,USA,CT,Wallingford,24.2.218.232,[TREATS],[TREATS],took,n/a,124,51,147,146,61,RO-may_treat,820132-FS1,"The patient took in 120 mgs prajmaline and 600 mgs METOPROLOL during the day of the case, which leads to cardiogenic shock, VENTRICULAR TACHYCARDIA and ventricular fibrillation.",VENTRICULAR TACHYCARDIA,METOPROLOL
790085242,9/17/2015 13:27:56,1740419836,9/17/2015 13:27:37,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,[TREATS],[TREATS],took,n/a,124,51,147,146,61,RO-may_treat,820132-FS1,"The patient took in 120 mgs prajmaline and 600 mgs METOPROLOL during the day of the case, which leads to cardiogenic shock, VENTRICULAR TACHYCARDIA and ventricular fibrillation.",VENTRICULAR TACHYCARDIA,METOPROLOL
790085242,9/17/2015 13:29:01,1740420150,9/17/2015 13:28:25,false,neodev,1.0,12115558,USA,OH,Twinsburg,98.27.164.131,[SIDE_EFFECT],[SIDE_EFFECT],"took METOPROLOL which leads cardiogenic shock, VENTRICULAR TACHYCARDIA",N/A,124,51,147,146,61,RO-may_treat,820132-FS1,"The patient took in 120 mgs prajmaline and 600 mgs METOPROLOL during the day of the case, which leads to cardiogenic shock, VENTRICULAR TACHYCARDIA and ventricular fibrillation.",VENTRICULAR TACHYCARDIA,METOPROLOL
790085242,9/17/2015 13:30:20,1740420569,9/17/2015 13:29:54,false,prodege,1.0,27934334,GBR,C8,Croydon,81.159.60.206,[CAUSES],[CAUSES],leads to,N/A,124,51,147,146,61,RO-may_treat,820132-FS1,"The patient took in 120 mgs prajmaline and 600 mgs METOPROLOL during the day of the case, which leads to cardiogenic shock, VENTRICULAR TACHYCARDIA and ventricular fibrillation.",VENTRICULAR TACHYCARDIA,METOPROLOL
790085242,9/17/2015 13:58:11,1740431625,9/17/2015 13:55:22,false,neodev,1.0,31329809,USA,DE,Wilmington,162.223.93.194,[PART_OF],[PART_OF],of,N/A,124,51,147,146,61,RO-may_treat,820132-FS1,"The patient took in 120 mgs prajmaline and 600 mgs METOPROLOL during the day of the case, which leads to cardiogenic shock, VENTRICULAR TACHYCARDIA and ventricular fibrillation.",VENTRICULAR TACHYCARDIA,METOPROLOL
790085242,9/17/2015 14:03:13,1740433436,9/17/2015 14:02:42,false,gifthunterclub,1.0,30901412,GBR,H9,London,77.89.149.62,[SIDE_EFFECT],[SIDE_EFFECT],"METOPROLOL leads to cardiogenic shock, VENTRICULAR TACHYCARDIA",N/A,124,51,147,146,61,RO-may_treat,820132-FS1,"The patient took in 120 mgs prajmaline and 600 mgs METOPROLOL during the day of the case, which leads to cardiogenic shock, VENTRICULAR TACHYCARDIA and ventricular fibrillation.",VENTRICULAR TACHYCARDIA,METOPROLOL
790085242,9/17/2015 14:06:31,1740434719,9/17/2015 14:05:16,false,zoombucks,1.0,6744840,CAN,BC,Kelowna,174.4.58.160,[CAUSES],[CAUSES],which leads to,N/A,124,51,147,146,61,RO-may_treat,820132-FS1,"The patient took in 120 mgs prajmaline and 600 mgs METOPROLOL during the day of the case, which leads to cardiogenic shock, VENTRICULAR TACHYCARDIA and ventricular fibrillation.",VENTRICULAR TACHYCARDIA,METOPROLOL
790085242,9/17/2015 14:08:37,1740435514,9/17/2015 14:06:02,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.124.79,[CAUSES],[CAUSES],leads to,N/A,124,51,147,146,61,RO-may_treat,820132-FS1,"The patient took in 120 mgs prajmaline and 600 mgs METOPROLOL during the day of the case, which leads to cardiogenic shock, VENTRICULAR TACHYCARDIA and ventricular fibrillation.",VENTRICULAR TACHYCARDIA,METOPROLOL
790085242,9/17/2015 14:14:08,1740437496,9/17/2015 14:13:08,false,elite,1.0,33238902,NLD,06,Budel,77.248.148.5,[CAUSES],[CAUSES],"600 mgs METOPROLOL leads to cardiogenic shock, VENTRICULAR TACHYCARDIA",n/a,124,51,147,146,61,RO-may_treat,820132-FS1,"The patient took in 120 mgs prajmaline and 600 mgs METOPROLOL during the day of the case, which leads to cardiogenic shock, VENTRICULAR TACHYCARDIA and ventricular fibrillation.",VENTRICULAR TACHYCARDIA,METOPROLOL
790085242,9/17/2015 14:27:28,1740442141,9/17/2015 14:25:14,false,prodege,1.0,34497719,GBR,N5,Haverhill,151.230.78.163,[CAUSES],[CAUSES],leads to,n/a,124,51,147,146,61,RO-may_treat,820132-FS1,"The patient took in 120 mgs prajmaline and 600 mgs METOPROLOL during the day of the case, which leads to cardiogenic shock, VENTRICULAR TACHYCARDIA and ventricular fibrillation.",VENTRICULAR TACHYCARDIA,METOPROLOL
790085242,9/17/2015 14:28:26,1740442585,9/17/2015 14:26:10,false,instagc,1.0,22981457,CAN,ON,Ottawa,67.69.8.122,[CAUSES] [DIAGNOSE_BY_TEST_OR_DRUG],"[DIAGNOSE_BY_TEST_OR_DRUG]
[CAUSES]",leads to,N/A,124,51,147,146,61,RO-may_treat,820132-FS1,"The patient took in 120 mgs prajmaline and 600 mgs METOPROLOL during the day of the case, which leads to cardiogenic shock, VENTRICULAR TACHYCARDIA and ventricular fibrillation.",VENTRICULAR TACHYCARDIA,METOPROLOL
790085243,9/17/2015 13:34:49,1740422033,9/17/2015 13:34:31,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],screening test,n/a,107,60,126,124,74,RO-may_treat,820055-FS1,"• Do not use response to an aldosterone antagonist, such as SPIRONOLACTONE as a screening test for primary HYPERALDOSTERONISM",HYPERALDOSTERONISM,SPIRONOLACTONE
790085243,9/17/2015 14:11:01,1740436346,9/17/2015 14:10:32,false,gifthunterclub,1.0,30901412,GBR,H9,London,77.89.149.62,[CONTRAINDICATES],[CONTRAINDICATES],Do not use SPIRONOLACTONE screening test for primary HYPERALDOSTERONISM,N/A,107,60,126,124,74,RO-may_treat,820055-FS1,"• Do not use response to an aldosterone antagonist, such as SPIRONOLACTONE as a screening test for primary HYPERALDOSTERONISM",HYPERALDOSTERONISM,SPIRONOLACTONE
790085243,9/17/2015 14:17:55,1740439004,9/17/2015 14:17:38,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.124.79,[CONTRAINDICATES],[CONTRAINDICATES],Do not use,N/A,107,60,126,124,74,RO-may_treat,820055-FS1,"• Do not use response to an aldosterone antagonist, such as SPIRONOLACTONE as a screening test for primary HYPERALDOSTERONISM",HYPERALDOSTERONISM,SPIRONOLACTONE
790085243,9/17/2015 14:28:58,1740442731,9/17/2015 14:27:10,false,zoombucks,1.0,6744840,CAN,BC,Kelowna,174.4.58.160,[TREATS],[TREATS],response to,N/A,107,60,126,124,74,RO-may_treat,820055-FS1,"• Do not use response to an aldosterone antagonist, such as SPIRONOLACTONE as a screening test for primary HYPERALDOSTERONISM",HYPERALDOSTERONISM,SPIRONOLACTONE
790085243,9/17/2015 14:35:23,1740445241,9/17/2015 14:35:06,false,bitcoinget,1.0,32306192,USA,MA,Amherst,72.19.88.245,[TREATS],[TREATS],SPIRONOLACTONE,N/a,107,60,126,124,74,RO-may_treat,820055-FS1,"• Do not use response to an aldosterone antagonist, such as SPIRONOLACTONE as a screening test for primary HYPERALDOSTERONISM",HYPERALDOSTERONISM,SPIRONOLACTONE
790085243,9/17/2015 14:54:14,1740452821,9/17/2015 14:51:48,false,clixsense,1.0,32049531,USA,"","",38.95.108.252,[NONE],[NONE],none,none,107,60,126,124,74,RO-may_treat,820055-FS1,"• Do not use response to an aldosterone antagonist, such as SPIRONOLACTONE as a screening test for primary HYPERALDOSTERONISM",HYPERALDOSTERONISM,SPIRONOLACTONE
790085243,9/17/2015 14:56:20,1740453496,9/17/2015 14:55:16,false,instagc,1.0,22981457,CAN,ON,Ottawa,67.69.8.122,[NONE],[NONE],N/A,It just say not to use one as a screening test for the other,107,60,126,124,74,RO-may_treat,820055-FS1,"• Do not use response to an aldosterone antagonist, such as SPIRONOLACTONE as a screening test for primary HYPERALDOSTERONISM",HYPERALDOSTERONISM,SPIRONOLACTONE
790085243,9/17/2015 15:04:01,1740456513,9/17/2015 15:03:45,false,neodev,1.0,31329809,USA,DE,Wilmington,162.223.93.194,[IS_A],[IS_A],an a,N/A,107,60,126,124,74,RO-may_treat,820055-FS1,"• Do not use response to an aldosterone antagonist, such as SPIRONOLACTONE as a screening test for primary HYPERALDOSTERONISM",HYPERALDOSTERONISM,SPIRONOLACTONE
790085243,9/17/2015 15:05:48,1740457106,9/17/2015 15:05:20,false,clixsense,1.0,33115750,GBR,I3,Rochester,90.222.106.192,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],screening test for,N/A,107,60,126,124,74,RO-may_treat,820055-FS1,"• Do not use response to an aldosterone antagonist, such as SPIRONOLACTONE as a screening test for primary HYPERALDOSTERONISM",HYPERALDOSTERONISM,SPIRONOLACTONE
790085243,9/17/2015 15:13:30,1740459315,9/17/2015 15:13:15,false,neodev,1.0,34431172,USA,CA,Torrance,66.171.228.183,[CAUSES] [LOCATION] [NONE],"[CAUSES]
[LOCATION]
[NONE]",no,no,107,60,126,124,74,RO-may_treat,820055-FS1,"• Do not use response to an aldosterone antagonist, such as SPIRONOLACTONE as a screening test for primary HYPERALDOSTERONISM",HYPERALDOSTERONISM,SPIRONOLACTONE
790085243,9/17/2015 15:15:06,1740459881,9/17/2015 15:14:52,false,neodev,1.0,30321275,USA,NV,Las Vegas,192.30.80.4,[IS_A],[IS_A],an,N/A,107,60,126,124,74,RO-may_treat,820055-FS1,"• Do not use response to an aldosterone antagonist, such as SPIRONOLACTONE as a screening test for primary HYPERALDOSTERONISM",HYPERALDOSTERONISM,SPIRONOLACTONE
790085243,9/17/2015 15:21:06,1740462293,9/17/2015 15:20:51,false,neodev,1.0,29363385,USA,DE,Wilmington,162.223.93.162,[IS_A],[IS_A],an a,N/A,107,60,126,124,74,RO-may_treat,820055-FS1,"• Do not use response to an aldosterone antagonist, such as SPIRONOLACTONE as a screening test for primary HYPERALDOSTERONISM",HYPERALDOSTERONISM,SPIRONOLACTONE
790085243,9/17/2015 15:25:21,1740463695,9/17/2015 15:24:51,false,neodev,1.0,12115558,USA,OH,Twinsburg,98.27.164.131,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],screening test for primary HYPERALDOSTERONISM,N/A,107,60,126,124,74,RO-may_treat,820055-FS1,"• Do not use response to an aldosterone antagonist, such as SPIRONOLACTONE as a screening test for primary HYPERALDOSTERONISM",HYPERALDOSTERONISM,SPIRONOLACTONE
790085243,9/17/2015 15:27:23,1740464482,9/17/2015 15:27:11,false,neodev,1.0,33435788,USA,DE,Wilmington,162.223.93.179,[IS_A],[IS_A],an,N/A,107,60,126,124,74,RO-may_treat,820055-FS1,"• Do not use response to an aldosterone antagonist, such as SPIRONOLACTONE as a screening test for primary HYPERALDOSTERONISM",HYPERALDOSTERONISM,SPIRONOLACTONE
790085243,9/17/2015 15:28:29,1740464863,9/17/2015 15:27:45,false,clixsense,1.0,6340330,USA,NY,Canajoharie,67.248.115.74,[TREATS],[TREATS],screening test,N/A,107,60,126,124,74,RO-may_treat,820055-FS1,"• Do not use response to an aldosterone antagonist, such as SPIRONOLACTONE as a screening test for primary HYPERALDOSTERONISM",HYPERALDOSTERONISM,SPIRONOLACTONE
790085244,9/17/2015 11:05:32,1740386601,9/17/2015 11:05:16,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[PREVENTS],[PREVENTS],coexisting,N/A,78,39,94,104,59,RO-may_prevent,820177-FS1,Among 4 Asian patients with coexisting ANTI HCV AND HBSAG 1 was found to have SERUM HEPATITIS B VIRAL DNA and the other 3 had hepatitis C viral RNA.,SERUM HEPATITIS B VIRAL DNA,ANTI HCV AND HBSAG 1
790085244,9/17/2015 11:16:47,1740388869,9/17/2015 11:14:49,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[PART_OF],[PART_OF],was found to have,N/A,78,39,94,104,59,RO-may_prevent,820177-FS1,Among 4 Asian patients with coexisting ANTI HCV AND HBSAG 1 was found to have SERUM HEPATITIS B VIRAL DNA and the other 3 had hepatitis C viral RNA.,SERUM HEPATITIS B VIRAL DNA,ANTI HCV AND HBSAG 1
790085244,9/17/2015 11:18:51,1740389293,9/17/2015 11:18:37,false,neodev,1.0,32695853,USA,NV,Las Vegas,192.30.80.172,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,N/A,78,39,94,104,59,RO-may_prevent,820177-FS1,Among 4 Asian patients with coexisting ANTI HCV AND HBSAG 1 was found to have SERUM HEPATITIS B VIRAL DNA and the other 3 had hepatitis C viral RNA.,SERUM HEPATITIS B VIRAL DNA,ANTI HCV AND HBSAG 1
790085244,9/17/2015 11:22:08,1740389762,9/17/2015 11:21:01,false,neodev,1.0,30581619,USA,CA,San Jose,50.118.162.56,[NONE],[NONE],good,good,78,39,94,104,59,RO-may_prevent,820177-FS1,Among 4 Asian patients with coexisting ANTI HCV AND HBSAG 1 was found to have SERUM HEPATITIS B VIRAL DNA and the other 3 had hepatitis C viral RNA.,SERUM HEPATITIS B VIRAL DNA,ANTI HCV AND HBSAG 1
790085244,9/17/2015 11:30:51,1740391366,9/17/2015 11:30:36,false,neodev,1.0,30941227,USA,NV,Las Vegas,192.30.80.166,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,N/A,78,39,94,104,59,RO-may_prevent,820177-FS1,Among 4 Asian patients with coexisting ANTI HCV AND HBSAG 1 was found to have SERUM HEPATITIS B VIRAL DNA and the other 3 had hepatitis C viral RNA.,SERUM HEPATITIS B VIRAL DNA,ANTI HCV AND HBSAG 1
790085244,9/17/2015 11:41:36,1740393423,9/17/2015 11:41:24,false,neodev,1.0,33701549,USA,CA,Torrance,66.171.228.66,[DIAGNOSE_BY_TEST_OR_DRUG] [PREVENTS] [ASSOCIATED_WITH] [IS_A] [NONE],"[PREVENTS]
[DIAGNOSE_BY_TEST_OR_DRUG]
[ASSOCIATED_WITH]
[IS_A]
[NONE]",[IS_A],N/A,78,39,94,104,59,RO-may_prevent,820177-FS1,Among 4 Asian patients with coexisting ANTI HCV AND HBSAG 1 was found to have SERUM HEPATITIS B VIRAL DNA and the other 3 had hepatitis C viral RNA.,SERUM HEPATITIS B VIRAL DNA,ANTI HCV AND HBSAG 1
790085244,9/17/2015 12:05:51,1740398250,9/17/2015 12:03:14,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[CAUSES],[CAUSES],coexisting,N/A,78,39,94,104,59,RO-may_prevent,820177-FS1,Among 4 Asian patients with coexisting ANTI HCV AND HBSAG 1 was found to have SERUM HEPATITIS B VIRAL DNA and the other 3 had hepatitis C viral RNA.,SERUM HEPATITIS B VIRAL DNA,ANTI HCV AND HBSAG 1
790085244,9/17/2015 12:28:44,1740403282,9/17/2015 12:28:23,false,neodev,1.0,30588889,NLD,07,Amsterdam,77.248.175.222,[MANIFESTATION],[MANIFESTATION],found to have,N/A,78,39,94,104,59,RO-may_prevent,820177-FS1,Among 4 Asian patients with coexisting ANTI HCV AND HBSAG 1 was found to have SERUM HEPATITIS B VIRAL DNA and the other 3 had hepatitis C viral RNA.,SERUM HEPATITIS B VIRAL DNA,ANTI HCV AND HBSAG 1
790085244,9/17/2015 12:37:46,1740405519,9/17/2015 12:37:20,false,prodege,1.0,2145087,USA,NY,New York,107.107.57.52,[ASSOCIATED_WITH],[ASSOCIATED_WITH],was found to have,N/A,78,39,94,104,59,RO-may_prevent,820177-FS1,Among 4 Asian patients with coexisting ANTI HCV AND HBSAG 1 was found to have SERUM HEPATITIS B VIRAL DNA and the other 3 had hepatitis C viral RNA.,SERUM HEPATITIS B VIRAL DNA,ANTI HCV AND HBSAG 1
790085244,9/17/2015 12:38:30,1740405687,9/17/2015 12:37:48,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,[SYMPTOM],[SYMPTOM],patients with ANTI HCV AND HBSAG 1 found to have SERUM HEPATITIS B VIRAL DNA,na,78,39,94,104,59,RO-may_prevent,820177-FS1,Among 4 Asian patients with coexisting ANTI HCV AND HBSAG 1 was found to have SERUM HEPATITIS B VIRAL DNA and the other 3 had hepatitis C viral RNA.,SERUM HEPATITIS B VIRAL DNA,ANTI HCV AND HBSAG 1
790085244,9/17/2015 12:42:32,1740406703,9/17/2015 12:41:58,false,instagc,1.0,22981457,CAN,ON,Welland,76.67.127.43,[ASSOCIATED_WITH],[ASSOCIATED_WITH],coexisting found to have,N/A,78,39,94,104,59,RO-may_prevent,820177-FS1,Among 4 Asian patients with coexisting ANTI HCV AND HBSAG 1 was found to have SERUM HEPATITIS B VIRAL DNA and the other 3 had hepatitis C viral RNA.,SERUM HEPATITIS B VIRAL DNA,ANTI HCV AND HBSAG 1
790085244,9/17/2015 12:53:08,1740409804,9/17/2015 12:50:37,false,neodev,1.0,34215189,GBR,I2,Manchester,82.8.21.5,[SIDE_EFFECT],[SIDE_EFFECT],Among 4 Asian patients with coexisting ANTI HCV AND HBSAG 1 was found to have SERUM HEPATITIS B VIRAL DNA and the other 3 had hepatitis C viral RNA.,N/A,78,39,94,104,59,RO-may_prevent,820177-FS1,Among 4 Asian patients with coexisting ANTI HCV AND HBSAG 1 was found to have SERUM HEPATITIS B VIRAL DNA and the other 3 had hepatitis C viral RNA.,SERUM HEPATITIS B VIRAL DNA,ANTI HCV AND HBSAG 1
790085244,9/17/2015 13:13:44,1740415546,9/17/2015 13:13:06,false,elite,1.0,31883685,GBR,"","",79.66.244.188,[NONE],[NONE],N/A,JUST different conditiosn,78,39,94,104,59,RO-may_prevent,820177-FS1,Among 4 Asian patients with coexisting ANTI HCV AND HBSAG 1 was found to have SERUM HEPATITIS B VIRAL DNA and the other 3 had hepatitis C viral RNA.,SERUM HEPATITIS B VIRAL DNA,ANTI HCV AND HBSAG 1
790085244,9/17/2015 13:13:48,1740415570,9/17/2015 13:13:24,false,prodege,1.0,33854929,USA,CT,Wallingford,24.2.218.232,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],found,n/a,78,39,94,104,59,RO-may_prevent,820177-FS1,Among 4 Asian patients with coexisting ANTI HCV AND HBSAG 1 was found to have SERUM HEPATITIS B VIRAL DNA and the other 3 had hepatitis C viral RNA.,SERUM HEPATITIS B VIRAL DNA,ANTI HCV AND HBSAG 1
790085244,9/17/2015 13:14:20,1740415731,9/17/2015 13:13:54,false,neodev,1.0,33228343,USA,"","",38.95.108.251,[TREATS] [DIAGNOSE_BY_TEST_OR_DRUG] [CAUSES] [LOCATION] [SYMPTOM] [CONTRAINDICATES] [ASSOCIATED_WITH] [PART_OF] [NONE],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]
[CAUSES]
[LOCATION]
[SYMPTOM]
[CONTRAINDICATES]
[ASSOCIATED_WITH]
[PART_OF]
[NONE]",Among 4 Asian patients with coexisting ANTI HCV AND HBSAG 1 was found to have SERUM HEPATITIS B VIRAL DNA and the other 3 had hepatitis C viral RNA.  Is  SERUM HEPATITIS B VIRAL DNA ----related-to----   ANTI HCV AND HBSAG 1?,"Among 4 Asian patients with coexisting ANTI HCV AND HBSAG 1 was found to have SERUM HEPATITIS B VIRAL DNA and the other 3 had hepatitis C viral RNA.

Is  SERUM HEPATITIS B VIRAL DNA ----related-to----   ANTI HCV AND HBSAG 1?",78,39,94,104,59,RO-may_prevent,820177-FS1,Among 4 Asian patients with coexisting ANTI HCV AND HBSAG 1 was found to have SERUM HEPATITIS B VIRAL DNA and the other 3 had hepatitis C viral RNA.,SERUM HEPATITIS B VIRAL DNA,ANTI HCV AND HBSAG 1
790085245,9/17/2015 11:03:40,1740386215,9/17/2015 11:03:23,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[ASSOCIATED_WITH],[ASSOCIATED_WITH],or,N/A,111,86,125,144,107,RO-may_treat,820012-FS1,133  Cautions  Contraindications  •  Known hypersensitivity to commercially available ANTIHEMOPHILIC FACTOR or VON WILLEBRAND FACTOR PREPARATIONS or any ingredient in the formulations.,VON WILLEBRAND FACTOR PREPARATIONS,ANTIHEMOPHILIC FACTOR
790085245,9/17/2015 11:09:34,1740387482,9/17/2015 11:08:58,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[OTHER],[OTHER],hypersensitivity to or,N/A,111,86,125,144,107,RO-may_treat,820012-FS1,133  Cautions  Contraindications  •  Known hypersensitivity to commercially available ANTIHEMOPHILIC FACTOR or VON WILLEBRAND FACTOR PREPARATIONS or any ingredient in the formulations.,VON WILLEBRAND FACTOR PREPARATIONS,ANTIHEMOPHILIC FACTOR
790085245,9/17/2015 11:16:16,1740388801,9/17/2015 11:15:50,false,neodev,1.0,30581619,USA,CA,San Jose,50.118.162.56,[NONE],[NONE],good,good,111,86,125,144,107,RO-may_treat,820012-FS1,133  Cautions  Contraindications  •  Known hypersensitivity to commercially available ANTIHEMOPHILIC FACTOR or VON WILLEBRAND FACTOR PREPARATIONS or any ingredient in the formulations.,VON WILLEBRAND FACTOR PREPARATIONS,ANTIHEMOPHILIC FACTOR
790085245,9/17/2015 11:17:09,1740388941,9/17/2015 11:16:54,false,neodev,1.0,32695853,USA,NV,Las Vegas,192.30.80.172,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],or or,N/A,111,86,125,144,107,RO-may_treat,820012-FS1,133  Cautions  Contraindications  •  Known hypersensitivity to commercially available ANTIHEMOPHILIC FACTOR or VON WILLEBRAND FACTOR PREPARATIONS or any ingredient in the formulations.,VON WILLEBRAND FACTOR PREPARATIONS,ANTIHEMOPHILIC FACTOR
790085245,9/17/2015 11:23:52,1740390006,9/17/2015 11:21:45,false,gifthulk,1.0,18666417,USA,PA,Meadville,24.101.32.13,[ASSOCIATED_WITH],[ASSOCIATED_WITH],ANTIHEMOPHILIC FACTOR or VON WILLEBRAND FACTOR PREPARATIONS or any ingredient in formulations.,n/a,111,86,125,144,107,RO-may_treat,820012-FS1,133  Cautions  Contraindications  •  Known hypersensitivity to commercially available ANTIHEMOPHILIC FACTOR or VON WILLEBRAND FACTOR PREPARATIONS or any ingredient in the formulations.,VON WILLEBRAND FACTOR PREPARATIONS,ANTIHEMOPHILIC FACTOR
790085245,9/17/2015 11:29:20,1740391079,9/17/2015 11:29:05,false,neodev,1.0,30941227,USA,NV,Las Vegas,192.30.80.166,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],or or,N/A,111,86,125,144,107,RO-may_treat,820012-FS1,133  Cautions  Contraindications  •  Known hypersensitivity to commercially available ANTIHEMOPHILIC FACTOR or VON WILLEBRAND FACTOR PREPARATIONS or any ingredient in the formulations.,VON WILLEBRAND FACTOR PREPARATIONS,ANTIHEMOPHILIC FACTOR
790085245,9/17/2015 11:40:10,1740393191,9/17/2015 11:40:00,false,neodev,1.0,33701549,USA,CA,Torrance,66.171.228.66,[NONE] [IS_A] [CONTRAINDICATES] [SYMPTOM] [OTHER],"[SYMPTOM]
[CONTRAINDICATES]
[IS_A]
[OTHER]
[NONE]",[IS_A],N/A,111,86,125,144,107,RO-may_treat,820012-FS1,133  Cautions  Contraindications  •  Known hypersensitivity to commercially available ANTIHEMOPHILIC FACTOR or VON WILLEBRAND FACTOR PREPARATIONS or any ingredient in the formulations.,VON WILLEBRAND FACTOR PREPARATIONS,ANTIHEMOPHILIC FACTOR
790085245,9/17/2015 12:00:41,1740397166,9/17/2015 11:59:26,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[ASSOCIATED_WITH],[ASSOCIATED_WITH],or,N/A,111,86,125,144,107,RO-may_treat,820012-FS1,133  Cautions  Contraindications  •  Known hypersensitivity to commercially available ANTIHEMOPHILIC FACTOR or VON WILLEBRAND FACTOR PREPARATIONS or any ingredient in the formulations.,VON WILLEBRAND FACTOR PREPARATIONS,ANTIHEMOPHILIC FACTOR
790085245,9/17/2015 12:03:38,1740397798,9/17/2015 12:02:15,false,prodege,1.0,14848125,GBR,V8,Airdrie,86.151.77.161,[OTHER] [CONTRAINDICATES],"[CONTRAINDICATES]
[OTHER]",hypersensitivity,no relationship stated,111,86,125,144,107,RO-may_treat,820012-FS1,133  Cautions  Contraindications  •  Known hypersensitivity to commercially available ANTIHEMOPHILIC FACTOR or VON WILLEBRAND FACTOR PREPARATIONS or any ingredient in the formulations.,VON WILLEBRAND FACTOR PREPARATIONS,ANTIHEMOPHILIC FACTOR
790085245,9/17/2015 12:24:12,1740402264,9/17/2015 12:23:39,false,neodev,1.0,30588889,NLD,07,Amsterdam,77.248.175.222,[ASSOCIATED_WITH],[ASSOCIATED_WITH],or,N/A,111,86,125,144,107,RO-may_treat,820012-FS1,133  Cautions  Contraindications  •  Known hypersensitivity to commercially available ANTIHEMOPHILIC FACTOR or VON WILLEBRAND FACTOR PREPARATIONS or any ingredient in the formulations.,VON WILLEBRAND FACTOR PREPARATIONS,ANTIHEMOPHILIC FACTOR
790085245,9/17/2015 12:35:04,1740404789,9/17/2015 12:34:38,false,prodege,1.0,2145087,USA,NY,New York,107.107.57.52,[ASSOCIATED_WITH],[ASSOCIATED_WITH],or,N/A,111,86,125,144,107,RO-may_treat,820012-FS1,133  Cautions  Contraindications  •  Known hypersensitivity to commercially available ANTIHEMOPHILIC FACTOR or VON WILLEBRAND FACTOR PREPARATIONS or any ingredient in the formulations.,VON WILLEBRAND FACTOR PREPARATIONS,ANTIHEMOPHILIC FACTOR
790085245,9/17/2015 12:35:53,1740405020,9/17/2015 12:35:30,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,[ASSOCIATED_WITH],[ASSOCIATED_WITH],ANTIHEMOPHILIC FACTOR or VON WILLEBRAND FACTOR PREPARATIONS,na,111,86,125,144,107,RO-may_treat,820012-FS1,133  Cautions  Contraindications  •  Known hypersensitivity to commercially available ANTIHEMOPHILIC FACTOR or VON WILLEBRAND FACTOR PREPARATIONS or any ingredient in the formulations.,VON WILLEBRAND FACTOR PREPARATIONS,ANTIHEMOPHILIC FACTOR
790085245,9/17/2015 12:38:12,1740405615,9/17/2015 12:36:46,false,instagc,1.0,22981457,CAN,ON,Welland,76.67.127.43,[CONTRAINDICATES],[CONTRAINDICATES],Contraindications,N/A,111,86,125,144,107,RO-may_treat,820012-FS1,133  Cautions  Contraindications  •  Known hypersensitivity to commercially available ANTIHEMOPHILIC FACTOR or VON WILLEBRAND FACTOR PREPARATIONS or any ingredient in the formulations.,VON WILLEBRAND FACTOR PREPARATIONS,ANTIHEMOPHILIC FACTOR
790085245,9/17/2015 12:41:35,1740406447,9/17/2015 12:41:19,false,neodev,1.0,34215189,GBR,I2,Manchester,82.8.21.5,[CONTRAINDICATES],[CONTRAINDICATES],133 Cautions Contraindications,N/A,111,86,125,144,107,RO-may_treat,820012-FS1,133  Cautions  Contraindications  •  Known hypersensitivity to commercially available ANTIHEMOPHILIC FACTOR or VON WILLEBRAND FACTOR PREPARATIONS or any ingredient in the formulations.,VON WILLEBRAND FACTOR PREPARATIONS,ANTIHEMOPHILIC FACTOR
790085245,9/17/2015 13:10:22,1740414568,9/17/2015 13:09:35,false,prodege,1.0,33854929,USA,CT,Wallingford,24.2.218.232,[OTHER],[OTHER],or,n/a,111,86,125,144,107,RO-may_treat,820012-FS1,133  Cautions  Contraindications  •  Known hypersensitivity to commercially available ANTIHEMOPHILIC FACTOR or VON WILLEBRAND FACTOR PREPARATIONS or any ingredient in the formulations.,VON WILLEBRAND FACTOR PREPARATIONS,ANTIHEMOPHILIC FACTOR
790085246,9/17/2015 11:24:17,1740390099,9/17/2015 11:23:51,false,neodev,1.0,32695853,USA,NV,Las Vegas,192.30.80.172,[SYMPTOM],[SYMPTOM],DIABETICS (IDDM (NIDDM.,N/A,16,70,41,40,101,RO-may_treat,820134-FS1,10 were insulin DEPENDENT DIABETICS (IDDM 24 insulin requiring and 66 NON INSULIN DEPENDENT DIABETICS (NIDDM.,DEPENDENT DIABETICS (IDDM),NON INSULIN DEPENDENT DIABETICS
790085246,9/17/2015 11:35:11,1740392080,9/17/2015 11:34:56,false,neodev,1.0,30941227,USA,NV,Las Vegas,192.30.80.166,[OTHER],[OTHER],(IDDM (NIDDM.,N/A,16,70,41,40,101,RO-may_treat,820134-FS1,10 were insulin DEPENDENT DIABETICS (IDDM 24 insulin requiring and 66 NON INSULIN DEPENDENT DIABETICS (NIDDM.,DEPENDENT DIABETICS (IDDM),NON INSULIN DEPENDENT DIABETICS
790085246,9/17/2015 11:40:59,1740393356,9/17/2015 11:39:45,false,neodev,1.0,30581619,USA,CA,San Jose,50.118.162.56,[NONE],[NONE],good,good,16,70,41,40,101,RO-may_treat,820134-FS1,10 were insulin DEPENDENT DIABETICS (IDDM 24 insulin requiring and 66 NON INSULIN DEPENDENT DIABETICS (NIDDM.,DEPENDENT DIABETICS (IDDM),NON INSULIN DEPENDENT DIABETICS
790085246,9/17/2015 12:10:04,1740399243,9/17/2015 12:09:42,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],requiring,N/A,16,70,41,40,101,RO-may_treat,820134-FS1,10 were insulin DEPENDENT DIABETICS (IDDM 24 insulin requiring and 66 NON INSULIN DEPENDENT DIABETICS (NIDDM.,DEPENDENT DIABETICS (IDDM),NON INSULIN DEPENDENT DIABETICS
790085246,9/17/2015 12:36:15,1740405112,9/17/2015 12:35:38,false,neodev,1.0,30588889,NLD,07,Amsterdam,77.248.175.222,[ASSOCIATED_WITH] [IS_A],"[ASSOCIATED_WITH]
[IS_A]",and,N/A,16,70,41,40,101,RO-may_treat,820134-FS1,10 were insulin DEPENDENT DIABETICS (IDDM 24 insulin requiring and 66 NON INSULIN DEPENDENT DIABETICS (NIDDM.,DEPENDENT DIABETICS (IDDM),NON INSULIN DEPENDENT DIABETICS
790085246,9/17/2015 12:44:32,1740407447,9/17/2015 12:44:10,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,[ASSOCIATED_WITH],[ASSOCIATED_WITH],insulin DEPENDENT DIABETICS and NON INSULIN DEPENDENT DIABETICS,na,16,70,41,40,101,RO-may_treat,820134-FS1,10 were insulin DEPENDENT DIABETICS (IDDM 24 insulin requiring and 66 NON INSULIN DEPENDENT DIABETICS (NIDDM.,DEPENDENT DIABETICS (IDDM),NON INSULIN DEPENDENT DIABETICS
790085246,9/17/2015 12:46:15,1740407943,9/17/2015 12:45:50,false,prodege,1.0,2145087,USA,NY,New York,107.107.57.52,[NONE],[NONE],N/A,Two separate groups,16,70,41,40,101,RO-may_treat,820134-FS1,10 were insulin DEPENDENT DIABETICS (IDDM 24 insulin requiring and 66 NON INSULIN DEPENDENT DIABETICS (NIDDM.,DEPENDENT DIABETICS (IDDM),NON INSULIN DEPENDENT DIABETICS
790085246,9/17/2015 13:17:23,1740416591,9/17/2015 13:17:11,false,neodev,1.0,33228343,USA,"","",38.95.108.251,[TREATS] [CAUSES] [LOCATION] [MANIFESTATION] [CONTRAINDICATES] [ASSOCIATED_WITH] [NONE],"[TREATS]
[CAUSES]
[LOCATION]
[MANIFESTATION]
[CONTRAINDICATES]
[ASSOCIATED_WITH]
[NONE]",10 were insulin DEPENDENT DIABETICS (IDDM 24 insulin requiring and 66 NON INSULIN DEPENDENT DIABETICS (NIDDM.,10 were insulin DEPENDENT DIABETICS (IDDM 24 insulin requiring and 66 NON INSULIN DEPENDENT DIABETICS (NIDDM.,16,70,41,40,101,RO-may_treat,820134-FS1,10 were insulin DEPENDENT DIABETICS (IDDM 24 insulin requiring and 66 NON INSULIN DEPENDENT DIABETICS (NIDDM.,DEPENDENT DIABETICS (IDDM),NON INSULIN DEPENDENT DIABETICS
790085246,9/17/2015 13:17:52,1740416705,9/17/2015 13:17:09,false,elite,1.0,31883685,GBR,"","",79.66.244.188,[ASSOCIATED_WITH],[ASSOCIATED_WITH],DIABETICS,n/a,16,70,41,40,101,RO-may_treat,820134-FS1,10 were insulin DEPENDENT DIABETICS (IDDM 24 insulin requiring and 66 NON INSULIN DEPENDENT DIABETICS (NIDDM.,DEPENDENT DIABETICS (IDDM),NON INSULIN DEPENDENT DIABETICS
790085246,9/17/2015 13:18:45,1740416982,9/17/2015 13:18:22,false,prodege,1.0,33854929,USA,CT,Wallingford,24.2.218.232,[OTHER],[OTHER],10 were,n/a,16,70,41,40,101,RO-may_treat,820134-FS1,10 were insulin DEPENDENT DIABETICS (IDDM 24 insulin requiring and 66 NON INSULIN DEPENDENT DIABETICS (NIDDM.,DEPENDENT DIABETICS (IDDM),NON INSULIN DEPENDENT DIABETICS
790085246,9/17/2015 13:24:21,1740418811,9/17/2015 13:23:38,false,neodev,1.0,12115558,USA,OH,Twinsburg,98.27.164.131,[OTHER],[OTHER],10 were insulin DEPENDENT and 66 NON INSULIN DEPENDENT,N/A,16,70,41,40,101,RO-may_treat,820134-FS1,10 were insulin DEPENDENT DIABETICS (IDDM 24 insulin requiring and 66 NON INSULIN DEPENDENT DIABETICS (NIDDM.,DEPENDENT DIABETICS (IDDM),NON INSULIN DEPENDENT DIABETICS
790085246,9/17/2015 13:24:54,1740418957,9/17/2015 13:24:28,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,n/a,16,70,41,40,101,RO-may_treat,820134-FS1,10 were insulin DEPENDENT DIABETICS (IDDM 24 insulin requiring and 66 NON INSULIN DEPENDENT DIABETICS (NIDDM.,DEPENDENT DIABETICS (IDDM),NON INSULIN DEPENDENT DIABETICS
790085246,9/17/2015 13:25:41,1740419119,9/17/2015 13:24:58,false,prodege,1.0,27934334,GBR,C8,Croydon,81.159.60.206,[OTHER],[OTHER],DIABETICS,N/A,16,70,41,40,101,RO-may_treat,820134-FS1,10 were insulin DEPENDENT DIABETICS (IDDM 24 insulin requiring and 66 NON INSULIN DEPENDENT DIABETICS (NIDDM.,DEPENDENT DIABETICS (IDDM),NON INSULIN DEPENDENT DIABETICS
790085246,9/17/2015 13:35:08,1740422120,9/17/2015 13:34:52,false,bitcoinget,1.0,31256687,USA,NY,Poughkeepsie,67.82.252.135,[OTHER],[OTHER],and,n/a,16,70,41,40,101,RO-may_treat,820134-FS1,10 were insulin DEPENDENT DIABETICS (IDDM 24 insulin requiring and 66 NON INSULIN DEPENDENT DIABETICS (NIDDM.,DEPENDENT DIABETICS (IDDM),NON INSULIN DEPENDENT DIABETICS
790085246,9/17/2015 13:50:47,1740429248,9/17/2015 13:50:33,false,neodev,1.0,31329809,USA,DE,Wilmington,162.223.93.194,[OTHER],[OTHER],(NIDDM.,N/A,16,70,41,40,101,RO-may_treat,820134-FS1,10 were insulin DEPENDENT DIABETICS (IDDM 24 insulin requiring and 66 NON INSULIN DEPENDENT DIABETICS (NIDDM.,DEPENDENT DIABETICS (IDDM),NON INSULIN DEPENDENT DIABETICS
790085247,9/17/2015 09:11:11,1740361978,9/17/2015 09:10:40,false,neodev,1.0,32053642,GBR,I7,Newcastle Upon Tyne,92.23.136.205,[TREATS],[TREATS],Treatment with,N/A,69,15,83,82,25,RO-may_prevent,820211-FS1,Treatment with RANITIDINE for a maximum of six weeks healed 97.1% of DUODENAL ULCER patients (172 out of 177) and 96.5% of gastric ulcer patients (77 out of 81.,DUODENAL ULCER,RANITIDINE
790085247,9/17/2015 09:14:02,1740362742,9/17/2015 09:13:45,false,elite,1.0,30659754,USA,"","",162.250.145.204,[TREATS],[TREATS],Treatment,N/A,69,15,83,82,25,RO-may_prevent,820211-FS1,Treatment with RANITIDINE for a maximum of six weeks healed 97.1% of DUODENAL ULCER patients (172 out of 177) and 96.5% of gastric ulcer patients (77 out of 81.,DUODENAL ULCER,RANITIDINE
790085247,9/17/2015 09:16:46,1740363367,9/17/2015 09:15:07,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[TREATS],[TREATS],Treatment,N/A,69,15,83,82,25,RO-may_prevent,820211-FS1,Treatment with RANITIDINE for a maximum of six weeks healed 97.1% of DUODENAL ULCER patients (172 out of 177) and 96.5% of gastric ulcer patients (77 out of 81.,DUODENAL ULCER,RANITIDINE
790085247,9/17/2015 09:18:37,1740363703,9/17/2015 09:18:22,false,instagc,1.0,18960682,GBR,U2,Annan,92.18.213.181,[TREATS],[TREATS],Treatment with,N/A,69,15,83,82,25,RO-may_prevent,820211-FS1,Treatment with RANITIDINE for a maximum of six weeks healed 97.1% of DUODENAL ULCER patients (172 out of 177) and 96.5% of gastric ulcer patients (77 out of 81.,DUODENAL ULCER,RANITIDINE
790085247,9/17/2015 09:19:29,1740363860,9/17/2015 09:19:05,false,neodev,1.0,33644825,USA,FL,Fort Lauderdale,65.111.173.161,[PREVENTS],[PREVENTS],RANITIDINE DUODENAL ULCER,prevents,69,15,83,82,25,RO-may_prevent,820211-FS1,Treatment with RANITIDINE for a maximum of six weeks healed 97.1% of DUODENAL ULCER patients (172 out of 177) and 96.5% of gastric ulcer patients (77 out of 81.,DUODENAL ULCER,RANITIDINE
790085247,9/17/2015 09:20:14,1740364036,9/17/2015 09:19:35,false,neodev,1.0,15848372,AUS,02,Jannali,14.200.59.55,[CONTRAINDICATES],[CONTRAINDICATES],Treatment with,n/a,69,15,83,82,25,RO-may_prevent,820211-FS1,Treatment with RANITIDINE for a maximum of six weeks healed 97.1% of DUODENAL ULCER patients (172 out of 177) and 96.5% of gastric ulcer patients (77 out of 81.,DUODENAL ULCER,RANITIDINE
790085247,9/17/2015 09:23:16,1740364648,9/17/2015 09:21:16,false,neodev,1.0,30627835,GBR,D8,Bishop Auckland,217.44.84.223,[OTHER],[OTHER],healed,N/A,69,15,83,82,25,RO-may_prevent,820211-FS1,Treatment with RANITIDINE for a maximum of six weeks healed 97.1% of DUODENAL ULCER patients (172 out of 177) and 96.5% of gastric ulcer patients (77 out of 81.,DUODENAL ULCER,RANITIDINE
790085247,9/17/2015 09:28:21,1740365702,9/17/2015 09:28:08,false,elite,1.0,30659615,USA,"","",162.250.145.234,[TREATS],[TREATS],Treatment,N/A,69,15,83,82,25,RO-may_prevent,820211-FS1,Treatment with RANITIDINE for a maximum of six weeks healed 97.1% of DUODENAL ULCER patients (172 out of 177) and 96.5% of gastric ulcer patients (77 out of 81.,DUODENAL ULCER,RANITIDINE
790085247,9/17/2015 09:28:58,1740365851,9/17/2015 09:28:06,false,pocketmoneygpt,1.0,21432964,GBR,F8,Borehamwood,81.159.185.70,[TREATS],[TREATS],Treatment with,N/A,69,15,83,82,25,RO-may_prevent,820211-FS1,Treatment with RANITIDINE for a maximum of six weeks healed 97.1% of DUODENAL ULCER patients (172 out of 177) and 96.5% of gastric ulcer patients (77 out of 81.,DUODENAL ULCER,RANITIDINE
790085247,9/17/2015 09:35:05,1740367316,9/17/2015 09:34:49,false,neodev,1.0,21515166,NLD,11,Nieuwkoop,83.84.200.25,[TREATS],[TREATS],Treatment with,n/a,69,15,83,82,25,RO-may_prevent,820211-FS1,Treatment with RANITIDINE for a maximum of six weeks healed 97.1% of DUODENAL ULCER patients (172 out of 177) and 96.5% of gastric ulcer patients (77 out of 81.,DUODENAL ULCER,RANITIDINE
790085247,9/17/2015 09:47:54,1740370294,9/17/2015 09:47:42,false,elite,1.0,30659677,USA,"","",162.252.172.126,[TREATS],[TREATS],Treatment,N/A,69,15,83,82,25,RO-may_prevent,820211-FS1,Treatment with RANITIDINE for a maximum of six weeks healed 97.1% of DUODENAL ULCER patients (172 out of 177) and 96.5% of gastric ulcer patients (77 out of 81.,DUODENAL ULCER,RANITIDINE
790085247,9/17/2015 09:48:10,1740370358,9/17/2015 09:46:46,false,neodev,1.0,34081836,USA,CA,San Jose,23.27.248.146,[TREATS],[TREATS],Treatment with RANITIDINE for a maximum of six weeks healed 97.1% of DUODENAL ULCER patients,N/A,69,15,83,82,25,RO-may_prevent,820211-FS1,Treatment with RANITIDINE for a maximum of six weeks healed 97.1% of DUODENAL ULCER patients (172 out of 177) and 96.5% of gastric ulcer patients (77 out of 81.,DUODENAL ULCER,RANITIDINE
790085247,9/17/2015 09:51:45,1740371203,9/17/2015 09:51:19,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[TREATS],[TREATS],Treatment,N/A,69,15,83,82,25,RO-may_prevent,820211-FS1,Treatment with RANITIDINE for a maximum of six weeks healed 97.1% of DUODENAL ULCER patients (172 out of 177) and 96.5% of gastric ulcer patients (77 out of 81.,DUODENAL ULCER,RANITIDINE
790085247,9/17/2015 10:23:52,1740378598,9/17/2015 10:23:36,false,pocketmoneygpt,1.0,28884030,USA,WI,Minocqua,75.143.134.247,[TREATS],[TREATS],Treatment,n/a,69,15,83,82,25,RO-may_prevent,820211-FS1,Treatment with RANITIDINE for a maximum of six weeks healed 97.1% of DUODENAL ULCER patients (172 out of 177) and 96.5% of gastric ulcer patients (77 out of 81.,DUODENAL ULCER,RANITIDINE
790085247,9/17/2015 10:23:53,1740378602,9/17/2015 10:23:36,false,clixsense,1.0,31482589,NLD,11,Gouda,77.167.232.121,[TREATS],[TREATS],healed,n/a,69,15,83,82,25,RO-may_prevent,820211-FS1,Treatment with RANITIDINE for a maximum of six weeks healed 97.1% of DUODENAL ULCER patients (172 out of 177) and 96.5% of gastric ulcer patients (77 out of 81.,DUODENAL ULCER,RANITIDINE
790085248,9/17/2015 13:34:06,1740421791,9/17/2015 13:33:50,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,[TREATS],[TREATS],"single bedtime dose,",n/a,122,84,136,135,101,RO-may_prevent,820334-FS1,"The author compares the efficacy of ranitidine 300 mg in a single bedtime dose, and RANITIDINE 150 MG twice daily, in 509 DUODENAL ULCER patients treated in two Italian multicentre trials.",DUODENAL ULCER,RANITIDINE 150 MG
790085248,9/17/2015 13:40:54,1740426120,9/17/2015 13:40:33,false,prodege,1.0,27934334,GBR,C8,Croydon,81.159.60.206,[TREATS],[TREATS],treated,N/A,122,84,136,135,101,RO-may_prevent,820334-FS1,"The author compares the efficacy of ranitidine 300 mg in a single bedtime dose, and RANITIDINE 150 MG twice daily, in 509 DUODENAL ULCER patients treated in two Italian multicentre trials.",DUODENAL ULCER,RANITIDINE 150 MG
790085248,9/17/2015 14:09:47,1740435918,9/17/2015 14:09:28,false,gifthunterclub,1.0,30901412,GBR,H9,London,77.89.149.62,[TREATS],[TREATS],"dose, RANITIDINE 150 in 509 DUODENAL ULCER treated",n/a,122,84,136,135,101,RO-may_prevent,820334-FS1,"The author compares the efficacy of ranitidine 300 mg in a single bedtime dose, and RANITIDINE 150 MG twice daily, in 509 DUODENAL ULCER patients treated in two Italian multicentre trials.",DUODENAL ULCER,RANITIDINE 150 MG
790085248,9/17/2015 14:16:11,1740438256,9/17/2015 14:15:51,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.124.79,[TREATS],[TREATS],efficacy of,N/A,122,84,136,135,101,RO-may_prevent,820334-FS1,"The author compares the efficacy of ranitidine 300 mg in a single bedtime dose, and RANITIDINE 150 MG twice daily, in 509 DUODENAL ULCER patients treated in two Italian multicentre trials.",DUODENAL ULCER,RANITIDINE 150 MG
790085248,9/17/2015 14:25:50,1740441599,9/17/2015 14:23:41,false,zoombucks,1.0,6744840,CAN,BC,Kelowna,174.4.58.160,[TREATS],[TREATS],treated,N/A,122,84,136,135,101,RO-may_prevent,820334-FS1,"The author compares the efficacy of ranitidine 300 mg in a single bedtime dose, and RANITIDINE 150 MG twice daily, in 509 DUODENAL ULCER patients treated in two Italian multicentre trials.",DUODENAL ULCER,RANITIDINE 150 MG
790085248,9/17/2015 14:34:52,1740445056,9/17/2015 14:34:39,false,bitcoinget,1.0,32306192,USA,MA,Amherst,72.19.88.245,[TREATS],[TREATS],RANITIDINE 150 MG,N/a,122,84,136,135,101,RO-may_prevent,820334-FS1,"The author compares the efficacy of ranitidine 300 mg in a single bedtime dose, and RANITIDINE 150 MG twice daily, in 509 DUODENAL ULCER patients treated in two Italian multicentre trials.",DUODENAL ULCER,RANITIDINE 150 MG
790085248,9/17/2015 14:51:07,1740451716,9/17/2015 14:50:12,false,clixsense,1.0,32049531,USA,"","",38.95.108.252,[NONE],[NONE],none,none,122,84,136,135,101,RO-may_prevent,820334-FS1,"The author compares the efficacy of ranitidine 300 mg in a single bedtime dose, and RANITIDINE 150 MG twice daily, in 509 DUODENAL ULCER patients treated in two Italian multicentre trials.",DUODENAL ULCER,RANITIDINE 150 MG
790085248,9/17/2015 14:54:44,1740452963,9/17/2015 14:54:14,false,instagc,1.0,22981457,CAN,ON,Ottawa,67.69.8.122,[OTHER],[OTHER],compares,Comparison of two drugs,122,84,136,135,101,RO-may_prevent,820334-FS1,"The author compares the efficacy of ranitidine 300 mg in a single bedtime dose, and RANITIDINE 150 MG twice daily, in 509 DUODENAL ULCER patients treated in two Italian multicentre trials.",DUODENAL ULCER,RANITIDINE 150 MG
790085248,9/17/2015 15:03:22,1740456284,9/17/2015 15:03:03,false,neodev,1.0,31329809,USA,DE,Wilmington,162.223.93.194,[PART_OF] [TREATS] [IS_A],"[TREATS]
[IS_A]
[PART_OF]",of a treated,N/A,122,84,136,135,101,RO-may_prevent,820334-FS1,"The author compares the efficacy of ranitidine 300 mg in a single bedtime dose, and RANITIDINE 150 MG twice daily, in 509 DUODENAL ULCER patients treated in two Italian multicentre trials.",DUODENAL ULCER,RANITIDINE 150 MG
790085248,9/17/2015 15:03:57,1740456467,9/17/2015 15:02:59,false,clixsense,1.0,33115750,GBR,I3,Rochester,90.222.106.192,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],compares the efficacy,N/A,122,84,136,135,101,RO-may_prevent,820334-FS1,"The author compares the efficacy of ranitidine 300 mg in a single bedtime dose, and RANITIDINE 150 MG twice daily, in 509 DUODENAL ULCER patients treated in two Italian multicentre trials.",DUODENAL ULCER,RANITIDINE 150 MG
790085248,9/17/2015 15:12:59,1740459175,9/17/2015 15:12:49,false,neodev,1.0,34431172,USA,CA,Torrance,66.171.228.183,[MANIFESTATION] [NONE],"[MANIFESTATION]
[NONE]",no,no,122,84,136,135,101,RO-may_prevent,820334-FS1,"The author compares the efficacy of ranitidine 300 mg in a single bedtime dose, and RANITIDINE 150 MG twice daily, in 509 DUODENAL ULCER patients treated in two Italian multicentre trials.",DUODENAL ULCER,RANITIDINE 150 MG
790085248,9/17/2015 15:14:33,1740459713,9/17/2015 15:14:19,false,neodev,1.0,30321275,USA,NV,Las Vegas,192.30.80.4,[PART_OF],[PART_OF],of a,N/A,122,84,136,135,101,RO-may_prevent,820334-FS1,"The author compares the efficacy of ranitidine 300 mg in a single bedtime dose, and RANITIDINE 150 MG twice daily, in 509 DUODENAL ULCER patients treated in two Italian multicentre trials.",DUODENAL ULCER,RANITIDINE 150 MG
790085248,9/17/2015 15:20:31,1740462033,9/17/2015 15:20:03,false,neodev,1.0,29363385,USA,DE,Wilmington,162.223.93.162,[PART_OF] [TREATS] [IS_A],"[TREATS]
[IS_A]
[PART_OF]",of a treated,N/A,122,84,136,135,101,RO-may_prevent,820334-FS1,"The author compares the efficacy of ranitidine 300 mg in a single bedtime dose, and RANITIDINE 150 MG twice daily, in 509 DUODENAL ULCER patients treated in two Italian multicentre trials.",DUODENAL ULCER,RANITIDINE 150 MG
790085248,9/17/2015 15:23:49,1740463146,9/17/2015 15:23:11,false,neodev,1.0,12115558,USA,OH,Twinsburg,98.27.164.131,[TREATS],[TREATS],"efficacy ranitidine single bedtime dose, in 509 DUODENAL ULCER patients",N/A,122,84,136,135,101,RO-may_prevent,820334-FS1,"The author compares the efficacy of ranitidine 300 mg in a single bedtime dose, and RANITIDINE 150 MG twice daily, in 509 DUODENAL ULCER patients treated in two Italian multicentre trials.",DUODENAL ULCER,RANITIDINE 150 MG
790085248,9/17/2015 15:27:08,1740464397,9/17/2015 15:26:53,false,neodev,1.0,33435788,USA,DE,Wilmington,162.223.93.179,[PART_OF] [TREATS] [IS_A],"[TREATS]
[IS_A]
[PART_OF]",of a treated,N/A,122,84,136,135,101,RO-may_prevent,820334-FS1,"The author compares the efficacy of ranitidine 300 mg in a single bedtime dose, and RANITIDINE 150 MG twice daily, in 509 DUODENAL ULCER patients treated in two Italian multicentre trials.",DUODENAL ULCER,RANITIDINE 150 MG
790085249,9/17/2015 13:21:46,1740418033,9/17/2015 13:21:33,false,neodev,1.0,33228343,USA,"","",38.95.108.251,[PREVENTS] [TREATS] [SYMPTOM] [NONE] [ASSOCIATED_WITH] [PART_OF] [SIDE_EFFECT],"[TREATS]
[PREVENTS]
[SYMPTOM]
[ASSOCIATED_WITH]
[SIDE_EFFECT]
[PART_OF]
[NONE]",n contrast to difficulties in the management of puerperal ovarian vein thrombophlebitis occurring independently from HEPARIN INDUCED THROMBOCYTOPENIA (surgical treatment necessary in most cases) occurrence of PUERPERAL OVARIAN VEIN THROMBOPHLEBITIS in relation to heparin induced thrombocytopenia seems to response better to fibrinolysis and anticoagul,n contrast to difficulties in the management of puerperal ovarian vein thrombophlebitis occurring independently from HEPARIN INDUCED THROMBOCYTOPENIA (surgical treatment necessary in most cases) occurrence of PUERPERAL OVARIAN VEIN THROMBOPHLEBITIS in relation to heparin induced thrombocytopenia seems to response better to fibrinolysis and anticoagul,212,119,88,250,151,RO-may_treat,820136-FS1,In contrast to difficulties in the management of puerperal ovarian vein thrombophlebitis  occurring independently from HEPARIN INDUCED THROMBOCYTOPENIA (surgical treatment necessary in most cases)  occurrence of PUERPERAL OVARIAN VEIN THROMBOPHLEBITIS in relation to heparin induced thrombocytopenia seems to response better to fibrinolysis and anticoagulation.,PUERPERAL OVARIAN VEIN THROMBOPHLEBITIS,HEPARIN INDUCED THROMBOCYTOPENIA
790085249,9/17/2015 13:32:14,1740421192,9/17/2015 13:31:47,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],occurrence of,n/a,212,119,88,250,151,RO-may_treat,820136-FS1,In contrast to difficulties in the management of puerperal ovarian vein thrombophlebitis  occurring independently from HEPARIN INDUCED THROMBOCYTOPENIA (surgical treatment necessary in most cases)  occurrence of PUERPERAL OVARIAN VEIN THROMBOPHLEBITIS in relation to heparin induced thrombocytopenia seems to response better to fibrinolysis and anticoagulation.,PUERPERAL OVARIAN VEIN THROMBOPHLEBITIS,HEPARIN INDUCED THROMBOCYTOPENIA
790085249,9/17/2015 13:38:08,1740425161,9/17/2015 13:35:23,false,prodege,1.0,27934334,GBR,C8,Croydon,81.159.60.206,[MANIFESTATION] [OTHER],"[MANIFESTATION]
[OTHER]",vein,N/A,212,119,88,250,151,RO-may_treat,820136-FS1,In contrast to difficulties in the management of puerperal ovarian vein thrombophlebitis  occurring independently from HEPARIN INDUCED THROMBOCYTOPENIA (surgical treatment necessary in most cases)  occurrence of PUERPERAL OVARIAN VEIN THROMBOPHLEBITIS in relation to heparin induced thrombocytopenia seems to response better to fibrinolysis and anticoagulation.,PUERPERAL OVARIAN VEIN THROMBOPHLEBITIS,HEPARIN INDUCED THROMBOCYTOPENIA
790085249,9/17/2015 14:07:31,1740435098,9/17/2015 14:06:46,false,gifthunterclub,1.0,30901412,GBR,H9,London,77.89.149.62,[MANIFESTATION],[MANIFESTATION],HEPARIN INDUCED THROMBOCYTOPENIA (surgical treatment necessary occurrence of PUERPERAL OVARIAN VEIN THROMBOPHLEBITIS,N/A,212,119,88,250,151,RO-may_treat,820136-FS1,In contrast to difficulties in the management of puerperal ovarian vein thrombophlebitis  occurring independently from HEPARIN INDUCED THROMBOCYTOPENIA (surgical treatment necessary in most cases)  occurrence of PUERPERAL OVARIAN VEIN THROMBOPHLEBITIS in relation to heparin induced thrombocytopenia seems to response better to fibrinolysis and anticoagulation.,PUERPERAL OVARIAN VEIN THROMBOPHLEBITIS,HEPARIN INDUCED THROMBOCYTOPENIA
790085249,9/17/2015 14:14:14,1740437515,9/17/2015 14:13:39,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.124.79,[IS_A],[IS_A],contrast to ovarian vein thrombophlebitis,N/A,212,119,88,250,151,RO-may_treat,820136-FS1,In contrast to difficulties in the management of puerperal ovarian vein thrombophlebitis  occurring independently from HEPARIN INDUCED THROMBOCYTOPENIA (surgical treatment necessary in most cases)  occurrence of PUERPERAL OVARIAN VEIN THROMBOPHLEBITIS in relation to heparin induced thrombocytopenia seems to response better to fibrinolysis and anticoagulation.,PUERPERAL OVARIAN VEIN THROMBOPHLEBITIS,HEPARIN INDUCED THROMBOCYTOPENIA
790085249,9/17/2015 14:17:56,1740439008,9/17/2015 14:16:47,false,zoombucks,1.0,6744840,CAN,BC,Kelowna,174.4.58.160,[CAUSES],[CAUSES],in relation to,N/A,212,119,88,250,151,RO-may_treat,820136-FS1,In contrast to difficulties in the management of puerperal ovarian vein thrombophlebitis  occurring independently from HEPARIN INDUCED THROMBOCYTOPENIA (surgical treatment necessary in most cases)  occurrence of PUERPERAL OVARIAN VEIN THROMBOPHLEBITIS in relation to heparin induced thrombocytopenia seems to response better to fibrinolysis and anticoagulation.,PUERPERAL OVARIAN VEIN THROMBOPHLEBITIS,HEPARIN INDUCED THROMBOCYTOPENIA
790085249,9/17/2015 14:33:21,1740444502,9/17/2015 14:33:01,false,bitcoinget,1.0,32306192,USA,MA,Amherst,72.19.88.245,[ASSOCIATED_WITH],[ASSOCIATED_WITH],PUERPERAL OVARIAN VEIN THROMBOPHLEBITIS,N/a,212,119,88,250,151,RO-may_treat,820136-FS1,In contrast to difficulties in the management of puerperal ovarian vein thrombophlebitis  occurring independently from HEPARIN INDUCED THROMBOCYTOPENIA (surgical treatment necessary in most cases)  occurrence of PUERPERAL OVARIAN VEIN THROMBOPHLEBITIS in relation to heparin induced thrombocytopenia seems to response better to fibrinolysis and anticoagulation.,PUERPERAL OVARIAN VEIN THROMBOPHLEBITIS,HEPARIN INDUCED THROMBOCYTOPENIA
790085249,9/17/2015 14:45:41,1740449573,9/17/2015 14:44:13,false,clixsense,1.0,32049531,USA,"","",38.95.108.252,[NONE],[NONE],none,none,212,119,88,250,151,RO-may_treat,820136-FS1,In contrast to difficulties in the management of puerperal ovarian vein thrombophlebitis  occurring independently from HEPARIN INDUCED THROMBOCYTOPENIA (surgical treatment necessary in most cases)  occurrence of PUERPERAL OVARIAN VEIN THROMBOPHLEBITIS in relation to heparin induced thrombocytopenia seems to response better to fibrinolysis and anticoagulation.,PUERPERAL OVARIAN VEIN THROMBOPHLEBITIS,HEPARIN INDUCED THROMBOCYTOPENIA
790085249,9/17/2015 14:50:36,1740451523,9/17/2015 14:49:15,false,instagc,1.0,22981457,CAN,ON,Ottawa,67.69.8.122,[NONE],[NONE],N/A,It is just saying that one of the terms responds better to a treatment than the other one does,212,119,88,250,151,RO-may_treat,820136-FS1,In contrast to difficulties in the management of puerperal ovarian vein thrombophlebitis  occurring independently from HEPARIN INDUCED THROMBOCYTOPENIA (surgical treatment necessary in most cases)  occurrence of PUERPERAL OVARIAN VEIN THROMBOPHLEBITIS in relation to heparin induced thrombocytopenia seems to response better to fibrinolysis and anticoagulation.,PUERPERAL OVARIAN VEIN THROMBOPHLEBITIS,HEPARIN INDUCED THROMBOCYTOPENIA
790085249,9/17/2015 14:58:13,1740454232,9/17/2015 14:57:27,false,clixsense,1.0,33115750,GBR,I3,Rochester,90.222.106.192,[ASSOCIATED_WITH],[ASSOCIATED_WITH],occurrence of,N/A,212,119,88,250,151,RO-may_treat,820136-FS1,In contrast to difficulties in the management of puerperal ovarian vein thrombophlebitis  occurring independently from HEPARIN INDUCED THROMBOCYTOPENIA (surgical treatment necessary in most cases)  occurrence of PUERPERAL OVARIAN VEIN THROMBOPHLEBITIS in relation to heparin induced thrombocytopenia seems to response better to fibrinolysis and anticoagulation.,PUERPERAL OVARIAN VEIN THROMBOPHLEBITIS,HEPARIN INDUCED THROMBOCYTOPENIA
790085249,9/17/2015 15:00:52,1740455201,9/17/2015 15:00:21,false,neodev,1.0,31329809,USA,DE,Wilmington,162.223.93.194,[PART_OF],[PART_OF],of of,N/A,212,119,88,250,151,RO-may_treat,820136-FS1,In contrast to difficulties in the management of puerperal ovarian vein thrombophlebitis  occurring independently from HEPARIN INDUCED THROMBOCYTOPENIA (surgical treatment necessary in most cases)  occurrence of PUERPERAL OVARIAN VEIN THROMBOPHLEBITIS in relation to heparin induced thrombocytopenia seems to response better to fibrinolysis and anticoagulation.,PUERPERAL OVARIAN VEIN THROMBOPHLEBITIS,HEPARIN INDUCED THROMBOCYTOPENIA
790085249,9/17/2015 15:11:45,1740458794,9/17/2015 15:11:23,false,neodev,1.0,34431172,USA,CA,Torrance,66.171.228.183,[PREVENTS] [NONE],"[PREVENTS]
[NONE]",no,no,212,119,88,250,151,RO-may_treat,820136-FS1,In contrast to difficulties in the management of puerperal ovarian vein thrombophlebitis  occurring independently from HEPARIN INDUCED THROMBOCYTOPENIA (surgical treatment necessary in most cases)  occurrence of PUERPERAL OVARIAN VEIN THROMBOPHLEBITIS in relation to heparin induced thrombocytopenia seems to response better to fibrinolysis and anticoagulation.,PUERPERAL OVARIAN VEIN THROMBOPHLEBITIS,HEPARIN INDUCED THROMBOCYTOPENIA
790085249,9/17/2015 15:13:05,1740459198,9/17/2015 15:12:44,false,neodev,1.0,30321275,USA,NV,Las Vegas,192.30.80.4,[PART_OF],[PART_OF],of of,N/A,212,119,88,250,151,RO-may_treat,820136-FS1,In contrast to difficulties in the management of puerperal ovarian vein thrombophlebitis  occurring independently from HEPARIN INDUCED THROMBOCYTOPENIA (surgical treatment necessary in most cases)  occurrence of PUERPERAL OVARIAN VEIN THROMBOPHLEBITIS in relation to heparin induced thrombocytopenia seems to response better to fibrinolysis and anticoagulation.,PUERPERAL OVARIAN VEIN THROMBOPHLEBITIS,HEPARIN INDUCED THROMBOCYTOPENIA
790085249,9/17/2015 15:18:19,1740461049,9/17/2015 15:17:58,false,neodev,1.0,29363385,USA,DE,Wilmington,162.223.93.162,[PART_OF] [TREATS],"[TREATS]
[PART_OF]",of treatment,N/A,212,119,88,250,151,RO-may_treat,820136-FS1,In contrast to difficulties in the management of puerperal ovarian vein thrombophlebitis  occurring independently from HEPARIN INDUCED THROMBOCYTOPENIA (surgical treatment necessary in most cases)  occurrence of PUERPERAL OVARIAN VEIN THROMBOPHLEBITIS in relation to heparin induced thrombocytopenia seems to response better to fibrinolysis and anticoagulation.,PUERPERAL OVARIAN VEIN THROMBOPHLEBITIS,HEPARIN INDUCED THROMBOCYTOPENIA
790085249,9/17/2015 15:20:15,1740461957,9/17/2015 15:19:40,false,neodev,1.0,12115558,USA,OH,Twinsburg,98.27.164.131,[ASSOCIATED_WITH],[ASSOCIATED_WITH],occurring independently from,N/A,212,119,88,250,151,RO-may_treat,820136-FS1,In contrast to difficulties in the management of puerperal ovarian vein thrombophlebitis  occurring independently from HEPARIN INDUCED THROMBOCYTOPENIA (surgical treatment necessary in most cases)  occurrence of PUERPERAL OVARIAN VEIN THROMBOPHLEBITIS in relation to heparin induced thrombocytopenia seems to response better to fibrinolysis and anticoagulation.,PUERPERAL OVARIAN VEIN THROMBOPHLEBITIS,HEPARIN INDUCED THROMBOCYTOPENIA
790085250,9/17/2015 11:23:49,1740390002,9/17/2015 11:22:57,false,neodev,1.0,32695853,USA,NV,Las Vegas,192.30.80.172,[PART_OF] [SIDE_EFFECT] [IS_A],"[SIDE_EFFECT]
[IS_A]
[PART_OF]",efficacy of of a,N/A,179,119,183,202,128,RO-may_prevent,820379-FS1,The aim was to compare the efficacy of transcutaneous electrical nerve stimulation (TENS) and local infiltration of 2% LIDOCAINE in the relief of episiotomy pain measured using a PAIN VISUAL ANALOG SCALE (VAS.,PAIN VISUAL ANALOG SCALE,LIDOCAINE
790085250,9/17/2015 11:34:52,1740392049,9/17/2015 11:34:33,false,neodev,1.0,30941227,USA,NV,Las Vegas,192.30.80.166,[PART_OF] [SIDE_EFFECT] [IS_A],"[SIDE_EFFECT]
[IS_A]
[PART_OF]",efficacy of of of a,N/A,179,119,183,202,128,RO-may_prevent,820379-FS1,The aim was to compare the efficacy of transcutaneous electrical nerve stimulation (TENS) and local infiltration of 2% LIDOCAINE in the relief of episiotomy pain measured using a PAIN VISUAL ANALOG SCALE (VAS.,PAIN VISUAL ANALOG SCALE,LIDOCAINE
790085250,9/17/2015 11:39:44,1740393100,9/17/2015 11:38:34,false,neodev,1.0,30581619,USA,CA,San Jose,50.118.162.56,[NONE],[NONE],good,good,179,119,183,202,128,RO-may_prevent,820379-FS1,The aim was to compare the efficacy of transcutaneous electrical nerve stimulation (TENS) and local infiltration of 2% LIDOCAINE in the relief of episiotomy pain measured using a PAIN VISUAL ANALOG SCALE (VAS.,PAIN VISUAL ANALOG SCALE,LIDOCAINE
790085250,9/17/2015 12:09:41,1740399162,9/17/2015 12:09:26,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[PREVENTS],[PREVENTS],relief,N/A,179,119,183,202,128,RO-may_prevent,820379-FS1,The aim was to compare the efficacy of transcutaneous electrical nerve stimulation (TENS) and local infiltration of 2% LIDOCAINE in the relief of episiotomy pain measured using a PAIN VISUAL ANALOG SCALE (VAS.,PAIN VISUAL ANALOG SCALE,LIDOCAINE
790085250,9/17/2015 12:35:37,1740404922,9/17/2015 12:34:59,false,neodev,1.0,30588889,NLD,07,Amsterdam,77.248.175.222,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],measured using,N/A,179,119,183,202,128,RO-may_prevent,820379-FS1,The aim was to compare the efficacy of transcutaneous electrical nerve stimulation (TENS) and local infiltration of 2% LIDOCAINE in the relief of episiotomy pain measured using a PAIN VISUAL ANALOG SCALE (VAS.,PAIN VISUAL ANALOG SCALE,LIDOCAINE
790085250,9/17/2015 12:44:08,1740407269,9/17/2015 12:43:32,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,[ASSOCIATED_WITH],[ASSOCIATED_WITH],LIDOCAINE measured PAIN VISUAL ANALOG SCALE,na,179,119,183,202,128,RO-may_prevent,820379-FS1,The aim was to compare the efficacy of transcutaneous electrical nerve stimulation (TENS) and local infiltration of 2% LIDOCAINE in the relief of episiotomy pain measured using a PAIN VISUAL ANALOG SCALE (VAS.,PAIN VISUAL ANALOG SCALE,LIDOCAINE
790085250,9/17/2015 12:45:50,1740407835,9/17/2015 12:44:22,false,prodege,1.0,2145087,USA,NY,New York,107.107.57.52,[OTHER],[OTHER],measured using,One measures the effect of the other,179,119,183,202,128,RO-may_prevent,820379-FS1,The aim was to compare the efficacy of transcutaneous electrical nerve stimulation (TENS) and local infiltration of 2% LIDOCAINE in the relief of episiotomy pain measured using a PAIN VISUAL ANALOG SCALE (VAS.,PAIN VISUAL ANALOG SCALE,LIDOCAINE
790085250,9/17/2015 13:17:09,1740416509,9/17/2015 13:16:56,false,neodev,1.0,33228343,USA,"","",38.95.108.251,[TREATS] [DIAGNOSE_BY_TEST_OR_DRUG] [SYMPTOM] [MANIFESTATION] [CONTRAINDICATES] [PART_OF] [NONE],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]
[SYMPTOM]
[MANIFESTATION]
[CONTRAINDICATES]
[PART_OF]
[NONE]",The aim was to compare the efficacy of transcutaneous electrical nerve stimulation (TENS) and local infiltration of 2% LIDOCAINE in the relief of episiotomy pain measured using a PAIN VISUAL ANALOG SCALE (VAS.c,The aim was to compare the efficacy of transcutaneous electrical nerve stimulation (TENS) and local infiltration of 2% LIDOCAINE in the relief of episiotomy pain measured using a PAIN VISUAL ANALOG SCALE (VAS.,179,119,183,202,128,RO-may_prevent,820379-FS1,The aim was to compare the efficacy of transcutaneous electrical nerve stimulation (TENS) and local infiltration of 2% LIDOCAINE in the relief of episiotomy pain measured using a PAIN VISUAL ANALOG SCALE (VAS.,PAIN VISUAL ANALOG SCALE,LIDOCAINE
790085250,9/17/2015 13:17:08,1740416512,9/17/2015 13:16:36,false,elite,1.0,31883685,GBR,"","",79.66.244.188,[ASSOCIATED_WITH],[ASSOCIATED_WITH],using,n/a,179,119,183,202,128,RO-may_prevent,820379-FS1,The aim was to compare the efficacy of transcutaneous electrical nerve stimulation (TENS) and local infiltration of 2% LIDOCAINE in the relief of episiotomy pain measured using a PAIN VISUAL ANALOG SCALE (VAS.,PAIN VISUAL ANALOG SCALE,LIDOCAINE
790085250,9/17/2015 13:18:22,1740416885,9/17/2015 13:18:01,false,prodege,1.0,33854929,USA,CT,Wallingford,24.2.218.232,[TREATS],[TREATS],using,n/a,179,119,183,202,128,RO-may_prevent,820379-FS1,The aim was to compare the efficacy of transcutaneous electrical nerve stimulation (TENS) and local infiltration of 2% LIDOCAINE in the relief of episiotomy pain measured using a PAIN VISUAL ANALOG SCALE (VAS.,PAIN VISUAL ANALOG SCALE,LIDOCAINE
790085250,9/17/2015 13:23:38,1740418616,9/17/2015 13:22:51,false,neodev,1.0,12115558,USA,OH,Twinsburg,98.27.164.131,[TREATS] [DIAGNOSE_BY_TEST_OR_DRUG],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]",relief of episiotomy,N/A,179,119,183,202,128,RO-may_prevent,820379-FS1,The aim was to compare the efficacy of transcutaneous electrical nerve stimulation (TENS) and local infiltration of 2% LIDOCAINE in the relief of episiotomy pain measured using a PAIN VISUAL ANALOG SCALE (VAS.,PAIN VISUAL ANALOG SCALE,LIDOCAINE
790085250,9/17/2015 13:24:27,1740418847,9/17/2015 13:24:08,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,[TREATS],[TREATS],relief of,n/a,179,119,183,202,128,RO-may_prevent,820379-FS1,The aim was to compare the efficacy of transcutaneous electrical nerve stimulation (TENS) and local infiltration of 2% LIDOCAINE in the relief of episiotomy pain measured using a PAIN VISUAL ANALOG SCALE (VAS.,PAIN VISUAL ANALOG SCALE,LIDOCAINE
790085250,9/17/2015 13:24:58,1740418979,9/17/2015 13:23:49,false,prodege,1.0,27934334,GBR,C8,Croydon,81.159.60.206,[OTHER],[OTHER],relief of pain measured using,N/A,179,119,183,202,128,RO-may_prevent,820379-FS1,The aim was to compare the efficacy of transcutaneous electrical nerve stimulation (TENS) and local infiltration of 2% LIDOCAINE in the relief of episiotomy pain measured using a PAIN VISUAL ANALOG SCALE (VAS.,PAIN VISUAL ANALOG SCALE,LIDOCAINE
790085250,9/17/2015 13:34:29,1740421923,9/17/2015 13:31:48,false,fusioncash,1,14070474,USA,IL,Edwardsville,24.107.32.201,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],compare efficacy LIDOCAINE in relief of episiotomy pain PAIN VISUAL ANALOG SCALE,The relationship is shown by the comparison of using Lidocaine and TENS unit for relief of pain in the sentence.,179,119,183,202,128,RO-may_prevent,820379-FS1,The aim was to compare the efficacy of transcutaneous electrical nerve stimulation (TENS) and local infiltration of 2% LIDOCAINE in the relief of episiotomy pain measured using a PAIN VISUAL ANALOG SCALE (VAS.,PAIN VISUAL ANALOG SCALE,LIDOCAINE
790085250,9/17/2015 13:34:33,1740421984,9/17/2015 13:34:12,false,bitcoinget,1.0,31256687,USA,NY,Poughkeepsie,67.82.252.135,[OTHER],[OTHER],relief,n/a,179,119,183,202,128,RO-may_prevent,820379-FS1,The aim was to compare the efficacy of transcutaneous electrical nerve stimulation (TENS) and local infiltration of 2% LIDOCAINE in the relief of episiotomy pain measured using a PAIN VISUAL ANALOG SCALE (VAS.,PAIN VISUAL ANALOG SCALE,LIDOCAINE
790085251,9/17/2015 09:17:22,1740363450,9/17/2015 09:16:50,false,neodev,1.0,32053642,GBR,I7,Newcastle Upon Tyne,92.23.136.205,[TREATS],[TREATS],doses of,N/A,98,46,102,101,57,RO-may_prevent,820217-FS1,instillation of therapeutically safe doses of BUPIVACAINE was without effect in the management of PAIN postoperative pulmonary dysfunction and the stress response in this group of patients.,PAIN,BUPIVACAINE
790085251,9/17/2015 09:18:09,1740363623,9/17/2015 09:17:53,false,elite,1.0,30659754,USA,"","",162.250.145.204,[TREATS],[TREATS],therapeutically,N/A,98,46,102,101,57,RO-may_prevent,820217-FS1,instillation of therapeutically safe doses of BUPIVACAINE was without effect in the management of PAIN postoperative pulmonary dysfunction and the stress response in this group of patients.,PAIN,BUPIVACAINE
790085251,9/17/2015 09:24:50,1740365003,9/17/2015 09:24:34,false,instagc,1.0,18960682,GBR,U2,Annan,92.18.213.181,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",therapeutically safe doses of BUPIVACAINE,N/A,98,46,102,101,57,RO-may_prevent,820217-FS1,instillation of therapeutically safe doses of BUPIVACAINE was without effect in the management of PAIN postoperative pulmonary dysfunction and the stress response in this group of patients.,PAIN,BUPIVACAINE
790085251,9/17/2015 09:27:44,1740365547,9/17/2015 09:27:16,false,neodev,1.0,33644825,USA,FL,Fort Lauderdale,65.111.173.161,[PREVENTS],[PREVENTS],BUPIVACAINE PAIN,treats,98,46,102,101,57,RO-may_prevent,820217-FS1,instillation of therapeutically safe doses of BUPIVACAINE was without effect in the management of PAIN postoperative pulmonary dysfunction and the stress response in this group of patients.,PAIN,BUPIVACAINE
790085251,9/17/2015 09:27:49,1740365572,9/17/2015 09:27:28,false,neodev,1.0,15848372,AUS,02,Jannali,14.200.59.55,[MANIFESTATION],[MANIFESTATION],management,n/a,98,46,102,101,57,RO-may_prevent,820217-FS1,instillation of therapeutically safe doses of BUPIVACAINE was without effect in the management of PAIN postoperative pulmonary dysfunction and the stress response in this group of patients.,PAIN,BUPIVACAINE
790085251,9/17/2015 09:36:15,1740367563,9/17/2015 09:36:02,false,elite,1.0,30659615,USA,"","",162.250.145.234,[SIDE_EFFECT],[SIDE_EFFECT],effect,N/A,98,46,102,101,57,RO-may_prevent,820217-FS1,instillation of therapeutically safe doses of BUPIVACAINE was without effect in the management of PAIN postoperative pulmonary dysfunction and the stress response in this group of patients.,PAIN,BUPIVACAINE
790085251,9/17/2015 09:40:19,1740368522,9/17/2015 09:39:15,false,pocketmoneygpt,1.0,21432964,GBR,F8,Borehamwood,81.159.185.70,[TREATS],[TREATS],effect in the management of,N/A,98,46,102,101,57,RO-may_prevent,820217-FS1,instillation of therapeutically safe doses of BUPIVACAINE was without effect in the management of PAIN postoperative pulmonary dysfunction and the stress response in this group of patients.,PAIN,BUPIVACAINE
790085251,9/17/2015 09:40:58,1740368729,9/17/2015 09:40:14,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[TREATS],[TREATS],doses,N/A,98,46,102,101,57,RO-may_prevent,820217-FS1,instillation of therapeutically safe doses of BUPIVACAINE was without effect in the management of PAIN postoperative pulmonary dysfunction and the stress response in this group of patients.,PAIN,BUPIVACAINE
790085251,9/17/2015 09:44:21,1740369513,9/17/2015 09:43:55,false,neodev,1.0,21515166,NLD,11,Nieuwkoop,83.84.200.25,[SYMPTOM],[SYMPTOM],was without effect in,n/a,98,46,102,101,57,RO-may_prevent,820217-FS1,instillation of therapeutically safe doses of BUPIVACAINE was without effect in the management of PAIN postoperative pulmonary dysfunction and the stress response in this group of patients.,PAIN,BUPIVACAINE
790085251,9/17/2015 09:52:03,1740371272,9/17/2015 09:51:47,false,elite,1.0,30659677,USA,"","",162.252.172.126,[SIDE_EFFECT],[SIDE_EFFECT],effect,N/A,98,46,102,101,57,RO-may_prevent,820217-FS1,instillation of therapeutically safe doses of BUPIVACAINE was without effect in the management of PAIN postoperative pulmonary dysfunction and the stress response in this group of patients.,PAIN,BUPIVACAINE
790085251,9/17/2015 10:02:51,1740373843,9/17/2015 10:01:24,false,neodev,1.0,34081836,USA,CA,San Jose,23.27.248.146,[OTHER],[OTHER],BUPIVACAINE was without effect the management of PAIN,BUPIVACAINE was without effect in the management of PAIN postoperative,98,46,102,101,57,RO-may_prevent,820217-FS1,instillation of therapeutically safe doses of BUPIVACAINE was without effect in the management of PAIN postoperative pulmonary dysfunction and the stress response in this group of patients.,PAIN,BUPIVACAINE
790085251,9/17/2015 10:04:05,1740374263,9/17/2015 10:03:39,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[TREATS],[TREATS],BUPIVACAINE was without effect in the management of PAIN,N/A,98,46,102,101,57,RO-may_prevent,820217-FS1,instillation of therapeutically safe doses of BUPIVACAINE was without effect in the management of PAIN postoperative pulmonary dysfunction and the stress response in this group of patients.,PAIN,BUPIVACAINE
790085251,9/17/2015 10:30:01,1740379837,9/17/2015 10:29:44,false,pocketmoneygpt,1.0,28884030,USA,WI,Minocqua,75.143.134.247,[CONTRAINDICATES],[CONTRAINDICATES],without effect,n/a,98,46,102,101,57,RO-may_prevent,820217-FS1,instillation of therapeutically safe doses of BUPIVACAINE was without effect in the management of PAIN postoperative pulmonary dysfunction and the stress response in this group of patients.,PAIN,BUPIVACAINE
790085251,9/17/2015 10:39:39,1740381885,9/17/2015 10:39:06,false,clixsense,1.0,17950689,GBR,L9,Sheffield,146.200.192.103,[TREATS],[TREATS],pulmonary dysfunction,NONE,98,46,102,101,57,RO-may_prevent,820217-FS1,instillation of therapeutically safe doses of BUPIVACAINE was without effect in the management of PAIN postoperative pulmonary dysfunction and the stress response in this group of patients.,PAIN,BUPIVACAINE
790085251,9/17/2015 10:53:12,1740384273,9/17/2015 10:52:53,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[TREATS],[TREATS],therapeutically,N/A,98,46,102,101,57,RO-may_prevent,820217-FS1,instillation of therapeutically safe doses of BUPIVACAINE was without effect in the management of PAIN postoperative pulmonary dysfunction and the stress response in this group of patients.,PAIN,BUPIVACAINE
790085252,9/17/2015 11:04:33,1740386411,9/17/2015 11:03:58,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[PREVENTS],[PREVENTS],lower,N/A,148,165,162,188,174,RO-may_prevent,820218-FS1,Both malondialdehyde (MDA) and glutathione (GSH) levels were lower in renal and testicular tissues of the hypothyroidism group than the control and HYPOTHYROIDISM + THYROXINE ADMINISTRATION groups and the levels in hypothyroidism + THYROXINE administration group were higher than those in the control and hypothyroidism groups (p.,HYPOTHYROIDISM + THYROXINE ADMINISTRATION,THYROXINE
790085252,9/17/2015 11:12:26,1740388087,9/17/2015 11:10:55,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[OTHER],[OTHER],groups group,N/A,148,165,162,188,174,RO-may_prevent,820218-FS1,Both malondialdehyde (MDA) and glutathione (GSH) levels were lower in renal and testicular tissues of the hypothyroidism group than the control and HYPOTHYROIDISM + THYROXINE ADMINISTRATION groups and the levels in hypothyroidism + THYROXINE administration group were higher than those in the control and hypothyroidism groups (p.,HYPOTHYROIDISM + THYROXINE ADMINISTRATION,THYROXINE
790085252,9/17/2015 11:17:59,1740389098,9/17/2015 11:17:34,false,neodev,1.0,32695853,USA,NV,Las Vegas,192.30.80.172,[PART_OF],[PART_OF],of,N/A,148,165,162,188,174,RO-may_prevent,820218-FS1,Both malondialdehyde (MDA) and glutathione (GSH) levels were lower in renal and testicular tissues of the hypothyroidism group than the control and HYPOTHYROIDISM + THYROXINE ADMINISTRATION groups and the levels in hypothyroidism + THYROXINE administration group were higher than those in the control and hypothyroidism groups (p.,HYPOTHYROIDISM + THYROXINE ADMINISTRATION,THYROXINE
790085252,9/17/2015 11:18:51,1740389306,9/17/2015 11:17:41,false,neodev,1.0,30581619,USA,CA,San Jose,50.118.162.56,[NONE],[NONE],good,good,148,165,162,188,174,RO-may_prevent,820218-FS1,Both malondialdehyde (MDA) and glutathione (GSH) levels were lower in renal and testicular tissues of the hypothyroidism group than the control and HYPOTHYROIDISM + THYROXINE ADMINISTRATION groups and the levels in hypothyroidism + THYROXINE administration group were higher than those in the control and hypothyroidism groups (p.,HYPOTHYROIDISM + THYROXINE ADMINISTRATION,THYROXINE
790085252,9/17/2015 11:27:14,1740390717,9/17/2015 11:24:50,false,gifthulk,1.0,18666417,USA,PA,Meadville,24.101.32.13,[DIAGNOSE_BY_TEST_OR_DRUG] [TREATS],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]",(MDA) and (GSH) levels lower in renal and testicular tissues of HYPOTHYROIDISM + THYROXINE ADMINISTRATION groups,n/a,148,165,162,188,174,RO-may_prevent,820218-FS1,Both malondialdehyde (MDA) and glutathione (GSH) levels were lower in renal and testicular tissues of the hypothyroidism group than the control and HYPOTHYROIDISM + THYROXINE ADMINISTRATION groups and the levels in hypothyroidism + THYROXINE administration group were higher than those in the control and hypothyroidism groups (p.,HYPOTHYROIDISM + THYROXINE ADMINISTRATION,THYROXINE
790085252,9/17/2015 11:30:01,1740391223,9/17/2015 11:29:44,false,neodev,1.0,30941227,USA,NV,Las Vegas,192.30.80.166,[PART_OF],[PART_OF],of,N/A,148,165,162,188,174,RO-may_prevent,820218-FS1,Both malondialdehyde (MDA) and glutathione (GSH) levels were lower in renal and testicular tissues of the hypothyroidism group than the control and HYPOTHYROIDISM + THYROXINE ADMINISTRATION groups and the levels in hypothyroidism + THYROXINE administration group were higher than those in the control and hypothyroidism groups (p.,HYPOTHYROIDISM + THYROXINE ADMINISTRATION,THYROXINE
790085252,9/17/2015 11:40:53,1740393335,9/17/2015 11:40:27,false,neodev,1.0,33701549,USA,CA,Torrance,66.171.228.66,[TREATS] [CAUSES] [MANIFESTATION] [ASSOCIATED_WITH] [OTHER] [NONE],"[TREATS]
[CAUSES]
[MANIFESTATION]
[ASSOCIATED_WITH]
[OTHER]
[NONE]",[IS_A],N/A,148,165,162,188,174,RO-may_prevent,820218-FS1,Both malondialdehyde (MDA) and glutathione (GSH) levels were lower in renal and testicular tissues of the hypothyroidism group than the control and HYPOTHYROIDISM + THYROXINE ADMINISTRATION groups and the levels in hypothyroidism + THYROXINE administration group were higher than those in the control and hypothyroidism groups (p.,HYPOTHYROIDISM + THYROXINE ADMINISTRATION,THYROXINE
790085252,9/17/2015 12:01:44,1740397364,9/17/2015 12:00:58,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[PREVENTS],[PREVENTS],lower,N/A,148,165,162,188,174,RO-may_prevent,820218-FS1,Both malondialdehyde (MDA) and glutathione (GSH) levels were lower in renal and testicular tissues of the hypothyroidism group than the control and HYPOTHYROIDISM + THYROXINE ADMINISTRATION groups and the levels in hypothyroidism + THYROXINE administration group were higher than those in the control and hypothyroidism groups (p.,HYPOTHYROIDISM + THYROXINE ADMINISTRATION,THYROXINE
790085252,9/17/2015 12:25:46,1740402620,9/17/2015 12:24:50,false,neodev,1.0,30588889,NLD,07,Amsterdam,77.248.175.222,[ASSOCIATED_WITH] [OTHER],"[ASSOCIATED_WITH]
[OTHER]",ADMINISTRATION,N/A,148,165,162,188,174,RO-may_prevent,820218-FS1,Both malondialdehyde (MDA) and glutathione (GSH) levels were lower in renal and testicular tissues of the hypothyroidism group than the control and HYPOTHYROIDISM + THYROXINE ADMINISTRATION groups and the levels in hypothyroidism + THYROXINE administration group were higher than those in the control and hypothyroidism groups (p.,HYPOTHYROIDISM + THYROXINE ADMINISTRATION,THYROXINE
790085252,9/17/2015 12:36:43,1740405284,9/17/2015 12:35:48,false,prodege,1.0,2145087,USA,NY,New York,107.107.57.52,[NONE],[NONE],N/A,These are two different groups in a drug study,148,165,162,188,174,RO-may_prevent,820218-FS1,Both malondialdehyde (MDA) and glutathione (GSH) levels were lower in renal and testicular tissues of the hypothyroidism group than the control and HYPOTHYROIDISM + THYROXINE ADMINISTRATION groups and the levels in hypothyroidism + THYROXINE administration group were higher than those in the control and hypothyroidism groups (p.,HYPOTHYROIDISM + THYROXINE ADMINISTRATION,THYROXINE
790085252,9/17/2015 12:36:52,1740405310,9/17/2015 12:36:23,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,[ASSOCIATED_WITH],[ASSOCIATED_WITH],HYPOTHYROIDISM + THYROXINE ADMINISTRATION groups and THYROXINE administration group,na,148,165,162,188,174,RO-may_prevent,820218-FS1,Both malondialdehyde (MDA) and glutathione (GSH) levels were lower in renal and testicular tissues of the hypothyroidism group than the control and HYPOTHYROIDISM + THYROXINE ADMINISTRATION groups and the levels in hypothyroidism + THYROXINE administration group were higher than those in the control and hypothyroidism groups (p.,HYPOTHYROIDISM + THYROXINE ADMINISTRATION,THYROXINE
790085252,9/17/2015 12:39:52,1740406043,9/17/2015 12:38:43,false,instagc,1.0,22981457,CAN,ON,Welland,76.67.127.43,[ASSOCIATED_WITH],[ASSOCIATED_WITH],levels were higher,N/A,148,165,162,188,174,RO-may_prevent,820218-FS1,Both malondialdehyde (MDA) and glutathione (GSH) levels were lower in renal and testicular tissues of the hypothyroidism group than the control and HYPOTHYROIDISM + THYROXINE ADMINISTRATION groups and the levels in hypothyroidism + THYROXINE administration group were higher than those in the control and hypothyroidism groups (p.,HYPOTHYROIDISM + THYROXINE ADMINISTRATION,THYROXINE
790085252,9/17/2015 12:47:21,1740408253,9/17/2015 12:46:54,false,neodev,1.0,34215189,GBR,I2,Manchester,82.8.21.5,[OTHER],[OTHER],HYPOTHYROIDISM + THYROXINE ADMINISTRATION groups,N/A,148,165,162,188,174,RO-may_prevent,820218-FS1,Both malondialdehyde (MDA) and glutathione (GSH) levels were lower in renal and testicular tissues of the hypothyroidism group than the control and HYPOTHYROIDISM + THYROXINE ADMINISTRATION groups and the levels in hypothyroidism + THYROXINE administration group were higher than those in the control and hypothyroidism groups (p.,HYPOTHYROIDISM + THYROXINE ADMINISTRATION,THYROXINE
790085252,9/17/2015 13:12:25,1740415190,9/17/2015 13:11:19,false,prodege,1.0,33854929,USA,CT,Wallingford,24.2.218.232,[OTHER],[OTHER],and,n/a,148,165,162,188,174,RO-may_prevent,820218-FS1,Both malondialdehyde (MDA) and glutathione (GSH) levels were lower in renal and testicular tissues of the hypothyroidism group than the control and HYPOTHYROIDISM + THYROXINE ADMINISTRATION groups and the levels in hypothyroidism + THYROXINE administration group were higher than those in the control and hypothyroidism groups (p.,HYPOTHYROIDISM + THYROXINE ADMINISTRATION,THYROXINE
790085252,9/17/2015 13:12:28,1740415191,9/17/2015 13:12:01,false,elite,1.0,31883685,GBR,"","",79.66.244.188,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,148,165,162,188,174,RO-may_prevent,820218-FS1,Both malondialdehyde (MDA) and glutathione (GSH) levels were lower in renal and testicular tissues of the hypothyroidism group than the control and HYPOTHYROIDISM + THYROXINE ADMINISTRATION groups and the levels in hypothyroidism + THYROXINE administration group were higher than those in the control and hypothyroidism groups (p.,HYPOTHYROIDISM + THYROXINE ADMINISTRATION,THYROXINE
790085253,9/17/2015 11:22:41,1740389825,9/17/2015 11:22:31,false,neodev,1.0,32695853,USA,NV,Las Vegas,192.30.80.172,[PART_OF],[PART_OF],of,N/A,38,12,42,41,25,RO-may_treat,820062-FS1,Will giving ACETAMINOPHEN prevent the PAIN of the immunization.,PAIN,ACETAMINOPHEN
790085253,9/17/2015 11:34:14,1740391963,9/17/2015 11:34:04,false,neodev,1.0,30941227,USA,NV,Las Vegas,192.30.80.166,[PART_OF],[PART_OF],of,N/A,38,12,42,41,25,RO-may_treat,820062-FS1,Will giving ACETAMINOPHEN prevent the PAIN of the immunization.,PAIN,ACETAMINOPHEN
790085253,9/17/2015 11:37:44,1740392713,9/17/2015 11:35:53,false,neodev,1.0,30581619,USA,CA,San Jose,50.118.162.56,[NONE],[NONE],good,good,38,12,42,41,25,RO-may_treat,820062-FS1,Will giving ACETAMINOPHEN prevent the PAIN of the immunization.,PAIN,ACETAMINOPHEN
790085253,9/17/2015 12:08:58,1740398987,9/17/2015 12:08:05,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[PREVENTS],[PREVENTS],prevent,N/A,38,12,42,41,25,RO-may_treat,820062-FS1,Will giving ACETAMINOPHEN prevent the PAIN of the immunization.,PAIN,ACETAMINOPHEN
790085253,9/17/2015 12:33:57,1740404566,9/17/2015 12:33:41,false,neodev,1.0,30588889,NLD,07,Amsterdam,77.248.175.222,[PREVENTS],[PREVENTS],prevent,N/A,38,12,42,41,25,RO-may_treat,820062-FS1,Will giving ACETAMINOPHEN prevent the PAIN of the immunization.,PAIN,ACETAMINOPHEN
790085253,9/17/2015 12:43:06,1740406888,9/17/2015 12:42:44,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,[PREVENTS],[PREVENTS],ACETAMINOPHEN prevent PAIN,na,38,12,42,41,25,RO-may_treat,820062-FS1,Will giving ACETAMINOPHEN prevent the PAIN of the immunization.,PAIN,ACETAMINOPHEN
790085253,9/17/2015 12:43:44,1740407118,9/17/2015 12:43:27,false,prodege,1.0,2145087,USA,NY,New York,107.107.57.52,[PREVENTS],[PREVENTS],prevent the,N/A,38,12,42,41,25,RO-may_treat,820062-FS1,Will giving ACETAMINOPHEN prevent the PAIN of the immunization.,PAIN,ACETAMINOPHEN
790085253,9/17/2015 13:16:21,1740416285,9/17/2015 13:16:04,false,elite,1.0,31883685,GBR,"","",79.66.244.188,[PREVENTS],[PREVENTS],prevent,n/a,38,12,42,41,25,RO-may_treat,820062-FS1,Will giving ACETAMINOPHEN prevent the PAIN of the immunization.,PAIN,ACETAMINOPHEN
790085253,9/17/2015 13:16:37,1740416435,9/17/2015 13:16:22,false,neodev,1.0,33228343,USA,"","",38.95.108.251,[PREVENTS] [DIAGNOSE_BY_TEST_OR_DRUG] [LOCATION] [MANIFESTATION] [CONTRAINDICATES] [IS_A] [NONE],"[PREVENTS]
[DIAGNOSE_BY_TEST_OR_DRUG]
[LOCATION]
[MANIFESTATION]
[CONTRAINDICATES]
[IS_A]
[NONE]",Will giving ACETAMINOPHEN prevent the PAIN of the immunization.,Will giving ACETAMINOPHEN prevent the PAIN of the immunization.,38,12,42,41,25,RO-may_treat,820062-FS1,Will giving ACETAMINOPHEN prevent the PAIN of the immunization.,PAIN,ACETAMINOPHEN
790085253,9/17/2015 13:17:40,1740416629,9/17/2015 13:17:18,false,prodege,1.0,33854929,USA,CT,Wallingford,24.2.218.232,[PREVENTS],[PREVENTS],prevent,n/a,38,12,42,41,25,RO-may_treat,820062-FS1,Will giving ACETAMINOPHEN prevent the PAIN of the immunization.,PAIN,ACETAMINOPHEN
790085253,9/17/2015 13:22:21,1740418201,9/17/2015 13:21:50,false,neodev,1.0,12115558,USA,OH,Twinsburg,98.27.164.131,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",prevent,N/A,38,12,42,41,25,RO-may_treat,820062-FS1,Will giving ACETAMINOPHEN prevent the PAIN of the immunization.,PAIN,ACETAMINOPHEN
790085253,9/17/2015 13:23:08,1740418434,9/17/2015 13:22:50,false,prodege,1.0,27934334,GBR,C8,Croydon,81.159.60.206,[PREVENTS],[PREVENTS],prevent,N/A,38,12,42,41,25,RO-may_treat,820062-FS1,Will giving ACETAMINOPHEN prevent the PAIN of the immunization.,PAIN,ACETAMINOPHEN
790085253,9/17/2015 13:23:52,1740418700,9/17/2015 13:23:39,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,[PREVENTS],[PREVENTS],prevent,n/a,38,12,42,41,25,RO-may_treat,820062-FS1,Will giving ACETAMINOPHEN prevent the PAIN of the immunization.,PAIN,ACETAMINOPHEN
790085253,9/17/2015 13:29:45,1740420385,9/17/2015 13:27:14,false,fusioncash,1.0,14070474,USA,IL,Edwardsville,24.107.32.201,[TREATS],[TREATS],prevent the PAIN,prevent the pain shows the relationship between the medication and the problem.,38,12,42,41,25,RO-may_treat,820062-FS1,Will giving ACETAMINOPHEN prevent the PAIN of the immunization.,PAIN,ACETAMINOPHEN
790085253,9/17/2015 13:34:52,1740422059,9/17/2015 13:34:34,false,bitcoinget,1.0,31256687,USA,NY,Poughkeepsie,67.82.252.135,[OTHER],[OTHER],prevent,n/a,38,12,42,41,25,RO-may_treat,820062-FS1,Will giving ACETAMINOPHEN prevent the PAIN of the immunization.,PAIN,ACETAMINOPHEN
790085254,9/17/2015 11:25:03,1740390246,9/17/2015 11:24:45,false,neodev,1.0,32695853,USA,NV,Las Vegas,192.30.80.172,[TREATS] [PART_OF] [IS_A],"[TREATS]
[IS_A]
[PART_OF]",treatment of is of,N/A,49,0,73,72,19,RO-may_prevent,820260-FS1,"DIGITALIS COMPOUNDS are used in the treatment of CONGESTIVE HEART FAILURE as positive inotropic agents; their action is mainly due to the inhibition of Na(+),K(+) ATPase.",CONGESTIVE HEART FAILURE,DIGITALIS COMPOUNDS
790085254,9/17/2015 11:35:58,1740392261,9/17/2015 11:35:39,false,neodev,1.0,30941227,USA,NV,Las Vegas,192.30.80.166,[TREATS] [PART_OF] [IS_A],"[TREATS]
[IS_A]
[PART_OF]",treatment of is of,N/A,49,0,73,72,19,RO-may_prevent,820260-FS1,"DIGITALIS COMPOUNDS are used in the treatment of CONGESTIVE HEART FAILURE as positive inotropic agents; their action is mainly due to the inhibition of Na(+),K(+) ATPase.",CONGESTIVE HEART FAILURE,DIGITALIS COMPOUNDS
790085254,9/17/2015 12:11:24,1740399525,9/17/2015 12:10:39,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[TREATS],[TREATS],treatment,N/A,49,0,73,72,19,RO-may_prevent,820260-FS1,"DIGITALIS COMPOUNDS are used in the treatment of CONGESTIVE HEART FAILURE as positive inotropic agents; their action is mainly due to the inhibition of Na(+),K(+) ATPase.",CONGESTIVE HEART FAILURE,DIGITALIS COMPOUNDS
790085254,9/17/2015 12:36:55,1740405344,9/17/2015 12:36:43,false,neodev,1.0,30588889,NLD,07,Amsterdam,77.248.175.222,[TREATS],[TREATS],treatment,N/A,49,0,73,72,19,RO-may_prevent,820260-FS1,"DIGITALIS COMPOUNDS are used in the treatment of CONGESTIVE HEART FAILURE as positive inotropic agents; their action is mainly due to the inhibition of Na(+),K(+) ATPase.",CONGESTIVE HEART FAILURE,DIGITALIS COMPOUNDS
790085254,9/17/2015 12:45:40,1740407769,9/17/2015 12:45:04,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,[TREATS],[TREATS],DIGITALIS COMPOUNDS used in treatment of CONGESTIVE HEART FAILURE,na,49,0,73,72,19,RO-may_prevent,820260-FS1,"DIGITALIS COMPOUNDS are used in the treatment of CONGESTIVE HEART FAILURE as positive inotropic agents; their action is mainly due to the inhibition of Na(+),K(+) ATPase.",CONGESTIVE HEART FAILURE,DIGITALIS COMPOUNDS
790085254,9/17/2015 12:48:01,1740408515,9/17/2015 12:47:44,false,prodege,1.0,2145087,USA,NY,New York,107.107.57.52,[TREATS],[TREATS],used in the treatment of,N/A,49,0,73,72,19,RO-may_prevent,820260-FS1,"DIGITALIS COMPOUNDS are used in the treatment of CONGESTIVE HEART FAILURE as positive inotropic agents; their action is mainly due to the inhibition of Na(+),K(+) ATPase.",CONGESTIVE HEART FAILURE,DIGITALIS COMPOUNDS
790085254,9/17/2015 13:17:55,1740416728,9/17/2015 13:17:41,false,neodev,1.0,33228343,USA,"","",38.95.108.251,[CAUSES] [PREVENTS] [TREATS] [CONTRAINDICATES] [IS_A] [NONE],"[TREATS]
[PREVENTS]
[CAUSES]
[CONTRAINDICATES]
[IS_A]
[NONE]","DIGITALIS COMPOUNDS are used in the treatment of CONGESTIVE HEART FAILURE as positive inotropic agents; their action is mainly due to the inhibition of Na(+),K(+) ATPase.","DIGITALIS COMPOUNDS are used in the treatment of CONGESTIVE HEART FAILURE as positive inotropic agents; their action is mainly due to the inhibition of Na(+),K(+) ATPase.",49,0,73,72,19,RO-may_prevent,820260-FS1,"DIGITALIS COMPOUNDS are used in the treatment of CONGESTIVE HEART FAILURE as positive inotropic agents; their action is mainly due to the inhibition of Na(+),K(+) ATPase.",CONGESTIVE HEART FAILURE,DIGITALIS COMPOUNDS
790085254,9/17/2015 13:18:23,1740416901,9/17/2015 13:18:07,false,elite,1.0,31883685,GBR,"","",79.66.244.188,[TREATS],[TREATS],treatment,n/a,49,0,73,72,19,RO-may_prevent,820260-FS1,"DIGITALIS COMPOUNDS are used in the treatment of CONGESTIVE HEART FAILURE as positive inotropic agents; their action is mainly due to the inhibition of Na(+),K(+) ATPase.",CONGESTIVE HEART FAILURE,DIGITALIS COMPOUNDS
790085254,9/17/2015 13:19:19,1740417148,9/17/2015 13:19:07,false,prodege,1.0,33854929,USA,CT,Wallingford,24.2.218.232,[TREATS],[TREATS],treatment,n/a,49,0,73,72,19,RO-may_prevent,820260-FS1,"DIGITALIS COMPOUNDS are used in the treatment of CONGESTIVE HEART FAILURE as positive inotropic agents; their action is mainly due to the inhibition of Na(+),K(+) ATPase.",CONGESTIVE HEART FAILURE,DIGITALIS COMPOUNDS
790085254,9/17/2015 13:25:30,1740419077,9/17/2015 13:25:08,false,neodev,1.0,12115558,USA,OH,Twinsburg,98.27.164.131,[TREATS],[TREATS],used in the treatment,N/A,49,0,73,72,19,RO-may_prevent,820260-FS1,"DIGITALIS COMPOUNDS are used in the treatment of CONGESTIVE HEART FAILURE as positive inotropic agents; their action is mainly due to the inhibition of Na(+),K(+) ATPase.",CONGESTIVE HEART FAILURE,DIGITALIS COMPOUNDS
790085254,9/17/2015 13:25:50,1740419172,9/17/2015 13:25:37,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,[TREATS],[TREATS],treatment,n/a,49,0,73,72,19,RO-may_prevent,820260-FS1,"DIGITALIS COMPOUNDS are used in the treatment of CONGESTIVE HEART FAILURE as positive inotropic agents; their action is mainly due to the inhibition of Na(+),K(+) ATPase.",CONGESTIVE HEART FAILURE,DIGITALIS COMPOUNDS
790085254,9/17/2015 13:26:33,1740419448,9/17/2015 13:26:14,false,prodege,1.0,27934334,GBR,C8,Croydon,81.159.60.206,[TREATS],[TREATS],treatment of,N/A,49,0,73,72,19,RO-may_prevent,820260-FS1,"DIGITALIS COMPOUNDS are used in the treatment of CONGESTIVE HEART FAILURE as positive inotropic agents; their action is mainly due to the inhibition of Na(+),K(+) ATPase.",CONGESTIVE HEART FAILURE,DIGITALIS COMPOUNDS
790085254,9/17/2015 13:35:30,1740422231,9/17/2015 13:35:19,false,bitcoinget,1.0,31256687,USA,NY,Poughkeepsie,67.82.252.135,[OTHER],[OTHER],treatment,n/a,49,0,73,72,19,RO-may_prevent,820260-FS1,"DIGITALIS COMPOUNDS are used in the treatment of CONGESTIVE HEART FAILURE as positive inotropic agents; their action is mainly due to the inhibition of Na(+),K(+) ATPase.",CONGESTIVE HEART FAILURE,DIGITALIS COMPOUNDS
790085254,9/17/2015 13:50:01,1740428986,9/17/2015 13:49:20,false,neodev,1.0,31329809,USA,DE,Wilmington,162.223.93.194,[TREATS] [PART_OF] [IS_A],"[TREATS]
[IS_A]
[PART_OF]",treatment of is of,N/A,49,0,73,72,19,RO-may_prevent,820260-FS1,"DIGITALIS COMPOUNDS are used in the treatment of CONGESTIVE HEART FAILURE as positive inotropic agents; their action is mainly due to the inhibition of Na(+),K(+) ATPase.",CONGESTIVE HEART FAILURE,DIGITALIS COMPOUNDS
790085254,9/17/2015 14:00:48,1740432573,9/17/2015 13:58:36,false,zoombucks,1.0,6744840,CAN,BC,Kelowna,174.4.58.160,[TREATS],[TREATS],treatment of,N/A,49,0,73,72,19,RO-may_prevent,820260-FS1,"DIGITALIS COMPOUNDS are used in the treatment of CONGESTIVE HEART FAILURE as positive inotropic agents; their action is mainly due to the inhibition of Na(+),K(+) ATPase.",CONGESTIVE HEART FAILURE,DIGITALIS COMPOUNDS
790085255,9/17/2015 11:24:43,1740390176,9/17/2015 11:24:20,false,neodev,1.0,32695853,USA,NV,Las Vegas,192.30.80.172,[DIAGNOSE_BY_TEST_OR_DRUG] [PART_OF] [IS_A] [ASSOCIATED_WITH],"[DIAGNOSE_BY_TEST_OR_DRUG]
[ASSOCIATED_WITH]
[IS_A]
[PART_OF]",DRUG of with an without of,N/A,23,208,45,44,219,RO-may_prevent,820261-FS1,"We show that, even for DRUG RESISTANT MALARIA if 2 doses of chloroquine are given to a patient with an interval of some 10 days between them, parasites can be eliminated from the body without toxic levels of CHLOROQUINE being reached.",DRUG RESISTANT MALARIA,CHLOROQUINE
790085255,9/17/2015 11:35:36,1740392157,9/17/2015 11:35:14,false,neodev,1.0,30941227,USA,NV,Las Vegas,192.30.80.166,[PART_OF] [IS_A] [ASSOCIATED_WITH],"[ASSOCIATED_WITH]
[IS_A]
[PART_OF]",of with an of of,N/A,23,208,45,44,219,RO-may_prevent,820261-FS1,"We show that, even for DRUG RESISTANT MALARIA if 2 doses of chloroquine are given to a patient with an interval of some 10 days between them, parasites can be eliminated from the body without toxic levels of CHLOROQUINE being reached.",DRUG RESISTANT MALARIA,CHLOROQUINE
790085255,9/17/2015 11:42:17,1740393515,9/17/2015 11:41:00,false,neodev,1.0,30581619,USA,CA,San Jose,50.118.162.56,[NONE],[NONE],good,good,23,208,45,44,219,RO-may_prevent,820261-FS1,"We show that, even for DRUG RESISTANT MALARIA if 2 doses of chloroquine are given to a patient with an interval of some 10 days between them, parasites can be eliminated from the body without toxic levels of CHLOROQUINE being reached.",DRUG RESISTANT MALARIA,CHLOROQUINE
790085255,9/17/2015 12:10:38,1740399383,9/17/2015 12:10:05,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],eliminated,N/A,23,208,45,44,219,RO-may_prevent,820261-FS1,"We show that, even for DRUG RESISTANT MALARIA if 2 doses of chloroquine are given to a patient with an interval of some 10 days between them, parasites can be eliminated from the body without toxic levels of CHLOROQUINE being reached.",DRUG RESISTANT MALARIA,CHLOROQUINE
790085255,9/17/2015 12:36:42,1740405283,9/17/2015 12:36:16,false,neodev,1.0,30588889,NLD,07,Amsterdam,77.248.175.222,[ASSOCIATED_WITH],[ASSOCIATED_WITH],without being reached.,N/A,23,208,45,44,219,RO-may_prevent,820261-FS1,"We show that, even for DRUG RESISTANT MALARIA if 2 doses of chloroquine are given to a patient with an interval of some 10 days between them, parasites can be eliminated from the body without toxic levels of CHLOROQUINE being reached.",DRUG RESISTANT MALARIA,CHLOROQUINE
790085255,9/17/2015 12:45:01,1740407561,9/17/2015 12:44:33,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,[SYMPTOM],[SYMPTOM],DRUG RESISTANT MALARIA toxic levels of CHLOROQUINE,na,23,208,45,44,219,RO-may_prevent,820261-FS1,"We show that, even for DRUG RESISTANT MALARIA if 2 doses of chloroquine are given to a patient with an interval of some 10 days between them, parasites can be eliminated from the body without toxic levels of CHLOROQUINE being reached.",DRUG RESISTANT MALARIA,CHLOROQUINE
790085255,9/17/2015 12:47:43,1740408372,9/17/2015 12:46:16,false,prodege,1.0,2145087,USA,NY,New York,107.107.57.52,[ASSOCIATED_WITH],[ASSOCIATED_WITH],without,N/A,23,208,45,44,219,RO-may_prevent,820261-FS1,"We show that, even for DRUG RESISTANT MALARIA if 2 doses of chloroquine are given to a patient with an interval of some 10 days between them, parasites can be eliminated from the body without toxic levels of CHLOROQUINE being reached.",DRUG RESISTANT MALARIA,CHLOROQUINE
790085255,9/17/2015 13:17:39,1740416627,9/17/2015 13:17:26,false,neodev,1.0,33228343,USA,"","",38.95.108.251,[TREATS] [CAUSES] [SYMPTOM] [MANIFESTATION] [CONTRAINDICATES] [SIDE_EFFECT] [IS_A] [OTHER] [NONE],"[TREATS]
[CAUSES]
[SYMPTOM]
[MANIFESTATION]
[CONTRAINDICATES]
[SIDE_EFFECT]
[IS_A]
[OTHER]
[NONE]","We show that, even for DRUG RESISTANT MALARIA if 2 doses of chloroquine are given to a patient with an interval of some 10 days between them, parasites can be eliminated from the body without toxic levels of CHLOROQUINE being reached.","We show that, even for DRUG RESISTANT MALARIA if 2 doses of chloroquine are given to a patient with an interval of some 10 days between them, parasites can be eliminated from the body without toxic levels of CHLOROQUINE being reached.",23,208,45,44,219,RO-may_prevent,820261-FS1,"We show that, even for DRUG RESISTANT MALARIA if 2 doses of chloroquine are given to a patient with an interval of some 10 days between them, parasites can be eliminated from the body without toxic levels of CHLOROQUINE being reached.",DRUG RESISTANT MALARIA,CHLOROQUINE
790085255,9/17/2015 13:18:06,1740416807,9/17/2015 13:17:53,false,elite,1.0,31883685,GBR,"","",79.66.244.188,[TREATS],[TREATS],doses,n/a,23,208,45,44,219,RO-may_prevent,820261-FS1,"We show that, even for DRUG RESISTANT MALARIA if 2 doses of chloroquine are given to a patient with an interval of some 10 days between them, parasites can be eliminated from the body without toxic levels of CHLOROQUINE being reached.",DRUG RESISTANT MALARIA,CHLOROQUINE
790085255,9/17/2015 13:19:06,1740417077,9/17/2015 13:18:46,false,prodege,1.0,33854929,USA,CT,Wallingford,24.2.218.232,[TREATS],[TREATS],doses,n/a,23,208,45,44,219,RO-may_prevent,820261-FS1,"We show that, even for DRUG RESISTANT MALARIA if 2 doses of chloroquine are given to a patient with an interval of some 10 days between them, parasites can be eliminated from the body without toxic levels of CHLOROQUINE being reached.",DRUG RESISTANT MALARIA,CHLOROQUINE
790085255,9/17/2015 13:25:08,1740419023,9/17/2015 13:24:22,false,neodev,1.0,12115558,USA,OH,Twinsburg,98.27.164.131,[TREATS],[TREATS],DRUG RESISTANT MALARIA doses of chloroquine are given without toxic levels CHLOROQUINE,N/A,23,208,45,44,219,RO-may_prevent,820261-FS1,"We show that, even for DRUG RESISTANT MALARIA if 2 doses of chloroquine are given to a patient with an interval of some 10 days between them, parasites can be eliminated from the body without toxic levels of CHLOROQUINE being reached.",DRUG RESISTANT MALARIA,CHLOROQUINE
790085255,9/17/2015 13:25:17,1740419036,9/17/2015 13:24:55,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,[TREATS],[TREATS],given,n/a,23,208,45,44,219,RO-may_prevent,820261-FS1,"We show that, even for DRUG RESISTANT MALARIA if 2 doses of chloroquine are given to a patient with an interval of some 10 days between them, parasites can be eliminated from the body without toxic levels of CHLOROQUINE being reached.",DRUG RESISTANT MALARIA,CHLOROQUINE
790085255,9/17/2015 13:26:14,1740419323,9/17/2015 13:25:42,false,prodege,1.0,27934334,GBR,C8,Croydon,81.159.60.206,[TREATS],[TREATS],given to patient,N/A,23,208,45,44,219,RO-may_prevent,820261-FS1,"We show that, even for DRUG RESISTANT MALARIA if 2 doses of chloroquine are given to a patient with an interval of some 10 days between them, parasites can be eliminated from the body without toxic levels of CHLOROQUINE being reached.",DRUG RESISTANT MALARIA,CHLOROQUINE
790085255,9/17/2015 13:35:18,1740422156,9/17/2015 13:35:08,false,bitcoinget,1.0,31256687,USA,NY,Poughkeepsie,67.82.252.135,[TREATS],[TREATS],eliminated,n/a,23,208,45,44,219,RO-may_prevent,820261-FS1,"We show that, even for DRUG RESISTANT MALARIA if 2 doses of chloroquine are given to a patient with an interval of some 10 days between them, parasites can be eliminated from the body without toxic levels of CHLOROQUINE being reached.",DRUG RESISTANT MALARIA,CHLOROQUINE
790085255,9/17/2015 13:51:13,1740429453,9/17/2015 13:50:50,false,neodev,1.0,31329809,USA,DE,Wilmington,162.223.93.194,[DIAGNOSE_BY_TEST_OR_DRUG] [PART_OF] [IS_A] [ASSOCIATED_WITH],"[DIAGNOSE_BY_TEST_OR_DRUG]
[ASSOCIATED_WITH]
[IS_A]
[PART_OF]",DRUG of a with an of of,N/A,23,208,45,44,219,RO-may_prevent,820261-FS1,"We show that, even for DRUG RESISTANT MALARIA if 2 doses of chloroquine are given to a patient with an interval of some 10 days between them, parasites can be eliminated from the body without toxic levels of CHLOROQUINE being reached.",DRUG RESISTANT MALARIA,CHLOROQUINE
790085256,9/17/2015 11:27:21,1740390738,9/17/2015 11:25:52,false,neodev,1.0,32695853,USA,NV,Las Vegas,192.30.80.172,[OTHER],[OTHER],HBcAg),N/A,107,138,118,135,143,RO-may_prevent,820184-FS1,Forty five blood recipients were considered susceptible to hepatitis B virus infection because testing for HEPATITIS B SEROLOGY IN SERUM (HBSAG antibody to HBsAg and antibody to HBcAg) was negative before being transfused.,HEPATITIS B SEROLOGY IN SERUM,HBSAG
790085256,9/17/2015 11:36:46,1740392437,9/17/2015 11:36:27,false,neodev,1.0,30941227,USA,NV,Las Vegas,192.30.80.166,[OTHER],[OTHER],HBcAg),N/A,107,138,118,135,143,RO-may_prevent,820184-FS1,Forty five blood recipients were considered susceptible to hepatitis B virus infection because testing for HEPATITIS B SEROLOGY IN SERUM (HBSAG antibody to HBsAg and antibody to HBcAg) was negative before being transfused.,HEPATITIS B SEROLOGY IN SERUM,HBSAG
790085256,9/17/2015 12:12:03,1740399652,9/17/2015 12:11:47,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[CAUSES],[CAUSES],because,N/A,107,138,118,135,143,RO-may_prevent,820184-FS1,Forty five blood recipients were considered susceptible to hepatitis B virus infection because testing for HEPATITIS B SEROLOGY IN SERUM (HBSAG antibody to HBsAg and antibody to HBcAg) was negative before being transfused.,HEPATITIS B SEROLOGY IN SERUM,HBSAG
790085256,9/17/2015 12:37:39,1740405486,9/17/2015 12:37:10,false,neodev,1.0,30588889,NLD,07,Amsterdam,77.248.175.222,[IS_A],[IS_A],(HBSAG,N/A,107,138,118,135,143,RO-may_prevent,820184-FS1,Forty five blood recipients were considered susceptible to hepatitis B virus infection because testing for HEPATITIS B SEROLOGY IN SERUM (HBSAG antibody to HBsAg and antibody to HBcAg) was negative before being transfused.,HEPATITIS B SEROLOGY IN SERUM,HBSAG
790085256,9/17/2015 12:46:48,1740408092,9/17/2015 12:46:17,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,[ASSOCIATED_WITH],[ASSOCIATED_WITH],HEPATITIS B SEROLOGY IN SERUM and HBcAg),na,107,138,118,135,143,RO-may_prevent,820184-FS1,Forty five blood recipients were considered susceptible to hepatitis B virus infection because testing for HEPATITIS B SEROLOGY IN SERUM (HBSAG antibody to HBsAg and antibody to HBcAg) was negative before being transfused.,HEPATITIS B SEROLOGY IN SERUM,HBSAG
790085256,9/17/2015 12:48:55,1740408749,9/17/2015 12:48:21,false,prodege,1.0,2145087,USA,NY,New York,107.107.57.52,[ASSOCIATED_WITH],[ASSOCIATED_WITH],testing for,N/A,107,138,118,135,143,RO-may_prevent,820184-FS1,Forty five blood recipients were considered susceptible to hepatitis B virus infection because testing for HEPATITIS B SEROLOGY IN SERUM (HBSAG antibody to HBsAg and antibody to HBcAg) was negative before being transfused.,HEPATITIS B SEROLOGY IN SERUM,HBSAG
790085256,9/17/2015 13:18:28,1740416909,9/17/2015 13:18:12,false,neodev,1.0,33228343,USA,"","",38.95.108.251,[TREATS] [PREVENTS] [DIAGNOSE_BY_TEST_OR_DRUG] [CONTRAINDICATES] [OTHER] [NONE],"[TREATS]
[PREVENTS]
[DIAGNOSE_BY_TEST_OR_DRUG]
[CONTRAINDICATES]
[OTHER]
[NONE]",Forty five blood recipients were considered susceptible to hepatitis B virus infection because testing for HEPATITIS B SEROLOGY IN SERUM (HBSAG antibody to HBsAg and antibody to HBcAg) was negative before being transfused.,Forty five blood recipients were considered susceptible to hepatitis B virus infection because testing for HEPATITIS B SEROLOGY IN SERUM (HBSAG antibody to HBsAg and antibody to HBcAg) was negative before being transfused.,107,138,118,135,143,RO-may_prevent,820184-FS1,Forty five blood recipients were considered susceptible to hepatitis B virus infection because testing for HEPATITIS B SEROLOGY IN SERUM (HBSAG antibody to HBsAg and antibody to HBcAg) was negative before being transfused.,HEPATITIS B SEROLOGY IN SERUM,HBSAG
790085256,9/17/2015 13:19:00,1740417054,9/17/2015 13:18:42,false,elite,1.0,31883685,GBR,"","",79.66.244.188,[ASSOCIATED_WITH],[ASSOCIATED_WITH],antibody,n/a,107,138,118,135,143,RO-may_prevent,820184-FS1,Forty five blood recipients were considered susceptible to hepatitis B virus infection because testing for HEPATITIS B SEROLOGY IN SERUM (HBSAG antibody to HBsAg and antibody to HBcAg) was negative before being transfused.,HEPATITIS B SEROLOGY IN SERUM,HBSAG
790085256,9/17/2015 13:20:13,1740417530,9/17/2015 13:19:47,false,prodege,1.0,33854929,USA,CT,Wallingford,24.2.218.232,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],testing,n/a,107,138,118,135,143,RO-may_prevent,820184-FS1,Forty five blood recipients were considered susceptible to hepatitis B virus infection because testing for HEPATITIS B SEROLOGY IN SERUM (HBSAG antibody to HBsAg and antibody to HBcAg) was negative before being transfused.,HEPATITIS B SEROLOGY IN SERUM,HBSAG
790085256,9/17/2015 13:26:43,1740419526,9/17/2015 13:26:08,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,[CAUSES],[CAUSES],susceptible,n/a,107,138,118,135,143,RO-may_prevent,820184-FS1,Forty five blood recipients were considered susceptible to hepatitis B virus infection because testing for HEPATITIS B SEROLOGY IN SERUM (HBSAG antibody to HBsAg and antibody to HBcAg) was negative before being transfused.,HEPATITIS B SEROLOGY IN SERUM,HBSAG
790085256,9/17/2015 13:26:43,1740419538,9/17/2015 13:26:01,false,neodev,1.0,12115558,USA,OH,Twinsburg,98.27.164.131,[OTHER],[OTHER],HEPATITIS B SEROLOGY IN SERUM (HBSAG,N/A,107,138,118,135,143,RO-may_prevent,820184-FS1,Forty five blood recipients were considered susceptible to hepatitis B virus infection because testing for HEPATITIS B SEROLOGY IN SERUM (HBSAG antibody to HBsAg and antibody to HBcAg) was negative before being transfused.,HEPATITIS B SEROLOGY IN SERUM,HBSAG
790085256,9/17/2015 13:28:07,1740419880,9/17/2015 13:26:56,false,prodege,1.0,27934334,GBR,C8,Croydon,81.159.60.206,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],testing for,N/A,107,138,118,135,143,RO-may_prevent,820184-FS1,Forty five blood recipients were considered susceptible to hepatitis B virus infection because testing for HEPATITIS B SEROLOGY IN SERUM (HBSAG antibody to HBsAg and antibody to HBcAg) was negative before being transfused.,HEPATITIS B SEROLOGY IN SERUM,HBSAG
790085256,9/17/2015 13:36:07,1740422820,9/17/2015 13:35:52,false,bitcoinget,1.0,31256687,USA,NY,Poughkeepsie,67.82.252.135,[OTHER],[OTHER],negative,n/a,107,138,118,135,143,RO-may_prevent,820184-FS1,Forty five blood recipients were considered susceptible to hepatitis B virus infection because testing for HEPATITIS B SEROLOGY IN SERUM (HBSAG antibody to HBsAg and antibody to HBcAg) was negative before being transfused.,HEPATITIS B SEROLOGY IN SERUM,HBSAG
790085256,9/17/2015 13:51:41,1740429570,9/17/2015 13:51:16,false,neodev,1.0,31329809,USA,DE,Wilmington,162.223.93.194,[OTHER],[OTHER],HBsAg HBcAg),N/A,107,138,118,135,143,RO-may_prevent,820184-FS1,Forty five blood recipients were considered susceptible to hepatitis B virus infection because testing for HEPATITIS B SEROLOGY IN SERUM (HBSAG antibody to HBsAg and antibody to HBcAg) was negative before being transfused.,HEPATITIS B SEROLOGY IN SERUM,HBSAG
790085256,9/17/2015 14:04:52,1740434098,9/17/2015 14:04:02,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.124.79,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],testing for,N/A,107,138,118,135,143,RO-may_prevent,820184-FS1,Forty five blood recipients were considered susceptible to hepatitis B virus infection because testing for HEPATITIS B SEROLOGY IN SERUM (HBSAG antibody to HBsAg and antibody to HBcAg) was negative before being transfused.,HEPATITIS B SEROLOGY IN SERUM,HBSAG
790085257,9/17/2015 09:20:00,1740363994,9/17/2015 09:19:33,false,neodev,1.0,32053642,GBR,I7,Newcastle Upon Tyne,92.23.136.205,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],performed experiments,N/A,128,67,155,167,78,RO-may_prevent,820262-FS1,To investigate the antagonism between isoniazid (INH) and rifampin RIFAMPICIN (RIF) pyrazinamide (PZA) combination observed in MYCOBACTERIUM TUBERCULOSIS INFECTED MICE extensive pharmacokinetic studies of INH were performed and followed by experiments to assess the impact of increasing doses of INH on the antimicrobial activity of RIF PZA combination.,MYCOBACTERIUM TUBERCULOSIS INFECTED MICE,RIFAMPICIN
790085257,9/17/2015 09:20:08,1740364007,9/17/2015 09:19:53,false,elite,1.0,30659754,USA,"","",162.250.145.204,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],observed in,N/A,128,67,155,167,78,RO-may_prevent,820262-FS1,To investigate the antagonism between isoniazid (INH) and rifampin RIFAMPICIN (RIF) pyrazinamide (PZA) combination observed in MYCOBACTERIUM TUBERCULOSIS INFECTED MICE extensive pharmacokinetic studies of INH were performed and followed by experiments to assess the impact of increasing doses of INH on the antimicrobial activity of RIF PZA combination.,MYCOBACTERIUM TUBERCULOSIS INFECTED MICE,RIFAMPICIN
790085257,9/17/2015 09:27:29,1740365482,9/17/2015 09:26:52,false,instagc,1.0,18960682,GBR,U2,Annan,92.18.213.181,[CAUSES],[CAUSES],investigate the antagonism between isoniazid (INH) and rifampin observed in MYCOBACTERIUM TUBERCULOSIS INFECTED MICE,N/A,128,67,155,167,78,RO-may_prevent,820262-FS1,To investigate the antagonism between isoniazid (INH) and rifampin RIFAMPICIN (RIF) pyrazinamide (PZA) combination observed in MYCOBACTERIUM TUBERCULOSIS INFECTED MICE extensive pharmacokinetic studies of INH were performed and followed by experiments to assess the impact of increasing doses of INH on the antimicrobial activity of RIF PZA combination.,MYCOBACTERIUM TUBERCULOSIS INFECTED MICE,RIFAMPICIN
790085257,9/17/2015 09:31:14,1740366348,9/17/2015 09:30:47,false,neodev,1.0,15848372,AUS,02,Jannali,14.200.59.55,[ASSOCIATED_WITH],[ASSOCIATED_WITH],observed in,n/a,128,67,155,167,78,RO-may_prevent,820262-FS1,To investigate the antagonism between isoniazid (INH) and rifampin RIFAMPICIN (RIF) pyrazinamide (PZA) combination observed in MYCOBACTERIUM TUBERCULOSIS INFECTED MICE extensive pharmacokinetic studies of INH were performed and followed by experiments to assess the impact of increasing doses of INH on the antimicrobial activity of RIF PZA combination.,MYCOBACTERIUM TUBERCULOSIS INFECTED MICE,RIFAMPICIN
790085257,9/17/2015 09:32:09,1740366643,9/17/2015 09:31:20,false,neodev,1.0,33644825,USA,FL,Fort Lauderdale,65.111.173.161,[CAUSES],[CAUSES],RIFAMPICIN MYCOBACTERIUM TUBERCULOSIS INFECTED MICE,prevents,128,67,155,167,78,RO-may_prevent,820262-FS1,To investigate the antagonism between isoniazid (INH) and rifampin RIFAMPICIN (RIF) pyrazinamide (PZA) combination observed in MYCOBACTERIUM TUBERCULOSIS INFECTED MICE extensive pharmacokinetic studies of INH were performed and followed by experiments to assess the impact of increasing doses of INH on the antimicrobial activity of RIF PZA combination.,MYCOBACTERIUM TUBERCULOSIS INFECTED MICE,RIFAMPICIN
790085257,9/17/2015 09:38:07,1740367968,9/17/2015 09:37:53,false,elite,1.0,30659615,USA,"","",162.250.145.234,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],combination observed,N/A,128,67,155,167,78,RO-may_prevent,820262-FS1,To investigate the antagonism between isoniazid (INH) and rifampin RIFAMPICIN (RIF) pyrazinamide (PZA) combination observed in MYCOBACTERIUM TUBERCULOSIS INFECTED MICE extensive pharmacokinetic studies of INH were performed and followed by experiments to assess the impact of increasing doses of INH on the antimicrobial activity of RIF PZA combination.,MYCOBACTERIUM TUBERCULOSIS INFECTED MICE,RIFAMPICIN
790085257,9/17/2015 09:46:59,1740370103,9/17/2015 09:46:26,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[TREATS],[TREATS],increasing doses,N/A,128,67,155,167,78,RO-may_prevent,820262-FS1,To investigate the antagonism between isoniazid (INH) and rifampin RIFAMPICIN (RIF) pyrazinamide (PZA) combination observed in MYCOBACTERIUM TUBERCULOSIS INFECTED MICE extensive pharmacokinetic studies of INH were performed and followed by experiments to assess the impact of increasing doses of INH on the antimicrobial activity of RIF PZA combination.,MYCOBACTERIUM TUBERCULOSIS INFECTED MICE,RIFAMPICIN
790085257,9/17/2015 09:47:29,1740370173,9/17/2015 09:47:11,false,neodev,1.0,21515166,NLD,11,Nieuwkoop,83.84.200.25,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],observed in,n/a,128,67,155,167,78,RO-may_prevent,820262-FS1,To investigate the antagonism between isoniazid (INH) and rifampin RIFAMPICIN (RIF) pyrazinamide (PZA) combination observed in MYCOBACTERIUM TUBERCULOSIS INFECTED MICE extensive pharmacokinetic studies of INH were performed and followed by experiments to assess the impact of increasing doses of INH on the antimicrobial activity of RIF PZA combination.,MYCOBACTERIUM TUBERCULOSIS INFECTED MICE,RIFAMPICIN
790085257,9/17/2015 09:47:37,1740370196,9/17/2015 09:47:02,false,pocketmoneygpt,1.0,21432964,GBR,F8,Borehamwood,81.159.185.70,[ASSOCIATED_WITH],[ASSOCIATED_WITH],combination observed in,N/A,128,67,155,167,78,RO-may_prevent,820262-FS1,To investigate the antagonism between isoniazid (INH) and rifampin RIFAMPICIN (RIF) pyrazinamide (PZA) combination observed in MYCOBACTERIUM TUBERCULOSIS INFECTED MICE extensive pharmacokinetic studies of INH were performed and followed by experiments to assess the impact of increasing doses of INH on the antimicrobial activity of RIF PZA combination.,MYCOBACTERIUM TUBERCULOSIS INFECTED MICE,RIFAMPICIN
790085257,9/17/2015 09:54:01,1740371747,9/17/2015 09:53:46,false,elite,1.0,30659677,USA,"","",162.252.172.126,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],observed,N/A,128,67,155,167,78,RO-may_prevent,820262-FS1,To investigate the antagonism between isoniazid (INH) and rifampin RIFAMPICIN (RIF) pyrazinamide (PZA) combination observed in MYCOBACTERIUM TUBERCULOSIS INFECTED MICE extensive pharmacokinetic studies of INH were performed and followed by experiments to assess the impact of increasing doses of INH on the antimicrobial activity of RIF PZA combination.,MYCOBACTERIUM TUBERCULOSIS INFECTED MICE,RIFAMPICIN
790085257,9/17/2015 10:14:51,1740376937,9/17/2015 10:14:03,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[ASSOCIATED_WITH],[ASSOCIATED_WITH],investigate the antagonism between isoniazid (INH) and rifampin RIFAMPICIN (RIF) in MYCOBACTERIUM TUBERCULOSIS INFECTED MICE,N/A,128,67,155,167,78,RO-may_prevent,820262-FS1,To investigate the antagonism between isoniazid (INH) and rifampin RIFAMPICIN (RIF) pyrazinamide (PZA) combination observed in MYCOBACTERIUM TUBERCULOSIS INFECTED MICE extensive pharmacokinetic studies of INH were performed and followed by experiments to assess the impact of increasing doses of INH on the antimicrobial activity of RIF PZA combination.,MYCOBACTERIUM TUBERCULOSIS INFECTED MICE,RIFAMPICIN
790085257,9/17/2015 10:32:21,1740380302,9/17/2015 10:32:02,false,pocketmoneygpt,1.0,28884030,USA,WI,Minocqua,75.143.134.247,[PART_OF],[PART_OF],in,n/a,128,67,155,167,78,RO-may_prevent,820262-FS1,To investigate the antagonism between isoniazid (INH) and rifampin RIFAMPICIN (RIF) pyrazinamide (PZA) combination observed in MYCOBACTERIUM TUBERCULOSIS INFECTED MICE extensive pharmacokinetic studies of INH were performed and followed by experiments to assess the impact of increasing doses of INH on the antimicrobial activity of RIF PZA combination.,MYCOBACTERIUM TUBERCULOSIS INFECTED MICE,RIFAMPICIN
790085257,9/17/2015 10:43:25,1740382588,9/17/2015 10:43:05,false,clixsense,1.0,17950689,GBR,L9,Sheffield,146.200.192.103,[TREATS],[TREATS],TUBERCULOSIS,NONE,128,67,155,167,78,RO-may_prevent,820262-FS1,To investigate the antagonism between isoniazid (INH) and rifampin RIFAMPICIN (RIF) pyrazinamide (PZA) combination observed in MYCOBACTERIUM TUBERCULOSIS INFECTED MICE extensive pharmacokinetic studies of INH were performed and followed by experiments to assess the impact of increasing doses of INH on the antimicrobial activity of RIF PZA combination.,MYCOBACTERIUM TUBERCULOSIS INFECTED MICE,RIFAMPICIN
790085257,9/17/2015 10:56:03,1740384828,9/17/2015 10:55:22,false,neodev,1.0,30581619,USA,CA,San Jose,50.118.162.56,[TREATS] [NONE],"[TREATS]
[NONE]",good,good,128,67,155,167,78,RO-may_prevent,820262-FS1,To investigate the antagonism between isoniazid (INH) and rifampin RIFAMPICIN (RIF) pyrazinamide (PZA) combination observed in MYCOBACTERIUM TUBERCULOSIS INFECTED MICE extensive pharmacokinetic studies of INH were performed and followed by experiments to assess the impact of increasing doses of INH on the antimicrobial activity of RIF PZA combination.,MYCOBACTERIUM TUBERCULOSIS INFECTED MICE,RIFAMPICIN
790085257,9/17/2015 10:57:36,1740385128,9/17/2015 10:56:03,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[OTHER],[OTHER],observed in,N/A,128,67,155,167,78,RO-may_prevent,820262-FS1,To investigate the antagonism between isoniazid (INH) and rifampin RIFAMPICIN (RIF) pyrazinamide (PZA) combination observed in MYCOBACTERIUM TUBERCULOSIS INFECTED MICE extensive pharmacokinetic studies of INH were performed and followed by experiments to assess the impact of increasing doses of INH on the antimicrobial activity of RIF PZA combination.,MYCOBACTERIUM TUBERCULOSIS INFECTED MICE,RIFAMPICIN
790085258,9/17/2015 13:32:37,1740421392,9/17/2015 13:32:14,false,instagc,1,13581319,USA,IL,Trenton,208.70.36.12,[TREATS],[TREATS],treatment of,n/a,135,76,157,166,87,RO-may_prevent,820186-FS1,The aim of this study was to compare the anti emetic efficacy and safety of ONDANSETRON placebo and metoclopramide in the treatment of OPIOID INDUCED NAUSEA AND EMESIS (OIE) in cancer patients.,OPIOID INDUCED NAUSEA AND EMESIS,ONDANSETRON
790085258,9/17/2015 13:38:30,1740425300,9/17/2015 13:38:10,false,prodege,1,27934334,GBR,C8,Croydon,81.159.60.206,[TREATS],[TREATS],treatment of,N/A,135,76,157,166,87,RO-may_prevent,820186-FS1,The aim of this study was to compare the anti emetic efficacy and safety of ONDANSETRON placebo and metoclopramide in the treatment of OPIOID INDUCED NAUSEA AND EMESIS (OIE) in cancer patients.,OPIOID INDUCED NAUSEA AND EMESIS,ONDANSETRON
790085258,9/17/2015 14:07:58,1740435229,9/17/2015 14:07:32,false,gifthunterclub,1,30901412,GBR,H9,London,77.89.149.62,[TREATS],[TREATS],ONDANSETRON treatment of OPIOID INDUCED NAUSEA AND EMESIS (OIE),N/A,135,76,157,166,87,RO-may_prevent,820186-FS1,The aim of this study was to compare the anti emetic efficacy and safety of ONDANSETRON placebo and metoclopramide in the treatment of OPIOID INDUCED NAUSEA AND EMESIS (OIE) in cancer patients.,OPIOID INDUCED NAUSEA AND EMESIS,ONDANSETRON
790085258,9/17/2015 14:14:29,1740437609,9/17/2015 14:14:15,false,onestopgpt,1,21275875,CAN,ON,Hamilton,24.36.124.79,[TREATS],[TREATS],treatment of,N/A,135,76,157,166,87,RO-may_prevent,820186-FS1,The aim of this study was to compare the anti emetic efficacy and safety of ONDANSETRON placebo and metoclopramide in the treatment of OPIOID INDUCED NAUSEA AND EMESIS (OIE) in cancer patients.,OPIOID INDUCED NAUSEA AND EMESIS,ONDANSETRON
790085258,9/17/2015 14:19:10,1740439375,9/17/2015 14:18:02,false,zoombucks,1,6744840,CAN,BC,Kelowna,174.4.58.160,[TREATS],[TREATS],treatment,N/A,135,76,157,166,87,RO-may_prevent,820186-FS1,The aim of this study was to compare the anti emetic efficacy and safety of ONDANSETRON placebo and metoclopramide in the treatment of OPIOID INDUCED NAUSEA AND EMESIS (OIE) in cancer patients.,OPIOID INDUCED NAUSEA AND EMESIS,ONDANSETRON
790085258,9/17/2015 14:33:36,1740444603,9/17/2015 14:33:24,false,bitcoinget,1,32306192,USA,MA,Amherst,72.19.88.245,[TREATS],[TREATS],ONDANSETRON,N/a,135,76,157,166,87,RO-may_prevent,820186-FS1,The aim of this study was to compare the anti emetic efficacy and safety of ONDANSETRON placebo and metoclopramide in the treatment of OPIOID INDUCED NAUSEA AND EMESIS (OIE) in cancer patients.,OPIOID INDUCED NAUSEA AND EMESIS,ONDANSETRON
790085258,9/17/2015 14:46:47,1740449990,9/17/2015 14:45:43,false,clixsense,1,32049531,USA,"","",38.95.108.252,[NONE],[NONE],none,none,135,76,157,166,87,RO-may_prevent,820186-FS1,The aim of this study was to compare the anti emetic efficacy and safety of ONDANSETRON placebo and metoclopramide in the treatment of OPIOID INDUCED NAUSEA AND EMESIS (OIE) in cancer patients.,OPIOID INDUCED NAUSEA AND EMESIS,ONDANSETRON
790085258,9/17/2015 14:51:36,1740451838,9/17/2015 14:50:37,false,instagc,1.0,22981457,CAN,ON,Ottawa,67.69.8.122,[OTHER],[OTHER],placebo treatment,It is saying comparing two treatments,135,76,157,166,87,RO-may_prevent,820186-FS1,The aim of this study was to compare the anti emetic efficacy and safety of ONDANSETRON placebo and metoclopramide in the treatment of OPIOID INDUCED NAUSEA AND EMESIS (OIE) in cancer patients.,OPIOID INDUCED NAUSEA AND EMESIS,ONDANSETRON
790085258,9/17/2015 14:58:37,1740454348,9/17/2015 14:58:14,false,clixsense,1,33115750,GBR,I3,Rochester,90.222.106.192,[TREATS],[TREATS],treatment of,N/A,135,76,157,166,87,RO-may_prevent,820186-FS1,The aim of this study was to compare the anti emetic efficacy and safety of ONDANSETRON placebo and metoclopramide in the treatment of OPIOID INDUCED NAUSEA AND EMESIS (OIE) in cancer patients.,OPIOID INDUCED NAUSEA AND EMESIS,ONDANSETRON
790085258,9/17/2015 15:01:31,1740455450,9/17/2015 15:00:55,false,neodev,1.0,31329809,USA,DE,Wilmington,162.223.93.194,[PART_OF] [TREATS],"[TREATS]
[PART_OF]",of treatment of,N/A,135,76,157,166,87,RO-may_prevent,820186-FS1,The aim of this study was to compare the anti emetic efficacy and safety of ONDANSETRON placebo and metoclopramide in the treatment of OPIOID INDUCED NAUSEA AND EMESIS (OIE) in cancer patients.,OPIOID INDUCED NAUSEA AND EMESIS,ONDANSETRON
790085258,9/17/2015 15:11:58,1740458881,9/17/2015 15:11:47,false,neodev,1,34431172,USA,CA,Torrance,66.171.228.183,[SYMPTOM] [LOCATION] [NONE],"[LOCATION]
[SYMPTOM]
[NONE]",no,no,135,76,157,166,87,RO-may_prevent,820186-FS1,The aim of this study was to compare the anti emetic efficacy and safety of ONDANSETRON placebo and metoclopramide in the treatment of OPIOID INDUCED NAUSEA AND EMESIS (OIE) in cancer patients.,OPIOID INDUCED NAUSEA AND EMESIS,ONDANSETRON
790085258,9/17/2015 15:13:24,1740459289,9/17/2015 15:13:08,false,neodev,1,30321275,USA,NV,Las Vegas,192.30.80.4,[PART_OF] [TREATS],"[TREATS]
[PART_OF]",of of treatment of,N/A,135,76,157,166,87,RO-may_prevent,820186-FS1,The aim of this study was to compare the anti emetic efficacy and safety of ONDANSETRON placebo and metoclopramide in the treatment of OPIOID INDUCED NAUSEA AND EMESIS (OIE) in cancer patients.,OPIOID INDUCED NAUSEA AND EMESIS,ONDANSETRON
790085258,9/17/2015 15:18:47,1740461263,9/17/2015 15:18:23,false,neodev,1,29363385,USA,DE,Wilmington,162.223.93.162,[PART_OF] [TREATS],"[TREATS]
[PART_OF]",of of treatment of,N/A,135,76,157,166,87,RO-may_prevent,820186-FS1,The aim of this study was to compare the anti emetic efficacy and safety of ONDANSETRON placebo and metoclopramide in the treatment of OPIOID INDUCED NAUSEA AND EMESIS (OIE) in cancer patients.,OPIOID INDUCED NAUSEA AND EMESIS,ONDANSETRON
790085258,9/17/2015 15:20:44,1740462134,9/17/2015 15:20:16,false,neodev,1.0,12115558,USA,OH,Twinsburg,98.27.164.131,[TREATS],[TREATS],treatment,N/A,135,76,157,166,87,RO-may_prevent,820186-FS1,The aim of this study was to compare the anti emetic efficacy and safety of ONDANSETRON placebo and metoclopramide in the treatment of OPIOID INDUCED NAUSEA AND EMESIS (OIE) in cancer patients.,OPIOID INDUCED NAUSEA AND EMESIS,ONDANSETRON
790085258,9/17/2015 15:25:48,1740463877,9/17/2015 15:25:17,false,neodev,1,33435788,USA,DE,Wilmington,162.223.93.179,[PART_OF] [TREATS],"[TREATS]
[PART_OF]",of of treatment of,N/A,135,76,157,166,87,RO-may_prevent,820186-FS1,The aim of this study was to compare the anti emetic efficacy and safety of ONDANSETRON placebo and metoclopramide in the treatment of OPIOID INDUCED NAUSEA AND EMESIS (OIE) in cancer patients.,OPIOID INDUCED NAUSEA AND EMESIS,ONDANSETRON
790085259,9/17/2015 11:27:45,1740390780,9/17/2015 11:27:26,false,neodev,1.0,32695853,USA,NV,Las Vegas,192.30.80.172,[PART_OF],[PART_OF],of,N/A,110,63,18,122,70,RO-may_treat,820021-FS1,"109  Hyperglycemia  In diabetic patients, dosage adjustment of INSULIN or oral hypoglycemics may be required; HYPERGLYCEMIA may occur and latent diabetes mellitus may become evident.",HYPERGLYCEMIA,INSULIN
790085259,9/17/2015 11:37:04,1740392520,9/17/2015 11:36:49,false,neodev,1.0,30941227,USA,NV,Las Vegas,192.30.80.166,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],or,N/A,110,63,18,122,70,RO-may_treat,820021-FS1,"109  Hyperglycemia  In diabetic patients, dosage adjustment of INSULIN or oral hypoglycemics may be required; HYPERGLYCEMIA may occur and latent diabetes mellitus may become evident.",HYPERGLYCEMIA,INSULIN
790085259,9/17/2015 12:12:19,1740399725,9/17/2015 12:12:05,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],dosage,N/A,110,63,18,122,70,RO-may_treat,820021-FS1,"109  Hyperglycemia  In diabetic patients, dosage adjustment of INSULIN or oral hypoglycemics may be required; HYPERGLYCEMIA may occur and latent diabetes mellitus may become evident.",HYPERGLYCEMIA,INSULIN
790085259,9/17/2015 12:38:11,1740405582,9/17/2015 12:37:40,false,neodev,1.0,30588889,NLD,07,Amsterdam,77.248.175.222,[ASSOCIATED_WITH],[ASSOCIATED_WITH],may be required;,N/A,110,63,18,122,70,RO-may_treat,820021-FS1,"109  Hyperglycemia  In diabetic patients, dosage adjustment of INSULIN or oral hypoglycemics may be required; HYPERGLYCEMIA may occur and latent diabetes mellitus may become evident.",HYPERGLYCEMIA,INSULIN
790085259,9/17/2015 12:47:13,1740408220,9/17/2015 12:46:49,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,[MANIFESTATION],[MANIFESTATION],adjustment of INSULIN HYPERGLYCEMIA may occur,na,110,63,18,122,70,RO-may_treat,820021-FS1,"109  Hyperglycemia  In diabetic patients, dosage adjustment of INSULIN or oral hypoglycemics may be required; HYPERGLYCEMIA may occur and latent diabetes mellitus may become evident.",HYPERGLYCEMIA,INSULIN
790085259,9/17/2015 12:49:23,1740408900,9/17/2015 12:48:57,false,prodege,1.0,2145087,USA,NY,New York,107.107.57.52,[CAUSES],[CAUSES],dosage adjustment may be required;,N/A,110,63,18,122,70,RO-may_treat,820021-FS1,"109  Hyperglycemia  In diabetic patients, dosage adjustment of INSULIN or oral hypoglycemics may be required; HYPERGLYCEMIA may occur and latent diabetes mellitus may become evident.",HYPERGLYCEMIA,INSULIN
790085259,9/17/2015 13:18:44,1740416979,9/17/2015 13:18:30,false,neodev,1.0,33228343,USA,"","",38.95.108.251,[PREVENTS] [TREATS] [CAUSES] [MANIFESTATION] [ASSOCIATED_WITH] [IS_A] [PART_OF] [NONE],"[TREATS]
[PREVENTS]
[CAUSES]
[MANIFESTATION]
[ASSOCIATED_WITH]
[IS_A]
[PART_OF]
[NONE]","Hyperglycemia In diabetic patients, dosage adjustment of INSULIN or oral hypoglycemics may be required; HYPERGLYCEMIA may occur and latent diabetes mellitus may become evident.  Is  HYPERGLYCEMIA ----rela","Hyperglycemia In diabetic patients, dosage adjustment of INSULIN or oral hypoglycemics may be required; HYPERGLYCEMIA may occur and latent diabetes mellitus may become evident.

Is  HYPERGLYCEMIA ----rela",110,63,18,122,70,RO-may_treat,820021-FS1,"109  Hyperglycemia  In diabetic patients, dosage adjustment of INSULIN or oral hypoglycemics may be required; HYPERGLYCEMIA may occur and latent diabetes mellitus may become evident.",HYPERGLYCEMIA,INSULIN
790085259,9/17/2015 13:19:21,1740417164,9/17/2015 13:19:01,false,elite,1.0,31883685,GBR,"","",79.66.244.188,[SYMPTOM],[SYMPTOM],may occur,n/a,110,63,18,122,70,RO-may_treat,820021-FS1,"109  Hyperglycemia  In diabetic patients, dosage adjustment of INSULIN or oral hypoglycemics may be required; HYPERGLYCEMIA may occur and latent diabetes mellitus may become evident.",HYPERGLYCEMIA,INSULIN
790085259,9/17/2015 13:20:37,1740417702,9/17/2015 13:20:14,false,prodege,1.0,33854929,USA,CT,Wallingford,24.2.218.232,[TREATS],[TREATS],dosage,n/a,110,63,18,122,70,RO-may_treat,820021-FS1,"109  Hyperglycemia  In diabetic patients, dosage adjustment of INSULIN or oral hypoglycemics may be required; HYPERGLYCEMIA may occur and latent diabetes mellitus may become evident.",HYPERGLYCEMIA,INSULIN
790085259,9/17/2015 13:26:55,1740419572,9/17/2015 13:26:44,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,[TREATS],[TREATS],dosage adjustment,n/a,110,63,18,122,70,RO-may_treat,820021-FS1,"109  Hyperglycemia  In diabetic patients, dosage adjustment of INSULIN or oral hypoglycemics may be required; HYPERGLYCEMIA may occur and latent diabetes mellitus may become evident.",HYPERGLYCEMIA,INSULIN
790085259,9/17/2015 13:27:34,1740419765,9/17/2015 13:26:44,false,neodev,1.0,12115558,USA,OH,Twinsburg,98.27.164.131,[SYMPTOM] [TREATS],"[TREATS]
[SYMPTOM]",Hyperglycemia dosage adjustment of INSULIN,N/A,110,63,18,122,70,RO-may_treat,820021-FS1,"109  Hyperglycemia  In diabetic patients, dosage adjustment of INSULIN or oral hypoglycemics may be required; HYPERGLYCEMIA may occur and latent diabetes mellitus may become evident.",HYPERGLYCEMIA,INSULIN
790085259,9/17/2015 13:29:07,1740420174,9/17/2015 13:28:08,false,prodege,1.0,27934334,GBR,C8,Croydon,81.159.60.206,[TREATS],[TREATS],dosage adjustment of,N/A,110,63,18,122,70,RO-may_treat,820021-FS1,"109  Hyperglycemia  In diabetic patients, dosage adjustment of INSULIN or oral hypoglycemics may be required; HYPERGLYCEMIA may occur and latent diabetes mellitus may become evident.",HYPERGLYCEMIA,INSULIN
790085259,9/17/2015 13:36:16,1740423073,9/17/2015 13:36:07,false,bitcoinget,1,31256687,USA,NY,Poughkeepsie,67.82.252.135,[TREATS],[TREATS],required;,n/a,110,63,18,122,70,RO-may_treat,820021-FS1,"109  Hyperglycemia  In diabetic patients, dosage adjustment of INSULIN or oral hypoglycemics may be required; HYPERGLYCEMIA may occur and latent diabetes mellitus may become evident.",HYPERGLYCEMIA,INSULIN
790085259,9/17/2015 13:52:05,1740429693,9/17/2015 13:51:44,false,neodev,1.0,31329809,USA,DE,Wilmington,162.223.93.194,[PART_OF],[PART_OF],of,N/A,110,63,18,122,70,RO-may_treat,820021-FS1,"109  Hyperglycemia  In diabetic patients, dosage adjustment of INSULIN or oral hypoglycemics may be required; HYPERGLYCEMIA may occur and latent diabetes mellitus may become evident.",HYPERGLYCEMIA,INSULIN
790085259,9/17/2015 14:02:18,1740433171,9/17/2015 14:00:49,false,zoombucks,1.0,6744840,CAN,BC,Kelowna,174.4.58.160,[TREATS],[TREATS],dosage,N/A,110,63,18,122,70,RO-may_treat,820021-FS1,"109  Hyperglycemia  In diabetic patients, dosage adjustment of INSULIN or oral hypoglycemics may be required; HYPERGLYCEMIA may occur and latent diabetes mellitus may become evident.",HYPERGLYCEMIA,INSULIN
790085260,9/17/2015 09:20:45,1740364191,9/17/2015 09:20:28,false,elite,1.0,30659754,USA,"","",162.250.145.204,[CONTRAINDICATES],[CONTRAINDICATES],normal range,N/A,266,218,289,288,230,RO-may_treat,820143-FS1,"Gonadal hormone levels were categorised into three groups: 1: All gonadal hormones within normal range (normal), 2: Isolated elevated FSH, with LH, SHBG and testosterone within normal range (exocrine hypogonadism), 3: TESTOSTERONE below and/or LH above normal range (ENDOCRINE HYPOGONADISM",ENDOCRINE HYPOGONADISM,TESTOSTERONE
790085260,9/17/2015 09:20:50,1740364200,9/17/2015 09:20:31,false,neodev,1.0,32053642,GBR,I7,Newcastle Upon Tyne,92.23.136.205,[SYMPTOM],[SYMPTOM],categorised into,N/A,266,218,289,288,230,RO-may_treat,820143-FS1,"Gonadal hormone levels were categorised into three groups: 1: All gonadal hormones within normal range (normal), 2: Isolated elevated FSH, with LH, SHBG and testosterone within normal range (exocrine hypogonadism), 3: TESTOSTERONE below and/or LH above normal range (ENDOCRINE HYPOGONADISM",ENDOCRINE HYPOGONADISM,TESTOSTERONE
790085260,9/17/2015 09:28:09,1740365656,9/17/2015 09:27:50,false,instagc,1.0,18960682,GBR,U2,Annan,92.18.213.181,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],TESTOSTERONE below and/or LH above normal range,N/A,266,218,289,288,230,RO-may_treat,820143-FS1,"Gonadal hormone levels were categorised into three groups: 1: All gonadal hormones within normal range (normal), 2: Isolated elevated FSH, with LH, SHBG and testosterone within normal range (exocrine hypogonadism), 3: TESTOSTERONE below and/or LH above normal range (ENDOCRINE HYPOGONADISM",ENDOCRINE HYPOGONADISM,TESTOSTERONE
790085260,9/17/2015 09:32:01,1740366603,9/17/2015 09:31:35,false,neodev,1.0,15848372,AUS,02,Jannali,14.200.59.55,[PART_OF],[PART_OF],and/or,n/a,266,218,289,288,230,RO-may_treat,820143-FS1,"Gonadal hormone levels were categorised into three groups: 1: All gonadal hormones within normal range (normal), 2: Isolated elevated FSH, with LH, SHBG and testosterone within normal range (exocrine hypogonadism), 3: TESTOSTERONE below and/or LH above normal range (ENDOCRINE HYPOGONADISM",ENDOCRINE HYPOGONADISM,TESTOSTERONE
790085260,9/17/2015 09:33:14,1740366930,9/17/2015 09:32:35,false,neodev,1.0,33644825,USA,FL,Fort Lauderdale,65.111.173.161,[TREATS],[TREATS],TESTOSTERONE (ENDOCRINE HYPOGONADISM,causes,266,218,289,288,230,RO-may_treat,820143-FS1,"Gonadal hormone levels were categorised into three groups: 1: All gonadal hormones within normal range (normal), 2: Isolated elevated FSH, with LH, SHBG and testosterone within normal range (exocrine hypogonadism), 3: TESTOSTERONE below and/or LH above normal range (ENDOCRINE HYPOGONADISM",ENDOCRINE HYPOGONADISM,TESTOSTERONE
790085260,9/17/2015 09:38:44,1740368145,9/17/2015 09:38:29,false,elite,1.0,30659615,USA,"","",162.250.145.234,[CONTRAINDICATES],[CONTRAINDICATES],normal range,N/A,266,218,289,288,230,RO-may_treat,820143-FS1,"Gonadal hormone levels were categorised into three groups: 1: All gonadal hormones within normal range (normal), 2: Isolated elevated FSH, with LH, SHBG and testosterone within normal range (exocrine hypogonadism), 3: TESTOSTERONE below and/or LH above normal range (ENDOCRINE HYPOGONADISM",ENDOCRINE HYPOGONADISM,TESTOSTERONE
790085260,9/17/2015 09:48:16,1740370367,9/17/2015 09:47:54,false,neodev,1.0,21515166,NLD,11,Nieuwkoop,83.84.200.25,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],were categorised into groups:,n/a,266,218,289,288,230,RO-may_treat,820143-FS1,"Gonadal hormone levels were categorised into three groups: 1: All gonadal hormones within normal range (normal), 2: Isolated elevated FSH, with LH, SHBG and testosterone within normal range (exocrine hypogonadism), 3: TESTOSTERONE below and/or LH above normal range (ENDOCRINE HYPOGONADISM",ENDOCRINE HYPOGONADISM,TESTOSTERONE
790085260,9/17/2015 09:49:11,1740370623,9/17/2015 09:48:31,false,pocketmoneygpt,1.0,21432964,GBR,F8,Borehamwood,81.159.185.70,[ASSOCIATED_WITH] [IS_A] [PART_OF],"[ASSOCIATED_WITH]
[IS_A]
[PART_OF]",categorised into three groups:,N/A,266,218,289,288,230,RO-may_treat,820143-FS1,"Gonadal hormone levels were categorised into three groups: 1: All gonadal hormones within normal range (normal), 2: Isolated elevated FSH, with LH, SHBG and testosterone within normal range (exocrine hypogonadism), 3: TESTOSTERONE below and/or LH above normal range (ENDOCRINE HYPOGONADISM",ENDOCRINE HYPOGONADISM,TESTOSTERONE
790085260,9/17/2015 09:49:23,1740370641,9/17/2015 09:47:21,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[IS_A],[IS_A],above normal range,N/A,266,218,289,288,230,RO-may_treat,820143-FS1,"Gonadal hormone levels were categorised into three groups: 1: All gonadal hormones within normal range (normal), 2: Isolated elevated FSH, with LH, SHBG and testosterone within normal range (exocrine hypogonadism), 3: TESTOSTERONE below and/or LH above normal range (ENDOCRINE HYPOGONADISM",ENDOCRINE HYPOGONADISM,TESTOSTERONE
790085260,9/17/2015 09:54:35,1740371918,9/17/2015 09:54:20,false,elite,1.0,30659677,USA,"","",162.252.172.126,[LOCATION],[LOCATION],above,N/A,266,218,289,288,230,RO-may_treat,820143-FS1,"Gonadal hormone levels were categorised into three groups: 1: All gonadal hormones within normal range (normal), 2: Isolated elevated FSH, with LH, SHBG and testosterone within normal range (exocrine hypogonadism), 3: TESTOSTERONE below and/or LH above normal range (ENDOCRINE HYPOGONADISM",ENDOCRINE HYPOGONADISM,TESTOSTERONE
790085260,9/17/2015 10:16:16,1740377218,9/17/2015 10:15:48,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[ASSOCIATED_WITH],[ASSOCIATED_WITH],hormones TESTOSTERONE (ENDOCRINE HYPOGONADISM,N/A,266,218,289,288,230,RO-may_treat,820143-FS1,"Gonadal hormone levels were categorised into three groups: 1: All gonadal hormones within normal range (normal), 2: Isolated elevated FSH, with LH, SHBG and testosterone within normal range (exocrine hypogonadism), 3: TESTOSTERONE below and/or LH above normal range (ENDOCRINE HYPOGONADISM",ENDOCRINE HYPOGONADISM,TESTOSTERONE
790085260,9/17/2015 10:33:05,1740380489,9/17/2015 10:32:46,false,pocketmoneygpt,1.0,28884030,USA,WI,Minocqua,75.143.134.247,[PART_OF],[PART_OF],and/or,n/a,266,218,289,288,230,RO-may_treat,820143-FS1,"Gonadal hormone levels were categorised into three groups: 1: All gonadal hormones within normal range (normal), 2: Isolated elevated FSH, with LH, SHBG and testosterone within normal range (exocrine hypogonadism), 3: TESTOSTERONE below and/or LH above normal range (ENDOCRINE HYPOGONADISM",ENDOCRINE HYPOGONADISM,TESTOSTERONE
790085260,9/17/2015 10:44:12,1740382752,9/17/2015 10:43:48,false,clixsense,1.0,17950689,GBR,L9,Sheffield,146.200.192.103,[TREATS],[TREATS],(ENDOCRINE HYPOGONADISM,NONE,266,218,289,288,230,RO-may_treat,820143-FS1,"Gonadal hormone levels were categorised into three groups: 1: All gonadal hormones within normal range (normal), 2: Isolated elevated FSH, with LH, SHBG and testosterone within normal range (exocrine hypogonadism), 3: TESTOSTERONE below and/or LH above normal range (ENDOCRINE HYPOGONADISM",ENDOCRINE HYPOGONADISM,TESTOSTERONE
790085260,9/17/2015 10:58:18,1740385243,9/17/2015 10:57:35,false,neodev,1.0,30581619,USA,CA,San Jose,50.118.162.56,[TREATS] [NONE],"[TREATS]
[NONE]",good,good,266,218,289,288,230,RO-may_treat,820143-FS1,"Gonadal hormone levels were categorised into three groups: 1: All gonadal hormones within normal range (normal), 2: Isolated elevated FSH, with LH, SHBG and testosterone within normal range (exocrine hypogonadism), 3: TESTOSTERONE below and/or LH above normal range (ENDOCRINE HYPOGONADISM",ENDOCRINE HYPOGONADISM,TESTOSTERONE
790085260,9/17/2015 10:59:54,1740385546,9/17/2015 10:58:25,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[OTHER],[OTHER],normal range,N/A,266,218,289,288,230,RO-may_treat,820143-FS1,"Gonadal hormone levels were categorised into three groups: 1: All gonadal hormones within normal range (normal), 2: Isolated elevated FSH, with LH, SHBG and testosterone within normal range (exocrine hypogonadism), 3: TESTOSTERONE below and/or LH above normal range (ENDOCRINE HYPOGONADISM",ENDOCRINE HYPOGONADISM,TESTOSTERONE
790085261,9/17/2015 14:12:01,1740436696,9/17/2015 14:11:31,false,gifthunterclub,1.0,30901412,GBR,H9,London,77.89.149.62,[PREVENTS],[PREVENTS],treatment CHLOROQUINE recommended by NATIONAL MALARIA PROGRAM,N/A,159,125,175,182,136,RO-may_prevent,820343-FS1,"Children with symptomatic malaria in Bissau, Guinea Bissau were randomly assigned to treatment with a 25 mg/kg total dose of CHLOROQUINE as recommended by the NATIONAL MALARIA PROGRAM or with a higher total dose of 50 mg/kg.",NATIONAL MALARIA PROGRAM,CHLOROQUINE
790085261,9/17/2015 14:18:54,1740439309,9/17/2015 14:18:33,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.124.79,[TREATS],[TREATS],treatment,N/A,159,125,175,182,136,RO-may_prevent,820343-FS1,"Children with symptomatic malaria in Bissau, Guinea Bissau were randomly assigned to treatment with a 25 mg/kg total dose of CHLOROQUINE as recommended by the NATIONAL MALARIA PROGRAM or with a higher total dose of 50 mg/kg.",NATIONAL MALARIA PROGRAM,CHLOROQUINE
790085261,9/17/2015 14:31:30,1740443883,9/17/2015 14:30:13,false,zoombucks,1.0,6744840,CAN,BC,Kelowna,174.4.58.160,[TREATS],[TREATS],treatment,N/A,159,125,175,182,136,RO-may_prevent,820343-FS1,"Children with symptomatic malaria in Bissau, Guinea Bissau were randomly assigned to treatment with a 25 mg/kg total dose of CHLOROQUINE as recommended by the NATIONAL MALARIA PROGRAM or with a higher total dose of 50 mg/kg.",NATIONAL MALARIA PROGRAM,CHLOROQUINE
790085261,9/17/2015 14:35:50,1740445431,9/17/2015 14:35:37,false,bitcoinget,1.0,32306192,USA,MA,Amherst,72.19.88.245,[TREATS],[TREATS],NATIONAL MALARIA PROGRAM,N/a,159,125,175,182,136,RO-may_prevent,820343-FS1,"Children with symptomatic malaria in Bissau, Guinea Bissau were randomly assigned to treatment with a 25 mg/kg total dose of CHLOROQUINE as recommended by the NATIONAL MALARIA PROGRAM or with a higher total dose of 50 mg/kg.",NATIONAL MALARIA PROGRAM,CHLOROQUINE
790085261,9/17/2015 14:56:38,1740453621,9/17/2015 14:55:36,false,clixsense,1.0,32049531,USA,"","",38.95.108.252,[NONE],[NONE],none,none,159,125,175,182,136,RO-may_prevent,820343-FS1,"Children with symptomatic malaria in Bissau, Guinea Bissau were randomly assigned to treatment with a 25 mg/kg total dose of CHLOROQUINE as recommended by the NATIONAL MALARIA PROGRAM or with a higher total dose of 50 mg/kg.",NATIONAL MALARIA PROGRAM,CHLOROQUINE
790085261,9/17/2015 15:04:51,1740456741,9/17/2015 15:04:29,false,neodev,1.0,31329809,USA,DE,Wilmington,162.223.93.194,[ASSOCIATED_WITH] [IS_A] [PART_OF] [DIAGNOSE_BY_TEST_OR_DRUG],"[DIAGNOSE_BY_TEST_OR_DRUG]
[ASSOCIATED_WITH]
[IS_A]
[PART_OF]",with with a of by with a,N/A,159,125,175,182,136,RO-may_prevent,820343-FS1,"Children with symptomatic malaria in Bissau, Guinea Bissau were randomly assigned to treatment with a 25 mg/kg total dose of CHLOROQUINE as recommended by the NATIONAL MALARIA PROGRAM or with a higher total dose of 50 mg/kg.",NATIONAL MALARIA PROGRAM,CHLOROQUINE
790085261,9/17/2015 15:07:29,1740457578,9/17/2015 15:06:58,false,clixsense,1.0,33115750,GBR,I3,Rochester,90.222.106.192,[OTHER],[OTHER],recommended by the,N/A,159,125,175,182,136,RO-may_prevent,820343-FS1,"Children with symptomatic malaria in Bissau, Guinea Bissau were randomly assigned to treatment with a 25 mg/kg total dose of CHLOROQUINE as recommended by the NATIONAL MALARIA PROGRAM or with a higher total dose of 50 mg/kg.",NATIONAL MALARIA PROGRAM,CHLOROQUINE
790085261,9/17/2015 15:15:52,1740460121,9/17/2015 15:15:30,false,neodev,1.0,30321275,USA,NV,Las Vegas,192.30.80.4,[ASSOCIATED_WITH] [DIAGNOSE_BY_TEST_OR_DRUG] [IS_A],"[DIAGNOSE_BY_TEST_OR_DRUG]
[ASSOCIATED_WITH]
[IS_A]",with treatment with a by with a,N/A,159,125,175,182,136,RO-may_prevent,820343-FS1,"Children with symptomatic malaria in Bissau, Guinea Bissau were randomly assigned to treatment with a 25 mg/kg total dose of CHLOROQUINE as recommended by the NATIONAL MALARIA PROGRAM or with a higher total dose of 50 mg/kg.",NATIONAL MALARIA PROGRAM,CHLOROQUINE
790085261,9/17/2015 15:21:49,1740462497,9/17/2015 15:21:31,false,neodev,1.0,29363385,USA,DE,Wilmington,162.223.93.162,[ASSOCIATED_WITH] [DIAGNOSE_BY_TEST_OR_DRUG] [IS_A],"[DIAGNOSE_BY_TEST_OR_DRUG]
[ASSOCIATED_WITH]
[IS_A]",with with a by or with a,N/A,159,125,175,182,136,RO-may_prevent,820343-FS1,"Children with symptomatic malaria in Bissau, Guinea Bissau were randomly assigned to treatment with a 25 mg/kg total dose of CHLOROQUINE as recommended by the NATIONAL MALARIA PROGRAM or with a higher total dose of 50 mg/kg.",NATIONAL MALARIA PROGRAM,CHLOROQUINE
790085261,9/17/2015 15:28:22,1740464847,9/17/2015 15:27:53,false,neodev,1.0,33435788,USA,DE,Wilmington,162.223.93.179,[ASSOCIATED_WITH] [DIAGNOSE_BY_TEST_OR_DRUG] [PART_OF] [IS_A],"[DIAGNOSE_BY_TEST_OR_DRUG]
[ASSOCIATED_WITH]
[IS_A]
[PART_OF]",with treatment with a of by a,N/A,159,125,175,182,136,RO-may_prevent,820343-FS1,"Children with symptomatic malaria in Bissau, Guinea Bissau were randomly assigned to treatment with a 25 mg/kg total dose of CHLOROQUINE as recommended by the NATIONAL MALARIA PROGRAM or with a higher total dose of 50 mg/kg.",NATIONAL MALARIA PROGRAM,CHLOROQUINE
790085261,9/17/2015 15:29:10,1740465216,9/17/2015 15:28:34,false,clixsense,1,6340330,USA,NY,Canajoharie,67.248.115.74,[ASSOCIATED_WITH],[ASSOCIATED_WITH],assigned,N/A,159,125,175,182,136,RO-may_prevent,820343-FS1,"Children with symptomatic malaria in Bissau, Guinea Bissau were randomly assigned to treatment with a 25 mg/kg total dose of CHLOROQUINE as recommended by the NATIONAL MALARIA PROGRAM or with a higher total dose of 50 mg/kg.",NATIONAL MALARIA PROGRAM,CHLOROQUINE
790085261,9/17/2015 15:30:21,1740465667,9/17/2015 15:29:51,false,neodev,1,33018272,USA,DE,Wilmington,162.223.93.180,[ASSOCIATED_WITH] [DIAGNOSE_BY_TEST_OR_DRUG] [IS_A] [PART_OF],"[DIAGNOSE_BY_TEST_OR_DRUG]
[ASSOCIATED_WITH]
[IS_A]
[PART_OF]",with treatment with a of by or with a of,N/A,159,125,175,182,136,RO-may_prevent,820343-FS1,"Children with symptomatic malaria in Bissau, Guinea Bissau were randomly assigned to treatment with a 25 mg/kg total dose of CHLOROQUINE as recommended by the NATIONAL MALARIA PROGRAM or with a higher total dose of 50 mg/kg.",NATIONAL MALARIA PROGRAM,CHLOROQUINE
790085261,9/17/2015 15:31:34,1740466152,9/17/2015 15:29:09,false,clixsense,1,6833057,NLD,05,Venray,84.31.86.92,[TREATS],[TREATS],treatment CHLOROQUINE,That's a medicin,159,125,175,182,136,RO-may_prevent,820343-FS1,"Children with symptomatic malaria in Bissau, Guinea Bissau were randomly assigned to treatment with a 25 mg/kg total dose of CHLOROQUINE as recommended by the NATIONAL MALARIA PROGRAM or with a higher total dose of 50 mg/kg.",NATIONAL MALARIA PROGRAM,CHLOROQUINE
790085261,9/17/2015 15:50:14,1740473795,9/17/2015 15:48:47,false,elite,1,30312592,CAN,ON,Sudbury,66.103.55.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],recommended by,N/A,159,125,175,182,136,RO-may_prevent,820343-FS1,"Children with symptomatic malaria in Bissau, Guinea Bissau were randomly assigned to treatment with a 25 mg/kg total dose of CHLOROQUINE as recommended by the NATIONAL MALARIA PROGRAM or with a higher total dose of 50 mg/kg.",NATIONAL MALARIA PROGRAM,CHLOROQUINE
790085261,9/17/2015 15:52:51,1740475166,9/17/2015 15:52:22,false,bitcoinget,1,21743413,USA,WA,Port Angeles,24.113.29.97,[TREATS],[TREATS],treatment,N/A,159,125,175,182,136,RO-may_prevent,820343-FS1,"Children with symptomatic malaria in Bissau, Guinea Bissau were randomly assigned to treatment with a 25 mg/kg total dose of CHLOROQUINE as recommended by the NATIONAL MALARIA PROGRAM or with a higher total dose of 50 mg/kg.",NATIONAL MALARIA PROGRAM,CHLOROQUINE
790085262,9/17/2015 09:19:08,1740363788,9/17/2015 09:18:54,false,neodev,1.0,32053642,GBR,I7,Newcastle Upon Tyne,92.23.136.205,[TREATS],[TREATS],Treat:,N/A,410,426,420,419,451,RO-may_treat,820025-FS1,"BC]  Specific recommendation: • Treat: ◊ Sialorrhea with amitriptyline, glycopyrrolate, or transdermal scopolamine patches; if sialorrhea is refractory, consider radiation therapy of the salivary glands or botulinum toxin injections of the salivary glands ◊ Thick mucus with propranolol or metoprolol ◊ Pseudobulbar affect or emotional lability with dextromethorphan/quinidine, amitriptyline, or fluvoxamine ◊ DEPRESSION with TRICYCLIC ANTIDEPRESSANTS such as amitriptyline or newer agents such as sertraline ◊ Anxiety with anxiolytics such as benzodiazepines ◊ Insomnia with noninvasive ventilation, pain management, antidepressants, or hypnotics, depending on.",DEPRESSION,TRICYCLIC ANTIDEPRESSANTS
790085262,9/17/2015 09:19:31,1740363868,9/17/2015 09:19:18,false,elite,1.0,30659754,USA,"","",162.250.145.204,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,N/A,410,426,420,419,451,RO-may_treat,820025-FS1,"BC]  Specific recommendation: • Treat: ◊ Sialorrhea with amitriptyline, glycopyrrolate, or transdermal scopolamine patches; if sialorrhea is refractory, consider radiation therapy of the salivary glands or botulinum toxin injections of the salivary glands ◊ Thick mucus with propranolol or metoprolol ◊ Pseudobulbar affect or emotional lability with dextromethorphan/quinidine, amitriptyline, or fluvoxamine ◊ DEPRESSION with TRICYCLIC ANTIDEPRESSANTS such as amitriptyline or newer agents such as sertraline ◊ Anxiety with anxiolytics such as benzodiazepines ◊ Insomnia with noninvasive ventilation, pain management, antidepressants, or hypnotics, depending on.",DEPRESSION,TRICYCLIC ANTIDEPRESSANTS
790085262,9/17/2015 09:26:35,1740365277,9/17/2015 09:26:17,false,instagc,1.0,18960682,GBR,U2,Annan,92.18.213.181,[TREATS],[TREATS],Treat:,N/A,410,426,420,419,451,RO-may_treat,820025-FS1,"BC]  Specific recommendation: • Treat: ◊ Sialorrhea with amitriptyline, glycopyrrolate, or transdermal scopolamine patches; if sialorrhea is refractory, consider radiation therapy of the salivary glands or botulinum toxin injections of the salivary glands ◊ Thick mucus with propranolol or metoprolol ◊ Pseudobulbar affect or emotional lability with dextromethorphan/quinidine, amitriptyline, or fluvoxamine ◊ DEPRESSION with TRICYCLIC ANTIDEPRESSANTS such as amitriptyline or newer agents such as sertraline ◊ Anxiety with anxiolytics such as benzodiazepines ◊ Insomnia with noninvasive ventilation, pain management, antidepressants, or hypnotics, depending on.",DEPRESSION,TRICYCLIC ANTIDEPRESSANTS
790085262,9/17/2015 09:30:23,1740366144,9/17/2015 09:29:57,false,neodev,1.0,15848372,AUS,02,Jannali,14.200.59.55,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,n/a,410,426,420,419,451,RO-may_treat,820025-FS1,"BC]  Specific recommendation: • Treat: ◊ Sialorrhea with amitriptyline, glycopyrrolate, or transdermal scopolamine patches; if sialorrhea is refractory, consider radiation therapy of the salivary glands or botulinum toxin injections of the salivary glands ◊ Thick mucus with propranolol or metoprolol ◊ Pseudobulbar affect or emotional lability with dextromethorphan/quinidine, amitriptyline, or fluvoxamine ◊ DEPRESSION with TRICYCLIC ANTIDEPRESSANTS such as amitriptyline or newer agents such as sertraline ◊ Anxiety with anxiolytics such as benzodiazepines ◊ Insomnia with noninvasive ventilation, pain management, antidepressants, or hypnotics, depending on.",DEPRESSION,TRICYCLIC ANTIDEPRESSANTS
790085262,9/17/2015 09:30:55,1740366274,9/17/2015 09:30:17,false,neodev,1.0,33644825,USA,FL,Fort Lauderdale,65.111.173.161,[PREVENTS],[PREVENTS],DEPRESSION TRICYCLIC ANTIDEPRESSANTS,cause,410,426,420,419,451,RO-may_treat,820025-FS1,"BC]  Specific recommendation: • Treat: ◊ Sialorrhea with amitriptyline, glycopyrrolate, or transdermal scopolamine patches; if sialorrhea is refractory, consider radiation therapy of the salivary glands or botulinum toxin injections of the salivary glands ◊ Thick mucus with propranolol or metoprolol ◊ Pseudobulbar affect or emotional lability with dextromethorphan/quinidine, amitriptyline, or fluvoxamine ◊ DEPRESSION with TRICYCLIC ANTIDEPRESSANTS such as amitriptyline or newer agents such as sertraline ◊ Anxiety with anxiolytics such as benzodiazepines ◊ Insomnia with noninvasive ventilation, pain management, antidepressants, or hypnotics, depending on.",DEPRESSION,TRICYCLIC ANTIDEPRESSANTS
790085262,9/17/2015 09:37:35,1740367804,9/17/2015 09:37:22,false,elite,1.0,30659615,USA,"","",162.250.145.234,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,N/A,410,426,420,419,451,RO-may_treat,820025-FS1,"BC]  Specific recommendation: • Treat: ◊ Sialorrhea with amitriptyline, glycopyrrolate, or transdermal scopolamine patches; if sialorrhea is refractory, consider radiation therapy of the salivary glands or botulinum toxin injections of the salivary glands ◊ Thick mucus with propranolol or metoprolol ◊ Pseudobulbar affect or emotional lability with dextromethorphan/quinidine, amitriptyline, or fluvoxamine ◊ DEPRESSION with TRICYCLIC ANTIDEPRESSANTS such as amitriptyline or newer agents such as sertraline ◊ Anxiety with anxiolytics such as benzodiazepines ◊ Insomnia with noninvasive ventilation, pain management, antidepressants, or hypnotics, depending on.",DEPRESSION,TRICYCLIC ANTIDEPRESSANTS
790085262,9/17/2015 09:46:00,1740369890,9/17/2015 09:44:50,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[TREATS],[TREATS],with,N/A,410,426,420,419,451,RO-may_treat,820025-FS1,"BC]  Specific recommendation: • Treat: ◊ Sialorrhea with amitriptyline, glycopyrrolate, or transdermal scopolamine patches; if sialorrhea is refractory, consider radiation therapy of the salivary glands or botulinum toxin injections of the salivary glands ◊ Thick mucus with propranolol or metoprolol ◊ Pseudobulbar affect or emotional lability with dextromethorphan/quinidine, amitriptyline, or fluvoxamine ◊ DEPRESSION with TRICYCLIC ANTIDEPRESSANTS such as amitriptyline or newer agents such as sertraline ◊ Anxiety with anxiolytics such as benzodiazepines ◊ Insomnia with noninvasive ventilation, pain management, antidepressants, or hypnotics, depending on.",DEPRESSION,TRICYCLIC ANTIDEPRESSANTS
790085262,9/17/2015 09:46:09,1740369919,9/17/2015 09:45:34,false,pocketmoneygpt,1.0,21432964,GBR,F8,Borehamwood,81.159.185.70,[TREATS],[TREATS],with,N/A,410,426,420,419,451,RO-may_treat,820025-FS1,"BC]  Specific recommendation: • Treat: ◊ Sialorrhea with amitriptyline, glycopyrrolate, or transdermal scopolamine patches; if sialorrhea is refractory, consider radiation therapy of the salivary glands or botulinum toxin injections of the salivary glands ◊ Thick mucus with propranolol or metoprolol ◊ Pseudobulbar affect or emotional lability with dextromethorphan/quinidine, amitriptyline, or fluvoxamine ◊ DEPRESSION with TRICYCLIC ANTIDEPRESSANTS such as amitriptyline or newer agents such as sertraline ◊ Anxiety with anxiolytics such as benzodiazepines ◊ Insomnia with noninvasive ventilation, pain management, antidepressants, or hypnotics, depending on.",DEPRESSION,TRICYCLIC ANTIDEPRESSANTS
790085262,9/17/2015 09:46:40,1740369994,9/17/2015 09:46:20,false,neodev,1.0,21515166,NLD,11,Nieuwkoop,83.84.200.25,[TREATS],[TREATS],Treat: with,n/a,410,426,420,419,451,RO-may_treat,820025-FS1,"BC]  Specific recommendation: • Treat: ◊ Sialorrhea with amitriptyline, glycopyrrolate, or transdermal scopolamine patches; if sialorrhea is refractory, consider radiation therapy of the salivary glands or botulinum toxin injections of the salivary glands ◊ Thick mucus with propranolol or metoprolol ◊ Pseudobulbar affect or emotional lability with dextromethorphan/quinidine, amitriptyline, or fluvoxamine ◊ DEPRESSION with TRICYCLIC ANTIDEPRESSANTS such as amitriptyline or newer agents such as sertraline ◊ Anxiety with anxiolytics such as benzodiazepines ◊ Insomnia with noninvasive ventilation, pain management, antidepressants, or hypnotics, depending on.",DEPRESSION,TRICYCLIC ANTIDEPRESSANTS
790085262,9/17/2015 09:53:28,1740371668,9/17/2015 09:53:15,false,elite,1.0,30659677,USA,"","",162.252.172.126,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,N/A,410,426,420,419,451,RO-may_treat,820025-FS1,"BC]  Specific recommendation: • Treat: ◊ Sialorrhea with amitriptyline, glycopyrrolate, or transdermal scopolamine patches; if sialorrhea is refractory, consider radiation therapy of the salivary glands or botulinum toxin injections of the salivary glands ◊ Thick mucus with propranolol or metoprolol ◊ Pseudobulbar affect or emotional lability with dextromethorphan/quinidine, amitriptyline, or fluvoxamine ◊ DEPRESSION with TRICYCLIC ANTIDEPRESSANTS such as amitriptyline or newer agents such as sertraline ◊ Anxiety with anxiolytics such as benzodiazepines ◊ Insomnia with noninvasive ventilation, pain management, antidepressants, or hypnotics, depending on.",DEPRESSION,TRICYCLIC ANTIDEPRESSANTS
790085262,9/17/2015 10:05:43,1740374676,9/17/2015 10:04:52,false,neodev,1.0,34081836,USA,CA,San Jose,23.27.248.146,[TREATS],[TREATS],DEPRESSION with TRICYCLIC ANTIDEPRESSANTS,NA,410,426,420,419,451,RO-may_treat,820025-FS1,"BC]  Specific recommendation: • Treat: ◊ Sialorrhea with amitriptyline, glycopyrrolate, or transdermal scopolamine patches; if sialorrhea is refractory, consider radiation therapy of the salivary glands or botulinum toxin injections of the salivary glands ◊ Thick mucus with propranolol or metoprolol ◊ Pseudobulbar affect or emotional lability with dextromethorphan/quinidine, amitriptyline, or fluvoxamine ◊ DEPRESSION with TRICYCLIC ANTIDEPRESSANTS such as amitriptyline or newer agents such as sertraline ◊ Anxiety with anxiolytics such as benzodiazepines ◊ Insomnia with noninvasive ventilation, pain management, antidepressants, or hypnotics, depending on.",DEPRESSION,TRICYCLIC ANTIDEPRESSANTS
790085262,9/17/2015 10:12:40,1740376505,9/17/2015 10:11:30,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[ASSOCIATED_WITH],[ASSOCIATED_WITH],DEPRESSION with TRICYCLIC ANTIDEPRESSANTS,N/A,410,426,420,419,451,RO-may_treat,820025-FS1,"BC]  Specific recommendation: • Treat: ◊ Sialorrhea with amitriptyline, glycopyrrolate, or transdermal scopolamine patches; if sialorrhea is refractory, consider radiation therapy of the salivary glands or botulinum toxin injections of the salivary glands ◊ Thick mucus with propranolol or metoprolol ◊ Pseudobulbar affect or emotional lability with dextromethorphan/quinidine, amitriptyline, or fluvoxamine ◊ DEPRESSION with TRICYCLIC ANTIDEPRESSANTS such as amitriptyline or newer agents such as sertraline ◊ Anxiety with anxiolytics such as benzodiazepines ◊ Insomnia with noninvasive ventilation, pain management, antidepressants, or hypnotics, depending on.",DEPRESSION,TRICYCLIC ANTIDEPRESSANTS
790085262,9/17/2015 10:31:45,1740380166,9/17/2015 10:31:21,false,pocketmoneygpt,1.0,28884030,USA,WI,Minocqua,75.143.134.247,[TREATS],[TREATS],with,n/a,410,426,420,419,451,RO-may_treat,820025-FS1,"BC]  Specific recommendation: • Treat: ◊ Sialorrhea with amitriptyline, glycopyrrolate, or transdermal scopolamine patches; if sialorrhea is refractory, consider radiation therapy of the salivary glands or botulinum toxin injections of the salivary glands ◊ Thick mucus with propranolol or metoprolol ◊ Pseudobulbar affect or emotional lability with dextromethorphan/quinidine, amitriptyline, or fluvoxamine ◊ DEPRESSION with TRICYCLIC ANTIDEPRESSANTS such as amitriptyline or newer agents such as sertraline ◊ Anxiety with anxiolytics such as benzodiazepines ◊ Insomnia with noninvasive ventilation, pain management, antidepressants, or hypnotics, depending on.",DEPRESSION,TRICYCLIC ANTIDEPRESSANTS
790085262,9/17/2015 10:42:12,1740382382,9/17/2015 10:41:22,false,clixsense,1.0,17950689,GBR,L9,Sheffield,146.200.192.103,[TREATS],[TREATS],DEPRESSION,NONE,410,426,420,419,451,RO-may_treat,820025-FS1,"BC]  Specific recommendation: • Treat: ◊ Sialorrhea with amitriptyline, glycopyrrolate, or transdermal scopolamine patches; if sialorrhea is refractory, consider radiation therapy of the salivary glands or botulinum toxin injections of the salivary glands ◊ Thick mucus with propranolol or metoprolol ◊ Pseudobulbar affect or emotional lability with dextromethorphan/quinidine, amitriptyline, or fluvoxamine ◊ DEPRESSION with TRICYCLIC ANTIDEPRESSANTS such as amitriptyline or newer agents such as sertraline ◊ Anxiety with anxiolytics such as benzodiazepines ◊ Insomnia with noninvasive ventilation, pain management, antidepressants, or hypnotics, depending on.",DEPRESSION,TRICYCLIC ANTIDEPRESSANTS
790085262,9/17/2015 10:54:58,1740384614,9/17/2015 10:54:21,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,N/A,410,426,420,419,451,RO-may_treat,820025-FS1,"BC]  Specific recommendation: • Treat: ◊ Sialorrhea with amitriptyline, glycopyrrolate, or transdermal scopolamine patches; if sialorrhea is refractory, consider radiation therapy of the salivary glands or botulinum toxin injections of the salivary glands ◊ Thick mucus with propranolol or metoprolol ◊ Pseudobulbar affect or emotional lability with dextromethorphan/quinidine, amitriptyline, or fluvoxamine ◊ DEPRESSION with TRICYCLIC ANTIDEPRESSANTS such as amitriptyline or newer agents such as sertraline ◊ Anxiety with anxiolytics such as benzodiazepines ◊ Insomnia with noninvasive ventilation, pain management, antidepressants, or hypnotics, depending on.",DEPRESSION,TRICYCLIC ANTIDEPRESSANTS
790085263,9/17/2015 09:18:53,1740363755,9/17/2015 09:18:32,false,neodev,1.0,32053642,GBR,I7,Newcastle Upon Tyne,92.23.136.205,[PREVENTS],[PREVENTS],use full dose,N/A,14,87,31,30,94,RO-may_prevent,820388-FS1,"However, once VENOUS THROMBOSIS has already occurred, it is necessary to use full dose HEPARIN preferably by the continuous intravenous route, with maintenance of the partial thromboplastin time (PTT) at 1 1/2 times the control at all times.",VENOUS THROMBOSIS,HEPARIN
790085263,9/17/2015 09:19:16,1740363809,9/17/2015 09:19:02,false,elite,1.0,30659754,USA,"","",162.250.145.204,[SYMPTOM],[SYMPTOM],"occurred,",N/A,14,87,31,30,94,RO-may_prevent,820388-FS1,"However, once VENOUS THROMBOSIS has already occurred, it is necessary to use full dose HEPARIN preferably by the continuous intravenous route, with maintenance of the partial thromboplastin time (PTT) at 1 1/2 times the control at all times.",VENOUS THROMBOSIS,HEPARIN
790085263,9/17/2015 09:26:16,1740365244,9/17/2015 09:26:02,false,instagc,1.0,18960682,GBR,U2,Annan,92.18.213.181,[TREATS],[TREATS],necessary to full dose,N/A,14,87,31,30,94,RO-may_prevent,820388-FS1,"However, once VENOUS THROMBOSIS has already occurred, it is necessary to use full dose HEPARIN preferably by the continuous intravenous route, with maintenance of the partial thromboplastin time (PTT) at 1 1/2 times the control at all times.",VENOUS THROMBOSIS,HEPARIN
790085263,9/17/2015 09:29:56,1740366065,9/17/2015 09:29:29,false,neodev,1.0,15848372,AUS,02,Jannali,14.200.59.55,[MANIFESTATION],[MANIFESTATION],"has already occurred,",n/a,14,87,31,30,94,RO-may_prevent,820388-FS1,"However, once VENOUS THROMBOSIS has already occurred, it is necessary to use full dose HEPARIN preferably by the continuous intravenous route, with maintenance of the partial thromboplastin time (PTT) at 1 1/2 times the control at all times.",VENOUS THROMBOSIS,HEPARIN
790085263,9/17/2015 09:30:15,1740366137,9/17/2015 09:29:27,false,neodev,1.0,33644825,USA,FL,Fort Lauderdale,65.111.173.161,[PREVENTS],[PREVENTS],VENOUS THROMBOSIS HEPARIN,cures,14,87,31,30,94,RO-may_prevent,820388-FS1,"However, once VENOUS THROMBOSIS has already occurred, it is necessary to use full dose HEPARIN preferably by the continuous intravenous route, with maintenance of the partial thromboplastin time (PTT) at 1 1/2 times the control at all times.",VENOUS THROMBOSIS,HEPARIN
790085263,9/17/2015 09:37:20,1740367774,9/17/2015 09:37:06,false,elite,1.0,30659615,USA,"","",162.250.145.234,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],full dose,N/A,14,87,31,30,94,RO-may_prevent,820388-FS1,"However, once VENOUS THROMBOSIS has already occurred, it is necessary to use full dose HEPARIN preferably by the continuous intravenous route, with maintenance of the partial thromboplastin time (PTT) at 1 1/2 times the control at all times.",VENOUS THROMBOSIS,HEPARIN
790085263,9/17/2015 09:44:49,1740369587,9/17/2015 09:44:14,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[TREATS],[TREATS],full dose,N/A,14,87,31,30,94,RO-may_prevent,820388-FS1,"However, once VENOUS THROMBOSIS has already occurred, it is necessary to use full dose HEPARIN preferably by the continuous intravenous route, with maintenance of the partial thromboplastin time (PTT) at 1 1/2 times the control at all times.",VENOUS THROMBOSIS,HEPARIN
790085263,9/17/2015 09:45:33,1740369785,9/17/2015 09:45:00,false,pocketmoneygpt,1.0,21432964,GBR,F8,Borehamwood,81.159.185.70,[TREATS],[TREATS],use full dose,N/A,14,87,31,30,94,RO-may_prevent,820388-FS1,"However, once VENOUS THROMBOSIS has already occurred, it is necessary to use full dose HEPARIN preferably by the continuous intravenous route, with maintenance of the partial thromboplastin time (PTT) at 1 1/2 times the control at all times.",VENOUS THROMBOSIS,HEPARIN
790085263,9/17/2015 09:46:19,1740369932,9/17/2015 09:45:44,false,neodev,1.0,21515166,NLD,11,Nieuwkoop,83.84.200.25,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]","has occurred, to use",n/a,14,87,31,30,94,RO-may_prevent,820388-FS1,"However, once VENOUS THROMBOSIS has already occurred, it is necessary to use full dose HEPARIN preferably by the continuous intravenous route, with maintenance of the partial thromboplastin time (PTT) at 1 1/2 times the control at all times.",VENOUS THROMBOSIS,HEPARIN
790085263,9/17/2015 09:53:12,1740371604,9/17/2015 09:52:57,false,elite,1.0,30659677,USA,"","",162.252.172.126,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],full dose,N/A,14,87,31,30,94,RO-may_prevent,820388-FS1,"However, once VENOUS THROMBOSIS has already occurred, it is necessary to use full dose HEPARIN preferably by the continuous intravenous route, with maintenance of the partial thromboplastin time (PTT) at 1 1/2 times the control at all times.",VENOUS THROMBOSIS,HEPARIN
790085263,9/17/2015 10:04:50,1740374459,9/17/2015 10:04:23,false,neodev,1.0,34081836,USA,CA,San Jose,23.27.248.146,[TREATS],[TREATS],"VENOUS THROMBOSIS has already occurred, it necessary to use full dose HEPARIN",N/A,14,87,31,30,94,RO-may_prevent,820388-FS1,"However, once VENOUS THROMBOSIS has already occurred, it is necessary to use full dose HEPARIN preferably by the continuous intravenous route, with maintenance of the partial thromboplastin time (PTT) at 1 1/2 times the control at all times.",VENOUS THROMBOSIS,HEPARIN
790085263,9/17/2015 10:11:29,1740376238,9/17/2015 10:10:17,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[TREATS],[TREATS],necessary to use full dose HEPARIN,N/A,14,87,31,30,94,RO-may_prevent,820388-FS1,"However, once VENOUS THROMBOSIS has already occurred, it is necessary to use full dose HEPARIN preferably by the continuous intravenous route, with maintenance of the partial thromboplastin time (PTT) at 1 1/2 times the control at all times.",VENOUS THROMBOSIS,HEPARIN
790085263,9/17/2015 10:31:20,1740380091,9/17/2015 10:31:01,false,pocketmoneygpt,1.0,28884030,USA,WI,Minocqua,75.143.134.247,[TREATS],[TREATS],control,n/a,14,87,31,30,94,RO-may_prevent,820388-FS1,"However, once VENOUS THROMBOSIS has already occurred, it is necessary to use full dose HEPARIN preferably by the continuous intravenous route, with maintenance of the partial thromboplastin time (PTT) at 1 1/2 times the control at all times.",VENOUS THROMBOSIS,HEPARIN
790085263,9/17/2015 10:41:20,1740382232,9/17/2015 10:41:03,false,clixsense,1.0,17950689,GBR,L9,Sheffield,146.200.192.103,[PREVENTS],[PREVENTS],THROMBOSIS,NONE,14,87,31,30,94,RO-may_prevent,820388-FS1,"However, once VENOUS THROMBOSIS has already occurred, it is necessary to use full dose HEPARIN preferably by the continuous intravenous route, with maintenance of the partial thromboplastin time (PTT) at 1 1/2 times the control at all times.",VENOUS THROMBOSIS,HEPARIN
790085263,9/17/2015 10:55:21,1740384694,9/17/2015 10:54:18,false,neodev,1.0,30581619,USA,CA,San Jose,50.118.162.56,[TREATS] [NONE],"[TREATS]
[NONE]",good,good,14,87,31,30,94,RO-may_prevent,820388-FS1,"However, once VENOUS THROMBOSIS has already occurred, it is necessary to use full dose HEPARIN preferably by the continuous intravenous route, with maintenance of the partial thromboplastin time (PTT) at 1 1/2 times the control at all times.",VENOUS THROMBOSIS,HEPARIN
790085264,9/17/2015 10:49:39,1740383676,9/17/2015 10:46:58,false,clixsense,1.0,17950689,GBR,L9,Sheffield,146.200.192.103,[TREATS],[TREATS],DUODENAL ULCER,NONE,21,129,35,34,139,RO-may_prevent,820300-FS1,Eighty patients with DUODENAL ULCER were randomly allocated to treatment with tripotassium dicitrato bismuthate (TDB) tablets or CIMETIDINE,DUODENAL ULCER,CIMETIDINE
790085264,9/17/2015 11:01:23,1740385816,9/17/2015 11:01:08,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[TREATS],[TREATS],treatment,N/A,21,129,35,34,139,RO-may_prevent,820300-FS1,Eighty patients with DUODENAL ULCER were randomly allocated to treatment with tripotassium dicitrato bismuthate (TDB) tablets or CIMETIDINE,DUODENAL ULCER,CIMETIDINE
790085264,9/17/2015 11:05:00,1740386501,9/17/2015 11:03:52,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[TREATS],[TREATS],treatment,N/A,21,129,35,34,139,RO-may_prevent,820300-FS1,Eighty patients with DUODENAL ULCER were randomly allocated to treatment with tripotassium dicitrato bismuthate (TDB) tablets or CIMETIDINE,DUODENAL ULCER,CIMETIDINE
790085264,9/17/2015 11:06:10,1740386746,9/17/2015 11:05:53,false,neodev,1.0,30941227,USA,NV,Las Vegas,192.30.80.166,[ASSOCIATED_WITH] [DIAGNOSE_BY_TEST_OR_DRUG],"[DIAGNOSE_BY_TEST_OR_DRUG]
[ASSOCIATED_WITH]",with with or,N/A,21,129,35,34,139,RO-may_prevent,820300-FS1,Eighty patients with DUODENAL ULCER were randomly allocated to treatment with tripotassium dicitrato bismuthate (TDB) tablets or CIMETIDINE,DUODENAL ULCER,CIMETIDINE
790085264,9/17/2015 11:09:21,1740387462,9/17/2015 11:07:58,false,neodev,1.0,30581619,USA,CA,San Jose,50.118.162.56,[NONE],[NONE],good,good,21,129,35,34,139,RO-may_prevent,820300-FS1,Eighty patients with DUODENAL ULCER were randomly allocated to treatment with tripotassium dicitrato bismuthate (TDB) tablets or CIMETIDINE,DUODENAL ULCER,CIMETIDINE
790085264,9/17/2015 11:15:56,1740388749,9/17/2015 11:15:39,false,neodev,1.0,32695853,USA,NV,Las Vegas,192.30.80.172,[ASSOCIATED_WITH] [TREATS] [DIAGNOSE_BY_TEST_OR_DRUG],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]
[ASSOCIATED_WITH]",with treatment with or,N/A,21,129,35,34,139,RO-may_prevent,820300-FS1,Eighty patients with DUODENAL ULCER were randomly allocated to treatment with tripotassium dicitrato bismuthate (TDB) tablets or CIMETIDINE,DUODENAL ULCER,CIMETIDINE
790085264,9/17/2015 11:18:22,1740389171,9/17/2015 11:17:29,false,gifthulk,1.0,18666417,USA,PA,Meadville,24.101.32.13,[TREATS] [DIAGNOSE_BY_TEST_OR_DRUG],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]",Eighty patients with DUODENAL ULCER were allocated to treatment with CIMETIDINE,n/a,21,129,35,34,139,RO-may_prevent,820300-FS1,Eighty patients with DUODENAL ULCER were randomly allocated to treatment with tripotassium dicitrato bismuthate (TDB) tablets or CIMETIDINE,DUODENAL ULCER,CIMETIDINE
790085264,9/17/2015 11:26:03,1740390488,9/17/2015 11:25:34,false,elite,1.0,33798502,USA,VA,Manassas,207.244.86.212,[TREATS],[TREATS],DUODENAL,makes sense,21,129,35,34,139,RO-may_prevent,820300-FS1,Eighty patients with DUODENAL ULCER were randomly allocated to treatment with tripotassium dicitrato bismuthate (TDB) tablets or CIMETIDINE,DUODENAL ULCER,CIMETIDINE
790085264,9/17/2015 11:39:16,1740392994,9/17/2015 11:39:05,false,neodev,1.0,33701549,USA,CA,Torrance,66.171.228.66,[MANIFESTATION] [PREVENTS] [LOCATION] [ASSOCIATED_WITH] [NONE],"[PREVENTS]
[LOCATION]
[MANIFESTATION]
[ASSOCIATED_WITH]
[NONE]",[IS_A],N/A,21,129,35,34,139,RO-may_prevent,820300-FS1,Eighty patients with DUODENAL ULCER were randomly allocated to treatment with tripotassium dicitrato bismuthate (TDB) tablets or CIMETIDINE,DUODENAL ULCER,CIMETIDINE
790085264,9/17/2015 11:57:21,1740396525,9/17/2015 11:56:34,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[TREATS],[TREATS],treatment,N/A,21,129,35,34,139,RO-may_prevent,820300-FS1,Eighty patients with DUODENAL ULCER were randomly allocated to treatment with tripotassium dicitrato bismuthate (TDB) tablets or CIMETIDINE,DUODENAL ULCER,CIMETIDINE
790085264,9/17/2015 12:01:14,1740397270,9/17/2015 12:00:58,false,prodege,1.0,14848125,GBR,V8,Airdrie,86.151.77.161,[TREATS],[TREATS],treatment with,n/a,21,129,35,34,139,RO-may_prevent,820300-FS1,Eighty patients with DUODENAL ULCER were randomly allocated to treatment with tripotassium dicitrato bismuthate (TDB) tablets or CIMETIDINE,DUODENAL ULCER,CIMETIDINE
790085264,9/17/2015 12:21:35,1740401671,9/17/2015 12:21:11,false,neodev,1.0,30588889,NLD,07,Amsterdam,77.248.175.222,[TREATS],[TREATS],treatment,N/A,21,129,35,34,139,RO-may_prevent,820300-FS1,Eighty patients with DUODENAL ULCER were randomly allocated to treatment with tripotassium dicitrato bismuthate (TDB) tablets or CIMETIDINE,DUODENAL ULCER,CIMETIDINE
790085264,9/17/2015 12:33:18,1740404375,9/17/2015 12:32:53,false,prodege,1.0,2145087,USA,NY,New York,107.107.57.52,[TREATS],[TREATS],to treatment with,N/A,21,129,35,34,139,RO-may_prevent,820300-FS1,Eighty patients with DUODENAL ULCER were randomly allocated to treatment with tripotassium dicitrato bismuthate (TDB) tablets or CIMETIDINE,DUODENAL ULCER,CIMETIDINE
790085264,9/17/2015 12:34:28,1740404689,9/17/2015 12:34:10,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,[TREATS],[TREATS],DUODENAL ULCER treatment with CIMETIDINE,na,21,129,35,34,139,RO-may_prevent,820300-FS1,Eighty patients with DUODENAL ULCER were randomly allocated to treatment with tripotassium dicitrato bismuthate (TDB) tablets or CIMETIDINE,DUODENAL ULCER,CIMETIDINE
790085264,9/17/2015 12:35:51,1740405016,9/17/2015 12:35:07,false,neodev,1,31988911,USA,CA,Saratoga,107.178.33.18,[TREATS],[TREATS],treatment,None not selected,21,129,35,34,139,RO-may_prevent,820300-FS1,Eighty patients with DUODENAL ULCER were randomly allocated to treatment with tripotassium dicitrato bismuthate (TDB) tablets or CIMETIDINE,DUODENAL ULCER,CIMETIDINE
790085265,9/17/2015 13:35:04,1740422117,9/17/2015 13:34:49,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,[TREATS],[TREATS],Oral Use treatment,n/a,18,49,22,27,59,RO-may_prevent,820146-FS1,152  Treatment of GOUT FLARE  >     Oral  Use of COLCHICINE for treatment of gout flare is not recommended in patients with renal impairment who are receiving the drug for prevention of gout flares.,GOUT FLARE,COLCHICINE
790085265,9/17/2015 14:11:29,1740436508,9/17/2015 14:11:03,false,gifthunterclub,1.0,30901412,GBR,H9,London,77.89.149.62,[TREATS],[TREATS],Treatment GOUT FLARE Oral Use of COLCHICINE,N/a,18,49,22,27,59,RO-may_prevent,820146-FS1,152  Treatment of GOUT FLARE  >     Oral  Use of COLCHICINE for treatment of gout flare is not recommended in patients with renal impairment who are receiving the drug for prevention of gout flares.,GOUT FLARE,COLCHICINE
790085265,9/17/2015 14:18:32,1740439229,9/17/2015 14:17:56,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.124.79,[CONTRAINDICATES],[CONTRAINDICATES],treatment not recommended,N/A,18,49,22,27,59,RO-may_prevent,820146-FS1,152  Treatment of GOUT FLARE  >     Oral  Use of COLCHICINE for treatment of gout flare is not recommended in patients with renal impairment who are receiving the drug for prevention of gout flares.,GOUT FLARE,COLCHICINE
790085265,9/17/2015 14:30:08,1740443238,9/17/2015 14:28:59,false,zoombucks,1.0,6744840,CAN,BC,Kelowna,174.4.58.160,[CONTRAINDICATES],[CONTRAINDICATES],not recommended,N/A,18,49,22,27,59,RO-may_prevent,820146-FS1,152  Treatment of GOUT FLARE  >     Oral  Use of COLCHICINE for treatment of gout flare is not recommended in patients with renal impairment who are receiving the drug for prevention of gout flares.,GOUT FLARE,COLCHICINE
790085265,9/17/2015 14:35:35,1740445308,9/17/2015 14:35:25,false,bitcoinget,1.0,32306192,USA,MA,Amherst,72.19.88.245,[TREATS],[TREATS],COLCHICINE,N/a,18,49,22,27,59,RO-may_prevent,820146-FS1,152  Treatment of GOUT FLARE  >     Oral  Use of COLCHICINE for treatment of gout flare is not recommended in patients with renal impairment who are receiving the drug for prevention of gout flares.,GOUT FLARE,COLCHICINE
790085265,9/17/2015 14:55:34,1740453288,9/17/2015 14:54:15,false,clixsense,1.0,32049531,USA,"","",38.95.108.252,[NONE],[NONE],none,none,18,49,22,27,59,RO-may_prevent,820146-FS1,152  Treatment of GOUT FLARE  >     Oral  Use of COLCHICINE for treatment of gout flare is not recommended in patients with renal impairment who are receiving the drug for prevention of gout flares.,GOUT FLARE,COLCHICINE
790085265,9/17/2015 14:56:59,1740453736,9/17/2015 14:56:22,false,instagc,1.0,22981457,CAN,ON,Ottawa,67.69.8.122,[TREATS],[TREATS],for treatment of,N/A,18,49,22,27,59,RO-may_prevent,820146-FS1,152  Treatment of GOUT FLARE  >     Oral  Use of COLCHICINE for treatment of gout flare is not recommended in patients with renal impairment who are receiving the drug for prevention of gout flares.,GOUT FLARE,COLCHICINE
790085265,9/17/2015 15:04:26,1740456622,9/17/2015 15:04:04,false,neodev,1.0,31329809,USA,DE,Wilmington,162.223.93.194,[TREATS] [PART_OF] [DIAGNOSE_BY_TEST_OR_DRUG] [IS_A] [ASSOCIATED_WITH],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]
[ASSOCIATED_WITH]
[IS_A]
[PART_OF]",Treatment of of of is with drug,N/A,18,49,22,27,59,RO-may_prevent,820146-FS1,152  Treatment of GOUT FLARE  >     Oral  Use of COLCHICINE for treatment of gout flare is not recommended in patients with renal impairment who are receiving the drug for prevention of gout flares.,GOUT FLARE,COLCHICINE
790085265,9/17/2015 15:06:57,1740457428,9/17/2015 15:05:48,false,clixsense,1.0,33115750,GBR,I3,Rochester,90.222.106.192,[TREATS],[TREATS],for treatment of,N/A,18,49,22,27,59,RO-may_prevent,820146-FS1,152  Treatment of GOUT FLARE  >     Oral  Use of COLCHICINE for treatment of gout flare is not recommended in patients with renal impairment who are receiving the drug for prevention of gout flares.,GOUT FLARE,COLCHICINE
790085265,9/17/2015 15:13:41,1740459356,9/17/2015 15:13:31,false,neodev,1.0,34431172,USA,CA,Torrance,66.171.228.183,[LOCATION] [NONE],"[LOCATION]
[NONE]",no,no,18,49,22,27,59,RO-may_prevent,820146-FS1,152  Treatment of GOUT FLARE  >     Oral  Use of COLCHICINE for treatment of gout flare is not recommended in patients with renal impairment who are receiving the drug for prevention of gout flares.,GOUT FLARE,COLCHICINE
790085265,9/17/2015 15:15:27,1740459957,9/17/2015 15:15:08,false,neodev,1.0,30321275,USA,NV,Las Vegas,192.30.80.4,[TREATS] [PART_OF] [DIAGNOSE_BY_TEST_OR_DRUG] [ASSOCIATED_WITH],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]
[ASSOCIATED_WITH]
[PART_OF]",Treatment of of treatment of with drug,N/A,18,49,22,27,59,RO-may_prevent,820146-FS1,152  Treatment of GOUT FLARE  >     Oral  Use of COLCHICINE for treatment of gout flare is not recommended in patients with renal impairment who are receiving the drug for prevention of gout flares.,GOUT FLARE,COLCHICINE
790085265,9/17/2015 15:21:28,1740462373,9/17/2015 15:21:09,false,neodev,1.0,29363385,USA,DE,Wilmington,162.223.93.162,[TREATS] [PART_OF] [IS_A] [ASSOCIATED_WITH],"[TREATS]
[ASSOCIATED_WITH]
[IS_A]
[PART_OF]",Treatment of of of is with of,N/A,18,49,22,27,59,RO-may_prevent,820146-FS1,152  Treatment of GOUT FLARE  >     Oral  Use of COLCHICINE for treatment of gout flare is not recommended in patients with renal impairment who are receiving the drug for prevention of gout flares.,GOUT FLARE,COLCHICINE
790085265,9/17/2015 15:25:51,1740463891,9/17/2015 15:25:21,false,neodev,1.0,12115558,USA,OH,Twinsburg,98.27.164.131,[TREATS],[TREATS],Oral Use COLCHICINE for treatment of gout flare,N/A,18,49,22,27,59,RO-may_prevent,820146-FS1,152  Treatment of GOUT FLARE  >     Oral  Use of COLCHICINE for treatment of gout flare is not recommended in patients with renal impairment who are receiving the drug for prevention of gout flares.,GOUT FLARE,COLCHICINE
790085265,9/17/2015 15:27:50,1740464660,9/17/2015 15:27:27,false,neodev,1.0,33435788,USA,DE,Wilmington,162.223.93.179,[PART_OF] [TREATS] [DIAGNOSE_BY_TEST_OR_DRUG] [IS_A] [ASSOCIATED_WITH],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]
[ASSOCIATED_WITH]
[IS_A]
[PART_OF]",Treatment of of treatment of is with drug of,N/A,18,49,22,27,59,RO-may_prevent,820146-FS1,152  Treatment of GOUT FLARE  >     Oral  Use of COLCHICINE for treatment of gout flare is not recommended in patients with renal impairment who are receiving the drug for prevention of gout flares.,GOUT FLARE,COLCHICINE
790085265,9/17/2015 15:33:25,1740466825,9/17/2015 15:31:35,false,clixsense,1.0,6833057,NLD,05,Venray,84.31.86.92,[PREVENTS] [TREATS],"[TREATS]
[PREVENTS]",not recommended prevention of gout flares.,Better not use it for pregnancy,18,49,22,27,59,RO-may_prevent,820146-FS1,152  Treatment of GOUT FLARE  >     Oral  Use of COLCHICINE for treatment of gout flare is not recommended in patients with renal impairment who are receiving the drug for prevention of gout flares.,GOUT FLARE,COLCHICINE
790085266,9/17/2015 09:17:48,1740363513,9/17/2015 09:17:23,false,neodev,1.0,32053642,GBR,I7,Newcastle Upon Tyne,92.23.136.205,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],underused in,N/A,132,90,159,156,115,RO-may_prevent,820223-FS1,This article reviews the relevant published literature in order to assess whether aspirin (ACETYLSALICYLIC ACID ASA) is underused in MYOCARDIAL INFARCTION (MI) taking into account: (i) the evidence of efficacy and safety from clinical trials; (ii) authoritative recommendations about its use; and (iii) published drug utilisation studies.,MYOCARDIAL INFARCTION (MI),ACETYLSALICYLIC ACID ASA
790085266,9/17/2015 09:18:25,1740363669,9/17/2015 09:18:10,false,elite,1.0,30659754,USA,"","",162.250.145.204,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],underused,N/A,132,90,159,156,115,RO-may_prevent,820223-FS1,This article reviews the relevant published literature in order to assess whether aspirin (ACETYLSALICYLIC ACID ASA) is underused in MYOCARDIAL INFARCTION (MI) taking into account: (i) the evidence of efficacy and safety from clinical trials; (ii) authoritative recommendations about its use; and (iii) published drug utilisation studies.,MYOCARDIAL INFARCTION (MI),ACETYLSALICYLIC ACID ASA
790085266,9/17/2015 09:25:10,1740365061,9/17/2015 09:24:51,false,instagc,1.0,18960682,GBR,U2,Annan,92.18.213.181,[TREATS],[TREATS],(ACETYLSALICYLIC ACID ASA) is underused in,N/A,132,90,159,156,115,RO-may_prevent,820223-FS1,This article reviews the relevant published literature in order to assess whether aspirin (ACETYLSALICYLIC ACID ASA) is underused in MYOCARDIAL INFARCTION (MI) taking into account: (i) the evidence of efficacy and safety from clinical trials; (ii) authoritative recommendations about its use; and (iii) published drug utilisation studies.,MYOCARDIAL INFARCTION (MI),ACETYLSALICYLIC ACID ASA
790085266,9/17/2015 09:28:19,1740365697,9/17/2015 09:27:51,false,neodev,1.0,15848372,AUS,02,Jannali,14.200.59.55,[ASSOCIATED_WITH],[ASSOCIATED_WITH],is underused in,n/a,132,90,159,156,115,RO-may_prevent,820223-FS1,This article reviews the relevant published literature in order to assess whether aspirin (ACETYLSALICYLIC ACID ASA) is underused in MYOCARDIAL INFARCTION (MI) taking into account: (i) the evidence of efficacy and safety from clinical trials; (ii) authoritative recommendations about its use; and (iii) published drug utilisation studies.,MYOCARDIAL INFARCTION (MI),ACETYLSALICYLIC ACID ASA
790085266,9/17/2015 09:28:26,1740365722,9/17/2015 09:27:45,false,neodev,1.0,33644825,USA,FL,Fort Lauderdale,65.111.173.161,[TREATS],[TREATS],(ACETYLSALICYLIC ACID MYOCARDIAL INFARCTION,prevents,132,90,159,156,115,RO-may_prevent,820223-FS1,This article reviews the relevant published literature in order to assess whether aspirin (ACETYLSALICYLIC ACID ASA) is underused in MYOCARDIAL INFARCTION (MI) taking into account: (i) the evidence of efficacy and safety from clinical trials; (ii) authoritative recommendations about its use; and (iii) published drug utilisation studies.,MYOCARDIAL INFARCTION (MI),ACETYLSALICYLIC ACID ASA
790085266,9/17/2015 09:36:31,1740367612,9/17/2015 09:36:17,false,elite,1.0,30659615,USA,"","",162.250.145.234,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],underused,N/A,132,90,159,156,115,RO-may_prevent,820223-FS1,This article reviews the relevant published literature in order to assess whether aspirin (ACETYLSALICYLIC ACID ASA) is underused in MYOCARDIAL INFARCTION (MI) taking into account: (i) the evidence of efficacy and safety from clinical trials; (ii) authoritative recommendations about its use; and (iii) published drug utilisation studies.,MYOCARDIAL INFARCTION (MI),ACETYLSALICYLIC ACID ASA
790085266,9/17/2015 09:41:50,1740368999,9/17/2015 09:40:59,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[TREATS],[TREATS],underused in,N/A,132,90,159,156,115,RO-may_prevent,820223-FS1,This article reviews the relevant published literature in order to assess whether aspirin (ACETYLSALICYLIC ACID ASA) is underused in MYOCARDIAL INFARCTION (MI) taking into account: (i) the evidence of efficacy and safety from clinical trials; (ii) authoritative recommendations about its use; and (iii) published drug utilisation studies.,MYOCARDIAL INFARCTION (MI),ACETYLSALICYLIC ACID ASA
790085266,9/17/2015 09:41:58,1740369023,9/17/2015 09:40:19,false,pocketmoneygpt,1.0,21432964,GBR,F8,Borehamwood,81.159.185.70,[TREATS],[TREATS],underused in,N/A,132,90,159,156,115,RO-may_prevent,820223-FS1,This article reviews the relevant published literature in order to assess whether aspirin (ACETYLSALICYLIC ACID ASA) is underused in MYOCARDIAL INFARCTION (MI) taking into account: (i) the evidence of efficacy and safety from clinical trials; (ii) authoritative recommendations about its use; and (iii) published drug utilisation studies.,MYOCARDIAL INFARCTION (MI),ACETYLSALICYLIC ACID ASA
790085266,9/17/2015 09:45:02,1740369674,9/17/2015 09:44:22,false,neodev,1.0,21515166,NLD,11,Nieuwkoop,83.84.200.25,[PREVENTS],[PREVENTS],use;,n/a,132,90,159,156,115,RO-may_prevent,820223-FS1,This article reviews the relevant published literature in order to assess whether aspirin (ACETYLSALICYLIC ACID ASA) is underused in MYOCARDIAL INFARCTION (MI) taking into account: (i) the evidence of efficacy and safety from clinical trials; (ii) authoritative recommendations about its use; and (iii) published drug utilisation studies.,MYOCARDIAL INFARCTION (MI),ACETYLSALICYLIC ACID ASA
790085266,9/17/2015 09:52:20,1740371351,9/17/2015 09:52:06,false,elite,1.0,30659677,USA,"","",162.252.172.126,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],underused,N/A,132,90,159,156,115,RO-may_prevent,820223-FS1,This article reviews the relevant published literature in order to assess whether aspirin (ACETYLSALICYLIC ACID ASA) is underused in MYOCARDIAL INFARCTION (MI) taking into account: (i) the evidence of efficacy and safety from clinical trials; (ii) authoritative recommendations about its use; and (iii) published drug utilisation studies.,MYOCARDIAL INFARCTION (MI),ACETYLSALICYLIC ACID ASA
790085266,9/17/2015 10:03:39,1740374068,9/17/2015 10:02:53,false,neodev,1.0,34081836,USA,CA,San Jose,23.27.248.146,[TREATS],[TREATS],(ACETYLSALICYLIC ACID ASA) underused in MYOCARDIAL INFARCTION,N/a,132,90,159,156,115,RO-may_prevent,820223-FS1,This article reviews the relevant published literature in order to assess whether aspirin (ACETYLSALICYLIC ACID ASA) is underused in MYOCARDIAL INFARCTION (MI) taking into account: (i) the evidence of efficacy and safety from clinical trials; (ii) authoritative recommendations about its use; and (iii) published drug utilisation studies.,MYOCARDIAL INFARCTION (MI),ACETYLSALICYLIC ACID ASA
790085266,9/17/2015 10:05:32,1740374630,9/17/2015 10:04:08,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[ASSOCIATED_WITH],[ASSOCIATED_WITH],assess whether aspirin (ACETYLSALICYLIC ACID ASA) is underused in MYOCARDIAL INFARCTION,N/A,132,90,159,156,115,RO-may_prevent,820223-FS1,This article reviews the relevant published literature in order to assess whether aspirin (ACETYLSALICYLIC ACID ASA) is underused in MYOCARDIAL INFARCTION (MI) taking into account: (i) the evidence of efficacy and safety from clinical trials; (ii) authoritative recommendations about its use; and (iii) published drug utilisation studies.,MYOCARDIAL INFARCTION (MI),ACETYLSALICYLIC ACID ASA
790085266,9/17/2015 10:30:25,1740379897,9/17/2015 10:30:02,false,pocketmoneygpt,1.0,28884030,USA,WI,Minocqua,75.143.134.247,[TREATS],[TREATS],underused,n/a,132,90,159,156,115,RO-may_prevent,820223-FS1,This article reviews the relevant published literature in order to assess whether aspirin (ACETYLSALICYLIC ACID ASA) is underused in MYOCARDIAL INFARCTION (MI) taking into account: (i) the evidence of efficacy and safety from clinical trials; (ii) authoritative recommendations about its use; and (iii) published drug utilisation studies.,MYOCARDIAL INFARCTION (MI),ACETYLSALICYLIC ACID ASA
790085266,9/17/2015 10:40:26,1740382014,9/17/2015 10:39:40,false,clixsense,1.0,17950689,GBR,L9,Sheffield,146.200.192.103,[SIDE_EFFECT],[SIDE_EFFECT],clinical trials;,NONE,132,90,159,156,115,RO-may_prevent,820223-FS1,This article reviews the relevant published literature in order to assess whether aspirin (ACETYLSALICYLIC ACID ASA) is underused in MYOCARDIAL INFARCTION (MI) taking into account: (i) the evidence of efficacy and safety from clinical trials; (ii) authoritative recommendations about its use; and (iii) published drug utilisation studies.,MYOCARDIAL INFARCTION (MI),ACETYLSALICYLIC ACID ASA
790085266,9/17/2015 10:53:41,1740384357,9/17/2015 10:53:13,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],underused,N/A,132,90,159,156,115,RO-may_prevent,820223-FS1,This article reviews the relevant published literature in order to assess whether aspirin (ACETYLSALICYLIC ACID ASA) is underused in MYOCARDIAL INFARCTION (MI) taking into account: (i) the evidence of efficacy and safety from clinical trials; (ii) authoritative recommendations about its use; and (iii) published drug utilisation studies.,MYOCARDIAL INFARCTION (MI),ACETYLSALICYLIC ACID ASA
790085267,9/17/2015 11:21:47,1740389723,9/17/2015 11:21:05,false,neodev,1.0,32695853,USA,NV,Las Vegas,192.30.80.172,[PART_OF] [ASSOCIATED_WITH] [IS_A],"[ASSOCIATED_WITH]
[IS_A]
[PART_OF]",OF with OF a with of of of,N/A,90,30,117,135,71,RO-may_treat,820103-FS1,"Noteworthy were 1) the marked ELEVATION OF SERUM THYROGLOBULIN IN WOMEN with past history OF THYROID DISORDER GOITER AND THYROID NODULES; 2) the increase in goiter size in a third of the goitrous women, associated with biochemical evidence of functional stimulation of the gland; 3) the indirect evidence of partial thyroidal autonomy in goitrous patients; and 4) the increase in the number and size of thyroid nodules during gestation.",THYROID DISORDER GOITER AND THYROID NODULES,ELEVATION OF SERUM THYROGLOBULIN
790085267,9/17/2015 11:24:01,1740390042,9/17/2015 11:22:28,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[MANIFESTATION],[MANIFESTATION],with past history,N/A,90,30,117,135,71,RO-may_treat,820103-FS1,"Noteworthy were 1) the marked ELEVATION OF SERUM THYROGLOBULIN IN WOMEN with past history OF THYROID DISORDER GOITER AND THYROID NODULES; 2) the increase in goiter size in a third of the goitrous women, associated with biochemical evidence of functional stimulation of the gland; 3) the indirect evidence of partial thyroidal autonomy in goitrous patients; and 4) the increase in the number and size of thyroid nodules during gestation.",THYROID DISORDER GOITER AND THYROID NODULES,ELEVATION OF SERUM THYROGLOBULIN
790085267,9/17/2015 11:30:45,1740391336,9/17/2015 11:28:21,false,neodev,1.0,30581619,USA,CA,San Jose,50.118.162.56,[OTHER] [NONE],"[OTHER]
[NONE]",good,good,90,30,117,135,71,RO-may_treat,820103-FS1,"Noteworthy were 1) the marked ELEVATION OF SERUM THYROGLOBULIN IN WOMEN with past history OF THYROID DISORDER GOITER AND THYROID NODULES; 2) the increase in goiter size in a third of the goitrous women, associated with biochemical evidence of functional stimulation of the gland; 3) the indirect evidence of partial thyroidal autonomy in goitrous patients; and 4) the increase in the number and size of thyroid nodules during gestation.",THYROID DISORDER GOITER AND THYROID NODULES,ELEVATION OF SERUM THYROGLOBULIN
790085267,9/17/2015 11:33:09,1740391758,9/17/2015 11:32:44,false,neodev,1.0,30941227,USA,NV,Las Vegas,192.30.80.166,[PART_OF] [ASSOCIATED_WITH],"[ASSOCIATED_WITH]
[PART_OF]",with OF with of of of,N/A,90,30,117,135,71,RO-may_treat,820103-FS1,"Noteworthy were 1) the marked ELEVATION OF SERUM THYROGLOBULIN IN WOMEN with past history OF THYROID DISORDER GOITER AND THYROID NODULES; 2) the increase in goiter size in a third of the goitrous women, associated with biochemical evidence of functional stimulation of the gland; 3) the indirect evidence of partial thyroidal autonomy in goitrous patients; and 4) the increase in the number and size of thyroid nodules during gestation.",THYROID DISORDER GOITER AND THYROID NODULES,ELEVATION OF SERUM THYROGLOBULIN
790085267,9/17/2015 11:42:54,1740393572,9/17/2015 11:42:40,false,neodev,1.0,33701549,USA,CA,Torrance,66.171.228.66,[CAUSES] [SIDE_EFFECT] [CONTRAINDICATES] [SYMPTOM] [NONE],"[CAUSES]
[SYMPTOM]
[CONTRAINDICATES]
[SIDE_EFFECT]
[NONE]",[IS_A],N/A,90,30,117,135,71,RO-may_treat,820103-FS1,"Noteworthy were 1) the marked ELEVATION OF SERUM THYROGLOBULIN IN WOMEN with past history OF THYROID DISORDER GOITER AND THYROID NODULES; 2) the increase in goiter size in a third of the goitrous women, associated with biochemical evidence of functional stimulation of the gland; 3) the indirect evidence of partial thyroidal autonomy in goitrous patients; and 4) the increase in the number and size of thyroid nodules during gestation.",THYROID DISORDER GOITER AND THYROID NODULES,ELEVATION OF SERUM THYROGLOBULIN
790085267,9/17/2015 12:07:23,1740398637,9/17/2015 12:07:09,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[CAUSES],[CAUSES],increase,N/A,90,30,117,135,71,RO-may_treat,820103-FS1,"Noteworthy were 1) the marked ELEVATION OF SERUM THYROGLOBULIN IN WOMEN with past history OF THYROID DISORDER GOITER AND THYROID NODULES; 2) the increase in goiter size in a third of the goitrous women, associated with biochemical evidence of functional stimulation of the gland; 3) the indirect evidence of partial thyroidal autonomy in goitrous patients; and 4) the increase in the number and size of thyroid nodules during gestation.",THYROID DISORDER GOITER AND THYROID NODULES,ELEVATION OF SERUM THYROGLOBULIN
790085267,9/17/2015 12:32:54,1740404259,9/17/2015 12:32:33,false,neodev,1.0,30588889,NLD,07,Amsterdam,77.248.175.222,[SYMPTOM],[SYMPTOM],past history OF,N/A,90,30,117,135,71,RO-may_treat,820103-FS1,"Noteworthy were 1) the marked ELEVATION OF SERUM THYROGLOBULIN IN WOMEN with past history OF THYROID DISORDER GOITER AND THYROID NODULES; 2) the increase in goiter size in a third of the goitrous women, associated with biochemical evidence of functional stimulation of the gland; 3) the indirect evidence of partial thyroidal autonomy in goitrous patients; and 4) the increase in the number and size of thyroid nodules during gestation.",THYROID DISORDER GOITER AND THYROID NODULES,ELEVATION OF SERUM THYROGLOBULIN
790085267,9/17/2015 12:41:26,1740406412,9/17/2015 12:40:47,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,[SYMPTOM],[SYMPTOM],ELEVATION OF SERUM THYROGLOBULIN IN WOMEN with history OF THYROID DISORDER GOITER AND THYROID NODULES;,na,90,30,117,135,71,RO-may_treat,820103-FS1,"Noteworthy were 1) the marked ELEVATION OF SERUM THYROGLOBULIN IN WOMEN with past history OF THYROID DISORDER GOITER AND THYROID NODULES; 2) the increase in goiter size in a third of the goitrous women, associated with biochemical evidence of functional stimulation of the gland; 3) the indirect evidence of partial thyroidal autonomy in goitrous patients; and 4) the increase in the number and size of thyroid nodules during gestation.",THYROID DISORDER GOITER AND THYROID NODULES,ELEVATION OF SERUM THYROGLOBULIN
790085267,9/17/2015 12:42:31,1740406689,9/17/2015 12:41:29,false,prodege,1.0,2145087,USA,NY,New York,107.107.57.52,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with past history OF,N/A,90,30,117,135,71,RO-may_treat,820103-FS1,"Noteworthy were 1) the marked ELEVATION OF SERUM THYROGLOBULIN IN WOMEN with past history OF THYROID DISORDER GOITER AND THYROID NODULES; 2) the increase in goiter size in a third of the goitrous women, associated with biochemical evidence of functional stimulation of the gland; 3) the indirect evidence of partial thyroidal autonomy in goitrous patients; and 4) the increase in the number and size of thyroid nodules during gestation.",THYROID DISORDER GOITER AND THYROID NODULES,ELEVATION OF SERUM THYROGLOBULIN
790085267,9/17/2015 13:15:23,1740416029,9/17/2015 13:15:09,false,elite,1.0,31883685,GBR,"","",79.66.244.188,[SYMPTOM],[SYMPTOM],with past history,n/a,90,30,117,135,71,RO-may_treat,820103-FS1,"Noteworthy were 1) the marked ELEVATION OF SERUM THYROGLOBULIN IN WOMEN with past history OF THYROID DISORDER GOITER AND THYROID NODULES; 2) the increase in goiter size in a third of the goitrous women, associated with biochemical evidence of functional stimulation of the gland; 3) the indirect evidence of partial thyroidal autonomy in goitrous patients; and 4) the increase in the number and size of thyroid nodules during gestation.",THYROID DISORDER GOITER AND THYROID NODULES,ELEVATION OF SERUM THYROGLOBULIN
790085267,9/17/2015 13:15:45,1740416147,9/17/2015 13:15:33,false,neodev,1.0,33228343,USA,"","",38.95.108.251,[TREATS] [DIAGNOSE_BY_TEST_OR_DRUG] [SYMPTOM] [CONTRAINDICATES] [ASSOCIATED_WITH] [SIDE_EFFECT] [NONE],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]
[SYMPTOM]
[CONTRAINDICATES]
[ASSOCIATED_WITH]
[SIDE_EFFECT]
[NONE]",oteworthy were 1) the marked ELEVATION OF SERUM THYROGLOBULIN IN WOMEN with past history OF THYROID DISORDER GOITER AND THYROID NODULES; 2) the incr,oteworthy were 1) the marked ELEVATION OF SERUM THYROGLOBULIN IN WOMEN with past history OF THYROID DISORDER GOITER AND THYROID NODULES; 2) the incr,90,30,117,135,71,RO-may_treat,820103-FS1,"Noteworthy were 1) the marked ELEVATION OF SERUM THYROGLOBULIN IN WOMEN with past history OF THYROID DISORDER GOITER AND THYROID NODULES; 2) the increase in goiter size in a third of the goitrous women, associated with biochemical evidence of functional stimulation of the gland; 3) the indirect evidence of partial thyroidal autonomy in goitrous patients; and 4) the increase in the number and size of thyroid nodules during gestation.",THYROID DISORDER GOITER AND THYROID NODULES,ELEVATION OF SERUM THYROGLOBULIN
790085267,9/17/2015 13:16:39,1740416441,9/17/2015 13:15:40,false,prodege,1.0,33854929,USA,CT,Wallingford,24.2.218.232,[OTHER],[OTHER],history,n/a,90,30,117,135,71,RO-may_treat,820103-FS1,"Noteworthy were 1) the marked ELEVATION OF SERUM THYROGLOBULIN IN WOMEN with past history OF THYROID DISORDER GOITER AND THYROID NODULES; 2) the increase in goiter size in a third of the goitrous women, associated with biochemical evidence of functional stimulation of the gland; 3) the indirect evidence of partial thyroidal autonomy in goitrous patients; and 4) the increase in the number and size of thyroid nodules during gestation.",THYROID DISORDER GOITER AND THYROID NODULES,ELEVATION OF SERUM THYROGLOBULIN
790085267,9/17/2015 13:20:09,1740417508,9/17/2015 13:19:21,false,neodev,1.0,12115558,USA,OH,Twinsburg,98.27.164.131,[MANIFESTATION] [SYMPTOM],"[SYMPTOM]
[MANIFESTATION]",increase in the number and size of thyroid nodules,N/A,90,30,117,135,71,RO-may_treat,820103-FS1,"Noteworthy were 1) the marked ELEVATION OF SERUM THYROGLOBULIN IN WOMEN with past history OF THYROID DISORDER GOITER AND THYROID NODULES; 2) the increase in goiter size in a third of the goitrous women, associated with biochemical evidence of functional stimulation of the gland; 3) the indirect evidence of partial thyroidal autonomy in goitrous patients; and 4) the increase in the number and size of thyroid nodules during gestation.",THYROID DISORDER GOITER AND THYROID NODULES,ELEVATION OF SERUM THYROGLOBULIN
790085267,9/17/2015 13:21:07,1740417830,9/17/2015 13:20:20,false,prodege,1.0,27934334,GBR,C8,Croydon,81.159.60.206,[SYMPTOM],[SYMPTOM],with history OF,N/A,90,30,117,135,71,RO-may_treat,820103-FS1,"Noteworthy were 1) the marked ELEVATION OF SERUM THYROGLOBULIN IN WOMEN with past history OF THYROID DISORDER GOITER AND THYROID NODULES; 2) the increase in goiter size in a third of the goitrous women, associated with biochemical evidence of functional stimulation of the gland; 3) the indirect evidence of partial thyroidal autonomy in goitrous patients; and 4) the increase in the number and size of thyroid nodules during gestation.",THYROID DISORDER GOITER AND THYROID NODULES,ELEVATION OF SERUM THYROGLOBULIN
790085267,9/17/2015 13:23:38,1740418615,9/17/2015 13:23:12,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,[CAUSES],[CAUSES],with history,n/a,90,30,117,135,71,RO-may_treat,820103-FS1,"Noteworthy were 1) the marked ELEVATION OF SERUM THYROGLOBULIN IN WOMEN with past history OF THYROID DISORDER GOITER AND THYROID NODULES; 2) the increase in goiter size in a third of the goitrous women, associated with biochemical evidence of functional stimulation of the gland; 3) the indirect evidence of partial thyroidal autonomy in goitrous patients; and 4) the increase in the number and size of thyroid nodules during gestation.",THYROID DISORDER GOITER AND THYROID NODULES,ELEVATION OF SERUM THYROGLOBULIN
790085268,9/17/2015 11:22:13,1740389777,9/17/2015 11:21:49,false,neodev,1.0,32695853,USA,NV,Las Vegas,192.30.80.172,[ASSOCIATED_WITH] [DIAGNOSE_BY_TEST_OR_DRUG] [IS_A],"[DIAGNOSE_BY_TEST_OR_DRUG]
[ASSOCIATED_WITH]
[IS_A]",with with with with (a drug,N/A,66,51,98,97,60,RO-may_prevent,820345-FS1,"We compared all patients in England and Wales with ISONIAZID  and MULTIDRUG RESISTANT TUBERCULOSIS in two time periods (1993 1994 and 1998 2000) with patients with fully sensitive tuberculosis, examining separately patients without and with previous tuberculosis (a proxy for primary and secondary drug resistant tuberculosis.",MULTIDRUG RESISTANT TUBERCULOSIS,ISONIAZID
790085268,9/17/2015 11:24:48,1740390203,9/17/2015 11:24:04,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[OTHER],[OTHER],patients in England and Wales with,N/A,66,51,98,97,60,RO-may_prevent,820345-FS1,"We compared all patients in England and Wales with ISONIAZID  and MULTIDRUG RESISTANT TUBERCULOSIS in two time periods (1993 1994 and 1998 2000) with patients with fully sensitive tuberculosis, examining separately patients without and with previous tuberculosis (a proxy for primary and secondary drug resistant tuberculosis.",MULTIDRUG RESISTANT TUBERCULOSIS,ISONIAZID
790085268,9/17/2015 11:30:59,1740391387,9/17/2015 11:30:46,false,neodev,1.0,30581619,USA,CA,San Jose,50.118.162.56,[NONE],[NONE],good,good,66,51,98,97,60,RO-may_prevent,820345-FS1,"We compared all patients in England and Wales with ISONIAZID  and MULTIDRUG RESISTANT TUBERCULOSIS in two time periods (1993 1994 and 1998 2000) with patients with fully sensitive tuberculosis, examining separately patients without and with previous tuberculosis (a proxy for primary and secondary drug resistant tuberculosis.",MULTIDRUG RESISTANT TUBERCULOSIS,ISONIAZID
790085268,9/17/2015 11:33:43,1740391855,9/17/2015 11:33:12,false,neodev,1.0,30941227,USA,NV,Las Vegas,192.30.80.166,[ASSOCIATED_WITH] [DIAGNOSE_BY_TEST_OR_DRUG] [IS_A],"[DIAGNOSE_BY_TEST_OR_DRUG]
[ASSOCIATED_WITH]
[IS_A]",with with with with (a drug,N/A,66,51,98,97,60,RO-may_prevent,820345-FS1,"We compared all patients in England and Wales with ISONIAZID  and MULTIDRUG RESISTANT TUBERCULOSIS in two time periods (1993 1994 and 1998 2000) with patients with fully sensitive tuberculosis, examining separately patients without and with previous tuberculosis (a proxy for primary and secondary drug resistant tuberculosis.",MULTIDRUG RESISTANT TUBERCULOSIS,ISONIAZID
790085268,9/17/2015 11:43:09,1740393636,9/17/2015 11:42:56,false,neodev,1.0,33701549,USA,CA,Torrance,66.171.228.66,[IS_A] [LOCATION] [TREATS] [DIAGNOSE_BY_TEST_OR_DRUG] [NONE],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]
[LOCATION]
[IS_A]
[NONE]",[IS_A],N/A,66,51,98,97,60,RO-may_prevent,820345-FS1,"We compared all patients in England and Wales with ISONIAZID  and MULTIDRUG RESISTANT TUBERCULOSIS in two time periods (1993 1994 and 1998 2000) with patients with fully sensitive tuberculosis, examining separately patients without and with previous tuberculosis (a proxy for primary and secondary drug resistant tuberculosis.",MULTIDRUG RESISTANT TUBERCULOSIS,ISONIAZID
790085268,9/17/2015 12:07:41,1740398719,9/17/2015 12:07:24,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],examining,N/A,66,51,98,97,60,RO-may_prevent,820345-FS1,"We compared all patients in England and Wales with ISONIAZID  and MULTIDRUG RESISTANT TUBERCULOSIS in two time periods (1993 1994 and 1998 2000) with patients with fully sensitive tuberculosis, examining separately patients without and with previous tuberculosis (a proxy for primary and secondary drug resistant tuberculosis.",MULTIDRUG RESISTANT TUBERCULOSIS,ISONIAZID
790085268,9/17/2015 12:33:18,1740404376,9/17/2015 12:32:56,false,neodev,1.0,30588889,NLD,07,Amsterdam,77.248.175.222,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,66,51,98,97,60,RO-may_prevent,820345-FS1,"We compared all patients in England and Wales with ISONIAZID  and MULTIDRUG RESISTANT TUBERCULOSIS in two time periods (1993 1994 and 1998 2000) with patients with fully sensitive tuberculosis, examining separately patients without and with previous tuberculosis (a proxy for primary and secondary drug resistant tuberculosis.",MULTIDRUG RESISTANT TUBERCULOSIS,ISONIAZID
790085268,9/17/2015 12:41:56,1740406537,9/17/2015 12:41:26,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,[ASSOCIATED_WITH],[ASSOCIATED_WITH],patients with ISONIAZID and MULTIDRUG RESISTANT TUBERCULOSIS,na,66,51,98,97,60,RO-may_prevent,820345-FS1,"We compared all patients in England and Wales with ISONIAZID  and MULTIDRUG RESISTANT TUBERCULOSIS in two time periods (1993 1994 and 1998 2000) with patients with fully sensitive tuberculosis, examining separately patients without and with previous tuberculosis (a proxy for primary and secondary drug resistant tuberculosis.",MULTIDRUG RESISTANT TUBERCULOSIS,ISONIAZID
790085268,9/17/2015 12:42:54,1740406850,9/17/2015 12:42:32,false,prodege,1.0,2145087,USA,NY,New York,107.107.57.52,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,66,51,98,97,60,RO-may_prevent,820345-FS1,"We compared all patients in England and Wales with ISONIAZID  and MULTIDRUG RESISTANT TUBERCULOSIS in two time periods (1993 1994 and 1998 2000) with patients with fully sensitive tuberculosis, examining separately patients without and with previous tuberculosis (a proxy for primary and secondary drug resistant tuberculosis.",MULTIDRUG RESISTANT TUBERCULOSIS,ISONIAZID
790085268,9/17/2015 13:15:44,1740416143,9/17/2015 13:15:24,false,elite,1.0,31883685,GBR,"","",79.66.244.188,[TREATS],[TREATS],and,n/a,66,51,98,97,60,RO-may_prevent,820345-FS1,"We compared all patients in England and Wales with ISONIAZID  and MULTIDRUG RESISTANT TUBERCULOSIS in two time periods (1993 1994 and 1998 2000) with patients with fully sensitive tuberculosis, examining separately patients without and with previous tuberculosis (a proxy for primary and secondary drug resistant tuberculosis.",MULTIDRUG RESISTANT TUBERCULOSIS,ISONIAZID
790085268,9/17/2015 13:16:02,1740416236,9/17/2015 13:15:47,false,neodev,1.0,33228343,USA,"","",38.95.108.251,[TREATS] [LOCATION] [SYMPTOM] [SIDE_EFFECT] [ASSOCIATED_WITH] [NONE],"[TREATS]
[LOCATION]
[SYMPTOM]
[ASSOCIATED_WITH]
[SIDE_EFFECT]
[NONE]","th patients with fully sensitive tuberculosis, examining separately patients without and with previous tuberculosis (a proxy for primary and secondary drug resistant tuberculosis.","th patients with fully sensitive tuberculosis, examining separately patients without and with previous tuberculosis (a proxy for primary and secondary drug resistant tuberculosis.",66,51,98,97,60,RO-may_prevent,820345-FS1,"We compared all patients in England and Wales with ISONIAZID  and MULTIDRUG RESISTANT TUBERCULOSIS in two time periods (1993 1994 and 1998 2000) with patients with fully sensitive tuberculosis, examining separately patients without and with previous tuberculosis (a proxy for primary and secondary drug resistant tuberculosis.",MULTIDRUG RESISTANT TUBERCULOSIS,ISONIAZID
790085268,9/17/2015 13:16:56,1740416469,9/17/2015 13:16:39,false,prodege,1.0,33854929,USA,CT,Wallingford,24.2.218.232,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,n/a,66,51,98,97,60,RO-may_prevent,820345-FS1,"We compared all patients in England and Wales with ISONIAZID  and MULTIDRUG RESISTANT TUBERCULOSIS in two time periods (1993 1994 and 1998 2000) with patients with fully sensitive tuberculosis, examining separately patients without and with previous tuberculosis (a proxy for primary and secondary drug resistant tuberculosis.",MULTIDRUG RESISTANT TUBERCULOSIS,ISONIAZID
790085268,9/17/2015 13:21:11,1740417873,9/17/2015 13:20:10,false,neodev,1.0,12115558,USA,OH,Twinsburg,98.27.164.131,[OTHER],[OTHER],ISONIAZID and MULTIDRUG RESISTANT TUBERCULOSIS,N/A,66,51,98,97,60,RO-may_prevent,820345-FS1,"We compared all patients in England and Wales with ISONIAZID  and MULTIDRUG RESISTANT TUBERCULOSIS in two time periods (1993 1994 and 1998 2000) with patients with fully sensitive tuberculosis, examining separately patients without and with previous tuberculosis (a proxy for primary and secondary drug resistant tuberculosis.",MULTIDRUG RESISTANT TUBERCULOSIS,ISONIAZID
790085268,9/17/2015 13:22:11,1740418158,9/17/2015 13:21:08,false,prodege,1.0,27934334,GBR,C8,Croydon,81.159.60.206,[TREATS],[TREATS],"patients with fully sensitive tuberculosis,",N/A,66,51,98,97,60,RO-may_prevent,820345-FS1,"We compared all patients in England and Wales with ISONIAZID  and MULTIDRUG RESISTANT TUBERCULOSIS in two time periods (1993 1994 and 1998 2000) with patients with fully sensitive tuberculosis, examining separately patients without and with previous tuberculosis (a proxy for primary and secondary drug resistant tuberculosis.",MULTIDRUG RESISTANT TUBERCULOSIS,ISONIAZID
790085268,9/17/2015 13:22:14,1740418180,9/17/2015 13:20:37,false,prodege,1,14571439,CAN,ON,Toronto,142.20.20.193,[CAUSES],[CAUSES],ISONIAZID and MULTIDRUG RESISTANT TUBERCULOSIS,N/A,66,51,98,97,60,RO-may_prevent,820345-FS1,"We compared all patients in England and Wales with ISONIAZID  and MULTIDRUG RESISTANT TUBERCULOSIS in two time periods (1993 1994 and 1998 2000) with patients with fully sensitive tuberculosis, examining separately patients without and with previous tuberculosis (a proxy for primary and secondary drug resistant tuberculosis.",MULTIDRUG RESISTANT TUBERCULOSIS,ISONIAZID
790085269,9/17/2015 09:09:18,1740361617,9/17/2015 09:08:48,false,neodev,1.0,32053642,GBR,I7,Newcastle Upon Tyne,92.23.136.205,[TREATS],[TREATS],Dosage adjustments needed;,N/A,483,550,495,494,578,RO-may_treat,820026-FS1,"prolonged QT interval, torsades de pointes) [ 1 ] Concomitant use contraindicated [ 1 ]   Digoxin Increased digoxin plasma concentrations [ 1 ] If used concomitantly, monitor digoxin plasma concentrations [ 1 ]   Ergot alkaloids (ergotamine, dihydroergotamine) Possible pharmacokinetic interaction (increased plasma concentrations of ergot alkaloids resulting in ergotism) [ 1 ] Concomitant use contraindicated [ 1 ]   Glipizide No clinically important pharmacokinetic interactions; HYPOGLYCEMIA reported [ 1 ] Dosage adjustments not needed; monitor BLOOD GLUCOSE CONCENTRATIONS according to current recommendations for patients with diabetes [ 1 ]   Halofantrine.",HYPOGLYCEMIA,BLOOD GLUCOSE CONCENTRATIONS
790085269,9/17/2015 09:11:32,1740362117,9/17/2015 09:11:21,false,clixsense,1.0,19162475,GBR,P8,Trowbridge,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],HYPOGLYCEMIA BLOOD GLUCOSE CONCENTRATIONS,n/a,483,550,495,494,578,RO-may_treat,820026-FS1,"prolonged QT interval, torsades de pointes) [ 1 ] Concomitant use contraindicated [ 1 ]   Digoxin Increased digoxin plasma concentrations [ 1 ] If used concomitantly, monitor digoxin plasma concentrations [ 1 ]   Ergot alkaloids (ergotamine, dihydroergotamine) Possible pharmacokinetic interaction (increased plasma concentrations of ergot alkaloids resulting in ergotism) [ 1 ] Concomitant use contraindicated [ 1 ]   Glipizide No clinically important pharmacokinetic interactions; HYPOGLYCEMIA reported [ 1 ] Dosage adjustments not needed; monitor BLOOD GLUCOSE CONCENTRATIONS according to current recommendations for patients with diabetes [ 1 ]   Halofantrine.",HYPOGLYCEMIA,BLOOD GLUCOSE CONCENTRATIONS
790085269,9/17/2015 09:11:46,1740362148,9/17/2015 09:09:45,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[NONE],[NONE],N/A,no relations,483,550,495,494,578,RO-may_treat,820026-FS1,"prolonged QT interval, torsades de pointes) [ 1 ] Concomitant use contraindicated [ 1 ]   Digoxin Increased digoxin plasma concentrations [ 1 ] If used concomitantly, monitor digoxin plasma concentrations [ 1 ]   Ergot alkaloids (ergotamine, dihydroergotamine) Possible pharmacokinetic interaction (increased plasma concentrations of ergot alkaloids resulting in ergotism) [ 1 ] Concomitant use contraindicated [ 1 ]   Glipizide No clinically important pharmacokinetic interactions; HYPOGLYCEMIA reported [ 1 ] Dosage adjustments not needed; monitor BLOOD GLUCOSE CONCENTRATIONS according to current recommendations for patients with diabetes [ 1 ]   Halofantrine.",HYPOGLYCEMIA,BLOOD GLUCOSE CONCENTRATIONS
790085269,9/17/2015 09:12:52,1740362457,9/17/2015 09:12:37,false,elite,1.0,30659754,USA,"","",162.250.145.204,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],monitor,N/A,483,550,495,494,578,RO-may_treat,820026-FS1,"prolonged QT interval, torsades de pointes) [ 1 ] Concomitant use contraindicated [ 1 ]   Digoxin Increased digoxin plasma concentrations [ 1 ] If used concomitantly, monitor digoxin plasma concentrations [ 1 ]   Ergot alkaloids (ergotamine, dihydroergotamine) Possible pharmacokinetic interaction (increased plasma concentrations of ergot alkaloids resulting in ergotism) [ 1 ] Concomitant use contraindicated [ 1 ]   Glipizide No clinically important pharmacokinetic interactions; HYPOGLYCEMIA reported [ 1 ] Dosage adjustments not needed; monitor BLOOD GLUCOSE CONCENTRATIONS according to current recommendations for patients with diabetes [ 1 ]   Halofantrine.",HYPOGLYCEMIA,BLOOD GLUCOSE CONCENTRATIONS
790085269,9/17/2015 09:16:26,1740363265,9/17/2015 09:15:09,false,neodev,1.0,33644825,USA,FL,Fort Lauderdale,65.111.173.161,[PREVENTS],[PREVENTS],HYPOGLYCEMIA BLOOD GLUCOSE CONCENTRATIONS,reduced,483,550,495,494,578,RO-may_treat,820026-FS1,"prolonged QT interval, torsades de pointes) [ 1 ] Concomitant use contraindicated [ 1 ]   Digoxin Increased digoxin plasma concentrations [ 1 ] If used concomitantly, monitor digoxin plasma concentrations [ 1 ]   Ergot alkaloids (ergotamine, dihydroergotamine) Possible pharmacokinetic interaction (increased plasma concentrations of ergot alkaloids resulting in ergotism) [ 1 ] Concomitant use contraindicated [ 1 ]   Glipizide No clinically important pharmacokinetic interactions; HYPOGLYCEMIA reported [ 1 ] Dosage adjustments not needed; monitor BLOOD GLUCOSE CONCENTRATIONS according to current recommendations for patients with diabetes [ 1 ]   Halofantrine.",HYPOGLYCEMIA,BLOOD GLUCOSE CONCENTRATIONS
790085269,9/17/2015 09:16:57,1740363390,9/17/2015 09:16:31,false,instagc,1.0,18960682,GBR,U2,Annan,92.18.213.181,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],monitor BLOOD GLUCOSE CONCENTRATIONS according to current recommendations,N/A,483,550,495,494,578,RO-may_treat,820026-FS1,"prolonged QT interval, torsades de pointes) [ 1 ] Concomitant use contraindicated [ 1 ]   Digoxin Increased digoxin plasma concentrations [ 1 ] If used concomitantly, monitor digoxin plasma concentrations [ 1 ]   Ergot alkaloids (ergotamine, dihydroergotamine) Possible pharmacokinetic interaction (increased plasma concentrations of ergot alkaloids resulting in ergotism) [ 1 ] Concomitant use contraindicated [ 1 ]   Glipizide No clinically important pharmacokinetic interactions; HYPOGLYCEMIA reported [ 1 ] Dosage adjustments not needed; monitor BLOOD GLUCOSE CONCENTRATIONS according to current recommendations for patients with diabetes [ 1 ]   Halofantrine.",HYPOGLYCEMIA,BLOOD GLUCOSE CONCENTRATIONS
790085269,9/17/2015 09:17:06,1740363418,9/17/2015 09:16:32,false,neodev,1.0,15848372,AUS,02,Jannali,14.200.59.55,[MANIFESTATION],[MANIFESTATION],monitor,n/a,483,550,495,494,578,RO-may_treat,820026-FS1,"prolonged QT interval, torsades de pointes) [ 1 ] Concomitant use contraindicated [ 1 ]   Digoxin Increased digoxin plasma concentrations [ 1 ] If used concomitantly, monitor digoxin plasma concentrations [ 1 ]   Ergot alkaloids (ergotamine, dihydroergotamine) Possible pharmacokinetic interaction (increased plasma concentrations of ergot alkaloids resulting in ergotism) [ 1 ] Concomitant use contraindicated [ 1 ]   Glipizide No clinically important pharmacokinetic interactions; HYPOGLYCEMIA reported [ 1 ] Dosage adjustments not needed; monitor BLOOD GLUCOSE CONCENTRATIONS according to current recommendations for patients with diabetes [ 1 ]   Halofantrine.",HYPOGLYCEMIA,BLOOD GLUCOSE CONCENTRATIONS
790085269,9/17/2015 09:17:46,1740363508,9/17/2015 09:17:12,false,neodev,1.0,30627835,GBR,D8,Bishop Auckland,217.44.84.223,[NONE],[NONE],N/A,The words appear in two different sentences and are not related.,483,550,495,494,578,RO-may_treat,820026-FS1,"prolonged QT interval, torsades de pointes) [ 1 ] Concomitant use contraindicated [ 1 ]   Digoxin Increased digoxin plasma concentrations [ 1 ] If used concomitantly, monitor digoxin plasma concentrations [ 1 ]   Ergot alkaloids (ergotamine, dihydroergotamine) Possible pharmacokinetic interaction (increased plasma concentrations of ergot alkaloids resulting in ergotism) [ 1 ] Concomitant use contraindicated [ 1 ]   Glipizide No clinically important pharmacokinetic interactions; HYPOGLYCEMIA reported [ 1 ] Dosage adjustments not needed; monitor BLOOD GLUCOSE CONCENTRATIONS according to current recommendations for patients with diabetes [ 1 ]   Halofantrine.",HYPOGLYCEMIA,BLOOD GLUCOSE CONCENTRATIONS
790085269,9/17/2015 09:24:29,1740364922,9/17/2015 09:22:44,false,pocketmoneygpt,1.0,21432964,GBR,F8,Borehamwood,81.159.185.70,[TREATS],[TREATS],reported Dosage adjustments,N/A,483,550,495,494,578,RO-may_treat,820026-FS1,"prolonged QT interval, torsades de pointes) [ 1 ] Concomitant use contraindicated [ 1 ]   Digoxin Increased digoxin plasma concentrations [ 1 ] If used concomitantly, monitor digoxin plasma concentrations [ 1 ]   Ergot alkaloids (ergotamine, dihydroergotamine) Possible pharmacokinetic interaction (increased plasma concentrations of ergot alkaloids resulting in ergotism) [ 1 ] Concomitant use contraindicated [ 1 ]   Glipizide No clinically important pharmacokinetic interactions; HYPOGLYCEMIA reported [ 1 ] Dosage adjustments not needed; monitor BLOOD GLUCOSE CONCENTRATIONS according to current recommendations for patients with diabetes [ 1 ]   Halofantrine.",HYPOGLYCEMIA,BLOOD GLUCOSE CONCENTRATIONS
790085269,9/17/2015 09:27:17,1740365433,9/17/2015 09:27:04,false,elite,1.0,30659615,USA,"","",162.250.145.234,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],monitor,N/A,483,550,495,494,578,RO-may_treat,820026-FS1,"prolonged QT interval, torsades de pointes) [ 1 ] Concomitant use contraindicated [ 1 ]   Digoxin Increased digoxin plasma concentrations [ 1 ] If used concomitantly, monitor digoxin plasma concentrations [ 1 ]   Ergot alkaloids (ergotamine, dihydroergotamine) Possible pharmacokinetic interaction (increased plasma concentrations of ergot alkaloids resulting in ergotism) [ 1 ] Concomitant use contraindicated [ 1 ]   Glipizide No clinically important pharmacokinetic interactions; HYPOGLYCEMIA reported [ 1 ] Dosage adjustments not needed; monitor BLOOD GLUCOSE CONCENTRATIONS according to current recommendations for patients with diabetes [ 1 ]   Halofantrine.",HYPOGLYCEMIA,BLOOD GLUCOSE CONCENTRATIONS
790085269,9/17/2015 09:33:22,1740366964,9/17/2015 09:31:14,false,neodev,1.0,21515166,NLD,11,Nieuwkoop,83.84.200.25,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],according to,n/a,483,550,495,494,578,RO-may_treat,820026-FS1,"prolonged QT interval, torsades de pointes) [ 1 ] Concomitant use contraindicated [ 1 ]   Digoxin Increased digoxin plasma concentrations [ 1 ] If used concomitantly, monitor digoxin plasma concentrations [ 1 ]   Ergot alkaloids (ergotamine, dihydroergotamine) Possible pharmacokinetic interaction (increased plasma concentrations of ergot alkaloids resulting in ergotism) [ 1 ] Concomitant use contraindicated [ 1 ]   Glipizide No clinically important pharmacokinetic interactions; HYPOGLYCEMIA reported [ 1 ] Dosage adjustments not needed; monitor BLOOD GLUCOSE CONCENTRATIONS according to current recommendations for patients with diabetes [ 1 ]   Halofantrine.",HYPOGLYCEMIA,BLOOD GLUCOSE CONCENTRATIONS
790085269,9/17/2015 09:42:42,1740369182,9/17/2015 09:41:41,false,neodev,1.0,34081836,USA,CA,San Jose,23.27.248.146,[OTHER],[OTHER],HYPOGLYCEMIA reported Dosage adjustments not needed; monitor BLOOD GLUCOSE CONCENTRATIONS according to current recommendations,N/A,483,550,495,494,578,RO-may_treat,820026-FS1,"prolonged QT interval, torsades de pointes) [ 1 ] Concomitant use contraindicated [ 1 ]   Digoxin Increased digoxin plasma concentrations [ 1 ] If used concomitantly, monitor digoxin plasma concentrations [ 1 ]   Ergot alkaloids (ergotamine, dihydroergotamine) Possible pharmacokinetic interaction (increased plasma concentrations of ergot alkaloids resulting in ergotism) [ 1 ] Concomitant use contraindicated [ 1 ]   Glipizide No clinically important pharmacokinetic interactions; HYPOGLYCEMIA reported [ 1 ] Dosage adjustments not needed; monitor BLOOD GLUCOSE CONCENTRATIONS according to current recommendations for patients with diabetes [ 1 ]   Halofantrine.",HYPOGLYCEMIA,BLOOD GLUCOSE CONCENTRATIONS
790085269,9/17/2015 09:46:48,1740370031,9/17/2015 09:46:34,false,elite,1.0,30659677,USA,"","",162.252.172.126,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],Dosage adjustments monitor,N/A,483,550,495,494,578,RO-may_treat,820026-FS1,"prolonged QT interval, torsades de pointes) [ 1 ] Concomitant use contraindicated [ 1 ]   Digoxin Increased digoxin plasma concentrations [ 1 ] If used concomitantly, monitor digoxin plasma concentrations [ 1 ]   Ergot alkaloids (ergotamine, dihydroergotamine) Possible pharmacokinetic interaction (increased plasma concentrations of ergot alkaloids resulting in ergotism) [ 1 ] Concomitant use contraindicated [ 1 ]   Glipizide No clinically important pharmacokinetic interactions; HYPOGLYCEMIA reported [ 1 ] Dosage adjustments not needed; monitor BLOOD GLUCOSE CONCENTRATIONS according to current recommendations for patients with diabetes [ 1 ]   Halofantrine.",HYPOGLYCEMIA,BLOOD GLUCOSE CONCENTRATIONS
790085269,9/17/2015 09:49:37,1740370690,9/17/2015 09:49:09,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[OTHER],[OTHER],No clinically important pharmacokinetic interactions; HYPOGLYCEMIA reported 1 Dosage adjustments not needed; monitor BLOOD GLUCOSE CONCENTRATIONS,N/A,483,550,495,494,578,RO-may_treat,820026-FS1,"prolonged QT interval, torsades de pointes) [ 1 ] Concomitant use contraindicated [ 1 ]   Digoxin Increased digoxin plasma concentrations [ 1 ] If used concomitantly, monitor digoxin plasma concentrations [ 1 ]   Ergot alkaloids (ergotamine, dihydroergotamine) Possible pharmacokinetic interaction (increased plasma concentrations of ergot alkaloids resulting in ergotism) [ 1 ] Concomitant use contraindicated [ 1 ]   Glipizide No clinically important pharmacokinetic interactions; HYPOGLYCEMIA reported [ 1 ] Dosage adjustments not needed; monitor BLOOD GLUCOSE CONCENTRATIONS according to current recommendations for patients with diabetes [ 1 ]   Halofantrine.",HYPOGLYCEMIA,BLOOD GLUCOSE CONCENTRATIONS
790085269,9/17/2015 10:02:15,1740373637,9/17/2015 10:01:40,false,prodege,1.0,14848125,GBR,V8,Airdrie,86.151.77.161,[MANIFESTATION],[MANIFESTATION],monitor,n/a,483,550,495,494,578,RO-may_treat,820026-FS1,"prolonged QT interval, torsades de pointes) [ 1 ] Concomitant use contraindicated [ 1 ]   Digoxin Increased digoxin plasma concentrations [ 1 ] If used concomitantly, monitor digoxin plasma concentrations [ 1 ]   Ergot alkaloids (ergotamine, dihydroergotamine) Possible pharmacokinetic interaction (increased plasma concentrations of ergot alkaloids resulting in ergotism) [ 1 ] Concomitant use contraindicated [ 1 ]   Glipizide No clinically important pharmacokinetic interactions; HYPOGLYCEMIA reported [ 1 ] Dosage adjustments not needed; monitor BLOOD GLUCOSE CONCENTRATIONS according to current recommendations for patients with diabetes [ 1 ]   Halofantrine.",HYPOGLYCEMIA,BLOOD GLUCOSE CONCENTRATIONS
790085270,9/17/2015 09:13:15,1740362528,9/17/2015 09:12:36,false,neodev,1.0,32053642,GBR,I7,Newcastle Upon Tyne,92.23.136.205,[CAUSES],[CAUSES],transmission of,N/A,111,55,129,137,66,RO-may_prevent,820225-FS1,Changes in the pattern of transmission of new cases of HEPATITIS B inform us of changes in the epidemiology of VIRAL HEPATITIS B INFECTION.,VIRAL HEPATITIS B INFECTION,HEPATITIS B
790085270,9/17/2015 09:15:11,1740362991,9/17/2015 09:14:54,false,elite,1.0,30659754,USA,"","",162.250.145.204,[SIDE_EFFECT],[SIDE_EFFECT],inform,N/A,111,55,129,137,66,RO-may_prevent,820225-FS1,Changes in the pattern of transmission of new cases of HEPATITIS B inform us of changes in the epidemiology of VIRAL HEPATITIS B INFECTION.,VIRAL HEPATITIS B INFECTION,HEPATITIS B
790085270,9/17/2015 09:20:42,1740364180,9/17/2015 09:20:08,false,instagc,1.0,18960682,GBR,U2,Annan,92.18.213.181,[PART_OF],[PART_OF],new cases of HEPATITIS B changes in VIRAL HEPATITIS B INFECTION.,N/A,111,55,129,137,66,RO-may_prevent,820225-FS1,Changes in the pattern of transmission of new cases of HEPATITIS B inform us of changes in the epidemiology of VIRAL HEPATITIS B INFECTION.,VIRAL HEPATITIS B INFECTION,HEPATITIS B
790085270,9/17/2015 09:21:39,1740364359,9/17/2015 09:21:14,false,neodev,1.0,33644825,USA,FL,Fort Lauderdale,65.111.173.161,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],HEPATITIS B VIRAL HEPATITIS B INFECTION.,treats,111,55,129,137,66,RO-may_prevent,820225-FS1,Changes in the pattern of transmission of new cases of HEPATITIS B inform us of changes in the epidemiology of VIRAL HEPATITIS B INFECTION.,VIRAL HEPATITIS B INFECTION,HEPATITIS B
790085270,9/17/2015 09:21:56,1740364434,9/17/2015 09:21:37,false,neodev,1.0,15848372,AUS,02,Jannali,14.200.59.55,[ASSOCIATED_WITH],[ASSOCIATED_WITH],Changes in the pattern,n/a,111,55,129,137,66,RO-may_prevent,820225-FS1,Changes in the pattern of transmission of new cases of HEPATITIS B inform us of changes in the epidemiology of VIRAL HEPATITIS B INFECTION.,VIRAL HEPATITIS B INFECTION,HEPATITIS B
790085270,9/17/2015 09:24:21,1740364874,9/17/2015 09:22:05,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[OTHER],[OTHER],changes,N/A,111,55,129,137,66,RO-may_prevent,820225-FS1,Changes in the pattern of transmission of new cases of HEPATITIS B inform us of changes in the epidemiology of VIRAL HEPATITIS B INFECTION.,VIRAL HEPATITIS B INFECTION,HEPATITIS B
790085270,9/17/2015 09:29:28,1740365990,9/17/2015 09:29:14,false,elite,1.0,30659615,USA,"","",162.250.145.234,[SYMPTOM],[SYMPTOM],inform us of changes,N/A,111,55,129,137,66,RO-may_prevent,820225-FS1,Changes in the pattern of transmission of new cases of HEPATITIS B inform us of changes in the epidemiology of VIRAL HEPATITIS B INFECTION.,VIRAL HEPATITIS B INFECTION,HEPATITIS B
790085270,9/17/2015 09:32:57,1740366862,9/17/2015 09:31:58,false,pocketmoneygpt,1.0,21432964,GBR,F8,Borehamwood,81.159.185.70,[ASSOCIATED_WITH],[ASSOCIATED_WITH],pattern of transmission,N/A,111,55,129,137,66,RO-may_prevent,820225-FS1,Changes in the pattern of transmission of new cases of HEPATITIS B inform us of changes in the epidemiology of VIRAL HEPATITIS B INFECTION.,VIRAL HEPATITIS B INFECTION,HEPATITIS B
790085270,9/17/2015 09:37:30,1740367795,9/17/2015 09:36:49,false,neodev,1.0,21515166,NLD,11,Nieuwkoop,83.84.200.25,[IS_A],[IS_A],changes in,n/a,111,55,129,137,66,RO-may_prevent,820225-FS1,Changes in the pattern of transmission of new cases of HEPATITIS B inform us of changes in the epidemiology of VIRAL HEPATITIS B INFECTION.,VIRAL HEPATITIS B INFECTION,HEPATITIS B
790085270,9/17/2015 09:49:10,1740370622,9/17/2015 09:48:51,false,elite,1.0,30659677,USA,"","",162.252.172.126,[SYMPTOM],[SYMPTOM],transmission,N/A,111,55,129,137,66,RO-may_prevent,820225-FS1,Changes in the pattern of transmission of new cases of HEPATITIS B inform us of changes in the epidemiology of VIRAL HEPATITIS B INFECTION.,VIRAL HEPATITIS B INFECTION,HEPATITIS B
790085270,9/17/2015 09:52:16,1740371321,9/17/2015 09:51:18,false,neodev,1.0,34081836,USA,CA,San Jose,23.27.248.146,[SYMPTOM] [CAUSES] [MANIFESTATION],"[CAUSES]
[SYMPTOM]
[MANIFESTATION]",HEPATITIS B inform us of changes in the epidemiology of VIRAL HEPATITIS B INFECTION.,N/A,111,55,129,137,66,RO-may_prevent,820225-FS1,Changes in the pattern of transmission of new cases of HEPATITIS B inform us of changes in the epidemiology of VIRAL HEPATITIS B INFECTION.,VIRAL HEPATITIS B INFECTION,HEPATITIS B
790085270,9/17/2015 09:56:04,1740372240,9/17/2015 09:55:10,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[SYMPTOM],[SYMPTOM],Changes in the pattern of transmission of new cases of HEPATITIS B inform us of changes of VIRAL HEPATITIS B INFECTION.,N/A,111,55,129,137,66,RO-may_prevent,820225-FS1,Changes in the pattern of transmission of new cases of HEPATITIS B inform us of changes in the epidemiology of VIRAL HEPATITIS B INFECTION.,VIRAL HEPATITIS B INFECTION,HEPATITIS B
790085270,9/17/2015 10:25:57,1740379016,9/17/2015 10:25:35,false,pocketmoneygpt,1.0,28884030,USA,WI,Minocqua,75.143.134.247,[IS_A],[IS_A],in,n/a,111,55,129,137,66,RO-may_prevent,820225-FS1,Changes in the pattern of transmission of new cases of HEPATITIS B inform us of changes in the epidemiology of VIRAL HEPATITIS B INFECTION.,VIRAL HEPATITIS B INFECTION,HEPATITIS B
790085270,9/17/2015 10:27:51,1740379381,9/17/2015 10:26:28,false,clixsense,1.0,17950689,GBR,L9,Sheffield,146.200.192.103,[TREATS],[TREATS],HEPATITIS B,NONE,111,55,129,137,66,RO-may_prevent,820225-FS1,Changes in the pattern of transmission of new cases of HEPATITIS B inform us of changes in the epidemiology of VIRAL HEPATITIS B INFECTION.,VIRAL HEPATITIS B INFECTION,HEPATITIS B
790085270,9/17/2015 10:49:31,1740383645,9/17/2015 10:48:45,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[MANIFESTATION],[MANIFESTATION],Changes in the pattern of transmission of,N/A,111,55,129,137,66,RO-may_prevent,820225-FS1,Changes in the pattern of transmission of new cases of HEPATITIS B inform us of changes in the epidemiology of VIRAL HEPATITIS B INFECTION.,VIRAL HEPATITIS B INFECTION,HEPATITIS B
790085271,9/17/2015 09:11:44,1740362145,9/17/2015 09:11:11,false,neodev,1.0,32053642,GBR,I7,Newcastle Upon Tyne,92.23.136.205,[SYMPTOM],[SYMPTOM],determined in,N/A,77,77,131,83,90,RO-may_prevent,820347-FS1,"The occurrence of antibodies to the nucleoprotein and matrix (M) antigens of MEASLES VIRUS was determined in early and late measles convalescent sera and in sera from patients with multiple sclerosis, subacute sclerosing panencephalitis, chronic active hepatitis, and atypical MEASLES.",MEASLES,MEASLES VIRUS
790085271,9/17/2015 09:14:19,1740362797,9/17/2015 09:14:05,false,elite,1.0,30659754,USA,"","",162.250.145.204,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],was determined,N/A,77,77,131,83,90,RO-may_prevent,820347-FS1,"The occurrence of antibodies to the nucleoprotein and matrix (M) antigens of MEASLES VIRUS was determined in early and late measles convalescent sera and in sera from patients with multiple sclerosis, subacute sclerosing panencephalitis, chronic active hepatitis, and atypical MEASLES.",MEASLES,MEASLES VIRUS
790085271,9/17/2015 09:18:45,1740363719,9/17/2015 09:16:47,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[ASSOCIATED_WITH],[ASSOCIATED_WITH],occurrence,N/A,77,77,131,83,90,RO-may_prevent,820347-FS1,"The occurrence of antibodies to the nucleoprotein and matrix (M) antigens of MEASLES VIRUS was determined in early and late measles convalescent sera and in sera from patients with multiple sclerosis, subacute sclerosing panencephalitis, chronic active hepatitis, and atypical MEASLES.",MEASLES,MEASLES VIRUS
790085271,9/17/2015 09:19:04,1740363781,9/17/2015 09:18:39,false,instagc,1.0,18960682,GBR,U2,Annan,92.18.213.181,[CAUSES],[CAUSES],antigens of MEASLES VIRUS was determined,N/A,77,77,131,83,90,RO-may_prevent,820347-FS1,"The occurrence of antibodies to the nucleoprotein and matrix (M) antigens of MEASLES VIRUS was determined in early and late measles convalescent sera and in sera from patients with multiple sclerosis, subacute sclerosing panencephalitis, chronic active hepatitis, and atypical MEASLES.",MEASLES,MEASLES VIRUS
790085271,9/17/2015 09:20:07,1740364011,9/17/2015 09:19:30,false,neodev,1.0,33644825,USA,FL,Fort Lauderdale,65.111.173.161,[TREATS],[TREATS],MEASLES VIRUS MEASLES.,cures,77,77,131,83,90,RO-may_prevent,820347-FS1,"The occurrence of antibodies to the nucleoprotein and matrix (M) antigens of MEASLES VIRUS was determined in early and late measles convalescent sera and in sera from patients with multiple sclerosis, subacute sclerosing panencephalitis, chronic active hepatitis, and atypical MEASLES.",MEASLES,MEASLES VIRUS
790085271,9/17/2015 09:20:40,1740364173,9/17/2015 09:20:15,false,neodev,1.0,15848372,AUS,02,Jannali,14.200.59.55,[ASSOCIATED_WITH],[ASSOCIATED_WITH],was determined,n/a,77,77,131,83,90,RO-may_prevent,820347-FS1,"The occurrence of antibodies to the nucleoprotein and matrix (M) antigens of MEASLES VIRUS was determined in early and late measles convalescent sera and in sera from patients with multiple sclerosis, subacute sclerosing panencephalitis, chronic active hepatitis, and atypical MEASLES.",MEASLES,MEASLES VIRUS
790085271,9/17/2015 09:24:19,1740364873,9/17/2015 09:23:16,false,neodev,1.0,30627835,GBR,D8,Bishop Auckland,217.44.84.223,[MANIFESTATION],[MANIFESTATION],was determined in patients with,N/A,77,77,131,83,90,RO-may_prevent,820347-FS1,"The occurrence of antibodies to the nucleoprotein and matrix (M) antigens of MEASLES VIRUS was determined in early and late measles convalescent sera and in sera from patients with multiple sclerosis, subacute sclerosing panencephalitis, chronic active hepatitis, and atypical MEASLES.",MEASLES,MEASLES VIRUS
790085271,9/17/2015 09:28:42,1740365784,9/17/2015 09:28:23,false,elite,1.0,30659615,USA,"","",162.250.145.234,[SYMPTOM],[SYMPTOM],patients with,N/A,77,77,131,83,90,RO-may_prevent,820347-FS1,"The occurrence of antibodies to the nucleoprotein and matrix (M) antigens of MEASLES VIRUS was determined in early and late measles convalescent sera and in sera from patients with multiple sclerosis, subacute sclerosing panencephalitis, chronic active hepatitis, and atypical MEASLES.",MEASLES,MEASLES VIRUS
790085271,9/17/2015 09:29:54,1740366066,9/17/2015 09:28:59,false,pocketmoneygpt,1.0,21432964,GBR,F8,Borehamwood,81.159.185.70,[ASSOCIATED_WITH],[ASSOCIATED_WITH],occurrence of antibodies,N/A,77,77,131,83,90,RO-may_prevent,820347-FS1,"The occurrence of antibodies to the nucleoprotein and matrix (M) antigens of MEASLES VIRUS was determined in early and late measles convalescent sera and in sera from patients with multiple sclerosis, subacute sclerosing panencephalitis, chronic active hepatitis, and atypical MEASLES.",MEASLES,MEASLES VIRUS
790085271,9/17/2015 09:35:31,1740367372,9/17/2015 09:35:06,false,neodev,1.0,21515166,NLD,11,Nieuwkoop,83.84.200.25,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],was determined in,n/a,77,77,131,83,90,RO-may_prevent,820347-FS1,"The occurrence of antibodies to the nucleoprotein and matrix (M) antigens of MEASLES VIRUS was determined in early and late measles convalescent sera and in sera from patients with multiple sclerosis, subacute sclerosing panencephalitis, chronic active hepatitis, and atypical MEASLES.",MEASLES,MEASLES VIRUS
790085271,9/17/2015 09:48:15,1740370363,9/17/2015 09:47:56,false,elite,1.0,30659677,USA,"","",162.252.172.126,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],was determined,N/A,77,77,131,83,90,RO-may_prevent,820347-FS1,"The occurrence of antibodies to the nucleoprotein and matrix (M) antigens of MEASLES VIRUS was determined in early and late measles convalescent sera and in sera from patients with multiple sclerosis, subacute sclerosing panencephalitis, chronic active hepatitis, and atypical MEASLES.",MEASLES,MEASLES VIRUS
790085271,9/17/2015 09:49:07,1740370611,9/17/2015 09:48:11,false,neodev,1.0,34081836,USA,CA,San Jose,23.27.248.146,[MANIFESTATION] [CAUSES],"[CAUSES]
[MANIFESTATION]",MEASLES VIRUS was determined in early and atypical MEASLES.,N/A,77,77,131,83,90,RO-may_prevent,820347-FS1,"The occurrence of antibodies to the nucleoprotein and matrix (M) antigens of MEASLES VIRUS was determined in early and late measles convalescent sera and in sera from patients with multiple sclerosis, subacute sclerosing panencephalitis, chronic active hepatitis, and atypical MEASLES.",MEASLES,MEASLES VIRUS
790085271,9/17/2015 09:53:18,1740371625,9/17/2015 09:51:47,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[SIDE_EFFECT],[SIDE_EFFECT],The occurrence of antibodies nucleoprotein antigens of MEASLES VIRUS was determined in early and late measles,N/A,77,77,131,83,90,RO-may_prevent,820347-FS1,"The occurrence of antibodies to the nucleoprotein and matrix (M) antigens of MEASLES VIRUS was determined in early and late measles convalescent sera and in sera from patients with multiple sclerosis, subacute sclerosing panencephalitis, chronic active hepatitis, and atypical MEASLES.",MEASLES,MEASLES VIRUS
790085271,9/17/2015 10:24:19,1740378683,9/17/2015 10:23:52,false,pocketmoneygpt,1.0,28884030,USA,WI,Minocqua,75.143.134.247,[PART_OF],[PART_OF],in,n/a,77,77,131,83,90,RO-may_prevent,820347-FS1,"The occurrence of antibodies to the nucleoprotein and matrix (M) antigens of MEASLES VIRUS was determined in early and late measles convalescent sera and in sera from patients with multiple sclerosis, subacute sclerosing panencephalitis, chronic active hepatitis, and atypical MEASLES.",MEASLES,MEASLES VIRUS
790085271,9/17/2015 10:30:00,1740379807,9/17/2015 10:27:52,false,clixsense,1.0,17950689,GBR,L9,Sheffield,146.200.192.103,[TREATS],[TREATS],MEASLES,NONE,77,77,131,83,90,RO-may_prevent,820347-FS1,"The occurrence of antibodies to the nucleoprotein and matrix (M) antigens of MEASLES VIRUS was determined in early and late measles convalescent sera and in sera from patients with multiple sclerosis, subacute sclerosing panencephalitis, chronic active hepatitis, and atypical MEASLES.",MEASLES,MEASLES VIRUS
790085272,9/17/2015 09:16:03,1740363205,9/17/2015 09:15:48,false,neodev,1.0,32053642,GBR,I7,Newcastle Upon Tyne,92.23.136.205,[TREATS],[TREATS],treatment of,N/A,60,0,74,73,10,RO-may_prevent,820226-FS1,"SUCRALFATE and ranitidine were compared in the treatment of DUODENAL ULCER in this multicenter, randomized, double blind study.",DUODENAL ULCER,SUCRALFATE
790085272,9/17/2015 09:17:14,1740363429,9/17/2015 09:17:01,false,elite,1.0,30659754,USA,"","",162.250.145.204,[TREATS],[TREATS],treatment,N/A,60,0,74,73,10,RO-may_prevent,820226-FS1,"SUCRALFATE and ranitidine were compared in the treatment of DUODENAL ULCER in this multicenter, randomized, double blind study.",DUODENAL ULCER,SUCRALFATE
790085272,9/17/2015 09:23:30,1740364714,9/17/2015 09:23:16,false,instagc,1.0,18960682,GBR,U2,Annan,92.18.213.181,[TREATS],[TREATS],in the treatment of,N/A,60,0,74,73,10,RO-may_prevent,820226-FS1,"SUCRALFATE and ranitidine were compared in the treatment of DUODENAL ULCER in this multicenter, randomized, double blind study.",DUODENAL ULCER,SUCRALFATE
790085272,9/17/2015 09:25:46,1740365151,9/17/2015 09:24:50,false,neodev,1.0,33644825,USA,FL,Fort Lauderdale,65.111.173.161,[PREVENTS],[PREVENTS],SUCRALFATE DUODENAL ULCER,treats,60,0,74,73,10,RO-may_prevent,820226-FS1,"SUCRALFATE and ranitidine were compared in the treatment of DUODENAL ULCER in this multicenter, randomized, double blind study.",DUODENAL ULCER,SUCRALFATE
790085272,9/17/2015 09:25:58,1740365200,9/17/2015 09:25:14,false,neodev,1.0,15848372,AUS,02,Jannali,14.200.59.55,[ASSOCIATED_WITH],[ASSOCIATED_WITH],treatment of,n/a,60,0,74,73,10,RO-may_prevent,820226-FS1,"SUCRALFATE and ranitidine were compared in the treatment of DUODENAL ULCER in this multicenter, randomized, double blind study.",DUODENAL ULCER,SUCRALFATE
790085272,9/17/2015 09:35:19,1740367336,9/17/2015 09:34:02,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[TREATS],[TREATS],treatment,N/A,60,0,74,73,10,RO-may_prevent,820226-FS1,"SUCRALFATE and ranitidine were compared in the treatment of DUODENAL ULCER in this multicenter, randomized, double blind study.",DUODENAL ULCER,SUCRALFATE
790085272,9/17/2015 09:35:29,1740367366,9/17/2015 09:35:15,false,elite,1.0,30659615,USA,"","",162.250.145.234,[TREATS],[TREATS],treatment,N/A,60,0,74,73,10,RO-may_prevent,820226-FS1,"SUCRALFATE and ranitidine were compared in the treatment of DUODENAL ULCER in this multicenter, randomized, double blind study.",DUODENAL ULCER,SUCRALFATE
790085272,9/17/2015 09:37:40,1740367814,9/17/2015 09:37:09,false,pocketmoneygpt,1.0,21432964,GBR,F8,Borehamwood,81.159.185.70,[TREATS],[TREATS],treatment of,N/A,60,0,74,73,10,RO-may_prevent,820226-FS1,"SUCRALFATE and ranitidine were compared in the treatment of DUODENAL ULCER in this multicenter, randomized, double blind study.",DUODENAL ULCER,SUCRALFATE
790085272,9/17/2015 09:41:36,1740368945,9/17/2015 09:41:16,false,neodev,1.0,21515166,NLD,11,Nieuwkoop,83.84.200.25,[TREATS],[TREATS],were compared in the treatment of,n/a,60,0,74,73,10,RO-may_prevent,820226-FS1,"SUCRALFATE and ranitidine were compared in the treatment of DUODENAL ULCER in this multicenter, randomized, double blind study.",DUODENAL ULCER,SUCRALFATE
790085272,9/17/2015 09:51:10,1740371087,9/17/2015 09:50:56,false,elite,1.0,30659677,USA,"","",162.252.172.126,[TREATS],[TREATS],treatment,N/A,60,0,74,73,10,RO-may_prevent,820226-FS1,"SUCRALFATE and ranitidine were compared in the treatment of DUODENAL ULCER in this multicenter, randomized, double blind study.",DUODENAL ULCER,SUCRALFATE
790085272,9/17/2015 10:00:18,1740373230,9/17/2015 09:59:47,false,neodev,1.0,34081836,USA,CA,San Jose,23.27.248.146,[TREATS],[TREATS],SUCRALFATE were compared in the treatment of DUODENAL ULCER,N/A,60,0,74,73,10,RO-may_prevent,820226-FS1,"SUCRALFATE and ranitidine were compared in the treatment of DUODENAL ULCER in this multicenter, randomized, double blind study.",DUODENAL ULCER,SUCRALFATE
790085272,9/17/2015 10:02:27,1740373682,9/17/2015 10:01:37,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[TREATS],[TREATS],treatment,N/A,60,0,74,73,10,RO-may_prevent,820226-FS1,"SUCRALFATE and ranitidine were compared in the treatment of DUODENAL ULCER in this multicenter, randomized, double blind study.",DUODENAL ULCER,SUCRALFATE
790085272,9/17/2015 10:29:13,1740379627,9/17/2015 10:29:01,false,pocketmoneygpt,1.0,28884030,USA,WI,Minocqua,75.143.134.247,[TREATS],[TREATS],treatment,n/a,60,0,74,73,10,RO-may_prevent,820226-FS1,"SUCRALFATE and ranitidine were compared in the treatment of DUODENAL ULCER in this multicenter, randomized, double blind study.",DUODENAL ULCER,SUCRALFATE
790085272,9/17/2015 10:36:27,1740381300,9/17/2015 10:35:47,false,clixsense,1.0,17950689,GBR,L9,Sheffield,146.200.192.103,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],DUODENAL,NONE,60,0,74,73,10,RO-may_prevent,820226-FS1,"SUCRALFATE and ranitidine were compared in the treatment of DUODENAL ULCER in this multicenter, randomized, double blind study.",DUODENAL ULCER,SUCRALFATE
790085272,9/17/2015 10:52:18,1740384136,9/17/2015 10:52:01,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[TREATS],[TREATS],treatment,N/A,60,0,74,73,10,RO-may_prevent,820226-FS1,"SUCRALFATE and ranitidine were compared in the treatment of DUODENAL ULCER in this multicenter, randomized, double blind study.",DUODENAL ULCER,SUCRALFATE
790085273,9/17/2015 13:21:30,1740417964,9/17/2015 13:21:17,false,neodev,1.0,33228343,USA,"","",38.95.108.251,[DIAGNOSE_BY_TEST_OR_DRUG] [SYMPTOM] [CONTRAINDICATES] [IS_A] [PART_OF] [PREVENTS] [TREATS] [NONE],"[TREATS]
[PREVENTS]
[DIAGNOSE_BY_TEST_OR_DRUG]
[SYMPTOM]
[CONTRAINDICATES]
[IS_A]
[PART_OF]
[NONE]",Frequency of ANGINA and NITROGLYCERIN consumption were assessed by weekly patient diaries.,Frequency of ANGINA and NITROGLYCERIN consumption were assessed by weekly patient diaries.,13,24,19,18,37,RO-may_prevent,820305-FS1,Frequency of ANGINA and NITROGLYCERIN consumption were assessed by weekly patient diaries.,ANGINA,NITROGLYCERIN
790085273,9/17/2015 13:22:43,1740418353,9/17/2015 13:22:16,false,elite,1.0,31883685,GBR,"","",79.66.244.188,[TREATS] [SIDE_EFFECT],"[TREATS]
[SIDE_EFFECT]",consumption,n/a,13,24,19,18,37,RO-may_prevent,820305-FS1,Frequency of ANGINA and NITROGLYCERIN consumption were assessed by weekly patient diaries.,ANGINA,NITROGLYCERIN
790085273,9/17/2015 13:31:46,1740421068,9/17/2015 13:31:28,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,n/a,13,24,19,18,37,RO-may_prevent,820305-FS1,Frequency of ANGINA and NITROGLYCERIN consumption were assessed by weekly patient diaries.,ANGINA,NITROGLYCERIN
790085273,9/17/2015 13:35:22,1740422178,9/17/2015 13:35:00,false,prodege,1.0,27934334,GBR,C8,Croydon,81.159.60.206,[TREATS],[TREATS],consumption,N/A,13,24,19,18,37,RO-may_prevent,820305-FS1,Frequency of ANGINA and NITROGLYCERIN consumption were assessed by weekly patient diaries.,ANGINA,NITROGLYCERIN
790085273,9/17/2015 14:06:44,1740434793,9/17/2015 14:06:19,false,gifthunterclub,1.0,30901412,GBR,H9,London,77.89.149.62,[ASSOCIATED_WITH],[ASSOCIATED_WITH],Frequency of ANGINA NITROGLYCERIN consumption,N/A,13,24,19,18,37,RO-may_prevent,820305-FS1,Frequency of ANGINA and NITROGLYCERIN consumption were assessed by weekly patient diaries.,ANGINA,NITROGLYCERIN
790085273,9/17/2015 14:13:38,1740437255,9/17/2015 14:13:08,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.124.79,[TREATS],[TREATS],consumption,N/A,13,24,19,18,37,RO-may_prevent,820305-FS1,Frequency of ANGINA and NITROGLYCERIN consumption were assessed by weekly patient diaries.,ANGINA,NITROGLYCERIN
790085273,9/17/2015 14:16:31,1740438389,9/17/2015 14:15:26,false,zoombucks,1.0,6744840,CAN,BC,Kelowna,174.4.58.160,[TREATS],[TREATS],NITROGLYCERIN consumption,N/A,13,24,19,18,37,RO-may_prevent,820305-FS1,Frequency of ANGINA and NITROGLYCERIN consumption were assessed by weekly patient diaries.,ANGINA,NITROGLYCERIN
790085273,9/17/2015 14:32:59,1740444407,9/17/2015 14:32:46,false,bitcoinget,1.0,32306192,USA,MA,Amherst,72.19.88.245,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",ANGINA NITROGLYCERIN,N/a,13,24,19,18,37,RO-may_prevent,820305-FS1,Frequency of ANGINA and NITROGLYCERIN consumption were assessed by weekly patient diaries.,ANGINA,NITROGLYCERIN
790085273,9/17/2015 14:44:11,1740448928,9/17/2015 14:41:44,false,clixsense,1.0,32049531,USA,"","",38.95.108.252,[NONE],[NONE],none,none,13,24,19,18,37,RO-may_prevent,820305-FS1,Frequency of ANGINA and NITROGLYCERIN consumption were assessed by weekly patient diaries.,ANGINA,NITROGLYCERIN
790085273,9/17/2015 14:49:14,1740450990,9/17/2015 14:48:40,false,instagc,1.0,22981457,CAN,ON,Ottawa,67.69.8.122,[NONE],[NONE],N/A,Just says patients kept diaries which is how they were assessed,13,24,19,18,37,RO-may_prevent,820305-FS1,Frequency of ANGINA and NITROGLYCERIN consumption were assessed by weekly patient diaries.,ANGINA,NITROGLYCERIN
790085273,9/17/2015 14:57:25,1740453934,9/17/2015 14:56:41,false,clixsense,1.0,33115750,GBR,I3,Rochester,90.222.106.192,[TREATS],[TREATS],consumption,N/A,13,24,19,18,37,RO-may_prevent,820305-FS1,Frequency of ANGINA and NITROGLYCERIN consumption were assessed by weekly patient diaries.,ANGINA,NITROGLYCERIN
790085273,9/17/2015 15:00:18,1740454968,9/17/2015 14:59:52,false,neodev,1.0,31329809,USA,DE,Wilmington,162.223.93.194,[PART_OF],[PART_OF],of,N/A,13,24,19,18,37,RO-may_prevent,820305-FS1,Frequency of ANGINA and NITROGLYCERIN consumption were assessed by weekly patient diaries.,ANGINA,NITROGLYCERIN
790085273,9/17/2015 15:11:19,1740458653,9/17/2015 15:11:07,false,neodev,1.0,34431172,USA,CA,Torrance,66.171.228.183,[LOCATION] [NONE],"[LOCATION]
[NONE]",no,no,13,24,19,18,37,RO-may_prevent,820305-FS1,Frequency of ANGINA and NITROGLYCERIN consumption were assessed by weekly patient diaries.,ANGINA,NITROGLYCERIN
790085273,9/17/2015 15:12:41,1740459081,9/17/2015 15:12:29,false,neodev,1.0,30321275,USA,NV,Las Vegas,192.30.80.4,[PART_OF] [DIAGNOSE_BY_TEST_OR_DRUG],"[DIAGNOSE_BY_TEST_OR_DRUG]
[PART_OF]",of by,N/A,13,24,19,18,37,RO-may_prevent,820305-FS1,Frequency of ANGINA and NITROGLYCERIN consumption were assessed by weekly patient diaries.,ANGINA,NITROGLYCERIN
790085273,9/17/2015 15:17:55,1740460883,9/17/2015 15:17:44,false,neodev,1.0,29363385,USA,DE,Wilmington,162.223.93.162,[PART_OF] [DIAGNOSE_BY_TEST_OR_DRUG],"[DIAGNOSE_BY_TEST_OR_DRUG]
[PART_OF]",of by,N/A,13,24,19,18,37,RO-may_prevent,820305-FS1,Frequency of ANGINA and NITROGLYCERIN consumption were assessed by weekly patient diaries.,ANGINA,NITROGLYCERIN
790085274,9/17/2015 10:33:46,1740380666,9/17/2015 10:33:27,false,pocketmoneygpt,1.0,28884030,USA,WI,Minocqua,75.143.134.247,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,n/a,55,14,71,70,35,RO-may_treat,820107-FS1,"Comparison of ZEBRA ANTIBODY LEVELS with the degree of IMMUNODEFICIENCY (CD4 cell counts), CDC grouping, and HIV p24 antigen positivity showed little association, suggesting that induction of ZEBRA antibodies is an early event after HIV infection.",IMMUNODEFICIENCY,ZEBRA ANTIBODY LEVELS
790085274,9/17/2015 10:44:55,1740382869,9/17/2015 10:44:41,false,clixsense,1.0,17950689,GBR,L9,Sheffield,146.200.192.103,[TREATS],[TREATS],IMMUNODEFICIENCY,NONE,55,14,71,70,35,RO-may_treat,820107-FS1,"Comparison of ZEBRA ANTIBODY LEVELS with the degree of IMMUNODEFICIENCY (CD4 cell counts), CDC grouping, and HIV p24 antigen positivity showed little association, suggesting that induction of ZEBRA antibodies is an early event after HIV infection.",IMMUNODEFICIENCY,ZEBRA ANTIBODY LEVELS
790085274,9/17/2015 10:59:51,1740385540,9/17/2015 10:59:19,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[LOCATION],[LOCATION],and,N/A,55,14,71,70,35,RO-may_treat,820107-FS1,"Comparison of ZEBRA ANTIBODY LEVELS with the degree of IMMUNODEFICIENCY (CD4 cell counts), CDC grouping, and HIV p24 antigen positivity showed little association, suggesting that induction of ZEBRA antibodies is an early event after HIV infection.",IMMUNODEFICIENCY,ZEBRA ANTIBODY LEVELS
790085274,9/17/2015 11:01:14,1740385802,9/17/2015 11:00:36,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[OTHER],[OTHER],Comparison of,N/A,55,14,71,70,35,RO-may_treat,820107-FS1,"Comparison of ZEBRA ANTIBODY LEVELS with the degree of IMMUNODEFICIENCY (CD4 cell counts), CDC grouping, and HIV p24 antigen positivity showed little association, suggesting that induction of ZEBRA antibodies is an early event after HIV infection.",IMMUNODEFICIENCY,ZEBRA ANTIBODY LEVELS
790085274,9/17/2015 11:03:46,1740386230,9/17/2015 11:02:57,false,neodev,1.0,30941227,USA,NV,Las Vegas,192.30.80.166,[PART_OF] [IS_A] [ASSOCIATED_WITH],"[ASSOCIATED_WITH]
[IS_A]
[PART_OF]",of with of is an,N/A,55,14,71,70,35,RO-may_treat,820107-FS1,"Comparison of ZEBRA ANTIBODY LEVELS with the degree of IMMUNODEFICIENCY (CD4 cell counts), CDC grouping, and HIV p24 antigen positivity showed little association, suggesting that induction of ZEBRA antibodies is an early event after HIV infection.",IMMUNODEFICIENCY,ZEBRA ANTIBODY LEVELS
790085274,9/17/2015 11:05:53,1740386708,9/17/2015 11:04:55,false,neodev,1.0,30581619,USA,CA,San Jose,50.118.162.56,[TREATS] [NONE],"[TREATS]
[NONE]",good,good,55,14,71,70,35,RO-may_treat,820107-FS1,"Comparison of ZEBRA ANTIBODY LEVELS with the degree of IMMUNODEFICIENCY (CD4 cell counts), CDC grouping, and HIV p24 antigen positivity showed little association, suggesting that induction of ZEBRA antibodies is an early event after HIV infection.",IMMUNODEFICIENCY,ZEBRA ANTIBODY LEVELS
790085274,9/17/2015 11:14:16,1740388432,9/17/2015 11:13:09,false,clixsense,1,6330007,AUS,"","",1.136.96.69,[CONTRAINDICATES],[CONTRAINDICATES],"showed little association,",n/a,55,14,71,70,35,RO-may_treat,820107-FS1,"Comparison of ZEBRA ANTIBODY LEVELS with the degree of IMMUNODEFICIENCY (CD4 cell counts), CDC grouping, and HIV p24 antigen positivity showed little association, suggesting that induction of ZEBRA antibodies is an early event after HIV infection.",IMMUNODEFICIENCY,ZEBRA ANTIBODY LEVELS
790085274,9/17/2015 11:14:55,1740388555,9/17/2015 11:14:24,false,neodev,1.0,32695853,USA,NV,Las Vegas,192.30.80.172,[PART_OF] [ASSOCIATED_WITH] [IS_A],"[ASSOCIATED_WITH]
[IS_A]
[PART_OF]",of with of of is an,N/A,55,14,71,70,35,RO-may_treat,820107-FS1,"Comparison of ZEBRA ANTIBODY LEVELS with the degree of IMMUNODEFICIENCY (CD4 cell counts), CDC grouping, and HIV p24 antigen positivity showed little association, suggesting that induction of ZEBRA antibodies is an early event after HIV infection.",IMMUNODEFICIENCY,ZEBRA ANTIBODY LEVELS
790085274,9/17/2015 11:15:34,1740388668,9/17/2015 11:12:52,false,gifthulk,1.0,18666417,USA,PA,Meadville,24.101.32.13,[ASSOCIATED_WITH] [IS_A] [PART_OF] [SIDE_EFFECT] [SYMPTOM],"[SYMPTOM]
[ASSOCIATED_WITH]
[SIDE_EFFECT]
[IS_A]
[PART_OF]",Comparison of ZEBRA ANTIBODY LEVELS with degree of IMMUNODEFICIENCY,n/a,55,14,71,70,35,RO-may_treat,820107-FS1,"Comparison of ZEBRA ANTIBODY LEVELS with the degree of IMMUNODEFICIENCY (CD4 cell counts), CDC grouping, and HIV p24 antigen positivity showed little association, suggesting that induction of ZEBRA antibodies is an early event after HIV infection.",IMMUNODEFICIENCY,ZEBRA ANTIBODY LEVELS
790085274,9/17/2015 11:24:25,1740390133,9/17/2015 11:24:10,false,elite,1.0,33798502,USA,VA,Manassas,207.244.86.212,[TREATS],[TREATS],ZEBRA,makes sense,55,14,71,70,35,RO-may_treat,820107-FS1,"Comparison of ZEBRA ANTIBODY LEVELS with the degree of IMMUNODEFICIENCY (CD4 cell counts), CDC grouping, and HIV p24 antigen positivity showed little association, suggesting that induction of ZEBRA antibodies is an early event after HIV infection.",IMMUNODEFICIENCY,ZEBRA ANTIBODY LEVELS
790085274,9/17/2015 11:38:32,1740392855,9/17/2015 11:38:11,false,neodev,1.0,33701549,USA,CA,Torrance,66.171.228.66,[CONTRAINDICATES] [LOCATION] [DIAGNOSE_BY_TEST_OR_DRUG] [NONE],"[DIAGNOSE_BY_TEST_OR_DRUG]
[LOCATION]
[CONTRAINDICATES]
[NONE]",[IS_A],N/A,55,14,71,70,35,RO-may_treat,820107-FS1,"Comparison of ZEBRA ANTIBODY LEVELS with the degree of IMMUNODEFICIENCY (CD4 cell counts), CDC grouping, and HIV p24 antigen positivity showed little association, suggesting that induction of ZEBRA antibodies is an early event after HIV infection.",IMMUNODEFICIENCY,ZEBRA ANTIBODY LEVELS
790085274,9/17/2015 11:41:03,1740393357,9/17/2015 11:40:12,false,neodev,1.0,31329809,USA,DE,Wilmington,162.223.93.194,[PART_OF] [IS_A] [ASSOCIATED_WITH],"[ASSOCIATED_WITH]
[IS_A]
[PART_OF]",of with of of is an,N/A,55,14,71,70,35,RO-may_treat,820107-FS1,"Comparison of ZEBRA ANTIBODY LEVELS with the degree of IMMUNODEFICIENCY (CD4 cell counts), CDC grouping, and HIV p24 antigen positivity showed little association, suggesting that induction of ZEBRA antibodies is an early event after HIV infection.",IMMUNODEFICIENCY,ZEBRA ANTIBODY LEVELS
790085274,9/17/2015 11:55:50,1740396271,9/17/2015 11:53:48,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[CAUSES],[CAUSES],Comparison,N/A,55,14,71,70,35,RO-may_treat,820107-FS1,"Comparison of ZEBRA ANTIBODY LEVELS with the degree of IMMUNODEFICIENCY (CD4 cell counts), CDC grouping, and HIV p24 antigen positivity showed little association, suggesting that induction of ZEBRA antibodies is an early event after HIV infection.",IMMUNODEFICIENCY,ZEBRA ANTIBODY LEVELS
790085274,9/17/2015 11:59:57,1740397041,9/17/2015 11:59:05,false,prodege,1.0,14848125,GBR,V8,Airdrie,86.151.77.161,[MANIFESTATION],[MANIFESTATION],induction of ZEBRA antibodies is early event after HIV infection.,n/a,55,14,71,70,35,RO-may_treat,820107-FS1,"Comparison of ZEBRA ANTIBODY LEVELS with the degree of IMMUNODEFICIENCY (CD4 cell counts), CDC grouping, and HIV p24 antigen positivity showed little association, suggesting that induction of ZEBRA antibodies is an early event after HIV infection.",IMMUNODEFICIENCY,ZEBRA ANTIBODY LEVELS
790085274,9/17/2015 12:18:53,1740401129,9/17/2015 12:18:32,false,neodev,1.0,30588889,NLD,07,Amsterdam,77.248.175.222,[ASSOCIATED_WITH],[ASSOCIATED_WITH],Comparison,N/A,55,14,71,70,35,RO-may_treat,820107-FS1,"Comparison of ZEBRA ANTIBODY LEVELS with the degree of IMMUNODEFICIENCY (CD4 cell counts), CDC grouping, and HIV p24 antigen positivity showed little association, suggesting that induction of ZEBRA antibodies is an early event after HIV infection.",IMMUNODEFICIENCY,ZEBRA ANTIBODY LEVELS
790085275,9/17/2015 11:28:04,1740390820,9/17/2015 11:27:47,false,neodev,1.0,32695853,USA,NV,Las Vegas,192.30.80.172,[TREATS] [PART_OF] [ASSOCIATED_WITH],"[TREATS]
[ASSOCIATED_WITH]
[PART_OF]",treatment of with,N/A,74,0,92,91,28,RO-may_prevent,820306-FS1,LOW MOLECULAR WEIGHT HEPARIN vs heparin in the treatment of patients with PULMONARY EMBOLISM,PULMONARY EMBOLISM,LOW MOLECULAR WEIGHT HEPARIN
790085275,9/17/2015 11:37:22,1740392573,9/17/2015 11:37:07,false,neodev,1.0,30941227,USA,NV,Las Vegas,192.30.80.166,[TREATS] [PART_OF] [ASSOCIATED_WITH],"[TREATS]
[ASSOCIATED_WITH]
[PART_OF]",of patients with,N/A,74,0,92,91,28,RO-may_prevent,820306-FS1,LOW MOLECULAR WEIGHT HEPARIN vs heparin in the treatment of patients with PULMONARY EMBOLISM,PULMONARY EMBOLISM,LOW MOLECULAR WEIGHT HEPARIN
790085275,9/17/2015 12:12:35,1740399822,9/17/2015 12:12:21,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[TREATS],[TREATS],treatment,N/A,74,0,92,91,28,RO-may_prevent,820306-FS1,LOW MOLECULAR WEIGHT HEPARIN vs heparin in the treatment of patients with PULMONARY EMBOLISM,PULMONARY EMBOLISM,LOW MOLECULAR WEIGHT HEPARIN
790085275,9/17/2015 12:38:26,1740405678,9/17/2015 12:38:12,false,neodev,1.0,30588889,NLD,07,Amsterdam,77.248.175.222,[TREATS],[TREATS],treatment,N/A,74,0,92,91,28,RO-may_prevent,820306-FS1,LOW MOLECULAR WEIGHT HEPARIN vs heparin in the treatment of patients with PULMONARY EMBOLISM,PULMONARY EMBOLISM,LOW MOLECULAR WEIGHT HEPARIN
790085275,9/17/2015 12:47:34,1740408308,9/17/2015 12:47:14,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,[TREATS],[TREATS],LOW MOLECULAR WEIGHT HEPARIN in treatment of PULMONARY EMBOLISM,na,74,0,92,91,28,RO-may_prevent,820306-FS1,LOW MOLECULAR WEIGHT HEPARIN vs heparin in the treatment of patients with PULMONARY EMBOLISM,PULMONARY EMBOLISM,LOW MOLECULAR WEIGHT HEPARIN
790085275,9/17/2015 12:51:29,1740409403,9/17/2015 12:49:24,false,prodege,1.0,2145087,USA,NY,New York,107.107.57.52,[TREATS],[TREATS],in the treatment of,N/A,74,0,92,91,28,RO-may_prevent,820306-FS1,LOW MOLECULAR WEIGHT HEPARIN vs heparin in the treatment of patients with PULMONARY EMBOLISM,PULMONARY EMBOLISM,LOW MOLECULAR WEIGHT HEPARIN
790085275,9/17/2015 13:19:01,1740417071,9/17/2015 13:18:46,false,neodev,1.0,33228343,USA,"","",38.95.108.251,[TREATS] [DIAGNOSE_BY_TEST_OR_DRUG] [NONE] [LOCATION] [SYMPTOM] [CONTRAINDICATES] [PART_OF],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]
[LOCATION]
[SYMPTOM]
[CONTRAINDICATES]
[PART_OF]
[NONE]",LOW MOLECULAR WEIGHT HEPARIN vs heparin in the treatment of patients with PULMONARY EMBOLISM,LOW MOLECULAR WEIGHT HEPARIN vs heparin in the treatment of patients with PULMONARY EMBOLISM,74,0,92,91,28,RO-may_prevent,820306-FS1,LOW MOLECULAR WEIGHT HEPARIN vs heparin in the treatment of patients with PULMONARY EMBOLISM,PULMONARY EMBOLISM,LOW MOLECULAR WEIGHT HEPARIN
790085275,9/17/2015 13:19:41,1740417258,9/17/2015 13:19:21,false,elite,1.0,31883685,GBR,"","",79.66.244.188,[TREATS],[TREATS],treatment,n/a,74,0,92,91,28,RO-may_prevent,820306-FS1,LOW MOLECULAR WEIGHT HEPARIN vs heparin in the treatment of patients with PULMONARY EMBOLISM,PULMONARY EMBOLISM,LOW MOLECULAR WEIGHT HEPARIN
790085275,9/17/2015 13:21:01,1740417817,9/17/2015 13:20:38,false,prodege,1.0,33854929,USA,CT,Wallingford,24.2.218.232,[OTHER],[OTHER],vs,n/a,74,0,92,91,28,RO-may_prevent,820306-FS1,LOW MOLECULAR WEIGHT HEPARIN vs heparin in the treatment of patients with PULMONARY EMBOLISM,PULMONARY EMBOLISM,LOW MOLECULAR WEIGHT HEPARIN
790085275,9/17/2015 13:27:21,1740419711,9/17/2015 13:26:56,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,[TREATS],[TREATS],treatment,n/a,74,0,92,91,28,RO-may_prevent,820306-FS1,LOW MOLECULAR WEIGHT HEPARIN vs heparin in the treatment of patients with PULMONARY EMBOLISM,PULMONARY EMBOLISM,LOW MOLECULAR WEIGHT HEPARIN
790085275,9/17/2015 13:28:03,1740419859,9/17/2015 13:27:35,false,neodev,1.0,12115558,USA,OH,Twinsburg,98.27.164.131,[TREATS],[TREATS],LOW MOLECULAR WEIGHT HEPARIN treatment of patients with,N/A,74,0,92,91,28,RO-may_prevent,820306-FS1,LOW MOLECULAR WEIGHT HEPARIN vs heparin in the treatment of patients with PULMONARY EMBOLISM,PULMONARY EMBOLISM,LOW MOLECULAR WEIGHT HEPARIN
790085275,9/17/2015 13:29:28,1740420261,9/17/2015 13:29:08,false,prodege,1.0,27934334,GBR,C8,Croydon,81.159.60.206,[TREATS],[TREATS],treatment of,N/A,74,0,92,91,28,RO-may_prevent,820306-FS1,LOW MOLECULAR WEIGHT HEPARIN vs heparin in the treatment of patients with PULMONARY EMBOLISM,PULMONARY EMBOLISM,LOW MOLECULAR WEIGHT HEPARIN
790085275,9/17/2015 13:52:36,1740429805,9/17/2015 13:52:07,false,neodev,1.0,31329809,USA,DE,Wilmington,162.223.93.194,[TREATS] [PART_OF] [ASSOCIATED_WITH],"[TREATS]
[ASSOCIATED_WITH]
[PART_OF]",treatment of with,N/A,74,0,92,91,28,RO-may_prevent,820306-FS1,LOW MOLECULAR WEIGHT HEPARIN vs heparin in the treatment of patients with PULMONARY EMBOLISM,PULMONARY EMBOLISM,LOW MOLECULAR WEIGHT HEPARIN
790085275,9/17/2015 14:01:57,1740433082,9/17/2015 14:01:38,false,gifthunterclub,1.0,30901412,GBR,H9,London,77.89.149.62,[TREATS],[TREATS],LOW MOLECULAR WEIGHT HEPARIN treatment PULMONARY EMBOLISM,N/A,74,0,92,91,28,RO-may_prevent,820306-FS1,LOW MOLECULAR WEIGHT HEPARIN vs heparin in the treatment of patients with PULMONARY EMBOLISM,PULMONARY EMBOLISM,LOW MOLECULAR WEIGHT HEPARIN
790085275,9/17/2015 14:03:35,1740433654,9/17/2015 14:02:19,false,zoombucks,1.0,6744840,CAN,BC,Kelowna,174.4.58.160,[TREATS],[TREATS],treatment,N/A,74,0,92,91,28,RO-may_prevent,820306-FS1,LOW MOLECULAR WEIGHT HEPARIN vs heparin in the treatment of patients with PULMONARY EMBOLISM,PULMONARY EMBOLISM,LOW MOLECULAR WEIGHT HEPARIN
790085276,9/17/2015 09:12:10,1740362237,9/17/2015 09:11:44,false,neodev,1.0,32053642,GBR,I7,Newcastle Upon Tyne,92.23.136.205,[TREATS],[TREATS],glucose and,N/A,180,77,130,203,84,RO-may_treat,820109-FS1,"Moreover, brain regions such as the hippocampus are sensitive to glucose and INSULIN and both type 1 and type 2 diabetes mellitus are associated with cognitive impairment and (for TYPE 2 DIABETES MELLITUS) increased risk for Alzheimer's disease.",TYPE 2 DIABETES MELLITUS,INSULIN
790085276,9/17/2015 09:14:35,1740362871,9/17/2015 09:14:21,false,elite,1.0,30659754,USA,"","",162.250.145.204,[CAUSES],[CAUSES],increased,N/A,180,77,130,203,84,RO-may_treat,820109-FS1,"Moreover, brain regions such as the hippocampus are sensitive to glucose and INSULIN and both type 1 and type 2 diabetes mellitus are associated with cognitive impairment and (for TYPE 2 DIABETES MELLITUS) increased risk for Alzheimer's disease.",TYPE 2 DIABETES MELLITUS,INSULIN
790085276,9/17/2015 09:19:39,1740363932,9/17/2015 09:19:04,false,instagc,1.0,18960682,GBR,U2,Annan,92.18.213.181,[TREATS] [CAUSES],"[TREATS]
[CAUSES]",are associated,N/A,180,77,130,203,84,RO-may_treat,820109-FS1,"Moreover, brain regions such as the hippocampus are sensitive to glucose and INSULIN and both type 1 and type 2 diabetes mellitus are associated with cognitive impairment and (for TYPE 2 DIABETES MELLITUS) increased risk for Alzheimer's disease.",TYPE 2 DIABETES MELLITUS,INSULIN
790085276,9/17/2015 09:20:19,1740364100,9/17/2015 09:18:45,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated,N/A,180,77,130,203,84,RO-may_treat,820109-FS1,"Moreover, brain regions such as the hippocampus are sensitive to glucose and INSULIN and both type 1 and type 2 diabetes mellitus are associated with cognitive impairment and (for TYPE 2 DIABETES MELLITUS) increased risk for Alzheimer's disease.",TYPE 2 DIABETES MELLITUS,INSULIN
790085276,9/17/2015 09:20:50,1740364199,9/17/2015 09:20:08,false,neodev,1.0,33644825,USA,FL,Fort Lauderdale,65.111.173.161,[TREATS],[TREATS],TYPE 2 DIABETES MELLITUS) Alzheimer's,prevents,180,77,130,203,84,RO-may_treat,820109-FS1,"Moreover, brain regions such as the hippocampus are sensitive to glucose and INSULIN and both type 1 and type 2 diabetes mellitus are associated with cognitive impairment and (for TYPE 2 DIABETES MELLITUS) increased risk for Alzheimer's disease.",TYPE 2 DIABETES MELLITUS,INSULIN
790085276,9/17/2015 09:21:10,1740364291,9/17/2015 09:20:40,false,neodev,1.0,15848372,AUS,02,Jannali,14.200.59.55,[MANIFESTATION],[MANIFESTATION],sensitive to,n/a,180,77,130,203,84,RO-may_treat,820109-FS1,"Moreover, brain regions such as the hippocampus are sensitive to glucose and INSULIN and both type 1 and type 2 diabetes mellitus are associated with cognitive impairment and (for TYPE 2 DIABETES MELLITUS) increased risk for Alzheimer's disease.",TYPE 2 DIABETES MELLITUS,INSULIN
790085276,9/17/2015 09:28:58,1740365835,9/17/2015 09:28:44,false,elite,1.0,30659615,USA,"","",162.250.145.234,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,N/A,180,77,130,203,84,RO-may_treat,820109-FS1,"Moreover, brain regions such as the hippocampus are sensitive to glucose and INSULIN and both type 1 and type 2 diabetes mellitus are associated with cognitive impairment and (for TYPE 2 DIABETES MELLITUS) increased risk for Alzheimer's disease.",TYPE 2 DIABETES MELLITUS,INSULIN
790085276,9/17/2015 09:30:57,1740366276,9/17/2015 09:29:55,false,pocketmoneygpt,1.0,21432964,GBR,F8,Borehamwood,81.159.185.70,[TREATS],[TREATS],associated with,N/A,180,77,130,203,84,RO-may_treat,820109-FS1,"Moreover, brain regions such as the hippocampus are sensitive to glucose and INSULIN and both type 1 and type 2 diabetes mellitus are associated with cognitive impairment and (for TYPE 2 DIABETES MELLITUS) increased risk for Alzheimer's disease.",TYPE 2 DIABETES MELLITUS,INSULIN
790085276,9/17/2015 09:35:59,1740367480,9/17/2015 09:35:32,false,neodev,1.0,21515166,NLD,11,Nieuwkoop,83.84.200.25,[ASSOCIATED_WITH],[ASSOCIATED_WITH],are associated with,n/a,180,77,130,203,84,RO-may_treat,820109-FS1,"Moreover, brain regions such as the hippocampus are sensitive to glucose and INSULIN and both type 1 and type 2 diabetes mellitus are associated with cognitive impairment and (for TYPE 2 DIABETES MELLITUS) increased risk for Alzheimer's disease.",TYPE 2 DIABETES MELLITUS,INSULIN
790085276,9/17/2015 09:48:33,1740370446,9/17/2015 09:48:18,false,elite,1.0,30659677,USA,"","",162.252.172.126,[CAUSES],[CAUSES],increased,N/A,180,77,130,203,84,RO-may_treat,820109-FS1,"Moreover, brain regions such as the hippocampus are sensitive to glucose and INSULIN and both type 1 and type 2 diabetes mellitus are associated with cognitive impairment and (for TYPE 2 DIABETES MELLITUS) increased risk for Alzheimer's disease.",TYPE 2 DIABETES MELLITUS,INSULIN
790085276,9/17/2015 09:50:27,1740370847,9/17/2015 09:49:08,false,neodev,1.0,34081836,USA,CA,San Jose,23.27.248.146,[ASSOCIATED_WITH] [TREATS],"[TREATS]
[ASSOCIATED_WITH]",INSULIN and type 2 diabetes mellitus are associated,N/A,180,77,130,203,84,RO-may_treat,820109-FS1,"Moreover, brain regions such as the hippocampus are sensitive to glucose and INSULIN and both type 1 and type 2 diabetes mellitus are associated with cognitive impairment and (for TYPE 2 DIABETES MELLITUS) increased risk for Alzheimer's disease.",TYPE 2 DIABETES MELLITUS,INSULIN
790085276,9/17/2015 09:53:46,1740371704,9/17/2015 09:53:20,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[CAUSES],[CAUSES],impairment,N/A,180,77,130,203,84,RO-may_treat,820109-FS1,"Moreover, brain regions such as the hippocampus are sensitive to glucose and INSULIN and both type 1 and type 2 diabetes mellitus are associated with cognitive impairment and (for TYPE 2 DIABETES MELLITUS) increased risk for Alzheimer's disease.",TYPE 2 DIABETES MELLITUS,INSULIN
790085276,9/17/2015 10:25:01,1740378836,9/17/2015 10:23:59,false,clixsense,1.0,17950689,GBR,L9,Sheffield,146.200.192.103,[TREATS],[TREATS],DIABETES MELLITUS),NONE,180,77,130,203,84,RO-may_treat,820109-FS1,"Moreover, brain regions such as the hippocampus are sensitive to glucose and INSULIN and both type 1 and type 2 diabetes mellitus are associated with cognitive impairment and (for TYPE 2 DIABETES MELLITUS) increased risk for Alzheimer's disease.",TYPE 2 DIABETES MELLITUS,INSULIN
790085276,9/17/2015 10:25:12,1740378883,9/17/2015 10:24:57,false,pocketmoneygpt,1.0,28884030,USA,WI,Minocqua,75.143.134.247,[TREATS],[TREATS],(for,n/a,180,77,130,203,84,RO-may_treat,820109-FS1,"Moreover, brain regions such as the hippocampus are sensitive to glucose and INSULIN and both type 1 and type 2 diabetes mellitus are associated with cognitive impairment and (for TYPE 2 DIABETES MELLITUS) increased risk for Alzheimer's disease.",TYPE 2 DIABETES MELLITUS,INSULIN
790085276,9/17/2015 10:43:53,1740382664,9/17/2015 10:43:10,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[NONE],[NONE],N/A,Their relation can't be highlighted in the sentence.,180,77,130,203,84,RO-may_treat,820109-FS1,"Moreover, brain regions such as the hippocampus are sensitive to glucose and INSULIN and both type 1 and type 2 diabetes mellitus are associated with cognitive impairment and (for TYPE 2 DIABETES MELLITUS) increased risk for Alzheimer's disease.",TYPE 2 DIABETES MELLITUS,INSULIN
790085277,9/17/2015 11:06:45,1740386846,9/17/2015 11:06:10,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[CAUSES],[CAUSES],papules,N/A,87,143,103,102,186,RO-may_prevent,820308-FS1,Findings of a biopsy specimen and viral culture of these papules subsequently revealed VARICELLA ZOSTER that eventually responded to prolonged HIGH DOSE ACYCLOVIR THERAPY AND DEBRIDEMENT.,VARICELLA ZOSTER,HIGH DOSE ACYCLOVIR THERAPY
790085277,9/17/2015 11:19:58,1740389456,9/17/2015 11:19:34,false,neodev,1.0,32695853,USA,NV,Las Vegas,192.30.80.172,[PART_OF] [IS_A],"[IS_A]
[PART_OF]",of a of,N/A,87,143,103,102,186,RO-may_prevent,820308-FS1,Findings of a biopsy specimen and viral culture of these papules subsequently revealed VARICELLA ZOSTER that eventually responded to prolonged HIGH DOSE ACYCLOVIR THERAPY AND DEBRIDEMENT.,VARICELLA ZOSTER,HIGH DOSE ACYCLOVIR THERAPY
790085277,9/17/2015 11:20:38,1740389531,9/17/2015 11:19:46,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[TREATS],[TREATS],eventually responded to prolonged,N/A,87,143,103,102,186,RO-may_prevent,820308-FS1,Findings of a biopsy specimen and viral culture of these papules subsequently revealed VARICELLA ZOSTER that eventually responded to prolonged HIGH DOSE ACYCLOVIR THERAPY AND DEBRIDEMENT.,VARICELLA ZOSTER,HIGH DOSE ACYCLOVIR THERAPY
790085277,9/17/2015 11:27:13,1740390710,9/17/2015 11:26:00,false,neodev,1.0,30581619,USA,CA,San Jose,50.118.162.56,[NONE],[NONE],good,good,87,143,103,102,186,RO-may_prevent,820308-FS1,Findings of a biopsy specimen and viral culture of these papules subsequently revealed VARICELLA ZOSTER that eventually responded to prolonged HIGH DOSE ACYCLOVIR THERAPY AND DEBRIDEMENT.,VARICELLA ZOSTER,HIGH DOSE ACYCLOVIR THERAPY
790085277,9/17/2015 11:32:00,1740391556,9/17/2015 11:31:46,false,neodev,1.0,30941227,USA,NV,Las Vegas,192.30.80.166,[IS_A] [PART_OF],"[IS_A]
[PART_OF]",of a of,N/A,87,143,103,102,186,RO-may_prevent,820308-FS1,Findings of a biopsy specimen and viral culture of these papules subsequently revealed VARICELLA ZOSTER that eventually responded to prolonged HIGH DOSE ACYCLOVIR THERAPY AND DEBRIDEMENT.,VARICELLA ZOSTER,HIGH DOSE ACYCLOVIR THERAPY
790085277,9/17/2015 11:42:22,1740393522,9/17/2015 11:42:05,false,neodev,1.0,33701549,USA,CA,Torrance,66.171.228.66,[CONTRAINDICATES] [CAUSES] [DIAGNOSE_BY_TEST_OR_DRUG] [SIDE_EFFECT] [NONE],"[DIAGNOSE_BY_TEST_OR_DRUG]
[CAUSES]
[CONTRAINDICATES]
[SIDE_EFFECT]
[NONE]",[IS_A],N/A,87,143,103,102,186,RO-may_prevent,820308-FS1,Findings of a biopsy specimen and viral culture of these papules subsequently revealed VARICELLA ZOSTER that eventually responded to prolonged HIGH DOSE ACYCLOVIR THERAPY AND DEBRIDEMENT.,VARICELLA ZOSTER,HIGH DOSE ACYCLOVIR THERAPY
790085277,9/17/2015 12:06:47,1740398519,9/17/2015 12:06:30,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[CAUSES],[CAUSES],papules,N/A,87,143,103,102,186,RO-may_prevent,820308-FS1,Findings of a biopsy specimen and viral culture of these papules subsequently revealed VARICELLA ZOSTER that eventually responded to prolonged HIGH DOSE ACYCLOVIR THERAPY AND DEBRIDEMENT.,VARICELLA ZOSTER,HIGH DOSE ACYCLOVIR THERAPY
790085277,9/17/2015 12:31:20,1740403901,9/17/2015 12:30:43,false,neodev,1.0,30588889,NLD,07,Amsterdam,77.248.175.222,[TREATS],[TREATS],responded,N/A,87,143,103,102,186,RO-may_prevent,820308-FS1,Findings of a biopsy specimen and viral culture of these papules subsequently revealed VARICELLA ZOSTER that eventually responded to prolonged HIGH DOSE ACYCLOVIR THERAPY AND DEBRIDEMENT.,VARICELLA ZOSTER,HIGH DOSE ACYCLOVIR THERAPY
790085277,9/17/2015 12:39:45,1740405975,9/17/2015 12:39:19,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,[TREATS],[TREATS],VARICELLA ZOSTER responded to HIGH DOSE ACYCLOVIR THERAPY AND DEBRIDEMENT.,na,87,143,103,102,186,RO-may_prevent,820308-FS1,Findings of a biopsy specimen and viral culture of these papules subsequently revealed VARICELLA ZOSTER that eventually responded to prolonged HIGH DOSE ACYCLOVIR THERAPY AND DEBRIDEMENT.,VARICELLA ZOSTER,HIGH DOSE ACYCLOVIR THERAPY
790085277,9/17/2015 12:40:06,1740406130,9/17/2015 12:39:21,false,prodege,1.0,2145087,USA,NY,New York,107.107.57.52,[TREATS],[TREATS],that eventually responded to,N/A,87,143,103,102,186,RO-may_prevent,820308-FS1,Findings of a biopsy specimen and viral culture of these papules subsequently revealed VARICELLA ZOSTER that eventually responded to prolonged HIGH DOSE ACYCLOVIR THERAPY AND DEBRIDEMENT.,VARICELLA ZOSTER,HIGH DOSE ACYCLOVIR THERAPY
790085277,9/17/2015 12:43:38,1740407085,9/17/2015 12:43:17,false,instagc,1.0,22981457,CAN,ON,Welland,76.67.127.43,[TREATS],[TREATS],responded to,N/A,87,143,103,102,186,RO-may_prevent,820308-FS1,Findings of a biopsy specimen and viral culture of these papules subsequently revealed VARICELLA ZOSTER that eventually responded to prolonged HIGH DOSE ACYCLOVIR THERAPY AND DEBRIDEMENT.,VARICELLA ZOSTER,HIGH DOSE ACYCLOVIR THERAPY
790085277,9/17/2015 13:14:47,1740415856,9/17/2015 13:14:29,false,elite,1.0,31883685,GBR,"","",79.66.244.188,[TREATS],[TREATS],responded to,n/a,87,143,103,102,186,RO-may_prevent,820308-FS1,Findings of a biopsy specimen and viral culture of these papules subsequently revealed VARICELLA ZOSTER that eventually responded to prolonged HIGH DOSE ACYCLOVIR THERAPY AND DEBRIDEMENT.,VARICELLA ZOSTER,HIGH DOSE ACYCLOVIR THERAPY
790085277,9/17/2015 13:15:10,1740415958,9/17/2015 13:14:49,false,prodege,1.0,33854929,USA,CT,Wallingford,24.2.218.232,[TREATS],[TREATS],responded,n/a,87,143,103,102,186,RO-may_prevent,820308-FS1,Findings of a biopsy specimen and viral culture of these papules subsequently revealed VARICELLA ZOSTER that eventually responded to prolonged HIGH DOSE ACYCLOVIR THERAPY AND DEBRIDEMENT.,VARICELLA ZOSTER,HIGH DOSE ACYCLOVIR THERAPY
790085277,9/17/2015 13:15:16,1740415972,9/17/2015 13:14:59,false,neodev,1.0,33228343,USA,"","",38.95.108.251,[TREATS] [DIAGNOSE_BY_TEST_OR_DRUG] [LOCATION] [CONTRAINDICATES] [ASSOCIATED_WITH] [IS_A] [PART_OF] [NONE],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]
[LOCATION]
[CONTRAINDICATES]
[ASSOCIATED_WITH]
[IS_A]
[PART_OF]
[NONE]",Findings of a biopsy specimen and viral culture of these papules subsequently revealed VARICELLA ZOSTER that eventually responded to prolonged HIGH DOSE ACYCLOVIR THERAPY AND DEBRIDEMENT.,Findings of a biopsy specimen and viral culture of these papules subsequently revealed VARICELLA ZOSTER that eventually responded to prolonged HIGH DOSE ACYCLOVIR THERAPY AND DEBRIDEMENT.,87,143,103,102,186,RO-may_prevent,820308-FS1,Findings of a biopsy specimen and viral culture of these papules subsequently revealed VARICELLA ZOSTER that eventually responded to prolonged HIGH DOSE ACYCLOVIR THERAPY AND DEBRIDEMENT.,VARICELLA ZOSTER,HIGH DOSE ACYCLOVIR THERAPY
790085277,9/17/2015 13:17:45,1740416670,9/17/2015 13:17:16,false,neodev,1.0,12115558,USA,OH,Twinsburg,98.27.164.131,[TREATS],[TREATS],responded to prolonged HIGH DOSE,N/A,87,143,103,102,186,RO-may_prevent,820308-FS1,Findings of a biopsy specimen and viral culture of these papules subsequently revealed VARICELLA ZOSTER that eventually responded to prolonged HIGH DOSE ACYCLOVIR THERAPY AND DEBRIDEMENT.,VARICELLA ZOSTER,HIGH DOSE ACYCLOVIR THERAPY
790085278,9/17/2015 11:22:55,1740389865,9/17/2015 11:22:45,false,neodev,1.0,32695853,USA,NV,Las Vegas,192.30.80.172,[TREATS],[TREATS],treat,N/A,95,29,119,118,73,RO-may_prevent,820309-FS1,"Initially, vasodilators were USED ONLY WHEN DIGITALIS AND DIURETICS COULD not adequately treat CONGESTIVE HEART FAILURE",CONGESTIVE HEART FAILURE,DIGITALIS AND DIURETICS
790085278,9/17/2015 11:34:29,1740392005,9/17/2015 11:34:17,false,neodev,1.0,30941227,USA,NV,Las Vegas,192.30.80.166,[TREATS],[TREATS],treat,N/A,95,29,119,118,73,RO-may_prevent,820309-FS1,"Initially, vasodilators were USED ONLY WHEN DIGITALIS AND DIURETICS COULD not adequately treat CONGESTIVE HEART FAILURE",CONGESTIVE HEART FAILURE,DIGITALIS AND DIURETICS
790085278,9/17/2015 11:38:32,1740392862,9/17/2015 11:37:45,false,neodev,1.0,30581619,USA,CA,San Jose,50.118.162.56,[NONE],[NONE],good,good,95,29,119,118,73,RO-may_prevent,820309-FS1,"Initially, vasodilators were USED ONLY WHEN DIGITALIS AND DIURETICS COULD not adequately treat CONGESTIVE HEART FAILURE",CONGESTIVE HEART FAILURE,DIGITALIS AND DIURETICS
790085278,9/17/2015 12:09:24,1740399069,9/17/2015 12:09:00,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[TREATS],[TREATS],treat,N/A,95,29,119,118,73,RO-may_prevent,820309-FS1,"Initially, vasodilators were USED ONLY WHEN DIGITALIS AND DIURETICS COULD not adequately treat CONGESTIVE HEART FAILURE",CONGESTIVE HEART FAILURE,DIGITALIS AND DIURETICS
790085278,9/17/2015 12:34:58,1740404780,9/17/2015 12:33:58,false,neodev,1.0,30588889,NLD,07,Amsterdam,77.248.175.222,[TREATS],[TREATS],treat,N/A,95,29,119,118,73,RO-may_prevent,820309-FS1,"Initially, vasodilators were USED ONLY WHEN DIGITALIS AND DIURETICS COULD not adequately treat CONGESTIVE HEART FAILURE",CONGESTIVE HEART FAILURE,DIGITALIS AND DIURETICS
790085278,9/17/2015 12:43:31,1740407034,9/17/2015 12:43:08,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,[CONTRAINDICATES],[CONTRAINDICATES],DIGITALIS AND DIURETICS COULD not treat CONGESTIVE HEART FAILURE,na,95,29,119,118,73,RO-may_prevent,820309-FS1,"Initially, vasodilators were USED ONLY WHEN DIGITALIS AND DIURETICS COULD not adequately treat CONGESTIVE HEART FAILURE",CONGESTIVE HEART FAILURE,DIGITALIS AND DIURETICS
790085278,9/17/2015 12:44:20,1740407353,9/17/2015 12:43:45,false,prodege,1.0,2145087,USA,NY,New York,107.107.57.52,[TREATS],[TREATS],COULD not adequately treat,N/A,95,29,119,118,73,RO-may_prevent,820309-FS1,"Initially, vasodilators were USED ONLY WHEN DIGITALIS AND DIURETICS COULD not adequately treat CONGESTIVE HEART FAILURE",CONGESTIVE HEART FAILURE,DIGITALIS AND DIURETICS
790085278,9/17/2015 13:16:35,1740416405,9/17/2015 13:16:22,false,elite,1.0,31883685,GBR,"","",79.66.244.188,[TREATS],[TREATS],treat,n/a,95,29,119,118,73,RO-may_prevent,820309-FS1,"Initially, vasodilators were USED ONLY WHEN DIGITALIS AND DIURETICS COULD not adequately treat CONGESTIVE HEART FAILURE",CONGESTIVE HEART FAILURE,DIGITALIS AND DIURETICS
790085278,9/17/2015 13:16:54,1740416470,9/17/2015 13:16:39,false,neodev,1.0,33228343,USA,"","",38.95.108.251,[PREVENTS] [SYMPTOM] [ASSOCIATED_WITH] [CAUSES] [NONE],"[PREVENTS]
[CAUSES]
[SYMPTOM]
[ASSOCIATED_WITH]
[NONE]","Initially, vasodilators were USED ONLY WHEN DIGITALIS AND DIURETICS COULD not adequately treat CONGESTIVE HEART FAILURE","Initially, vasodilators were USED ONLY WHEN DIGITALIS AND DIURETICS COULD not adequately treat CONGESTIVE HEART FAILURE",95,29,119,118,73,RO-may_prevent,820309-FS1,"Initially, vasodilators were USED ONLY WHEN DIGITALIS AND DIURETICS COULD not adequately treat CONGESTIVE HEART FAILURE",CONGESTIVE HEART FAILURE,DIGITALIS AND DIURETICS
790085278,9/17/2015 13:18:00,1740416782,9/17/2015 13:17:41,false,prodege,1.0,33854929,USA,CT,Wallingford,24.2.218.232,[TREATS],[TREATS],treat,n/a,95,29,119,118,73,RO-may_prevent,820309-FS1,"Initially, vasodilators were USED ONLY WHEN DIGITALIS AND DIURETICS COULD not adequately treat CONGESTIVE HEART FAILURE",CONGESTIVE HEART FAILURE,DIGITALIS AND DIURETICS
790085278,9/17/2015 13:22:51,1740418382,9/17/2015 13:22:22,false,neodev,1.0,12115558,USA,OH,Twinsburg,98.27.164.131,[TREATS],[TREATS],COULD not adequately treat,N/A,95,29,119,118,73,RO-may_prevent,820309-FS1,"Initially, vasodilators were USED ONLY WHEN DIGITALIS AND DIURETICS COULD not adequately treat CONGESTIVE HEART FAILURE",CONGESTIVE HEART FAILURE,DIGITALIS AND DIURETICS
790085278,9/17/2015 13:23:47,1740418685,9/17/2015 13:23:09,false,prodege,1.0,27934334,GBR,C8,Croydon,81.159.60.206,[TREATS],[TREATS],treat,N/A,95,29,119,118,73,RO-may_prevent,820309-FS1,"Initially, vasodilators were USED ONLY WHEN DIGITALIS AND DIURETICS COULD not adequately treat CONGESTIVE HEART FAILURE",CONGESTIVE HEART FAILURE,DIGITALIS AND DIURETICS
790085278,9/17/2015 13:24:07,1740418740,9/17/2015 13:23:53,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,[TREATS],[TREATS],treat,n/a,95,29,119,118,73,RO-may_prevent,820309-FS1,"Initially, vasodilators were USED ONLY WHEN DIGITALIS AND DIURETICS COULD not adequately treat CONGESTIVE HEART FAILURE",CONGESTIVE HEART FAILURE,DIGITALIS AND DIURETICS
790085278,9/17/2015 13:31:47,1740421079,9/17/2015 13:29:46,false,fusioncash,1.0,14070474,USA,IL,Edwardsville,24.107.32.201,[TREATS],[TREATS],DIGITALIS AND DIURETICS COULD not adequately treat CONGESTIVE FAILURE,Digitalis and diuretics were used to treat congestive heart failure and that is the relationship.,95,29,119,118,73,RO-may_prevent,820309-FS1,"Initially, vasodilators were USED ONLY WHEN DIGITALIS AND DIURETICS COULD not adequately treat CONGESTIVE HEART FAILURE",CONGESTIVE HEART FAILURE,DIGITALIS AND DIURETICS
790085278,9/17/2015 13:44:13,1740427318,9/17/2015 13:43:15,false,prodege,1.0,14571439,CAN,ON,Toronto,142.20.20.193,[OTHER],[OTHER],COULD not adequately treat,Congestive heart failure is not treatable by using digitalis and diaretics.,95,29,119,118,73,RO-may_prevent,820309-FS1,"Initially, vasodilators were USED ONLY WHEN DIGITALIS AND DIURETICS COULD not adequately treat CONGESTIVE HEART FAILURE",CONGESTIVE HEART FAILURE,DIGITALIS AND DIURETICS
790085279,9/17/2015 09:15:46,1740363101,9/17/2015 09:15:25,false,neodev,1.0,32053642,GBR,I7,Newcastle Upon Tyne,92.23.136.205,[TREATS],[TREATS],clearances in patients,N/A,142,106,166,165,113,RO-may_prevent,820193-FS1,"Cleland JGF, Dargie HJ, Pettigrew A et al. The effects of captopril on serum digoxin and urinary urea and DIGOXIN clearances in patients with CONGESTIVE HEART FAILURE",CONGESTIVE HEART FAILURE,DIGOXIN
790085279,9/17/2015 09:16:58,1740363399,9/17/2015 09:16:43,false,elite,1.0,30659754,USA,"","",162.250.145.204,[SYMPTOM],[SYMPTOM],in patients with,N/A,142,106,166,165,113,RO-may_prevent,820193-FS1,"Cleland JGF, Dargie HJ, Pettigrew A et al. The effects of captopril on serum digoxin and urinary urea and DIGOXIN clearances in patients with CONGESTIVE HEART FAILURE",CONGESTIVE HEART FAILURE,DIGOXIN
790085279,9/17/2015 09:23:13,1740364643,9/17/2015 09:22:45,false,instagc,1.0,18960682,GBR,U2,Annan,92.18.213.181,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and DIGOXIN clearances in patients with CONGESTIVE HEART FAILURE,N/A,142,106,166,165,113,RO-may_prevent,820193-FS1,"Cleland JGF, Dargie HJ, Pettigrew A et al. The effects of captopril on serum digoxin and urinary urea and DIGOXIN clearances in patients with CONGESTIVE HEART FAILURE",CONGESTIVE HEART FAILURE,DIGOXIN
790085279,9/17/2015 09:24:48,1740364991,9/17/2015 09:24:22,false,neodev,1.0,33644825,USA,FL,Fort Lauderdale,65.111.173.161,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],DIGOXIN CONGESTIVE HEART FAILURE,treats,142,106,166,165,113,RO-may_prevent,820193-FS1,"Cleland JGF, Dargie HJ, Pettigrew A et al. The effects of captopril on serum digoxin and urinary urea and DIGOXIN clearances in patients with CONGESTIVE HEART FAILURE",CONGESTIVE HEART FAILURE,DIGOXIN
790085279,9/17/2015 09:25:13,1740365077,9/17/2015 09:24:22,false,neodev,1.0,15848372,AUS,02,Jannali,14.200.59.55,[SYMPTOM],[SYMPTOM],clearances,n/a,142,106,166,165,113,RO-may_prevent,820193-FS1,"Cleland JGF, Dargie HJ, Pettigrew A et al. The effects of captopril on serum digoxin and urinary urea and DIGOXIN clearances in patients with CONGESTIVE HEART FAILURE",CONGESTIVE HEART FAILURE,DIGOXIN
790085279,9/17/2015 09:34:01,1740367074,9/17/2015 09:31:57,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[NONE],[NONE],N/A,one  of the effects of captopril,142,106,166,165,113,RO-may_prevent,820193-FS1,"Cleland JGF, Dargie HJ, Pettigrew A et al. The effects of captopril on serum digoxin and urinary urea and DIGOXIN clearances in patients with CONGESTIVE HEART FAILURE",CONGESTIVE HEART FAILURE,DIGOXIN
790085279,9/17/2015 09:35:13,1740367332,9/17/2015 09:34:58,false,elite,1.0,30659615,USA,"","",162.250.145.234,[CAUSES],[CAUSES],clearances,N/A,142,106,166,165,113,RO-may_prevent,820193-FS1,"Cleland JGF, Dargie HJ, Pettigrew A et al. The effects of captopril on serum digoxin and urinary urea and DIGOXIN clearances in patients with CONGESTIVE HEART FAILURE",CONGESTIVE HEART FAILURE,DIGOXIN
790085279,9/17/2015 09:37:07,1740367756,9/17/2015 09:35:56,false,pocketmoneygpt,1.0,21432964,GBR,F8,Borehamwood,81.159.185.70,[ASSOCIATED_WITH],[ASSOCIATED_WITH],patients with,N/A,142,106,166,165,113,RO-may_prevent,820193-FS1,"Cleland JGF, Dargie HJ, Pettigrew A et al. The effects of captopril on serum digoxin and urinary urea and DIGOXIN clearances in patients with CONGESTIVE HEART FAILURE",CONGESTIVE HEART FAILURE,DIGOXIN
790085279,9/17/2015 09:41:15,1740368829,9/17/2015 09:40:42,false,neodev,1.0,21515166,NLD,11,Nieuwkoop,83.84.200.25,[SYMPTOM],[SYMPTOM],effects of,n/a,142,106,166,165,113,RO-may_prevent,820193-FS1,"Cleland JGF, Dargie HJ, Pettigrew A et al. The effects of captopril on serum digoxin and urinary urea and DIGOXIN clearances in patients with CONGESTIVE HEART FAILURE",CONGESTIVE HEART FAILURE,DIGOXIN
790085279,9/17/2015 09:50:54,1740370965,9/17/2015 09:50:38,false,elite,1.0,30659677,USA,"","",162.252.172.126,[SIDE_EFFECT],[SIDE_EFFECT],effects,N/A,142,106,166,165,113,RO-may_prevent,820193-FS1,"Cleland JGF, Dargie HJ, Pettigrew A et al. The effects of captopril on serum digoxin and urinary urea and DIGOXIN clearances in patients with CONGESTIVE HEART FAILURE",CONGESTIVE HEART FAILURE,DIGOXIN
790085279,9/17/2015 09:59:47,1740373113,9/17/2015 09:59:13,false,neodev,1.0,34081836,USA,CA,San Jose,23.27.248.146,[CAUSES] [SIDE_EFFECT],"[CAUSES]
[SIDE_EFFECT]",DIGOXIN clearances in patients with CONGESTIVE HEART FAILURE,N/A,142,106,166,165,113,RO-may_prevent,820193-FS1,"Cleland JGF, Dargie HJ, Pettigrew A et al. The effects of captopril on serum digoxin and urinary urea and DIGOXIN clearances in patients with CONGESTIVE HEART FAILURE",CONGESTIVE HEART FAILURE,DIGOXIN
790085279,9/17/2015 10:01:35,1740373516,9/17/2015 10:00:48,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[ASSOCIATED_WITH],[ASSOCIATED_WITH],The effects,N/A,142,106,166,165,113,RO-may_prevent,820193-FS1,"Cleland JGF, Dargie HJ, Pettigrew A et al. The effects of captopril on serum digoxin and urinary urea and DIGOXIN clearances in patients with CONGESTIVE HEART FAILURE",CONGESTIVE HEART FAILURE,DIGOXIN
790085279,9/17/2015 10:29:00,1740379599,9/17/2015 10:28:39,false,pocketmoneygpt,1.0,28884030,USA,WI,Minocqua,75.143.134.247,[TREATS],[TREATS],effects,n/a,142,106,166,165,113,RO-may_prevent,820193-FS1,"Cleland JGF, Dargie HJ, Pettigrew A et al. The effects of captopril on serum digoxin and urinary urea and DIGOXIN clearances in patients with CONGESTIVE HEART FAILURE",CONGESTIVE HEART FAILURE,DIGOXIN
790085279,9/17/2015 10:35:46,1740381116,9/17/2015 10:34:57,false,clixsense,1.0,17950689,GBR,L9,Sheffield,146.200.192.103,[MANIFESTATION],[MANIFESTATION],CONGESTIVE,NONE,142,106,166,165,113,RO-may_prevent,820193-FS1,"Cleland JGF, Dargie HJ, Pettigrew A et al. The effects of captopril on serum digoxin and urinary urea and DIGOXIN clearances in patients with CONGESTIVE HEART FAILURE",CONGESTIVE HEART FAILURE,DIGOXIN
790085279,9/17/2015 10:52:00,1740384099,9/17/2015 10:51:45,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[SIDE_EFFECT],[SIDE_EFFECT],effects,N/A,142,106,166,165,113,RO-may_prevent,820193-FS1,"Cleland JGF, Dargie HJ, Pettigrew A et al. The effects of captopril on serum digoxin and urinary urea and DIGOXIN clearances in patients with CONGESTIVE HEART FAILURE",CONGESTIVE HEART FAILURE,DIGOXIN
790085280,9/17/2015 11:06:09,1740386745,9/17/2015 11:05:52,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[TREATS],[TREATS],treatment,N/A,108,157,115,114,179,RO-may_prevent,820150-FS1,"We conclude that pre hospital treatment ingested chloroquine contributes significantly to the resolution of MALARIA in children in Ghana, in the presence of CHLOROQUINE RESISTANCE.",MALARIA,CHLOROQUINE RESISTANCE
790085280,9/17/2015 11:19:32,1740389387,9/17/2015 11:19:16,false,neodev,1.0,32695853,USA,NV,Las Vegas,192.30.80.172,[TREATS] [PART_OF],"[TREATS]
[PART_OF]",treatment of of,N/A,108,157,115,114,179,RO-may_prevent,820150-FS1,"We conclude that pre hospital treatment ingested chloroquine contributes significantly to the resolution of MALARIA in children in Ghana, in the presence of CHLOROQUINE RESISTANCE.",MALARIA,CHLOROQUINE RESISTANCE
790085280,9/17/2015 11:19:41,1740389412,9/17/2015 11:17:57,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[OTHER],[OTHER],pre hospital treatment ingested chloroquine,N/A,108,157,115,114,179,RO-may_prevent,820150-FS1,"We conclude that pre hospital treatment ingested chloroquine contributes significantly to the resolution of MALARIA in children in Ghana, in the presence of CHLOROQUINE RESISTANCE.",MALARIA,CHLOROQUINE RESISTANCE
790085280,9/17/2015 11:25:59,1740390463,9/17/2015 11:24:34,false,neodev,1.0,30581619,USA,CA,San Jose,50.118.162.56,[NONE],[NONE],good,good,108,157,115,114,179,RO-may_prevent,820150-FS1,"We conclude that pre hospital treatment ingested chloroquine contributes significantly to the resolution of MALARIA in children in Ghana, in the presence of CHLOROQUINE RESISTANCE.",MALARIA,CHLOROQUINE RESISTANCE
790085280,9/17/2015 11:31:43,1740391510,9/17/2015 11:31:21,false,neodev,1.0,30941227,USA,NV,Las Vegas,192.30.80.166,[TREATS] [PART_OF],"[TREATS]
[PART_OF]",treatment of of,N/A,108,157,115,114,179,RO-may_prevent,820150-FS1,"We conclude that pre hospital treatment ingested chloroquine contributes significantly to the resolution of MALARIA in children in Ghana, in the presence of CHLOROQUINE RESISTANCE.",MALARIA,CHLOROQUINE RESISTANCE
790085280,9/17/2015 11:42:02,1740393505,9/17/2015 11:41:51,false,neodev,1.0,33701549,USA,CA,Torrance,66.171.228.66,[PART_OF] [SYMPTOM] [ASSOCIATED_WITH] [NONE],"[SYMPTOM]
[ASSOCIATED_WITH]
[PART_OF]
[NONE]",[IS_A],N/A,108,157,115,114,179,RO-may_prevent,820150-FS1,"We conclude that pre hospital treatment ingested chloroquine contributes significantly to the resolution of MALARIA in children in Ghana, in the presence of CHLOROQUINE RESISTANCE.",MALARIA,CHLOROQUINE RESISTANCE
790085280,9/17/2015 12:06:29,1740398427,9/17/2015 12:06:13,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[SYMPTOM],[SYMPTOM],the presence,N/A,108,157,115,114,179,RO-may_prevent,820150-FS1,"We conclude that pre hospital treatment ingested chloroquine contributes significantly to the resolution of MALARIA in children in Ghana, in the presence of CHLOROQUINE RESISTANCE.",MALARIA,CHLOROQUINE RESISTANCE
790085280,9/17/2015 12:30:42,1740403751,9/17/2015 12:30:17,false,neodev,1.0,30588889,NLD,07,Amsterdam,77.248.175.222,[ASSOCIATED_WITH],[ASSOCIATED_WITH],RESISTANCE.,N/A,108,157,115,114,179,RO-may_prevent,820150-FS1,"We conclude that pre hospital treatment ingested chloroquine contributes significantly to the resolution of MALARIA in children in Ghana, in the presence of CHLOROQUINE RESISTANCE.",MALARIA,CHLOROQUINE RESISTANCE
790085280,9/17/2015 12:39:18,1740405860,9/17/2015 12:38:50,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,[MANIFESTATION],[MANIFESTATION],MALARIA in presence of CHLOROQUINE RESISTANCE.,na,108,157,115,114,179,RO-may_prevent,820150-FS1,"We conclude that pre hospital treatment ingested chloroquine contributes significantly to the resolution of MALARIA in children in Ghana, in the presence of CHLOROQUINE RESISTANCE.",MALARIA,CHLOROQUINE RESISTANCE
790085280,9/17/2015 12:39:20,1740405869,9/17/2015 12:38:34,false,prodege,1.0,2145087,USA,NY,New York,107.107.57.52,[ASSOCIATED_WITH],[ASSOCIATED_WITH],in the presence of,N/A,108,157,115,114,179,RO-may_prevent,820150-FS1,"We conclude that pre hospital treatment ingested chloroquine contributes significantly to the resolution of MALARIA in children in Ghana, in the presence of CHLOROQUINE RESISTANCE.",MALARIA,CHLOROQUINE RESISTANCE
790085280,9/17/2015 12:43:16,1740406920,9/17/2015 12:42:59,false,instagc,1.0,22981457,CAN,ON,Welland,76.67.127.43,[TREATS],[TREATS],resolution,N/A,108,157,115,114,179,RO-may_prevent,820150-FS1,"We conclude that pre hospital treatment ingested chloroquine contributes significantly to the resolution of MALARIA in children in Ghana, in the presence of CHLOROQUINE RESISTANCE.",MALARIA,CHLOROQUINE RESISTANCE
790085280,9/17/2015 13:14:28,1740415766,9/17/2015 13:14:06,false,elite,1.0,31883685,GBR,"","",79.66.244.188,[SIDE_EFFECT],[SIDE_EFFECT],presence,n/a,108,157,115,114,179,RO-may_prevent,820150-FS1,"We conclude that pre hospital treatment ingested chloroquine contributes significantly to the resolution of MALARIA in children in Ghana, in the presence of CHLOROQUINE RESISTANCE.",MALARIA,CHLOROQUINE RESISTANCE
790085280,9/17/2015 13:14:49,1740415857,9/17/2015 13:14:16,false,prodege,1.0,33854929,USA,CT,Wallingford,24.2.218.232,[CAUSES],[CAUSES],presence of,n/a,108,157,115,114,179,RO-may_prevent,820150-FS1,"We conclude that pre hospital treatment ingested chloroquine contributes significantly to the resolution of MALARIA in children in Ghana, in the presence of CHLOROQUINE RESISTANCE.",MALARIA,CHLOROQUINE RESISTANCE
790085280,9/17/2015 13:14:58,1740415877,9/17/2015 13:14:45,false,neodev,1.0,33228343,USA,"","",38.95.108.251,[PREVENTS] [CAUSES] [LOCATION] [SYMPTOM] [CONTRAINDICATES] [IS_A] [NONE],"[PREVENTS]
[CAUSES]
[LOCATION]
[SYMPTOM]
[CONTRAINDICATES]
[IS_A]
[NONE]","We conclude that pre hospital treatment ingested chloroquine contributes significantly to the resolution of MALARIA in children in Ghana, in the presence of CHLOROQUINE RESISTANCE.","We conclude that pre hospital treatment ingested chloroquine contributes significantly to the resolution of MALARIA in children in Ghana, in the presence of CHLOROQUINE RESISTANCE.",108,157,115,114,179,RO-may_prevent,820150-FS1,"We conclude that pre hospital treatment ingested chloroquine contributes significantly to the resolution of MALARIA in children in Ghana, in the presence of CHLOROQUINE RESISTANCE.",MALARIA,CHLOROQUINE RESISTANCE
790085280,9/17/2015 13:17:15,1740416544,9/17/2015 13:16:33,false,neodev,1.0,12115558,USA,OH,Twinsburg,98.27.164.131,[TREATS],[TREATS],resolution of MALARIA,N/A,108,157,115,114,179,RO-may_prevent,820150-FS1,"We conclude that pre hospital treatment ingested chloroquine contributes significantly to the resolution of MALARIA in children in Ghana, in the presence of CHLOROQUINE RESISTANCE.",MALARIA,CHLOROQUINE RESISTANCE
790085281,9/17/2015 10:46:56,1740383250,9/17/2015 10:45:18,false,clixsense,1.0,17950689,GBR,L9,Sheffield,146.200.192.103,[TREATS],[TREATS],MALARIA,NONE,55,29,74,83,50,RO-may_prevent,820273-FS1,"Group I received placebo and CHLOROQUINE TREATMENT for SYMPTOMATIC MALARIA INFECTION (i.e., no presumptive anti malarial treatment given.",SYMPTOMATIC MALARIA INFECTION,CHLOROQUINE TREATMENT
790085281,9/17/2015 11:01:06,1740385777,9/17/2015 11:00:09,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[TREATS],[TREATS],TREATMENT for,N/A,55,29,74,83,50,RO-may_prevent,820273-FS1,"Group I received placebo and CHLOROQUINE TREATMENT for SYMPTOMATIC MALARIA INFECTION (i.e., no presumptive anti malarial treatment given.",SYMPTOMATIC MALARIA INFECTION,CHLOROQUINE TREATMENT
790085281,9/17/2015 11:03:49,1740386229,9/17/2015 11:02:44,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[TREATS],[TREATS],TREATMENT for,N/A,55,29,74,83,50,RO-may_prevent,820273-FS1,"Group I received placebo and CHLOROQUINE TREATMENT for SYMPTOMATIC MALARIA INFECTION (i.e., no presumptive anti malarial treatment given.",SYMPTOMATIC MALARIA INFECTION,CHLOROQUINE TREATMENT
790085281,9/17/2015 11:05:51,1740386677,9/17/2015 11:05:31,false,neodev,1.0,30941227,USA,NV,Las Vegas,192.30.80.166,[SYMPTOM],[SYMPTOM],SYMPTOMATIC,N/A,55,29,74,83,50,RO-may_prevent,820273-FS1,"Group I received placebo and CHLOROQUINE TREATMENT for SYMPTOMATIC MALARIA INFECTION (i.e., no presumptive anti malarial treatment given.",SYMPTOMATIC MALARIA INFECTION,CHLOROQUINE TREATMENT
790085281,9/17/2015 11:07:57,1740387153,9/17/2015 11:06:37,false,neodev,1.0,30581619,USA,CA,San Jose,50.118.162.56,[TREATS] [NONE],"[TREATS]
[NONE]",good,good,55,29,74,83,50,RO-may_prevent,820273-FS1,"Group I received placebo and CHLOROQUINE TREATMENT for SYMPTOMATIC MALARIA INFECTION (i.e., no presumptive anti malarial treatment given.",SYMPTOMATIC MALARIA INFECTION,CHLOROQUINE TREATMENT
790085281,9/17/2015 11:15:36,1740388675,9/17/2015 11:15:14,false,neodev,1.0,32695853,USA,NV,Las Vegas,192.30.80.172,[SYMPTOM] [TREATS],"[TREATS]
[SYMPTOM]",SYMPTOMATIC treatment,N/A,55,29,74,83,50,RO-may_prevent,820273-FS1,"Group I received placebo and CHLOROQUINE TREATMENT for SYMPTOMATIC MALARIA INFECTION (i.e., no presumptive anti malarial treatment given.",SYMPTOMATIC MALARIA INFECTION,CHLOROQUINE TREATMENT
790085281,9/17/2015 11:17:28,1740388991,9/17/2015 11:16:41,false,gifthulk,1.0,18666417,USA,PA,Meadville,24.101.32.13,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],Group I received CHLOROQUINE TREATMENT for SYMPTOMATIC MALARIA INFECTION,n/a,55,29,74,83,50,RO-may_prevent,820273-FS1,"Group I received placebo and CHLOROQUINE TREATMENT for SYMPTOMATIC MALARIA INFECTION (i.e., no presumptive anti malarial treatment given.",SYMPTOMATIC MALARIA INFECTION,CHLOROQUINE TREATMENT
790085281,9/17/2015 11:25:27,1740390345,9/17/2015 11:24:40,false,elite,1.0,33798502,USA,VA,Manassas,207.244.86.212,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",CHLOROQUINE TREATMENT,makes sense,55,29,74,83,50,RO-may_prevent,820273-FS1,"Group I received placebo and CHLOROQUINE TREATMENT for SYMPTOMATIC MALARIA INFECTION (i.e., no presumptive anti malarial treatment given.",SYMPTOMATIC MALARIA INFECTION,CHLOROQUINE TREATMENT
790085281,9/17/2015 11:39:03,1740392965,9/17/2015 11:38:51,false,neodev,1.0,33701549,USA,CA,Torrance,66.171.228.66,[PART_OF] [SIDE_EFFECT] [CONTRAINDICATES] [SYMPTOM] [CAUSES] [NONE],"[CAUSES]
[SYMPTOM]
[CONTRAINDICATES]
[SIDE_EFFECT]
[PART_OF]
[NONE]",[IS_A],N/A,55,29,74,83,50,RO-may_prevent,820273-FS1,"Group I received placebo and CHLOROQUINE TREATMENT for SYMPTOMATIC MALARIA INFECTION (i.e., no presumptive anti malarial treatment given.",SYMPTOMATIC MALARIA INFECTION,CHLOROQUINE TREATMENT
790085281,9/17/2015 11:56:32,1740396388,9/17/2015 11:56:17,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[TREATS],[TREATS],treatment,N/A,55,29,74,83,50,RO-may_prevent,820273-FS1,"Group I received placebo and CHLOROQUINE TREATMENT for SYMPTOMATIC MALARIA INFECTION (i.e., no presumptive anti malarial treatment given.",SYMPTOMATIC MALARIA INFECTION,CHLOROQUINE TREATMENT
790085281,9/17/2015 12:00:57,1740397211,9/17/2015 12:00:20,false,prodege,1.0,14848125,GBR,V8,Airdrie,86.151.77.161,[TREATS],[TREATS],placebo and CHLOROQUINE TREATMENT,n/a,55,29,74,83,50,RO-may_prevent,820273-FS1,"Group I received placebo and CHLOROQUINE TREATMENT for SYMPTOMATIC MALARIA INFECTION (i.e., no presumptive anti malarial treatment given.",SYMPTOMATIC MALARIA INFECTION,CHLOROQUINE TREATMENT
790085281,9/17/2015 12:21:09,1740401600,9/17/2015 12:19:57,false,neodev,1.0,30588889,NLD,07,Amsterdam,77.248.175.222,[TREATS],[TREATS],TREATMENT,N/A,55,29,74,83,50,RO-may_prevent,820273-FS1,"Group I received placebo and CHLOROQUINE TREATMENT for SYMPTOMATIC MALARIA INFECTION (i.e., no presumptive anti malarial treatment given.",SYMPTOMATIC MALARIA INFECTION,CHLOROQUINE TREATMENT
790085281,9/17/2015 12:32:52,1740404252,9/17/2015 12:32:05,false,prodege,1.0,2145087,USA,NY,New York,107.107.57.52,[TREATS],[TREATS],for,N/A,55,29,74,83,50,RO-may_prevent,820273-FS1,"Group I received placebo and CHLOROQUINE TREATMENT for SYMPTOMATIC MALARIA INFECTION (i.e., no presumptive anti malarial treatment given.",SYMPTOMATIC MALARIA INFECTION,CHLOROQUINE TREATMENT
790085281,9/17/2015 12:34:08,1740404591,9/17/2015 12:33:20,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,[TREATS],[TREATS],CHLOROQUINE TREATMENT for SYMPTOMATIC MALARIA INFECTION,na,55,29,74,83,50,RO-may_prevent,820273-FS1,"Group I received placebo and CHLOROQUINE TREATMENT for SYMPTOMATIC MALARIA INFECTION (i.e., no presumptive anti malarial treatment given.",SYMPTOMATIC MALARIA INFECTION,CHLOROQUINE TREATMENT
790085281,9/17/2015 12:36:38,1740405238,9/17/2015 12:34:18,false,neodev,1.0,34215189,GBR,I2,Manchester,82.8.21.5,[TREATS],[TREATS],CHLOROQUINE TREATMENT for SYMPTOMATIC MALARIA INFECTION,N/A,55,29,74,83,50,RO-may_prevent,820273-FS1,"Group I received placebo and CHLOROQUINE TREATMENT for SYMPTOMATIC MALARIA INFECTION (i.e., no presumptive anti malarial treatment given.",SYMPTOMATIC MALARIA INFECTION,CHLOROQUINE TREATMENT
790085282,9/17/2015 13:19:52,1740417342,9/17/2015 13:19:37,false,neodev,1.0,33228343,USA,"","",38.95.108.251,[PREVENTS] [TREATS] [DIAGNOSE_BY_TEST_OR_DRUG] [MANIFESTATION] [ASSOCIATED_WITH] [SYMPTOM] [IS_A] [NONE] [SIDE_EFFECT],"[TREATS]
[PREVENTS]
[DIAGNOSE_BY_TEST_OR_DRUG]
[SYMPTOM]
[MANIFESTATION]
[ASSOCIATED_WITH]
[SIDE_EFFECT]
[IS_A]
[NONE]","Berlin BS, Mitchell JR, Burgoyne GH et al. RHESUS DIPLOID RABIES VACCINE (adsorbed), a new RABIES VACCINE","Berlin BS, Mitchell JR, Burgoyne GH et al. RHESUS DIPLOID RABIES VACCINE (adsorbed), a new RABIES VACCINE",43,58,64,71,72,RO-may_prevent,820153-FS1,"Berlin BS, Mitchell JR, Burgoyne GH et al. RHESUS DIPLOID RABIES VACCINE (adsorbed), a new RABIES VACCINE",RHESUS DIPLOID RABIES VACCINE,RABIES VACCINE
790085282,9/17/2015 13:20:41,1740417724,9/17/2015 13:20:28,false,elite,1.0,31883685,GBR,"","",79.66.244.188,[TREATS],[TREATS],VACCINE,n/a,43,58,64,71,72,RO-may_prevent,820153-FS1,"Berlin BS, Mitchell JR, Burgoyne GH et al. RHESUS DIPLOID RABIES VACCINE (adsorbed), a new RABIES VACCINE",RHESUS DIPLOID RABIES VACCINE,RABIES VACCINE
790085282,9/17/2015 13:22:00,1740418102,9/17/2015 13:21:34,false,prodege,1.0,33854929,USA,CT,Wallingford,24.2.218.232,[OTHER],[OTHER],new,n/a,43,58,64,71,72,RO-may_prevent,820153-FS1,"Berlin BS, Mitchell JR, Burgoyne GH et al. RHESUS DIPLOID RABIES VACCINE (adsorbed), a new RABIES VACCINE",RHESUS DIPLOID RABIES VACCINE,RABIES VACCINE
790085282,9/17/2015 13:28:12,1740419906,9/17/2015 13:27:56,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],a new,n/a,43,58,64,71,72,RO-may_prevent,820153-FS1,"Berlin BS, Mitchell JR, Burgoyne GH et al. RHESUS DIPLOID RABIES VACCINE (adsorbed), a new RABIES VACCINE",RHESUS DIPLOID RABIES VACCINE,RABIES VACCINE
790085282,9/17/2015 13:29:41,1740420345,9/17/2015 13:29:02,false,neodev,1.0,12115558,USA,OH,Twinsburg,98.27.164.131,[PART_OF] [OTHER],"[PART_OF]
[OTHER]",RHESUS DIPLOID RABIES VACCINE new RABIES VACCINE,N/A,43,58,64,71,72,RO-may_prevent,820153-FS1,"Berlin BS, Mitchell JR, Burgoyne GH et al. RHESUS DIPLOID RABIES VACCINE (adsorbed), a new RABIES VACCINE",RHESUS DIPLOID RABIES VACCINE,RABIES VACCINE
790085282,9/17/2015 13:30:50,1740420758,9/17/2015 13:30:22,false,prodege,1.0,27934334,GBR,C8,Croydon,81.159.60.206,[IS_A],[IS_A],RABIES VACCINE,N/A,43,58,64,71,72,RO-may_prevent,820153-FS1,"Berlin BS, Mitchell JR, Burgoyne GH et al. RHESUS DIPLOID RABIES VACCINE (adsorbed), a new RABIES VACCINE",RHESUS DIPLOID RABIES VACCINE,RABIES VACCINE
790085282,9/17/2015 14:00:03,1740432311,9/17/2015 13:58:17,false,neodev,1.0,31329809,USA,DE,Wilmington,162.223.93.194,[IS_A],[IS_A],a,N/A,43,58,64,71,72,RO-may_prevent,820153-FS1,"Berlin BS, Mitchell JR, Burgoyne GH et al. RHESUS DIPLOID RABIES VACCINE (adsorbed), a new RABIES VACCINE",RHESUS DIPLOID RABIES VACCINE,RABIES VACCINE
790085282,9/17/2015 14:03:38,1740433665,9/17/2015 14:03:14,false,gifthunterclub,1.0,30901412,GBR,H9,London,77.89.149.62,[OTHER],[OTHER],RHESUS DIPLOID RABIES VACCINE new RABIES VACCINE,N/A,43,58,64,71,72,RO-may_prevent,820153-FS1,"Berlin BS, Mitchell JR, Burgoyne GH et al. RHESUS DIPLOID RABIES VACCINE (adsorbed), a new RABIES VACCINE",RHESUS DIPLOID RABIES VACCINE,RABIES VACCINE
790085282,9/17/2015 14:07:37,1740435145,9/17/2015 14:06:32,false,zoombucks,1.0,6744840,CAN,BC,Kelowna,174.4.58.160,[IS_A],[IS_A],a new RABIES VACCINE,N/A,43,58,64,71,72,RO-may_prevent,820153-FS1,"Berlin BS, Mitchell JR, Burgoyne GH et al. RHESUS DIPLOID RABIES VACCINE (adsorbed), a new RABIES VACCINE",RHESUS DIPLOID RABIES VACCINE,RABIES VACCINE
790085282,9/17/2015 14:09:09,1740435709,9/17/2015 14:08:38,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.124.79,[IS_A],[IS_A],a new,N/A,43,58,64,71,72,RO-may_prevent,820153-FS1,"Berlin BS, Mitchell JR, Burgoyne GH et al. RHESUS DIPLOID RABIES VACCINE (adsorbed), a new RABIES VACCINE",RHESUS DIPLOID RABIES VACCINE,RABIES VACCINE
790085282,9/17/2015 14:14:59,1740437781,9/17/2015 14:14:09,false,elite,1.0,33238902,NLD,06,Budel,77.248.148.5,[IS_A],[IS_A],RHESUS DIPLOID RABIES VACCINE a new RABIES VACCINE,n/a,43,58,64,71,72,RO-may_prevent,820153-FS1,"Berlin BS, Mitchell JR, Burgoyne GH et al. RHESUS DIPLOID RABIES VACCINE (adsorbed), a new RABIES VACCINE",RHESUS DIPLOID RABIES VACCINE,RABIES VACCINE
790085282,9/17/2015 14:28:00,1740442425,9/17/2015 14:27:29,false,prodege,1.0,34497719,GBR,N5,Haverhill,151.230.78.163,[IS_A],[IS_A],a new,n/a,43,58,64,71,72,RO-may_prevent,820153-FS1,"Berlin BS, Mitchell JR, Burgoyne GH et al. RHESUS DIPLOID RABIES VACCINE (adsorbed), a new RABIES VACCINE",RHESUS DIPLOID RABIES VACCINE,RABIES VACCINE
790085282,9/17/2015 14:30:56,1740443659,9/17/2015 14:29:47,false,bitcoinget,1.0,32306192,USA,MA,Amherst,72.19.88.245,[TREATS],[TREATS],RHESUS DIPLOID RABIES VACCINE,N/A,43,58,64,71,72,RO-may_prevent,820153-FS1,"Berlin BS, Mitchell JR, Burgoyne GH et al. RHESUS DIPLOID RABIES VACCINE (adsorbed), a new RABIES VACCINE",RHESUS DIPLOID RABIES VACCINE,RABIES VACCINE
790085282,9/17/2015 14:34:31,1740444932,9/17/2015 14:33:39,false,instagc,1.0,22981457,CAN,ON,Ottawa,67.69.8.122,[OTHER],[OTHER],"(adsorbed), new",They are related in that they are both vaccines,43,58,64,71,72,RO-may_prevent,820153-FS1,"Berlin BS, Mitchell JR, Burgoyne GH et al. RHESUS DIPLOID RABIES VACCINE (adsorbed), a new RABIES VACCINE",RHESUS DIPLOID RABIES VACCINE,RABIES VACCINE
790085282,9/17/2015 14:36:21,1740445610,9/17/2015 14:35:13,false,clixsense,1.0,32049531,USA,"","",38.95.108.252,[NONE],[NONE],none,none,43,58,64,71,72,RO-may_prevent,820153-FS1,"Berlin BS, Mitchell JR, Burgoyne GH et al. RHESUS DIPLOID RABIES VACCINE (adsorbed), a new RABIES VACCINE",RHESUS DIPLOID RABIES VACCINE,RABIES VACCINE
790085283,9/17/2015 10:34:04,1740380765,9/17/2015 10:33:47,false,pocketmoneygpt,1,28884030,USA,WI,Minocqua,75.143.134.247,[TREATS],[TREATS],with,n/a,132,101,146,145,114,RO-may_prevent,820154-FS1,"1]  Clyde PW, Harari AE, Getka EJ, Shakir KM. Combined levothyroxine plus liothyronine compared with LEVOTHYROXINE alone in primary HYPOTHYROIDISM: a randomized controlled trial.",HYPOTHYROIDISM,LEVOTHYROXINE
790085283,9/17/2015 10:45:16,1740382920,9/17/2015 10:44:55,false,clixsense,1,17950689,GBR,L9,Sheffield,146.200.192.103,[TREATS],[TREATS],HYPOTHYROIDISM:,NONE,132,101,146,145,114,RO-may_prevent,820154-FS1,"1]  Clyde PW, Harari AE, Getka EJ, Shakir KM. Combined levothyroxine plus liothyronine compared with LEVOTHYROXINE alone in primary HYPOTHYROIDISM: a randomized controlled trial.",HYPOTHYROIDISM,LEVOTHYROXINE
790085283,9/17/2015 11:00:08,1740385582,9/17/2015 10:59:53,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[ASSOCIATED_WITH],[ASSOCIATED_WITH],Combined,N/A,132,101,146,145,114,RO-may_prevent,820154-FS1,"1]  Clyde PW, Harari AE, Getka EJ, Shakir KM. Combined levothyroxine plus liothyronine compared with LEVOTHYROXINE alone in primary HYPOTHYROIDISM: a randomized controlled trial.",HYPOTHYROIDISM,LEVOTHYROXINE
790085283,9/17/2015 11:02:40,1740386063,9/17/2015 11:01:17,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[OTHER],[OTHER],a randomized controlled trial.,N/A,132,101,146,145,114,RO-may_prevent,820154-FS1,"1]  Clyde PW, Harari AE, Getka EJ, Shakir KM. Combined levothyroxine plus liothyronine compared with LEVOTHYROXINE alone in primary HYPOTHYROIDISM: a randomized controlled trial.",HYPOTHYROIDISM,LEVOTHYROXINE
790085283,9/17/2015 11:05:27,1740386584,9/17/2015 11:03:52,false,neodev,1.0,30941227,USA,NV,Las Vegas,192.30.80.166,[ASSOCIATED_WITH] [IS_A],"[ASSOCIATED_WITH]
[IS_A]",with a,N/A,132,101,146,145,114,RO-may_prevent,820154-FS1,"1]  Clyde PW, Harari AE, Getka EJ, Shakir KM. Combined levothyroxine plus liothyronine compared with LEVOTHYROXINE alone in primary HYPOTHYROIDISM: a randomized controlled trial.",HYPOTHYROIDISM,LEVOTHYROXINE
790085283,9/17/2015 11:06:36,1740386838,9/17/2015 11:05:55,false,neodev,1.0,30581619,USA,CA,San Jose,50.118.162.56,[TREATS] [NONE],"[TREATS]
[NONE]",good,good,132,101,146,145,114,RO-may_prevent,820154-FS1,"1]  Clyde PW, Harari AE, Getka EJ, Shakir KM. Combined levothyroxine plus liothyronine compared with LEVOTHYROXINE alone in primary HYPOTHYROIDISM: a randomized controlled trial.",HYPOTHYROIDISM,LEVOTHYROXINE
790085283,9/17/2015 11:15:12,1740388568,9/17/2015 11:14:57,false,neodev,1.0,32695853,USA,NV,Las Vegas,192.30.80.172,[ASSOCIATED_WITH] [IS_A],"[ASSOCIATED_WITH]
[IS_A]",with a,N/A,132,101,146,145,114,RO-may_prevent,820154-FS1,"1]  Clyde PW, Harari AE, Getka EJ, Shakir KM. Combined levothyroxine plus liothyronine compared with LEVOTHYROXINE alone in primary HYPOTHYROIDISM: a randomized controlled trial.",HYPOTHYROIDISM,LEVOTHYROXINE
790085283,9/17/2015 11:16:40,1740388857,9/17/2015 11:15:34,false,gifthulk,1,18666417,USA,PA,Meadville,24.101.32.13,[TREATS] [DIAGNOSE_BY_TEST_OR_DRUG],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]",LEVOTHYROXINE in HYPOTHYROIDISM: randomized controlled trial.,n/a,132,101,146,145,114,RO-may_prevent,820154-FS1,"1]  Clyde PW, Harari AE, Getka EJ, Shakir KM. Combined levothyroxine plus liothyronine compared with LEVOTHYROXINE alone in primary HYPOTHYROIDISM: a randomized controlled trial.",HYPOTHYROIDISM,LEVOTHYROXINE
790085283,9/17/2015 11:24:39,1740390171,9/17/2015 11:24:26,false,elite,1,33798502,USA,VA,Manassas,207.244.86.212,[PREVENTS] [TREATS],"[TREATS]
[PREVENTS]",Shakir Combined,makes sense,132,101,146,145,114,RO-may_prevent,820154-FS1,"1]  Clyde PW, Harari AE, Getka EJ, Shakir KM. Combined levothyroxine plus liothyronine compared with LEVOTHYROXINE alone in primary HYPOTHYROIDISM: a randomized controlled trial.",HYPOTHYROIDISM,LEVOTHYROXINE
790085283,9/17/2015 11:38:49,1740392923,9/17/2015 11:38:33,false,neodev,1.0,33701549,USA,CA,Torrance,66.171.228.66,[LOCATION] [DIAGNOSE_BY_TEST_OR_DRUG] [SYMPTOM] [SIDE_EFFECT] [NONE],"[DIAGNOSE_BY_TEST_OR_DRUG]
[LOCATION]
[SYMPTOM]
[SIDE_EFFECT]
[NONE]",[IS_A],N/A,132,101,146,145,114,RO-may_prevent,820154-FS1,"1]  Clyde PW, Harari AE, Getka EJ, Shakir KM. Combined levothyroxine plus liothyronine compared with LEVOTHYROXINE alone in primary HYPOTHYROIDISM: a randomized controlled trial.",HYPOTHYROIDISM,LEVOTHYROXINE
790085283,9/17/2015 11:41:43,1740393442,9/17/2015 11:41:12,false,neodev,1,31329809,USA,DE,Wilmington,162.223.93.194,[ASSOCIATED_WITH] [IS_A],"[ASSOCIATED_WITH]
[IS_A]",with a,N/A,132,101,146,145,114,RO-may_prevent,820154-FS1,"1]  Clyde PW, Harari AE, Getka EJ, Shakir KM. Combined levothyroxine plus liothyronine compared with LEVOTHYROXINE alone in primary HYPOTHYROIDISM: a randomized controlled trial.",HYPOTHYROIDISM,LEVOTHYROXINE
790085283,9/17/2015 11:56:15,1740396340,9/17/2015 11:55:52,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[ASSOCIATED_WITH],[ASSOCIATED_WITH],compared,N/A,132,101,146,145,114,RO-may_prevent,820154-FS1,"1]  Clyde PW, Harari AE, Getka EJ, Shakir KM. Combined levothyroxine plus liothyronine compared with LEVOTHYROXINE alone in primary HYPOTHYROIDISM: a randomized controlled trial.",HYPOTHYROIDISM,LEVOTHYROXINE
790085283,9/17/2015 12:00:19,1740397110,9/17/2015 11:59:59,false,prodege,1,14848125,GBR,V8,Airdrie,86.151.77.161,[TREATS],[TREATS],randomized controlled trial.,n/a,132,101,146,145,114,RO-may_prevent,820154-FS1,"1]  Clyde PW, Harari AE, Getka EJ, Shakir KM. Combined levothyroxine plus liothyronine compared with LEVOTHYROXINE alone in primary HYPOTHYROIDISM: a randomized controlled trial.",HYPOTHYROIDISM,LEVOTHYROXINE
790085283,9/17/2015 12:10:31,1740399361,9/17/2015 12:10:22,false,prodege,1,12656479,CAN,NB,Fredericton,198.164.157.90,[PREVENTS],[PREVENTS],Combined,N/A,132,101,146,145,114,RO-may_prevent,820154-FS1,"1]  Clyde PW, Harari AE, Getka EJ, Shakir KM. Combined levothyroxine plus liothyronine compared with LEVOTHYROXINE alone in primary HYPOTHYROIDISM: a randomized controlled trial.",HYPOTHYROIDISM,LEVOTHYROXINE
790085283,9/17/2015 12:19:56,1740401351,9/17/2015 12:18:53,false,neodev,1.0,30588889,NLD,07,Amsterdam,77.248.175.222,[TREATS],[TREATS],in,N/A,132,101,146,145,114,RO-may_prevent,820154-FS1,"1]  Clyde PW, Harari AE, Getka EJ, Shakir KM. Combined levothyroxine plus liothyronine compared with LEVOTHYROXINE alone in primary HYPOTHYROIDISM: a randomized controlled trial.",HYPOTHYROIDISM,LEVOTHYROXINE
790085284,9/17/2015 09:16:49,1740363370,9/17/2015 09:16:30,false,neodev,1,32053642,GBR,I7,Newcastle Upon Tyne,92.23.136.205,[TREATS],[TREATS],treatment with,N/A,29,89,63,62,117,RO-may_prevent,820199-FS1,CONCLUSION  In patients with SYMPTOMATIC VENOUS THROMBOEMBOLISM long term treatment with LOW MOLECULAR WEIGHT HEPARIN is possibly as effective and safe as long term treatment with vitamin K antagonists.,SYMPTOMATIC VENOUS THROMBOEMBOLISM,LOW MOLECULAR WEIGHT HEPARIN
790085284,9/17/2015 09:17:51,1740363533,9/17/2015 09:17:37,false,elite,1,30659754,USA,"","",162.250.145.204,[TREATS],[TREATS],treatment,N/A,29,89,63,62,117,RO-may_prevent,820199-FS1,CONCLUSION  In patients with SYMPTOMATIC VENOUS THROMBOEMBOLISM long term treatment with LOW MOLECULAR WEIGHT HEPARIN is possibly as effective and safe as long term treatment with vitamin K antagonists.,SYMPTOMATIC VENOUS THROMBOEMBOLISM,LOW MOLECULAR WEIGHT HEPARIN
790085284,9/17/2015 09:24:33,1740364934,9/17/2015 09:24:09,false,instagc,1,18960682,GBR,U2,Annan,92.18.213.181,[TREATS],[TREATS],long term treatment with LOW MOLECULAR WEIGHT HEPARIN,N/A,29,89,63,62,117,RO-may_prevent,820199-FS1,CONCLUSION  In patients with SYMPTOMATIC VENOUS THROMBOEMBOLISM long term treatment with LOW MOLECULAR WEIGHT HEPARIN is possibly as effective and safe as long term treatment with vitamin K antagonists.,SYMPTOMATIC VENOUS THROMBOEMBOLISM,LOW MOLECULAR WEIGHT HEPARIN
790085284,9/17/2015 09:27:14,1740365381,9/17/2015 09:26:37,false,neodev,1,33644825,USA,FL,Fort Lauderdale,65.111.173.161,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],SYMPTOMATIC VENOUS THROMBOEMBOLISM LOW MOLECULAR WEIGHT HEPARIN,prevents,29,89,63,62,117,RO-may_prevent,820199-FS1,CONCLUSION  In patients with SYMPTOMATIC VENOUS THROMBOEMBOLISM long term treatment with LOW MOLECULAR WEIGHT HEPARIN is possibly as effective and safe as long term treatment with vitamin K antagonists.,SYMPTOMATIC VENOUS THROMBOEMBOLISM,LOW MOLECULAR WEIGHT HEPARIN
790085284,9/17/2015 09:27:27,1740365470,9/17/2015 09:26:30,false,neodev,1,15848372,AUS,02,Jannali,14.200.59.55,[ASSOCIATED_WITH],[ASSOCIATED_WITH],long term treatment with,n/a,29,89,63,62,117,RO-may_prevent,820199-FS1,CONCLUSION  In patients with SYMPTOMATIC VENOUS THROMBOEMBOLISM long term treatment with LOW MOLECULAR WEIGHT HEPARIN is possibly as effective and safe as long term treatment with vitamin K antagonists.,SYMPTOMATIC VENOUS THROMBOEMBOLISM,LOW MOLECULAR WEIGHT HEPARIN
790085284,9/17/2015 09:35:59,1740367482,9/17/2015 09:35:45,false,elite,1,30659615,USA,"","",162.250.145.234,[TREATS],[TREATS],treatment,N/A,29,89,63,62,117,RO-may_prevent,820199-FS1,CONCLUSION  In patients with SYMPTOMATIC VENOUS THROMBOEMBOLISM long term treatment with LOW MOLECULAR WEIGHT HEPARIN is possibly as effective and safe as long term treatment with vitamin K antagonists.,SYMPTOMATIC VENOUS THROMBOEMBOLISM,LOW MOLECULAR WEIGHT HEPARIN
790085284,9/17/2015 09:39:14,1740368271,9/17/2015 09:38:34,false,pocketmoneygpt,1,21432964,GBR,F8,Borehamwood,81.159.185.70,[TREATS],[TREATS],long term treatment,N/A,29,89,63,62,117,RO-may_prevent,820199-FS1,CONCLUSION  In patients with SYMPTOMATIC VENOUS THROMBOEMBOLISM long term treatment with LOW MOLECULAR WEIGHT HEPARIN is possibly as effective and safe as long term treatment with vitamin K antagonists.,SYMPTOMATIC VENOUS THROMBOEMBOLISM,LOW MOLECULAR WEIGHT HEPARIN
790085284,9/17/2015 09:40:13,1740368511,9/17/2015 09:38:03,false,clixsense,1,30681826,GBR,I9,Diss,31.49.71.254,[TREATS],[TREATS],treatment,N/A,29,89,63,62,117,RO-may_prevent,820199-FS1,CONCLUSION  In patients with SYMPTOMATIC VENOUS THROMBOEMBOLISM long term treatment with LOW MOLECULAR WEIGHT HEPARIN is possibly as effective and safe as long term treatment with vitamin K antagonists.,SYMPTOMATIC VENOUS THROMBOEMBOLISM,LOW MOLECULAR WEIGHT HEPARIN
790085284,9/17/2015 09:43:54,1740369449,9/17/2015 09:43:38,false,neodev,1,21515166,NLD,11,Nieuwkoop,83.84.200.25,[TREATS],[TREATS],treatment with,n/a,29,89,63,62,117,RO-may_prevent,820199-FS1,CONCLUSION  In patients with SYMPTOMATIC VENOUS THROMBOEMBOLISM long term treatment with LOW MOLECULAR WEIGHT HEPARIN is possibly as effective and safe as long term treatment with vitamin K antagonists.,SYMPTOMATIC VENOUS THROMBOEMBOLISM,LOW MOLECULAR WEIGHT HEPARIN
790085284,9/17/2015 09:51:45,1740371204,9/17/2015 09:51:31,false,elite,1,30659677,USA,"","",162.252.172.126,[TREATS],[TREATS],treatment,N/A,29,89,63,62,117,RO-may_prevent,820199-FS1,CONCLUSION  In patients with SYMPTOMATIC VENOUS THROMBOEMBOLISM long term treatment with LOW MOLECULAR WEIGHT HEPARIN is possibly as effective and safe as long term treatment with vitamin K antagonists.,SYMPTOMATIC VENOUS THROMBOEMBOLISM,LOW MOLECULAR WEIGHT HEPARIN
790085284,9/17/2015 10:01:22,1740373484,9/17/2015 10:01:03,false,neodev,1,34081836,USA,CA,San Jose,23.27.248.146,[TREATS],[TREATS],SYMPTOMATIC VENOUS THROMBOEMBOLISM long term treatment with LOW MOLECULAR WEIGHT HEPARIN,N/A,29,89,63,62,117,RO-may_prevent,820199-FS1,CONCLUSION  In patients with SYMPTOMATIC VENOUS THROMBOEMBOLISM long term treatment with LOW MOLECULAR WEIGHT HEPARIN is possibly as effective and safe as long term treatment with vitamin K antagonists.,SYMPTOMATIC VENOUS THROMBOEMBOLISM,LOW MOLECULAR WEIGHT HEPARIN
790085284,9/17/2015 10:03:38,1740374040,9/17/2015 10:03:15,false,gifthunterclub,1,24043308,GBR,"","",94.102.147.250,[TREATS],[TREATS],treatment,N/A,29,89,63,62,117,RO-may_prevent,820199-FS1,CONCLUSION  In patients with SYMPTOMATIC VENOUS THROMBOEMBOLISM long term treatment with LOW MOLECULAR WEIGHT HEPARIN is possibly as effective and safe as long term treatment with vitamin K antagonists.,SYMPTOMATIC VENOUS THROMBOEMBOLISM,LOW MOLECULAR WEIGHT HEPARIN
790085284,9/17/2015 10:29:42,1740379729,9/17/2015 10:29:29,false,pocketmoneygpt,1.0,28884030,USA,WI,Minocqua,75.143.134.247,[TREATS],[TREATS],treatment,n/a,29,89,63,62,117,RO-may_prevent,820199-FS1,CONCLUSION  In patients with SYMPTOMATIC VENOUS THROMBOEMBOLISM long term treatment with LOW MOLECULAR WEIGHT HEPARIN is possibly as effective and safe as long term treatment with vitamin K antagonists.,SYMPTOMATIC VENOUS THROMBOEMBOLISM,LOW MOLECULAR WEIGHT HEPARIN
790085284,9/17/2015 10:39:06,1740381761,9/17/2015 10:38:46,false,clixsense,1.0,17950689,GBR,L9,Sheffield,146.200.192.103,[TREATS],[TREATS],HEPARIN,NONE,29,89,63,62,117,RO-may_prevent,820199-FS1,CONCLUSION  In patients with SYMPTOMATIC VENOUS THROMBOEMBOLISM long term treatment with LOW MOLECULAR WEIGHT HEPARIN is possibly as effective and safe as long term treatment with vitamin K antagonists.,SYMPTOMATIC VENOUS THROMBOEMBOLISM,LOW MOLECULAR WEIGHT HEPARIN
790085284,9/17/2015 10:52:51,1740384261,9/17/2015 10:52:20,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[TREATS],[TREATS],treatment,N/A,29,89,63,62,117,RO-may_prevent,820199-FS1,CONCLUSION  In patients with SYMPTOMATIC VENOUS THROMBOEMBOLISM long term treatment with LOW MOLECULAR WEIGHT HEPARIN is possibly as effective and safe as long term treatment with vitamin K antagonists.,SYMPTOMATIC VENOUS THROMBOEMBOLISM,LOW MOLECULAR WEIGHT HEPARIN
790085285,9/17/2015 09:15:06,1740362973,9/17/2015 09:14:36,false,neodev,1.0,32053642,GBR,I7,Newcastle Upon Tyne,92.23.136.205,[SYMPTOM],[SYMPTOM],patient in question,N/A,78,0,98,97,28,RO-may_prevent,820353-FS1,LOW COBALAMIN CONCENTRATIONS do not indicate that the patient in question has COBALAMIN DEFICIENCY and values in the lower half of the reference interval do not exclude cobalamin deficiency.,COBALAMIN DEFICIENCY,LOW COBALAMIN CONCENTRATIONS
790085285,9/17/2015 09:16:20,1740363250,9/17/2015 09:16:06,false,elite,1.0,30659754,USA,"","",162.250.145.204,[PREVENTS],[PREVENTS],lower,N/A,78,0,98,97,28,RO-may_prevent,820353-FS1,LOW COBALAMIN CONCENTRATIONS do not indicate that the patient in question has COBALAMIN DEFICIENCY and values in the lower half of the reference interval do not exclude cobalamin deficiency.,COBALAMIN DEFICIENCY,LOW COBALAMIN CONCENTRATIONS
790085285,9/17/2015 09:22:19,1740364493,9/17/2015 09:21:48,false,instagc,1.0,18960682,GBR,U2,Annan,92.18.213.181,[SYMPTOM],[SYMPTOM],indicate that the,N/A,78,0,98,97,28,RO-may_prevent,820353-FS1,LOW COBALAMIN CONCENTRATIONS do not indicate that the patient in question has COBALAMIN DEFICIENCY and values in the lower half of the reference interval do not exclude cobalamin deficiency.,COBALAMIN DEFICIENCY,LOW COBALAMIN CONCENTRATIONS
790085285,9/17/2015 09:23:52,1740364789,9/17/2015 09:23:05,false,neodev,1.0,33644825,USA,FL,Fort Lauderdale,65.111.173.161,[PREVENTS],[PREVENTS],LOW COBALAMIN CONCENTRATIONS COBALAMIN DEFICIENCY,prevents,78,0,98,97,28,RO-may_prevent,820353-FS1,LOW COBALAMIN CONCENTRATIONS do not indicate that the patient in question has COBALAMIN DEFICIENCY and values in the lower half of the reference interval do not exclude cobalamin deficiency.,COBALAMIN DEFICIENCY,LOW COBALAMIN CONCENTRATIONS
790085285,9/17/2015 09:23:54,1740364792,9/17/2015 09:23:33,false,neodev,1.0,15848372,AUS,02,Jannali,14.200.59.55,[CONTRAINDICATES],[CONTRAINDICATES],do not indicate,n/a,78,0,98,97,28,RO-may_prevent,820353-FS1,LOW COBALAMIN CONCENTRATIONS do not indicate that the patient in question has COBALAMIN DEFICIENCY and values in the lower half of the reference interval do not exclude cobalamin deficiency.,COBALAMIN DEFICIENCY,LOW COBALAMIN CONCENTRATIONS
790085285,9/17/2015 09:30:41,1740366212,9/17/2015 09:28:45,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[NONE],[NONE],N/A,does not indicate,78,0,98,97,28,RO-may_prevent,820353-FS1,LOW COBALAMIN CONCENTRATIONS do not indicate that the patient in question has COBALAMIN DEFICIENCY and values in the lower half of the reference interval do not exclude cobalamin deficiency.,COBALAMIN DEFICIENCY,LOW COBALAMIN CONCENTRATIONS
790085285,9/17/2015 09:34:40,1740367172,9/17/2015 09:34:24,false,elite,1.0,30659615,USA,"","",162.250.145.234,[SYMPTOM],[SYMPTOM],indicate,N/A,78,0,98,97,28,RO-may_prevent,820353-FS1,LOW COBALAMIN CONCENTRATIONS do not indicate that the patient in question has COBALAMIN DEFICIENCY and values in the lower half of the reference interval do not exclude cobalamin deficiency.,COBALAMIN DEFICIENCY,LOW COBALAMIN CONCENTRATIONS
790085285,9/17/2015 09:35:28,1740367368,9/17/2015 09:34:39,false,pocketmoneygpt,1.0,21432964,GBR,F8,Borehamwood,81.159.185.70,[ASSOCIATED_WITH],[ASSOCIATED_WITH],do not indicate that the patient in question has,N/A,78,0,98,97,28,RO-may_prevent,820353-FS1,LOW COBALAMIN CONCENTRATIONS do not indicate that the patient in question has COBALAMIN DEFICIENCY and values in the lower half of the reference interval do not exclude cobalamin deficiency.,COBALAMIN DEFICIENCY,LOW COBALAMIN CONCENTRATIONS
790085285,9/17/2015 09:40:21,1740368528,9/17/2015 09:39:26,false,neodev,1.0,21515166,NLD,11,Nieuwkoop,83.84.200.25,[CAUSES],[CAUSES],do not indicate,n/a,78,0,98,97,28,RO-may_prevent,820353-FS1,LOW COBALAMIN CONCENTRATIONS do not indicate that the patient in question has COBALAMIN DEFICIENCY and values in the lower half of the reference interval do not exclude cobalamin deficiency.,COBALAMIN DEFICIENCY,LOW COBALAMIN CONCENTRATIONS
790085285,9/17/2015 09:50:19,1740370828,9/17/2015 09:50:05,false,elite,1.0,30659677,USA,"","",162.252.172.126,[SYMPTOM],[SYMPTOM],indicate,N/A,78,0,98,97,28,RO-may_prevent,820353-FS1,LOW COBALAMIN CONCENTRATIONS do not indicate that the patient in question has COBALAMIN DEFICIENCY and values in the lower half of the reference interval do not exclude cobalamin deficiency.,COBALAMIN DEFICIENCY,LOW COBALAMIN CONCENTRATIONS
790085285,9/17/2015 09:57:19,1740372519,9/17/2015 09:56:11,false,neodev,1.0,34081836,USA,CA,San Jose,23.27.248.146,[PART_OF] [MANIFESTATION] [CAUSES],"[CAUSES]
[MANIFESTATION]
[PART_OF]",LOW COBALAMIN CONCENTRATIONS do not indicate that the patient in question has COBALAMIN DEFICIENCY,N/A,78,0,98,97,28,RO-may_prevent,820353-FS1,LOW COBALAMIN CONCENTRATIONS do not indicate that the patient in question has COBALAMIN DEFICIENCY and values in the lower half of the reference interval do not exclude cobalamin deficiency.,COBALAMIN DEFICIENCY,LOW COBALAMIN CONCENTRATIONS
790085285,9/17/2015 10:00:22,1740373246,9/17/2015 09:59:05,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[NONE],[NONE],N/A,it states that it does not indicate the patient has cobalamin,78,0,98,97,28,RO-may_prevent,820353-FS1,LOW COBALAMIN CONCENTRATIONS do not indicate that the patient in question has COBALAMIN DEFICIENCY and values in the lower half of the reference interval do not exclude cobalamin deficiency.,COBALAMIN DEFICIENCY,LOW COBALAMIN CONCENTRATIONS
790085285,9/17/2015 10:28:13,1740379422,9/17/2015 10:27:59,false,pocketmoneygpt,1.0,28884030,USA,WI,Minocqua,75.143.134.247,[SYMPTOM],[SYMPTOM],indicate,n/a,78,0,98,97,28,RO-may_prevent,820353-FS1,LOW COBALAMIN CONCENTRATIONS do not indicate that the patient in question has COBALAMIN DEFICIENCY and values in the lower half of the reference interval do not exclude cobalamin deficiency.,COBALAMIN DEFICIENCY,LOW COBALAMIN CONCENTRATIONS
790085285,9/17/2015 10:33:47,1740380684,9/17/2015 10:32:37,false,clixsense,1.0,17950689,GBR,L9,Sheffield,146.200.192.103,[SIDE_EFFECT],[SIDE_EFFECT],cobalamin deficiency.,NONE,78,0,98,97,28,RO-may_prevent,820353-FS1,LOW COBALAMIN CONCENTRATIONS do not indicate that the patient in question has COBALAMIN DEFICIENCY and values in the lower half of the reference interval do not exclude cobalamin deficiency.,COBALAMIN DEFICIENCY,LOW COBALAMIN CONCENTRATIONS
790085285,9/17/2015 10:51:25,1740384033,9/17/2015 10:51:08,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[SYMPTOM],[SYMPTOM],indicate,N/A,78,0,98,97,28,RO-may_prevent,820353-FS1,LOW COBALAMIN CONCENTRATIONS do not indicate that the patient in question has COBALAMIN DEFICIENCY and values in the lower half of the reference interval do not exclude cobalamin deficiency.,COBALAMIN DEFICIENCY,LOW COBALAMIN CONCENTRATIONS
790085286,9/17/2015 11:05:14,1740386550,9/17/2015 11:04:52,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[TREATS],[TREATS],treatments,N/A,114,51,142,140,86,RO-may_prevent,820354-FS1,Various bisphosphonates and the selective estrogen RECEPTOR MODULATOR (SERM) RALOXIFENE are approved treatments of POSTMENOPAUSAL OSTEOPOROSIS,POSTMENOPAUSAL OSTEOPOROSIS,RECEPTOR MODULATOR (SERM) RALOXIFENE
790085286,9/17/2015 11:14:43,1740388502,9/17/2015 11:13:58,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[TREATS],[TREATS],treatments of,N/A,114,51,142,140,86,RO-may_prevent,820354-FS1,Various bisphosphonates and the selective estrogen RECEPTOR MODULATOR (SERM) RALOXIFENE are approved treatments of POSTMENOPAUSAL OSTEOPOROSIS,POSTMENOPAUSAL OSTEOPOROSIS,RECEPTOR MODULATOR (SERM) RALOXIFENE
790085286,9/17/2015 11:18:35,1740389221,9/17/2015 11:18:16,false,neodev,1.0,32695853,USA,NV,Las Vegas,192.30.80.172,[TREATS] [PART_OF],"[TREATS]
[PART_OF]",treatments of,N/A,114,51,142,140,86,RO-may_prevent,820354-FS1,Various bisphosphonates and the selective estrogen RECEPTOR MODULATOR (SERM) RALOXIFENE are approved treatments of POSTMENOPAUSAL OSTEOPOROSIS,POSTMENOPAUSAL OSTEOPOROSIS,RECEPTOR MODULATOR (SERM) RALOXIFENE
790085286,9/17/2015 11:20:59,1740389595,9/17/2015 11:20:27,false,neodev,1.0,30581619,USA,CA,San Jose,50.118.162.56,[NONE],[NONE],good,good,114,51,142,140,86,RO-may_prevent,820354-FS1,Various bisphosphonates and the selective estrogen RECEPTOR MODULATOR (SERM) RALOXIFENE are approved treatments of POSTMENOPAUSAL OSTEOPOROSIS,POSTMENOPAUSAL OSTEOPOROSIS,RECEPTOR MODULATOR (SERM) RALOXIFENE
790085286,9/17/2015 11:30:32,1740391308,9/17/2015 11:30:19,false,neodev,1.0,30941227,USA,NV,Las Vegas,192.30.80.166,[TREATS] [PART_OF],"[TREATS]
[PART_OF]",treatments of,N/A,114,51,142,140,86,RO-may_prevent,820354-FS1,Various bisphosphonates and the selective estrogen RECEPTOR MODULATOR (SERM) RALOXIFENE are approved treatments of POSTMENOPAUSAL OSTEOPOROSIS,POSTMENOPAUSAL OSTEOPOROSIS,RECEPTOR MODULATOR (SERM) RALOXIFENE
790085286,9/17/2015 11:41:23,1740393417,9/17/2015 11:41:10,false,neodev,1.0,33701549,USA,CA,Torrance,66.171.228.66,[CAUSES] [PREVENTS] [SYMPTOM] [IS_A] [PART_OF] [NONE],"[PREVENTS]
[CAUSES]
[SYMPTOM]
[IS_A]
[PART_OF]
[NONE]",[IS_A],N/A,114,51,142,140,86,RO-may_prevent,820354-FS1,Various bisphosphonates and the selective estrogen RECEPTOR MODULATOR (SERM) RALOXIFENE are approved treatments of POSTMENOPAUSAL OSTEOPOROSIS,POSTMENOPAUSAL OSTEOPOROSIS,RECEPTOR MODULATOR (SERM) RALOXIFENE
790085286,9/17/2015 12:03:12,1740397702,9/17/2015 12:02:02,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[TREATS],[TREATS],treatments,N/A,114,51,142,140,86,RO-may_prevent,820354-FS1,Various bisphosphonates and the selective estrogen RECEPTOR MODULATOR (SERM) RALOXIFENE are approved treatments of POSTMENOPAUSAL OSTEOPOROSIS,POSTMENOPAUSAL OSTEOPOROSIS,RECEPTOR MODULATOR (SERM) RALOXIFENE
790085286,9/17/2015 12:28:21,1740403196,9/17/2015 12:26:18,false,neodev,1.0,30588889,NLD,07,Amsterdam,77.248.175.222,[TREATS],[TREATS],treatments,N/A,114,51,142,140,86,RO-may_prevent,820354-FS1,Various bisphosphonates and the selective estrogen RECEPTOR MODULATOR (SERM) RALOXIFENE are approved treatments of POSTMENOPAUSAL OSTEOPOROSIS,POSTMENOPAUSAL OSTEOPOROSIS,RECEPTOR MODULATOR (SERM) RALOXIFENE
790085286,9/17/2015 12:37:19,1740405437,9/17/2015 12:37:00,false,prodege,1.0,2145087,USA,NY,New York,107.107.57.52,[TREATS],[TREATS],treatments of,N/A,114,51,142,140,86,RO-may_prevent,820354-FS1,Various bisphosphonates and the selective estrogen RECEPTOR MODULATOR (SERM) RALOXIFENE are approved treatments of POSTMENOPAUSAL OSTEOPOROSIS,POSTMENOPAUSAL OSTEOPOROSIS,RECEPTOR MODULATOR (SERM) RALOXIFENE
790085286,9/17/2015 12:37:47,1740405520,9/17/2015 12:37:24,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,[TREATS],[TREATS],RECEPTOR MODULATOR (SERM) RALOXIFENE approved treatments of POSTMENOPAUSAL OSTEOPOROSIS,na,114,51,142,140,86,RO-may_prevent,820354-FS1,Various bisphosphonates and the selective estrogen RECEPTOR MODULATOR (SERM) RALOXIFENE are approved treatments of POSTMENOPAUSAL OSTEOPOROSIS,POSTMENOPAUSAL OSTEOPOROSIS,RECEPTOR MODULATOR (SERM) RALOXIFENE
790085286,9/17/2015 12:41:57,1740406541,9/17/2015 12:41:41,false,instagc,1.0,22981457,CAN,ON,Welland,76.67.127.43,[TREATS],[TREATS],approved treatments,N/A,114,51,142,140,86,RO-may_prevent,820354-FS1,Various bisphosphonates and the selective estrogen RECEPTOR MODULATOR (SERM) RALOXIFENE are approved treatments of POSTMENOPAUSAL OSTEOPOROSIS,POSTMENOPAUSAL OSTEOPOROSIS,RECEPTOR MODULATOR (SERM) RALOXIFENE
790085286,9/17/2015 12:50:36,1740409195,9/17/2015 12:50:00,false,neodev,1,34215189,GBR,I2,Manchester,82.8.21.5,[TREATS],[TREATS],RECEPTOR MODULATOR (SERM) RALOXIFENE are approved treatments of POSTMENOPAUSAL OSTEOPOROSIS,N/A,114,51,142,140,86,RO-may_prevent,820354-FS1,Various bisphosphonates and the selective estrogen RECEPTOR MODULATOR (SERM) RALOXIFENE are approved treatments of POSTMENOPAUSAL OSTEOPOROSIS,POSTMENOPAUSAL OSTEOPOROSIS,RECEPTOR MODULATOR (SERM) RALOXIFENE
790085286,9/17/2015 13:13:05,1740415346,9/17/2015 13:12:48,false,elite,1.0,31883685,GBR,"","",79.66.244.188,[TREATS],[TREATS],approved treatments,N/A,114,51,142,140,86,RO-may_prevent,820354-FS1,Various bisphosphonates and the selective estrogen RECEPTOR MODULATOR (SERM) RALOXIFENE are approved treatments of POSTMENOPAUSAL OSTEOPOROSIS,POSTMENOPAUSAL OSTEOPOROSIS,RECEPTOR MODULATOR (SERM) RALOXIFENE
790085286,9/17/2015 13:13:24,1740415440,9/17/2015 13:13:03,false,prodege,1.0,33854929,USA,CT,Wallingford,24.2.218.232,[TREATS],[TREATS],treatments,n/a,114,51,142,140,86,RO-may_prevent,820354-FS1,Various bisphosphonates and the selective estrogen RECEPTOR MODULATOR (SERM) RALOXIFENE are approved treatments of POSTMENOPAUSAL OSTEOPOROSIS,POSTMENOPAUSAL OSTEOPOROSIS,RECEPTOR MODULATOR (SERM) RALOXIFENE
790085286,9/17/2015 13:13:42,1740415541,9/17/2015 13:13:27,false,neodev,1.0,33228343,USA,"","",38.95.108.251,[TREATS] [MANIFESTATION] [CONTRAINDICATES] [SIDE_EFFECT] [NONE],"[TREATS]
[MANIFESTATION]
[CONTRAINDICATES]
[SIDE_EFFECT]
[NONE]",Various bisphosphonates and the selective estrogen RECEPTOR MODULATOR (SERM) RALOXIFENE are approved treatments of POSTMENOPAUSAL OSTEOPOROS,Various bisphosphonates and the selective estrogen RECEPTOR MODULATOR (SERM) RALOXIFENE are approved treatments of POSTMENOPAUSAL OSTEOPOROS,114,51,142,140,86,RO-may_prevent,820354-FS1,Various bisphosphonates and the selective estrogen RECEPTOR MODULATOR (SERM) RALOXIFENE are approved treatments of POSTMENOPAUSAL OSTEOPOROSIS,POSTMENOPAUSAL OSTEOPOROSIS,RECEPTOR MODULATOR (SERM) RALOXIFENE
790085287,9/17/2015 13:21:14,1740417886,9/17/2015 13:21:00,false,neodev,1.0,33228343,USA,"","",38.95.108.251,[DIAGNOSE_BY_TEST_OR_DRUG] [PREVENTS] [TREATS] [LOCATION] [SYMPTOM] [CONTRAINDICATES] [SIDE_EFFECT] [IS_A] [NONE],"[TREATS]
[PREVENTS]
[DIAGNOSE_BY_TEST_OR_DRUG]
[LOCATION]
[SYMPTOM]
[CONTRAINDICATES]
[SIDE_EFFECT]
[IS_A]
[NONE]",The serological results of 82 Whites showed that 1.2% were positive for serum hepatitis B SURFACE ANTIGEN (HBSAG) and 21% were positive for SERUM HEPATITIS B ANTIBODY (HBAb).,The serological results of 82 Whites showed that 1.2% were positive for serum hepatitis B SURFACE ANTIGEN (HBSAG) and 21% were positive for SERUM HEPATITIS B ANTIBODY (HBAb).,139,90,155,164,112,RO-may_prevent,820277-FS1,The serological results of 82 Whites showed that 1.2% were positive for serum hepatitis B SURFACE ANTIGEN (HBSAG) and 21% were positive for SERUM HEPATITIS B ANTIBODY (HBAb).,SERUM HEPATITIS B ANTIBODY,SURFACE ANTIGEN (HBSAG)
790085287,9/17/2015 13:22:15,1740418185,9/17/2015 13:21:58,false,elite,1.0,31883685,GBR,"","",79.66.244.188,[ASSOCIATED_WITH],[ASSOCIATED_WITH],HEPATITIS,n/a,139,90,155,164,112,RO-may_prevent,820277-FS1,The serological results of 82 Whites showed that 1.2% were positive for serum hepatitis B SURFACE ANTIGEN (HBSAG) and 21% were positive for SERUM HEPATITIS B ANTIBODY (HBAb).,SERUM HEPATITIS B ANTIBODY,SURFACE ANTIGEN (HBSAG)
790085287,9/17/2015 13:31:28,1740420930,9/17/2015 13:30:38,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,[PART_OF],[PART_OF],hepatitis B SURFACE ANTIGEN,n/a,139,90,155,164,112,RO-may_prevent,820277-FS1,The serological results of 82 Whites showed that 1.2% were positive for serum hepatitis B SURFACE ANTIGEN (HBSAG) and 21% were positive for SERUM HEPATITIS B ANTIBODY (HBAb).,SERUM HEPATITIS B ANTIBODY,SURFACE ANTIGEN (HBSAG)
790085287,9/17/2015 13:34:58,1740422092,9/17/2015 13:33:46,false,prodege,1.0,27934334,GBR,C8,Croydon,81.159.60.206,[OTHER],[OTHER],HEPATITIS B,N/A,139,90,155,164,112,RO-may_prevent,820277-FS1,The serological results of 82 Whites showed that 1.2% were positive for serum hepatitis B SURFACE ANTIGEN (HBSAG) and 21% were positive for SERUM HEPATITIS B ANTIBODY (HBAb).,SERUM HEPATITIS B ANTIBODY,SURFACE ANTIGEN (HBSAG)
790085287,9/17/2015 14:06:17,1740434603,9/17/2015 14:05:42,false,gifthunterclub,1.0,30901412,GBR,H9,London,77.89.149.62,[ASSOCIATED_WITH],[ASSOCIATED_WITH],serological results SURFACE ANTIGEN (HBSAG) SERUM HEPATITIS B ANTIBODY (HBAb).,N/A,139,90,155,164,112,RO-may_prevent,820277-FS1,The serological results of 82 Whites showed that 1.2% were positive for serum hepatitis B SURFACE ANTIGEN (HBSAG) and 21% were positive for SERUM HEPATITIS B ANTIBODY (HBAb).,SERUM HEPATITIS B ANTIBODY,SURFACE ANTIGEN (HBSAG)
790085287,9/17/2015 14:13:07,1740437069,9/17/2015 14:12:18,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.124.79,[IS_A] [DIAGNOSE_BY_TEST_OR_DRUG],"[DIAGNOSE_BY_TEST_OR_DRUG]
[IS_A]",serological results,N/A,139,90,155,164,112,RO-may_prevent,820277-FS1,The serological results of 82 Whites showed that 1.2% were positive for serum hepatitis B SURFACE ANTIGEN (HBSAG) and 21% were positive for SERUM HEPATITIS B ANTIBODY (HBAb).,SERUM HEPATITIS B ANTIBODY,SURFACE ANTIGEN (HBSAG)
790085287,9/17/2015 14:15:25,1740437909,9/17/2015 14:13:48,false,zoombucks,1.0,6744840,CAN,BC,Kelowna,174.4.58.160,[ASSOCIATED_WITH],[ASSOCIATED_WITH],positive and positive,N/A,139,90,155,164,112,RO-may_prevent,820277-FS1,The serological results of 82 Whites showed that 1.2% were positive for serum hepatitis B SURFACE ANTIGEN (HBSAG) and 21% were positive for SERUM HEPATITIS B ANTIBODY (HBAb).,SERUM HEPATITIS B ANTIBODY,SURFACE ANTIGEN (HBSAG)
790085287,9/17/2015 14:16:11,1740438257,9/17/2015 14:15:53,false,neodev,1.0,31329809,USA,DE,Wilmington,162.223.93.194,[PART_OF],[PART_OF],of,N/A,139,90,155,164,112,RO-may_prevent,820277-FS1,The serological results of 82 Whites showed that 1.2% were positive for serum hepatitis B SURFACE ANTIGEN (HBSAG) and 21% were positive for SERUM HEPATITIS B ANTIBODY (HBAb).,SERUM HEPATITIS B ANTIBODY,SURFACE ANTIGEN (HBSAG)
790085287,9/17/2015 14:32:44,1740444349,9/17/2015 14:32:21,false,bitcoinget,1.0,32306192,USA,MA,Amherst,72.19.88.245,[ASSOCIATED_WITH],[ASSOCIATED_WITH],SERUM HEPATITIS,N/a,139,90,155,164,112,RO-may_prevent,820277-FS1,The serological results of 82 Whites showed that 1.2% were positive for serum hepatitis B SURFACE ANTIGEN (HBSAG) and 21% were positive for SERUM HEPATITIS B ANTIBODY (HBAb).,SERUM HEPATITIS B ANTIBODY,SURFACE ANTIGEN (HBSAG)
790085287,9/17/2015 14:41:42,1740447894,9/17/2015 14:40:32,false,clixsense,1.0,32049531,USA,"","",38.95.108.252,[NONE],[NONE],none,none,139,90,155,164,112,RO-may_prevent,820277-FS1,The serological results of 82 Whites showed that 1.2% were positive for serum hepatitis B SURFACE ANTIGEN (HBSAG) and 21% were positive for SERUM HEPATITIS B ANTIBODY (HBAb).,SERUM HEPATITIS B ANTIBODY,SURFACE ANTIGEN (HBSAG)
790085287,9/17/2015 14:48:39,1740450749,9/17/2015 14:47:45,false,instagc,1.0,22981457,CAN,ON,Ottawa,67.69.8.122,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],positive for serum,N/A,139,90,155,164,112,RO-may_prevent,820277-FS1,The serological results of 82 Whites showed that 1.2% were positive for serum hepatitis B SURFACE ANTIGEN (HBSAG) and 21% were positive for SERUM HEPATITIS B ANTIBODY (HBAb).,SERUM HEPATITIS B ANTIBODY,SURFACE ANTIGEN (HBSAG)
790085287,9/17/2015 14:56:39,1740453631,9/17/2015 14:55:56,false,clixsense,1.0,33115750,GBR,I3,Rochester,90.222.106.192,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],results showed,N/A,139,90,155,164,112,RO-may_prevent,820277-FS1,The serological results of 82 Whites showed that 1.2% were positive for serum hepatitis B SURFACE ANTIGEN (HBSAG) and 21% were positive for SERUM HEPATITIS B ANTIBODY (HBAb).,SERUM HEPATITIS B ANTIBODY,SURFACE ANTIGEN (HBSAG)
790085287,9/17/2015 15:11:04,1740458593,9/17/2015 15:10:53,false,neodev,1.0,34431172,USA,CA,Torrance,66.171.228.183,[CAUSES] [LOCATION] [NONE],"[CAUSES]
[LOCATION]
[NONE]",no,no,139,90,155,164,112,RO-may_prevent,820277-FS1,The serological results of 82 Whites showed that 1.2% were positive for serum hepatitis B SURFACE ANTIGEN (HBSAG) and 21% were positive for SERUM HEPATITIS B ANTIBODY (HBAb).,SERUM HEPATITIS B ANTIBODY,SURFACE ANTIGEN (HBSAG)
790085287,9/17/2015 15:12:26,1740459020,9/17/2015 15:12:07,false,neodev,1.0,30321275,USA,NV,Las Vegas,192.30.80.4,[OTHER],[OTHER],(HBAb).,N/A,139,90,155,164,112,RO-may_prevent,820277-FS1,The serological results of 82 Whites showed that 1.2% were positive for serum hepatitis B SURFACE ANTIGEN (HBSAG) and 21% were positive for SERUM HEPATITIS B ANTIBODY (HBAb).,SERUM HEPATITIS B ANTIBODY,SURFACE ANTIGEN (HBSAG)
790085287,9/17/2015 15:17:41,1740460750,9/17/2015 15:17:20,false,neodev,1.0,29363385,USA,DE,Wilmington,162.223.93.162,[PART_OF],[PART_OF],of,N/A,139,90,155,164,112,RO-may_prevent,820277-FS1,The serological results of 82 Whites showed that 1.2% were positive for serum hepatitis B SURFACE ANTIGEN (HBSAG) and 21% were positive for SERUM HEPATITIS B ANTIBODY (HBAb).,SERUM HEPATITIS B ANTIBODY,SURFACE ANTIGEN (HBSAG)
790085288,9/17/2015 09:08:47,1740361534,9/17/2015 09:08:08,false,neodev,1.0,32053642,GBR,I7,Newcastle Upon Tyne,92.23.136.205,[TREATS],[TREATS],which acts directly on cells),N/A,284,224,293,291,238,RO-may_treat,820036-FS1,"Pituitary, anterior  Front portion of small gland below hypothalamus  Influences growth, sexual development, skin pigmentation, thyroid function, adrenocortical function through effects on other endocrine glands (except for GROWTH HORMONE which acts directly on cells)  Hypofunction: DWARFISM in child; decrease in all other endocrine gland functions except parathyroids Hyperfunction: Acromegaly in adult; giantism in child Pituitary, posterior  Back portion of small gland below hypothalamus  Oxytocin increases uterine contraction  Hypofunction: Diabetes insipidus Antidiuretic hormone increases absorption of water by kidney tubule  Hyperfunction: Unknown Testes and ovaries  Testes.",DWARFISM,GROWTH HORMONE
790085288,9/17/2015 09:09:44,1740361695,9/17/2015 09:08:08,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[CAUSES],[CAUSES],acts,N/A,284,224,293,291,238,RO-may_treat,820036-FS1,"Pituitary, anterior  Front portion of small gland below hypothalamus  Influences growth, sexual development, skin pigmentation, thyroid function, adrenocortical function through effects on other endocrine glands (except for GROWTH HORMONE which acts directly on cells)  Hypofunction: DWARFISM in child; decrease in all other endocrine gland functions except parathyroids Hyperfunction: Acromegaly in adult; giantism in child Pituitary, posterior  Back portion of small gland below hypothalamus  Oxytocin increases uterine contraction  Hypofunction: Diabetes insipidus Antidiuretic hormone increases absorption of water by kidney tubule  Hyperfunction: Unknown Testes and ovaries  Testes.",DWARFISM,GROWTH HORMONE
790085288,9/17/2015 09:11:20,1740362023,9/17/2015 09:10:51,false,clixsense,1,19162475,GBR,P8,Trowbridge,82.33.126.30,[TREATS],[TREATS],Hypofunction:,n/a,284,224,293,291,238,RO-may_treat,820036-FS1,"Pituitary, anterior  Front portion of small gland below hypothalamus  Influences growth, sexual development, skin pigmentation, thyroid function, adrenocortical function through effects on other endocrine glands (except for GROWTH HORMONE which acts directly on cells)  Hypofunction: DWARFISM in child; decrease in all other endocrine gland functions except parathyroids Hyperfunction: Acromegaly in adult; giantism in child Pituitary, posterior  Back portion of small gland below hypothalamus  Oxytocin increases uterine contraction  Hypofunction: Diabetes insipidus Antidiuretic hormone increases absorption of water by kidney tubule  Hyperfunction: Unknown Testes and ovaries  Testes.",DWARFISM,GROWTH HORMONE
790085288,9/17/2015 09:12:34,1740362366,9/17/2015 09:12:14,false,elite,1.0,30659754,USA,"","",162.250.145.204,[OTHER],[OTHER],acts,N/A,284,224,293,291,238,RO-may_treat,820036-FS1,"Pituitary, anterior  Front portion of small gland below hypothalamus  Influences growth, sexual development, skin pigmentation, thyroid function, adrenocortical function through effects on other endocrine glands (except for GROWTH HORMONE which acts directly on cells)  Hypofunction: DWARFISM in child; decrease in all other endocrine gland functions except parathyroids Hyperfunction: Acromegaly in adult; giantism in child Pituitary, posterior  Back portion of small gland below hypothalamus  Oxytocin increases uterine contraction  Hypofunction: Diabetes insipidus Antidiuretic hormone increases absorption of water by kidney tubule  Hyperfunction: Unknown Testes and ovaries  Testes.",DWARFISM,GROWTH HORMONE
790085288,9/17/2015 09:15:08,1740362981,9/17/2015 09:13:21,false,neodev,1.0,33644825,USA,FL,Fort Lauderdale,65.111.173.161,[TREATS],[TREATS],GROWTH HORMONE DWARFISM Hyperfunction:,cause,284,224,293,291,238,RO-may_treat,820036-FS1,"Pituitary, anterior  Front portion of small gland below hypothalamus  Influences growth, sexual development, skin pigmentation, thyroid function, adrenocortical function through effects on other endocrine glands (except for GROWTH HORMONE which acts directly on cells)  Hypofunction: DWARFISM in child; decrease in all other endocrine gland functions except parathyroids Hyperfunction: Acromegaly in adult; giantism in child Pituitary, posterior  Back portion of small gland below hypothalamus  Oxytocin increases uterine contraction  Hypofunction: Diabetes insipidus Antidiuretic hormone increases absorption of water by kidney tubule  Hyperfunction: Unknown Testes and ovaries  Testes.",DWARFISM,GROWTH HORMONE
790085288,9/17/2015 09:16:30,1740363272,9/17/2015 09:16:00,false,instagc,1.0,18960682,GBR,U2,Annan,92.18.213.181,[TREATS],[TREATS],GROWTH HORMONE acts directly on cells),N/A,284,224,293,291,238,RO-may_treat,820036-FS1,"Pituitary, anterior  Front portion of small gland below hypothalamus  Influences growth, sexual development, skin pigmentation, thyroid function, adrenocortical function through effects on other endocrine glands (except for GROWTH HORMONE which acts directly on cells)  Hypofunction: DWARFISM in child; decrease in all other endocrine gland functions except parathyroids Hyperfunction: Acromegaly in adult; giantism in child Pituitary, posterior  Back portion of small gland below hypothalamus  Oxytocin increases uterine contraction  Hypofunction: Diabetes insipidus Antidiuretic hormone increases absorption of water by kidney tubule  Hyperfunction: Unknown Testes and ovaries  Testes.",DWARFISM,GROWTH HORMONE
790085288,9/17/2015 09:16:31,1740363276,9/17/2015 09:15:39,false,neodev,1.0,15848372,AUS,02,Jannali,14.200.59.55,[CONTRAINDICATES],[CONTRAINDICATES],Hypofunction:,n/a,284,224,293,291,238,RO-may_treat,820036-FS1,"Pituitary, anterior  Front portion of small gland below hypothalamus  Influences growth, sexual development, skin pigmentation, thyroid function, adrenocortical function through effects on other endocrine glands (except for GROWTH HORMONE which acts directly on cells)  Hypofunction: DWARFISM in child; decrease in all other endocrine gland functions except parathyroids Hyperfunction: Acromegaly in adult; giantism in child Pituitary, posterior  Back portion of small gland below hypothalamus  Oxytocin increases uterine contraction  Hypofunction: Diabetes insipidus Antidiuretic hormone increases absorption of water by kidney tubule  Hyperfunction: Unknown Testes and ovaries  Testes.",DWARFISM,GROWTH HORMONE
790085288,9/17/2015 09:17:12,1740363420,9/17/2015 09:16:17,false,neodev,1,30627835,GBR,D8,Bishop Auckland,217.44.84.223,[NONE],[NONE],N/A,"The words appear in two different sentences, they are not related.",284,224,293,291,238,RO-may_treat,820036-FS1,"Pituitary, anterior  Front portion of small gland below hypothalamus  Influences growth, sexual development, skin pigmentation, thyroid function, adrenocortical function through effects on other endocrine glands (except for GROWTH HORMONE which acts directly on cells)  Hypofunction: DWARFISM in child; decrease in all other endocrine gland functions except parathyroids Hyperfunction: Acromegaly in adult; giantism in child Pituitary, posterior  Back portion of small gland below hypothalamus  Oxytocin increases uterine contraction  Hypofunction: Diabetes insipidus Antidiuretic hormone increases absorption of water by kidney tubule  Hyperfunction: Unknown Testes and ovaries  Testes.",DWARFISM,GROWTH HORMONE
790085288,9/17/2015 09:21:47,1740364405,9/17/2015 09:20:27,false,pocketmoneygpt,1.0,21432964,GBR,F8,Borehamwood,81.159.185.70,[ASSOCIATED_WITH],[ASSOCIATED_WITH],which acts directly on cells),N/A,284,224,293,291,238,RO-may_treat,820036-FS1,"Pituitary, anterior  Front portion of small gland below hypothalamus  Influences growth, sexual development, skin pigmentation, thyroid function, adrenocortical function through effects on other endocrine glands (except for GROWTH HORMONE which acts directly on cells)  Hypofunction: DWARFISM in child; decrease in all other endocrine gland functions except parathyroids Hyperfunction: Acromegaly in adult; giantism in child Pituitary, posterior  Back portion of small gland below hypothalamus  Oxytocin increases uterine contraction  Hypofunction: Diabetes insipidus Antidiuretic hormone increases absorption of water by kidney tubule  Hyperfunction: Unknown Testes and ovaries  Testes.",DWARFISM,GROWTH HORMONE
790085288,9/17/2015 09:27:03,1740365351,9/17/2015 09:26:46,false,elite,1.0,30659615,USA,"","",162.250.145.234,[SYMPTOM],[SYMPTOM],in child;,N/A,284,224,293,291,238,RO-may_treat,820036-FS1,"Pituitary, anterior  Front portion of small gland below hypothalamus  Influences growth, sexual development, skin pigmentation, thyroid function, adrenocortical function through effects on other endocrine glands (except for GROWTH HORMONE which acts directly on cells)  Hypofunction: DWARFISM in child; decrease in all other endocrine gland functions except parathyroids Hyperfunction: Acromegaly in adult; giantism in child Pituitary, posterior  Back portion of small gland below hypothalamus  Oxytocin increases uterine contraction  Hypofunction: Diabetes insipidus Antidiuretic hormone increases absorption of water by kidney tubule  Hyperfunction: Unknown Testes and ovaries  Testes.",DWARFISM,GROWTH HORMONE
790085288,9/17/2015 09:31:13,1740366347,9/17/2015 09:30:04,false,neodev,1.0,21515166,NLD,11,Nieuwkoop,83.84.200.25,[SYMPTOM] [MANIFESTATION],"[SYMPTOM]
[MANIFESTATION]",decrease,n/a,284,224,293,291,238,RO-may_treat,820036-FS1,"Pituitary, anterior  Front portion of small gland below hypothalamus  Influences growth, sexual development, skin pigmentation, thyroid function, adrenocortical function through effects on other endocrine glands (except for GROWTH HORMONE which acts directly on cells)  Hypofunction: DWARFISM in child; decrease in all other endocrine gland functions except parathyroids Hyperfunction: Acromegaly in adult; giantism in child Pituitary, posterior  Back portion of small gland below hypothalamus  Oxytocin increases uterine contraction  Hypofunction: Diabetes insipidus Antidiuretic hormone increases absorption of water by kidney tubule  Hyperfunction: Unknown Testes and ovaries  Testes.",DWARFISM,GROWTH HORMONE
790085288,9/17/2015 09:41:40,1740368957,9/17/2015 09:40:13,false,neodev,1.0,34081836,USA,CA,San Jose,23.27.248.146,[SYMPTOM] [MANIFESTATION],"[SYMPTOM]
[MANIFESTATION]",(except for GROWTH HORMONE which acts directly on cells) Hypofunction: DWARFISM child;,N/A,284,224,293,291,238,RO-may_treat,820036-FS1,"Pituitary, anterior  Front portion of small gland below hypothalamus  Influences growth, sexual development, skin pigmentation, thyroid function, adrenocortical function through effects on other endocrine glands (except for GROWTH HORMONE which acts directly on cells)  Hypofunction: DWARFISM in child; decrease in all other endocrine gland functions except parathyroids Hyperfunction: Acromegaly in adult; giantism in child Pituitary, posterior  Back portion of small gland below hypothalamus  Oxytocin increases uterine contraction  Hypofunction: Diabetes insipidus Antidiuretic hormone increases absorption of water by kidney tubule  Hyperfunction: Unknown Testes and ovaries  Testes.",DWARFISM,GROWTH HORMONE
790085288,9/17/2015 09:45:44,1740369845,9/17/2015 09:42:47,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[ASSOCIATED_WITH],[ASSOCIATED_WITH],GROWTH HORMONE which acts directly on cells) Hypofunction: DWARFISM,N/A,284,224,293,291,238,RO-may_treat,820036-FS1,"Pituitary, anterior  Front portion of small gland below hypothalamus  Influences growth, sexual development, skin pigmentation, thyroid function, adrenocortical function through effects on other endocrine glands (except for GROWTH HORMONE which acts directly on cells)  Hypofunction: DWARFISM in child; decrease in all other endocrine gland functions except parathyroids Hyperfunction: Acromegaly in adult; giantism in child Pituitary, posterior  Back portion of small gland below hypothalamus  Oxytocin increases uterine contraction  Hypofunction: Diabetes insipidus Antidiuretic hormone increases absorption of water by kidney tubule  Hyperfunction: Unknown Testes and ovaries  Testes.",DWARFISM,GROWTH HORMONE
790085288,9/17/2015 09:46:31,1740369964,9/17/2015 09:46:10,false,elite,1.0,30659677,USA,"","",162.252.172.126,[SYMPTOM],[SYMPTOM],Hypofunction:,N/A,284,224,293,291,238,RO-may_treat,820036-FS1,"Pituitary, anterior  Front portion of small gland below hypothalamus  Influences growth, sexual development, skin pigmentation, thyroid function, adrenocortical function through effects on other endocrine glands (except for GROWTH HORMONE which acts directly on cells)  Hypofunction: DWARFISM in child; decrease in all other endocrine gland functions except parathyroids Hyperfunction: Acromegaly in adult; giantism in child Pituitary, posterior  Back portion of small gland below hypothalamus  Oxytocin increases uterine contraction  Hypofunction: Diabetes insipidus Antidiuretic hormone increases absorption of water by kidney tubule  Hyperfunction: Unknown Testes and ovaries  Testes.",DWARFISM,GROWTH HORMONE
790085288,9/17/2015 10:24:55,1740378827,9/17/2015 10:24:19,false,pocketmoneygpt,1.0,28884030,USA,WI,Minocqua,75.143.134.247,[PREVENTS],[PREVENTS],acts directly,n/a,284,224,293,291,238,RO-may_treat,820036-FS1,"Pituitary, anterior  Front portion of small gland below hypothalamus  Influences growth, sexual development, skin pigmentation, thyroid function, adrenocortical function through effects on other endocrine glands (except for GROWTH HORMONE which acts directly on cells)  Hypofunction: DWARFISM in child; decrease in all other endocrine gland functions except parathyroids Hyperfunction: Acromegaly in adult; giantism in child Pituitary, posterior  Back portion of small gland below hypothalamus  Oxytocin increases uterine contraction  Hypofunction: Diabetes insipidus Antidiuretic hormone increases absorption of water by kidney tubule  Hyperfunction: Unknown Testes and ovaries  Testes.",DWARFISM,GROWTH HORMONE
790085289,9/17/2015 13:33:27,1740421606,9/17/2015 13:33:02,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],recorded together,n/a,22,4,42,25,36,RO-may_prevent,820278-FS1,"The CAPSAICIN INDUCED PAIN INTENSITY pain area, the area of secondary hyperalgesia, the area of visible flare and vasomotor reactions were recorded together with cutaneous heat, electrical and pressure PAIN thresholds.",PAIN,CAPSAICIN INDUCED PAIN INTENSITY
790085289,9/17/2015 13:39:59,1740425810,9/17/2015 13:39:23,false,prodege,1.0,27934334,GBR,C8,Croydon,81.159.60.206,[IS_A],[IS_A],pain,N/A,22,4,42,25,36,RO-may_prevent,820278-FS1,"The CAPSAICIN INDUCED PAIN INTENSITY pain area, the area of secondary hyperalgesia, the area of visible flare and vasomotor reactions were recorded together with cutaneous heat, electrical and pressure PAIN thresholds.",PAIN,CAPSAICIN INDUCED PAIN INTENSITY
790085289,9/17/2015 14:08:53,1740435604,9/17/2015 14:08:27,false,gifthunterclub,1.0,30901412,GBR,H9,London,77.89.149.62,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"CAPSAICIN INDUCED PAIN INTENSITY secondary hyperalgesia, pressure PAIN thresholds.",N/A,22,4,42,25,36,RO-may_prevent,820278-FS1,"The CAPSAICIN INDUCED PAIN INTENSITY pain area, the area of secondary hyperalgesia, the area of visible flare and vasomotor reactions were recorded together with cutaneous heat, electrical and pressure PAIN thresholds.",PAIN,CAPSAICIN INDUCED PAIN INTENSITY
790085289,9/17/2015 14:15:27,1740437925,9/17/2015 14:14:54,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.124.79,[IS_A],[IS_A],thresholds.,N/A,22,4,42,25,36,RO-may_prevent,820278-FS1,"The CAPSAICIN INDUCED PAIN INTENSITY pain area, the area of secondary hyperalgesia, the area of visible flare and vasomotor reactions were recorded together with cutaneous heat, electrical and pressure PAIN thresholds.",PAIN,CAPSAICIN INDUCED PAIN INTENSITY
790085289,9/17/2015 14:21:59,1740440256,9/17/2015 14:20:25,false,zoombucks,1.0,6744840,CAN,BC,Kelowna,174.4.58.160,[IS_A],[IS_A],thresholds.,N/A,22,4,42,25,36,RO-may_prevent,820278-FS1,"The CAPSAICIN INDUCED PAIN INTENSITY pain area, the area of secondary hyperalgesia, the area of visible flare and vasomotor reactions were recorded together with cutaneous heat, electrical and pressure PAIN thresholds.",PAIN,CAPSAICIN INDUCED PAIN INTENSITY
790085289,9/17/2015 14:34:19,1740444862,9/17/2015 14:34:01,false,bitcoinget,1.0,32306192,USA,MA,Amherst,72.19.88.245,[TREATS],[TREATS],PAIN,N/a,22,4,42,25,36,RO-may_prevent,820278-FS1,"The CAPSAICIN INDUCED PAIN INTENSITY pain area, the area of secondary hyperalgesia, the area of visible flare and vasomotor reactions were recorded together with cutaneous heat, electrical and pressure PAIN thresholds.",PAIN,CAPSAICIN INDUCED PAIN INTENSITY
790085289,9/17/2015 14:49:09,1740450942,9/17/2015 14:48:17,false,clixsense,1.0,32049531,USA,"","",38.95.108.252,[NONE],[NONE],none,none,22,4,42,25,36,RO-may_prevent,820278-FS1,"The CAPSAICIN INDUCED PAIN INTENSITY pain area, the area of secondary hyperalgesia, the area of visible flare and vasomotor reactions were recorded together with cutaneous heat, electrical and pressure PAIN thresholds.",PAIN,CAPSAICIN INDUCED PAIN INTENSITY
790085289,9/17/2015 14:52:26,1740452186,9/17/2015 14:52:04,false,instagc,1.0,22981457,CAN,ON,Ottawa,67.69.8.122,[NONE],[NONE],N/A,They were recording data,22,4,42,25,36,RO-may_prevent,820278-FS1,"The CAPSAICIN INDUCED PAIN INTENSITY pain area, the area of secondary hyperalgesia, the area of visible flare and vasomotor reactions were recorded together with cutaneous heat, electrical and pressure PAIN thresholds.",PAIN,CAPSAICIN INDUCED PAIN INTENSITY
790085289,9/17/2015 15:01:50,1740455611,9/17/2015 15:00:16,false,clixsense,1.0,33115750,GBR,I3,Rochester,90.222.106.192,[SYMPTOM] [DIAGNOSE_BY_TEST_OR_DRUG],"[DIAGNOSE_BY_TEST_OR_DRUG]
[SYMPTOM]",reactions were recorded,N/A,22,4,42,25,36,RO-may_prevent,820278-FS1,"The CAPSAICIN INDUCED PAIN INTENSITY pain area, the area of secondary hyperalgesia, the area of visible flare and vasomotor reactions were recorded together with cutaneous heat, electrical and pressure PAIN thresholds.",PAIN,CAPSAICIN INDUCED PAIN INTENSITY
790085289,9/17/2015 15:02:41,1740456005,9/17/2015 15:02:22,false,neodev,1.0,31329809,USA,DE,Wilmington,162.223.93.194,[PART_OF] [ASSOCIATED_WITH],"[ASSOCIATED_WITH]
[PART_OF]",of of with,N/A,22,4,42,25,36,RO-may_prevent,820278-FS1,"The CAPSAICIN INDUCED PAIN INTENSITY pain area, the area of secondary hyperalgesia, the area of visible flare and vasomotor reactions were recorded together with cutaneous heat, electrical and pressure PAIN thresholds.",PAIN,CAPSAICIN INDUCED PAIN INTENSITY
790085289,9/17/2015 15:12:28,1740459022,9/17/2015 15:12:15,false,neodev,1.0,34431172,USA,CA,Torrance,66.171.228.183,[CAUSES] [NONE],"[CAUSES]
[NONE]",no,no,22,4,42,25,36,RO-may_prevent,820278-FS1,"The CAPSAICIN INDUCED PAIN INTENSITY pain area, the area of secondary hyperalgesia, the area of visible flare and vasomotor reactions were recorded together with cutaneous heat, electrical and pressure PAIN thresholds.",PAIN,CAPSAICIN INDUCED PAIN INTENSITY
790085289,9/17/2015 15:14:00,1740459512,9/17/2015 15:13:44,false,neodev,1.0,30321275,USA,NV,Las Vegas,192.30.80.4,[PART_OF] [ASSOCIATED_WITH],"[ASSOCIATED_WITH]
[PART_OF]",of of with,N/A,22,4,42,25,36,RO-may_prevent,820278-FS1,"The CAPSAICIN INDUCED PAIN INTENSITY pain area, the area of secondary hyperalgesia, the area of visible flare and vasomotor reactions were recorded together with cutaneous heat, electrical and pressure PAIN thresholds.",PAIN,CAPSAICIN INDUCED PAIN INTENSITY
790085289,9/17/2015 15:19:25,1740461616,9/17/2015 15:19:08,false,neodev,1.0,29363385,USA,DE,Wilmington,162.223.93.162,[PART_OF] [ASSOCIATED_WITH],"[ASSOCIATED_WITH]
[PART_OF]",of with,N/A,22,4,42,25,36,RO-may_prevent,820278-FS1,"The CAPSAICIN INDUCED PAIN INTENSITY pain area, the area of secondary hyperalgesia, the area of visible flare and vasomotor reactions were recorded together with cutaneous heat, electrical and pressure PAIN thresholds.",PAIN,CAPSAICIN INDUCED PAIN INTENSITY
790085289,9/17/2015 15:22:34,1740462777,9/17/2015 15:21:22,false,neodev,1.0,12115558,USA,OH,Twinsburg,98.27.164.131,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],were recorded together,N/A,22,4,42,25,36,RO-may_prevent,820278-FS1,"The CAPSAICIN INDUCED PAIN INTENSITY pain area, the area of secondary hyperalgesia, the area of visible flare and vasomotor reactions were recorded together with cutaneous heat, electrical and pressure PAIN thresholds.",PAIN,CAPSAICIN INDUCED PAIN INTENSITY
790085289,9/17/2015 15:26:29,1740464131,9/17/2015 15:26:08,false,neodev,1.0,33435788,USA,DE,Wilmington,162.223.93.179,[PART_OF] [ASSOCIATED_WITH],"[ASSOCIATED_WITH]
[PART_OF]",of of with,N/A,22,4,42,25,36,RO-may_prevent,820278-FS1,"The CAPSAICIN INDUCED PAIN INTENSITY pain area, the area of secondary hyperalgesia, the area of visible flare and vasomotor reactions were recorded together with cutaneous heat, electrical and pressure PAIN thresholds.",PAIN,CAPSAICIN INDUCED PAIN INTENSITY
790085290,9/17/2015 09:10:15,1740361769,9/17/2015 09:09:49,false,neodev,1.0,32053642,GBR,I7,Newcastle Upon Tyne,92.23.136.205,[TREATS],[TREATS],reductions,N/A,77,140,90,96,158,RO-may_prevent,820311-FS1,"Dose dependent increases in cold and cold pain thresholds, and reductions in STROKING PAIN SCORES were noted in both the alfentanil and the KETAMINE INFUSIONS.",STROKING PAIN SCORES,KETAMINE INFUSIONS
790085290,9/17/2015 09:11:55,1740362193,9/17/2015 09:11:45,false,clixsense,1.0,19162475,GBR,P8,Trowbridge,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],alfentanil and the,n/a,77,140,90,96,158,RO-may_prevent,820311-FS1,"Dose dependent increases in cold and cold pain thresholds, and reductions in STROKING PAIN SCORES were noted in both the alfentanil and the KETAMINE INFUSIONS.",STROKING PAIN SCORES,KETAMINE INFUSIONS
790085290,9/17/2015 09:13:25,1740362569,9/17/2015 09:13:10,false,elite,1.0,30659754,USA,"","",162.250.145.204,[PREVENTS],[PREVENTS],reductions,N/A,77,140,90,96,158,RO-may_prevent,820311-FS1,"Dose dependent increases in cold and cold pain thresholds, and reductions in STROKING PAIN SCORES were noted in both the alfentanil and the KETAMINE INFUSIONS.",STROKING PAIN SCORES,KETAMINE INFUSIONS
790085290,9/17/2015 09:13:34,1740362603,9/17/2015 09:12:51,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[TREATS],[TREATS],INFUSIONS.,N/A,77,140,90,96,158,RO-may_prevent,820311-FS1,"Dose dependent increases in cold and cold pain thresholds, and reductions in STROKING PAIN SCORES were noted in both the alfentanil and the KETAMINE INFUSIONS.",STROKING PAIN SCORES,KETAMINE INFUSIONS
790085290,9/17/2015 09:18:01,1740363567,9/17/2015 09:17:33,false,instagc,1.0,18960682,GBR,U2,Annan,92.18.213.181,[TREATS],[TREATS],Dose dependent,N/A,77,140,90,96,158,RO-may_prevent,820311-FS1,"Dose dependent increases in cold and cold pain thresholds, and reductions in STROKING PAIN SCORES were noted in both the alfentanil and the KETAMINE INFUSIONS.",STROKING PAIN SCORES,KETAMINE INFUSIONS
790085290,9/17/2015 09:18:04,1740363569,9/17/2015 09:17:05,false,neodev,1.0,33644825,USA,FL,Fort Lauderdale,65.111.173.161,[CAUSES],[CAUSES],STROKING PAIN SCORES KETAMINE INFUSIONS.,causes,77,140,90,96,158,RO-may_prevent,820311-FS1,"Dose dependent increases in cold and cold pain thresholds, and reductions in STROKING PAIN SCORES were noted in both the alfentanil and the KETAMINE INFUSIONS.",STROKING PAIN SCORES,KETAMINE INFUSIONS
790085290,9/17/2015 09:18:36,1740363692,9/17/2015 09:17:41,false,neodev,1.0,15848372,AUS,02,Jannali,14.200.59.55,[ASSOCIATED_WITH],[ASSOCIATED_WITH],were noted in,n/a,77,140,90,96,158,RO-may_prevent,820311-FS1,"Dose dependent increases in cold and cold pain thresholds, and reductions in STROKING PAIN SCORES were noted in both the alfentanil and the KETAMINE INFUSIONS.",STROKING PAIN SCORES,KETAMINE INFUSIONS
790085290,9/17/2015 09:20:07,1740364012,9/17/2015 09:18:49,false,neodev,1.0,30627835,GBR,D8,Bishop Auckland,217.44.84.223,[ASSOCIATED_WITH],[ASSOCIATED_WITH],in the,N/A,77,140,90,96,158,RO-may_prevent,820311-FS1,"Dose dependent increases in cold and cold pain thresholds, and reductions in STROKING PAIN SCORES were noted in both the alfentanil and the KETAMINE INFUSIONS.",STROKING PAIN SCORES,KETAMINE INFUSIONS
790085290,9/17/2015 09:26:28,1740365271,9/17/2015 09:25:06,false,pocketmoneygpt,1.0,21432964,GBR,F8,Borehamwood,81.159.185.70,[ASSOCIATED_WITH],[ASSOCIATED_WITH],noted in both,N/A,77,140,90,96,158,RO-may_prevent,820311-FS1,"Dose dependent increases in cold and cold pain thresholds, and reductions in STROKING PAIN SCORES were noted in both the alfentanil and the KETAMINE INFUSIONS.",STROKING PAIN SCORES,KETAMINE INFUSIONS
790085290,9/17/2015 09:27:52,1740365559,9/17/2015 09:27:36,false,elite,1.0,30659615,USA,"","",162.250.145.234,[PREVENTS],[PREVENTS],reductions,N/A,77,140,90,96,158,RO-may_prevent,820311-FS1,"Dose dependent increases in cold and cold pain thresholds, and reductions in STROKING PAIN SCORES were noted in both the alfentanil and the KETAMINE INFUSIONS.",STROKING PAIN SCORES,KETAMINE INFUSIONS
790085290,9/17/2015 09:34:14,1740367131,9/17/2015 09:33:49,false,neodev,1.0,21515166,NLD,11,Nieuwkoop,83.84.200.25,[SYMPTOM],[SYMPTOM],were noted,n/a,77,140,90,96,158,RO-may_prevent,820311-FS1,"Dose dependent increases in cold and cold pain thresholds, and reductions in STROKING PAIN SCORES were noted in both the alfentanil and the KETAMINE INFUSIONS.",STROKING PAIN SCORES,KETAMINE INFUSIONS
790085290,9/17/2015 09:46:07,1740369900,9/17/2015 09:45:10,false,neodev,1.0,34081836,USA,CA,San Jose,23.27.248.146,[SYMPTOM] [CAUSES],"[CAUSES]
[SYMPTOM]",STROKING PAIN SCORES were noted in both the alfentanil and the KETAMINE INFUSIONS.,N/A,77,140,90,96,158,RO-may_prevent,820311-FS1,"Dose dependent increases in cold and cold pain thresholds, and reductions in STROKING PAIN SCORES were noted in both the alfentanil and the KETAMINE INFUSIONS.",STROKING PAIN SCORES,KETAMINE INFUSIONS
790085290,9/17/2015 09:47:22,1740370161,9/17/2015 09:47:05,false,elite,1.0,30659677,USA,"","",162.252.172.126,[SYMPTOM],[SYMPTOM],were noted in both,N/A,77,140,90,96,158,RO-may_prevent,820311-FS1,"Dose dependent increases in cold and cold pain thresholds, and reductions in STROKING PAIN SCORES were noted in both the alfentanil and the KETAMINE INFUSIONS.",STROKING PAIN SCORES,KETAMINE INFUSIONS
790085290,9/17/2015 09:50:38,1740370884,9/17/2015 09:50:13,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[TREATS],[TREATS],and reductions in,N/A,77,140,90,96,158,RO-may_prevent,820311-FS1,"Dose dependent increases in cold and cold pain thresholds, and reductions in STROKING PAIN SCORES were noted in both the alfentanil and the KETAMINE INFUSIONS.",STROKING PAIN SCORES,KETAMINE INFUSIONS
790085290,9/17/2015 10:23:14,1740378413,9/17/2015 10:22:35,false,pocketmoneygpt,1.0,28884030,USA,WI,Minocqua,75.143.134.247,[PREVENTS],[PREVENTS],reductions,n/a,77,140,90,96,158,RO-may_prevent,820311-FS1,"Dose dependent increases in cold and cold pain thresholds, and reductions in STROKING PAIN SCORES were noted in both the alfentanil and the KETAMINE INFUSIONS.",STROKING PAIN SCORES,KETAMINE INFUSIONS
790085291,9/17/2015 11:22:29,1740389804,9/17/2015 11:22:15,false,neodev,1.0,32695853,USA,NV,Las Vegas,192.30.80.172,[PART_OF],[PART_OF],of,N/A,92,57,105,104,67,RO-may_treat,820113-FS1,The correlation between liver cirrhosis and dysbolism of FOLIC ACID and vitamin B12 and the MEGALOBLASTIC changes and clinical significance were discussed.,MEGALOBLASTIC,FOLIC ACID
790085291,9/17/2015 11:25:45,1740390423,9/17/2015 11:24:51,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[OTHER],[OTHER],correlation between,N/A,92,57,105,104,67,RO-may_treat,820113-FS1,The correlation between liver cirrhosis and dysbolism of FOLIC ACID and vitamin B12 and the MEGALOBLASTIC changes and clinical significance were discussed.,MEGALOBLASTIC,FOLIC ACID
790085291,9/17/2015 11:34:01,1740391932,9/17/2015 11:33:48,false,neodev,1.0,30941227,USA,NV,Las Vegas,192.30.80.166,[PART_OF],[PART_OF],of,N/A,92,57,105,104,67,RO-may_treat,820113-FS1,The correlation between liver cirrhosis and dysbolism of FOLIC ACID and vitamin B12 and the MEGALOBLASTIC changes and clinical significance were discussed.,MEGALOBLASTIC,FOLIC ACID
790085291,9/17/2015 11:35:51,1740392209,9/17/2015 11:34:28,false,neodev,1.0,30581619,USA,CA,San Jose,50.118.162.56,[NONE],[NONE],good,good,92,57,105,104,67,RO-may_treat,820113-FS1,The correlation between liver cirrhosis and dysbolism of FOLIC ACID and vitamin B12 and the MEGALOBLASTIC changes and clinical significance were discussed.,MEGALOBLASTIC,FOLIC ACID
790085291,9/17/2015 11:43:20,1740393721,9/17/2015 11:43:11,false,neodev,1.0,33701549,USA,CA,Torrance,66.171.228.66,[MANIFESTATION] [CAUSES] [PREVENTS] [TREATS] [NONE],"[TREATS]
[PREVENTS]
[CAUSES]
[MANIFESTATION]
[NONE]",[IS_A],N/A,92,57,105,104,67,RO-may_treat,820113-FS1,The correlation between liver cirrhosis and dysbolism of FOLIC ACID and vitamin B12 and the MEGALOBLASTIC changes and clinical significance were discussed.,MEGALOBLASTIC,FOLIC ACID
790085291,9/17/2015 12:08:04,1740398809,9/17/2015 12:07:42,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[CAUSES],[CAUSES],correlation,N/A,92,57,105,104,67,RO-may_treat,820113-FS1,The correlation between liver cirrhosis and dysbolism of FOLIC ACID and vitamin B12 and the MEGALOBLASTIC changes and clinical significance were discussed.,MEGALOBLASTIC,FOLIC ACID
790085291,9/17/2015 12:33:40,1740404528,9/17/2015 12:33:19,false,neodev,1.0,30588889,NLD,07,Amsterdam,77.248.175.222,[ASSOCIATED_WITH],[ASSOCIATED_WITH],correlation,N/A,92,57,105,104,67,RO-may_treat,820113-FS1,The correlation between liver cirrhosis and dysbolism of FOLIC ACID and vitamin B12 and the MEGALOBLASTIC changes and clinical significance were discussed.,MEGALOBLASTIC,FOLIC ACID
790085291,9/17/2015 12:42:43,1740406808,9/17/2015 12:41:57,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,[ASSOCIATED_WITH],[ASSOCIATED_WITH],FOLIC ACID and MEGALOBLASTIC changes,na,92,57,105,104,67,RO-may_treat,820113-FS1,The correlation between liver cirrhosis and dysbolism of FOLIC ACID and vitamin B12 and the MEGALOBLASTIC changes and clinical significance were discussed.,MEGALOBLASTIC,FOLIC ACID
790085291,9/17/2015 12:43:25,1740407004,9/17/2015 12:42:55,false,prodege,1.0,2145087,USA,NY,New York,107.107.57.52,[ASSOCIATED_WITH],[ASSOCIATED_WITH],correlation between,N/A,92,57,105,104,67,RO-may_treat,820113-FS1,The correlation between liver cirrhosis and dysbolism of FOLIC ACID and vitamin B12 and the MEGALOBLASTIC changes and clinical significance were discussed.,MEGALOBLASTIC,FOLIC ACID
790085291,9/17/2015 13:16:02,1740416235,9/17/2015 13:15:44,false,elite,1.0,31883685,GBR,"","",79.66.244.188,[ASSOCIATED_WITH],[ASSOCIATED_WITH],correlation,n/a,92,57,105,104,67,RO-may_treat,820113-FS1,The correlation between liver cirrhosis and dysbolism of FOLIC ACID and vitamin B12 and the MEGALOBLASTIC changes and clinical significance were discussed.,MEGALOBLASTIC,FOLIC ACID
790085291,9/17/2015 13:16:20,1740416287,9/17/2015 13:16:04,false,neodev,1.0,33228343,USA,"","",38.95.108.251,[PREVENTS] [SYMPTOM] [MANIFESTATION] [ASSOCIATED_WITH] [IS_A] [NONE],"[PREVENTS]
[SYMPTOM]
[MANIFESTATION]
[ASSOCIATED_WITH]
[IS_A]
[NONE]",The correlation between liver cirrhosis and dysbolism of FOLIC ACID and vitamin B12 and the MEGALOBLASTIC changes and clinical significance were discussed.,The correlation between liver cirrhosis and dysbolism of FOLIC ACID and vitamin B12 and the MEGALOBLASTIC changes and clinical significance were discussed.,92,57,105,104,67,RO-may_treat,820113-FS1,The correlation between liver cirrhosis and dysbolism of FOLIC ACID and vitamin B12 and the MEGALOBLASTIC changes and clinical significance were discussed.,MEGALOBLASTIC,FOLIC ACID
790085291,9/17/2015 13:17:17,1740416551,9/17/2015 13:16:57,false,prodege,1.0,33854929,USA,CT,Wallingford,24.2.218.232,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,n/a,92,57,105,104,67,RO-may_treat,820113-FS1,The correlation between liver cirrhosis and dysbolism of FOLIC ACID and vitamin B12 and the MEGALOBLASTIC changes and clinical significance were discussed.,MEGALOBLASTIC,FOLIC ACID
790085291,9/17/2015 13:21:50,1740418041,9/17/2015 13:21:12,false,neodev,1.0,12115558,USA,OH,Twinsburg,98.27.164.131,[ASSOCIATED_WITH],[ASSOCIATED_WITH],correlation,N/A,92,57,105,104,67,RO-may_treat,820113-FS1,The correlation between liver cirrhosis and dysbolism of FOLIC ACID and vitamin B12 and the MEGALOBLASTIC changes and clinical significance were discussed.,MEGALOBLASTIC,FOLIC ACID
790085291,9/17/2015 13:22:49,1740418373,9/17/2015 13:22:12,false,prodege,1.0,27934334,GBR,C8,Croydon,81.159.60.206,[OTHER] [DIAGNOSE_BY_TEST_OR_DRUG],"[DIAGNOSE_BY_TEST_OR_DRUG]
[OTHER]",correlation between dysbolism,N/A,92,57,105,104,67,RO-may_treat,820113-FS1,The correlation between liver cirrhosis and dysbolism of FOLIC ACID and vitamin B12 and the MEGALOBLASTIC changes and clinical significance were discussed.,MEGALOBLASTIC,FOLIC ACID
790085291,9/17/2015 13:25:37,1740419113,9/17/2015 13:25:18,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],correlation between,n/a,92,57,105,104,67,RO-may_treat,820113-FS1,The correlation between liver cirrhosis and dysbolism of FOLIC ACID and vitamin B12 and the MEGALOBLASTIC changes and clinical significance were discussed.,MEGALOBLASTIC,FOLIC ACID
790085292,9/17/2015 13:33:49,1740421714,9/17/2015 13:33:30,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],suggest existence,n/a,103,184,109,108,196,RO-may_treat,820114-FS1,Excretory patterns after theophylline ingestion before and during the administration of allopurinol in ASTHMA patients and in rats suggest the existence of three metabolic pathways of THEOPHYLLINE.,ASTHMA,THEOPHYLLINE
790085292,9/17/2015 13:40:32,1740425990,9/17/2015 13:39:59,false,prodege,1.0,27934334,GBR,C8,Croydon,81.159.60.206,[TREATS],[TREATS],ingestion,N/A,103,184,109,108,196,RO-may_treat,820114-FS1,Excretory patterns after theophylline ingestion before and during the administration of allopurinol in ASTHMA patients and in rats suggest the existence of three metabolic pathways of THEOPHYLLINE.,ASTHMA,THEOPHYLLINE
790085292,9/17/2015 14:09:25,1740435810,9/17/2015 14:08:54,false,gifthunterclub,1.0,30901412,GBR,H9,London,77.89.149.62,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],ASTHMA patients metabolic pathways of THEOPHYLLINE.,N/A,103,184,109,108,196,RO-may_treat,820114-FS1,Excretory patterns after theophylline ingestion before and during the administration of allopurinol in ASTHMA patients and in rats suggest the existence of three metabolic pathways of THEOPHYLLINE.,ASTHMA,THEOPHYLLINE
790085292,9/17/2015 14:15:51,1740438122,9/17/2015 14:15:27,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.124.79,[TREATS],[TREATS],administration,N/A,103,184,109,108,196,RO-may_treat,820114-FS1,Excretory patterns after theophylline ingestion before and during the administration of allopurinol in ASTHMA patients and in rats suggest the existence of three metabolic pathways of THEOPHYLLINE.,ASTHMA,THEOPHYLLINE
790085292,9/17/2015 14:23:39,1740440840,9/17/2015 14:22:00,false,zoombucks,1.0,6744840,CAN,BC,Kelowna,174.4.58.160,[ASSOCIATED_WITH],[ASSOCIATED_WITH],existence of,N/A,103,184,109,108,196,RO-may_treat,820114-FS1,Excretory patterns after theophylline ingestion before and during the administration of allopurinol in ASTHMA patients and in rats suggest the existence of three metabolic pathways of THEOPHYLLINE.,ASTHMA,THEOPHYLLINE
790085292,9/17/2015 14:34:37,1740444970,9/17/2015 14:34:21,false,bitcoinget,1.0,32306192,USA,MA,Amherst,72.19.88.245,[MANIFESTATION],[MANIFESTATION],THEOPHYLLINE.,N/a,103,184,109,108,196,RO-may_treat,820114-FS1,Excretory patterns after theophylline ingestion before and during the administration of allopurinol in ASTHMA patients and in rats suggest the existence of three metabolic pathways of THEOPHYLLINE.,ASTHMA,THEOPHYLLINE
790085292,9/17/2015 14:50:10,1740451365,9/17/2015 14:49:10,false,clixsense,1.0,32049531,USA,"","",38.95.108.252,[NONE],[NONE],none,none,103,184,109,108,196,RO-may_treat,820114-FS1,Excretory patterns after theophylline ingestion before and during the administration of allopurinol in ASTHMA patients and in rats suggest the existence of three metabolic pathways of THEOPHYLLINE.,ASTHMA,THEOPHYLLINE
790085292,9/17/2015 14:54:13,1740452820,9/17/2015 14:52:26,false,instagc,1.0,22981457,CAN,ON,Ottawa,67.69.8.122,[ASSOCIATED_WITH],[ASSOCIATED_WITH],suggest existence of,N/A,103,184,109,108,196,RO-may_treat,820114-FS1,Excretory patterns after theophylline ingestion before and during the administration of allopurinol in ASTHMA patients and in rats suggest the existence of three metabolic pathways of THEOPHYLLINE.,ASTHMA,THEOPHYLLINE
790085292,9/17/2015 15:02:59,1740456146,9/17/2015 15:02:43,false,neodev,1.0,31329809,USA,DE,Wilmington,162.223.93.194,[PART_OF],[PART_OF],of of of,N/A,103,184,109,108,196,RO-may_treat,820114-FS1,Excretory patterns after theophylline ingestion before and during the administration of allopurinol in ASTHMA patients and in rats suggest the existence of three metabolic pathways of THEOPHYLLINE.,ASTHMA,THEOPHYLLINE
790085292,9/17/2015 15:02:59,1740456150,9/17/2015 15:01:52,false,clixsense,1.0,33115750,GBR,I3,Rochester,90.222.106.192,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],Excretory patterns after ingestion,N/A,103,184,109,108,196,RO-may_treat,820114-FS1,Excretory patterns after theophylline ingestion before and during the administration of allopurinol in ASTHMA patients and in rats suggest the existence of three metabolic pathways of THEOPHYLLINE.,ASTHMA,THEOPHYLLINE
790085292,9/17/2015 15:12:47,1740459116,9/17/2015 15:12:32,false,neodev,1.0,34431172,USA,CA,Torrance,66.171.228.183,[LOCATION] [MANIFESTATION] [NONE],"[LOCATION]
[MANIFESTATION]
[NONE]",no,no,103,184,109,108,196,RO-may_treat,820114-FS1,Excretory patterns after theophylline ingestion before and during the administration of allopurinol in ASTHMA patients and in rats suggest the existence of three metabolic pathways of THEOPHYLLINE.,ASTHMA,THEOPHYLLINE
790085292,9/17/2015 15:14:16,1740459586,9/17/2015 15:14:03,false,neodev,1.0,30321275,USA,NV,Las Vegas,192.30.80.4,[PART_OF],[PART_OF],of of of,N/A,103,184,109,108,196,RO-may_treat,820114-FS1,Excretory patterns after theophylline ingestion before and during the administration of allopurinol in ASTHMA patients and in rats suggest the existence of three metabolic pathways of THEOPHYLLINE.,ASTHMA,THEOPHYLLINE
790085292,9/17/2015 15:20:00,1740461851,9/17/2015 15:19:44,false,neodev,1.0,29363385,USA,DE,Wilmington,162.223.93.162,[PART_OF],[PART_OF],of of of,N/A,103,184,109,108,196,RO-may_treat,820114-FS1,Excretory patterns after theophylline ingestion before and during the administration of allopurinol in ASTHMA patients and in rats suggest the existence of three metabolic pathways of THEOPHYLLINE.,ASTHMA,THEOPHYLLINE
790085292,9/17/2015 15:23:10,1740462938,9/17/2015 15:22:35,false,neodev,1.0,12115558,USA,OH,Twinsburg,98.27.164.131,[LOCATION] [SYMPTOM],"[LOCATION]
[SYMPTOM]",suggest the existence three metabolic pathways,N/A,103,184,109,108,196,RO-may_treat,820114-FS1,Excretory patterns after theophylline ingestion before and during the administration of allopurinol in ASTHMA patients and in rats suggest the existence of three metabolic pathways of THEOPHYLLINE.,ASTHMA,THEOPHYLLINE
790085292,9/17/2015 15:26:50,1740464295,9/17/2015 15:26:31,false,neodev,1.0,33435788,USA,DE,Wilmington,162.223.93.179,[PART_OF],[PART_OF],of of of,N/A,103,184,109,108,196,RO-may_treat,820114-FS1,Excretory patterns after theophylline ingestion before and during the administration of allopurinol in ASTHMA patients and in rats suggest the existence of three metabolic pathways of THEOPHYLLINE.,ASTHMA,THEOPHYLLINE
790085293,9/17/2015 10:51:53,1740384089,9/17/2015 10:51:40,false,clixsense,1.0,17950689,GBR,L9,Sheffield,146.200.192.103,[TREATS],[TREATS],ASTHMA,NONE,151,168,157,156,179,RO-may_prevent,820236-FS1,"Wechsler ME, Garpestad E, Flier SR et al. Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with ASTHMA receiving ZAFIRLUKAST",ASTHMA,ZAFIRLUKAST
790085293,9/17/2015 11:02:22,1740386031,9/17/2015 11:02:05,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],receiving,N/A,151,168,157,156,179,RO-may_prevent,820236-FS1,"Wechsler ME, Garpestad E, Flier SR et al. Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with ASTHMA receiving ZAFIRLUKAST",ASTHMA,ZAFIRLUKAST
790085293,9/17/2015 11:07:02,1740386972,9/17/2015 11:06:46,false,neodev,1.0,30941227,USA,NV,Las Vegas,192.30.80.166,[SIDE_EFFECT],[SIDE_EFFECT],with,N/A,151,168,157,156,179,RO-may_prevent,820236-FS1,"Wechsler ME, Garpestad E, Flier SR et al. Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with ASTHMA receiving ZAFIRLUKAST",ASTHMA,ZAFIRLUKAST
790085293,9/17/2015 11:07:15,1740387011,9/17/2015 11:06:01,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",receiving,N/A,151,168,157,156,179,RO-may_prevent,820236-FS1,"Wechsler ME, Garpestad E, Flier SR et al. Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with ASTHMA receiving ZAFIRLUKAST",ASTHMA,ZAFIRLUKAST
790085293,9/17/2015 11:12:55,1740388128,9/17/2015 11:10:15,false,neodev,1.0,30581619,USA,CA,San Jose,50.118.162.56,[NONE],[NONE],good,good,151,168,157,156,179,RO-may_prevent,820236-FS1,"Wechsler ME, Garpestad E, Flier SR et al. Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with ASTHMA receiving ZAFIRLUKAST",ASTHMA,ZAFIRLUKAST
790085293,9/17/2015 11:16:27,1740388830,9/17/2015 11:16:15,false,neodev,1.0,32695853,USA,NV,Las Vegas,192.30.80.172,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,N/A,151,168,157,156,179,RO-may_prevent,820236-FS1,"Wechsler ME, Garpestad E, Flier SR et al. Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with ASTHMA receiving ZAFIRLUKAST",ASTHMA,ZAFIRLUKAST
790085293,9/17/2015 11:20:51,1740389557,9/17/2015 11:19:36,false,gifthulk,1.0,18666417,USA,PA,Meadville,24.101.32.13,[TREATS] [SIDE_EFFECT],"[TREATS]
[SIDE_EFFECT]",corticosteroid withdrawal in patients with ASTHMA receiving ZAFIRLUKAST,n/a,151,168,157,156,179,RO-may_prevent,820236-FS1,"Wechsler ME, Garpestad E, Flier SR et al. Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with ASTHMA receiving ZAFIRLUKAST",ASTHMA,ZAFIRLUKAST
790085293,9/17/2015 11:27:14,1740390711,9/17/2015 11:27:05,false,elite,1.0,33798502,USA,VA,Manassas,207.244.86.212,[TREATS],[TREATS],ZAFIRLUKAST,makes sense,151,168,157,156,179,RO-may_prevent,820236-FS1,"Wechsler ME, Garpestad E, Flier SR et al. Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with ASTHMA receiving ZAFIRLUKAST",ASTHMA,ZAFIRLUKAST
790085293,9/17/2015 11:39:43,1740393101,9/17/2015 11:39:31,false,neodev,1.0,33701549,USA,CA,Torrance,66.171.228.66,[PREVENTS] [LOCATION] [MANIFESTATION] [SIDE_EFFECT] [OTHER] [NONE],"[PREVENTS]
[LOCATION]
[MANIFESTATION]
[SIDE_EFFECT]
[OTHER]
[NONE]",[IS_A],N/A,151,168,157,156,179,RO-may_prevent,820236-FS1,"Wechsler ME, Garpestad E, Flier SR et al. Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with ASTHMA receiving ZAFIRLUKAST",ASTHMA,ZAFIRLUKAST
790085293,9/17/2015 11:58:56,1740396863,9/17/2015 11:57:41,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[SYMPTOM],[SYMPTOM],patients with,N/A,151,168,157,156,179,RO-may_prevent,820236-FS1,"Wechsler ME, Garpestad E, Flier SR et al. Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with ASTHMA receiving ZAFIRLUKAST",ASTHMA,ZAFIRLUKAST
790085293,9/17/2015 12:01:52,1740397406,9/17/2015 12:01:34,false,prodege,1.0,14848125,GBR,V8,Airdrie,86.151.77.161,[TREATS],[TREATS],ASTHMA receiving ZAFIRLUKAST,n/a,151,168,157,156,179,RO-may_prevent,820236-FS1,"Wechsler ME, Garpestad E, Flier SR et al. Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with ASTHMA receiving ZAFIRLUKAST",ASTHMA,ZAFIRLUKAST
790085293,9/17/2015 12:22:47,1740401954,9/17/2015 12:22:21,false,neodev,1.0,30588889,NLD,07,Amsterdam,77.248.175.222,[TREATS],[TREATS],receiving,N/A,151,168,157,156,179,RO-may_prevent,820236-FS1,"Wechsler ME, Garpestad E, Flier SR et al. Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with ASTHMA receiving ZAFIRLUKAST",ASTHMA,ZAFIRLUKAST
790085293,9/17/2015 12:34:12,1740404612,9/17/2015 12:33:49,false,prodege,1.0,2145087,USA,NY,New York,107.107.57.52,[TREATS],[TREATS],receiving,N/A,151,168,157,156,179,RO-may_prevent,820236-FS1,"Wechsler ME, Garpestad E, Flier SR et al. Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with ASTHMA receiving ZAFIRLUKAST",ASTHMA,ZAFIRLUKAST
790085293,9/17/2015 12:35:08,1740404808,9/17/2015 12:34:44,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,[TREATS],[TREATS],patients with ASTHMA receiving ZAFIRLUKAST,na,151,168,157,156,179,RO-may_prevent,820236-FS1,"Wechsler ME, Garpestad E, Flier SR et al. Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with ASTHMA receiving ZAFIRLUKAST",ASTHMA,ZAFIRLUKAST
790085293,9/17/2015 12:41:00,1740406319,9/17/2015 12:39:53,false,instagc,1.0,22981457,CAN,ON,Welland,76.67.127.43,[NONE],[NONE],N/A,Just that withdrawal occurs but no relationship between the two terms themselves,151,168,157,156,179,RO-may_prevent,820236-FS1,"Wechsler ME, Garpestad E, Flier SR et al. Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with ASTHMA receiving ZAFIRLUKAST",ASTHMA,ZAFIRLUKAST
790085294,9/17/2015 09:09:48,1740361701,9/17/2015 09:09:19,false,neodev,1.0,32053642,GBR,I7,Newcastle Upon Tyne,92.23.136.205,[SYMPTOM],[SYMPTOM],found during,N/A,226,189,238,237,197,RO-may_treat,820115-FS1,"To assess the effect of glucagon on renal and hepatic glutamine gluconeogenesis, we infused six normal healthy postabsorptive subjects with glucagon at a rate chosen to produce circulating GLUCAGON concentrations found during HYPOGLYCEMIA and, using a combination of isotopic and net balance techniques, determined the systemic, renal, and hepatic glucose release and renal and hepatic production of glucose from glutamine.",HYPOGLYCEMIA,GLUCAGON
790085294,9/17/2015 09:11:44,1740362147,9/17/2015 09:11:33,false,clixsense,1.0,19162475,GBR,P8,Trowbridge,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],GLUCAGON found during HYPOGLYCEMIA,n/a,226,189,238,237,197,RO-may_treat,820115-FS1,"To assess the effect of glucagon on renal and hepatic glutamine gluconeogenesis, we infused six normal healthy postabsorptive subjects with glucagon at a rate chosen to produce circulating GLUCAGON concentrations found during HYPOGLYCEMIA and, using a combination of isotopic and net balance techniques, determined the systemic, renal, and hepatic glucose release and renal and hepatic production of glucose from glutamine.",HYPOGLYCEMIA,GLUCAGON
790085294,9/17/2015 09:12:50,1740362456,9/17/2015 09:11:46,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[MANIFESTATION] [SYMPTOM],"[SYMPTOM]
[MANIFESTATION]",found during,N/A,226,189,238,237,197,RO-may_treat,820115-FS1,"To assess the effect of glucagon on renal and hepatic glutamine gluconeogenesis, we infused six normal healthy postabsorptive subjects with glucagon at a rate chosen to produce circulating GLUCAGON concentrations found during HYPOGLYCEMIA and, using a combination of isotopic and net balance techniques, determined the systemic, renal, and hepatic glucose release and renal and hepatic production of glucose from glutamine.",HYPOGLYCEMIA,GLUCAGON
790085294,9/17/2015 09:13:08,1740362492,9/17/2015 09:12:54,false,elite,1.0,30659754,USA,"","",162.250.145.204,[SYMPTOM],[SYMPTOM],found during,N/A,226,189,238,237,197,RO-may_treat,820115-FS1,"To assess the effect of glucagon on renal and hepatic glutamine gluconeogenesis, we infused six normal healthy postabsorptive subjects with glucagon at a rate chosen to produce circulating GLUCAGON concentrations found during HYPOGLYCEMIA and, using a combination of isotopic and net balance techniques, determined the systemic, renal, and hepatic glucose release and renal and hepatic production of glucose from glutamine.",HYPOGLYCEMIA,GLUCAGON
790085294,9/17/2015 09:17:04,1740363414,9/17/2015 09:16:27,false,neodev,1.0,33644825,USA,FL,Fort Lauderdale,65.111.173.161,[PREVENTS],[PREVENTS],GLUCAGON HYPOGLYCEMIA,treats,226,189,238,237,197,RO-may_treat,820115-FS1,"To assess the effect of glucagon on renal and hepatic glutamine gluconeogenesis, we infused six normal healthy postabsorptive subjects with glucagon at a rate chosen to produce circulating GLUCAGON concentrations found during HYPOGLYCEMIA and, using a combination of isotopic and net balance techniques, determined the systemic, renal, and hepatic glucose release and renal and hepatic production of glucose from glutamine.",HYPOGLYCEMIA,GLUCAGON
790085294,9/17/2015 09:17:32,1740363485,9/17/2015 09:16:58,false,instagc,1.0,18960682,GBR,U2,Annan,92.18.213.181,[TREATS],[TREATS],infused glucagon to produce circulating GLUCAGON,N/A,226,189,238,237,197,RO-may_treat,820115-FS1,"To assess the effect of glucagon on renal and hepatic glutamine gluconeogenesis, we infused six normal healthy postabsorptive subjects with glucagon at a rate chosen to produce circulating GLUCAGON concentrations found during HYPOGLYCEMIA and, using a combination of isotopic and net balance techniques, determined the systemic, renal, and hepatic glucose release and renal and hepatic production of glucose from glutamine.",HYPOGLYCEMIA,GLUCAGON
790085294,9/17/2015 09:17:41,1740363505,9/17/2015 09:17:08,false,neodev,1.0,15848372,AUS,02,Jannali,14.200.59.55,[ASSOCIATED_WITH],[ASSOCIATED_WITH],concentrations found during,n/a,226,189,238,237,197,RO-may_treat,820115-FS1,"To assess the effect of glucagon on renal and hepatic glutamine gluconeogenesis, we infused six normal healthy postabsorptive subjects with glucagon at a rate chosen to produce circulating GLUCAGON concentrations found during HYPOGLYCEMIA and, using a combination of isotopic and net balance techniques, determined the systemic, renal, and hepatic glucose release and renal and hepatic production of glucose from glutamine.",HYPOGLYCEMIA,GLUCAGON
790085294,9/17/2015 09:18:49,1740363744,9/17/2015 09:17:47,false,neodev,1.0,30627835,GBR,D8,Bishop Auckland,217.44.84.223,[ASSOCIATED_WITH],[ASSOCIATED_WITH],found during,N/A,226,189,238,237,197,RO-may_treat,820115-FS1,"To assess the effect of glucagon on renal and hepatic glutamine gluconeogenesis, we infused six normal healthy postabsorptive subjects with glucagon at a rate chosen to produce circulating GLUCAGON concentrations found during HYPOGLYCEMIA and, using a combination of isotopic and net balance techniques, determined the systemic, renal, and hepatic glucose release and renal and hepatic production of glucose from glutamine.",HYPOGLYCEMIA,GLUCAGON
790085294,9/17/2015 09:25:05,1740365050,9/17/2015 09:24:30,false,pocketmoneygpt,1.0,21432964,GBR,F8,Borehamwood,81.159.185.70,[ASSOCIATED_WITH],[ASSOCIATED_WITH],concentrations found,N/A,226,189,238,237,197,RO-may_treat,820115-FS1,"To assess the effect of glucagon on renal and hepatic glutamine gluconeogenesis, we infused six normal healthy postabsorptive subjects with glucagon at a rate chosen to produce circulating GLUCAGON concentrations found during HYPOGLYCEMIA and, using a combination of isotopic and net balance techniques, determined the systemic, renal, and hepatic glucose release and renal and hepatic production of glucose from glutamine.",HYPOGLYCEMIA,GLUCAGON
790085294,9/17/2015 09:27:34,1740365515,9/17/2015 09:27:19,false,elite,1.0,30659615,USA,"","",162.250.145.234,[SYMPTOM],[SYMPTOM],concentrations found,N/A,226,189,238,237,197,RO-may_treat,820115-FS1,"To assess the effect of glucagon on renal and hepatic glutamine gluconeogenesis, we infused six normal healthy postabsorptive subjects with glucagon at a rate chosen to produce circulating GLUCAGON concentrations found during HYPOGLYCEMIA and, using a combination of isotopic and net balance techniques, determined the systemic, renal, and hepatic glucose release and renal and hepatic production of glucose from glutamine.",HYPOGLYCEMIA,GLUCAGON
790085294,9/17/2015 09:33:48,1740367025,9/17/2015 09:33:24,false,neodev,1.0,21515166,NLD,11,Nieuwkoop,83.84.200.25,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],found,n/a,226,189,238,237,197,RO-may_treat,820115-FS1,"To assess the effect of glucagon on renal and hepatic glutamine gluconeogenesis, we infused six normal healthy postabsorptive subjects with glucagon at a rate chosen to produce circulating GLUCAGON concentrations found during HYPOGLYCEMIA and, using a combination of isotopic and net balance techniques, determined the systemic, renal, and hepatic glucose release and renal and hepatic production of glucose from glutamine.",HYPOGLYCEMIA,GLUCAGON
790085294,9/17/2015 09:45:08,1740369710,9/17/2015 09:42:44,false,neodev,1.0,34081836,USA,CA,San Jose,23.27.248.146,[SYMPTOM],[SYMPTOM],produce circulating GLUCAGON concentrations found during HYPOGLYCEMIA,N/A,226,189,238,237,197,RO-may_treat,820115-FS1,"To assess the effect of glucagon on renal and hepatic glutamine gluconeogenesis, we infused six normal healthy postabsorptive subjects with glucagon at a rate chosen to produce circulating GLUCAGON concentrations found during HYPOGLYCEMIA and, using a combination of isotopic and net balance techniques, determined the systemic, renal, and hepatic glucose release and renal and hepatic production of glucose from glutamine.",HYPOGLYCEMIA,GLUCAGON
790085294,9/17/2015 09:47:03,1740370114,9/17/2015 09:46:51,false,elite,1.0,30659677,USA,"","",162.252.172.126,[SYMPTOM],[SYMPTOM],found during,N/A,226,189,238,237,197,RO-may_treat,820115-FS1,"To assess the effect of glucagon on renal and hepatic glutamine gluconeogenesis, we infused six normal healthy postabsorptive subjects with glucagon at a rate chosen to produce circulating GLUCAGON concentrations found during HYPOGLYCEMIA and, using a combination of isotopic and net balance techniques, determined the systemic, renal, and hepatic glucose release and renal and hepatic production of glucose from glutamine.",HYPOGLYCEMIA,GLUCAGON
790085294,9/17/2015 09:50:12,1740370799,9/17/2015 09:49:40,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[SIDE_EFFECT],[SIDE_EFFECT],found during HYPOGLYCEMIA,N/A,226,189,238,237,197,RO-may_treat,820115-FS1,"To assess the effect of glucagon on renal and hepatic glutamine gluconeogenesis, we infused six normal healthy postabsorptive subjects with glucagon at a rate chosen to produce circulating GLUCAGON concentrations found during HYPOGLYCEMIA and, using a combination of isotopic and net balance techniques, determined the systemic, renal, and hepatic glucose release and renal and hepatic production of glucose from glutamine.",HYPOGLYCEMIA,GLUCAGON
790085294,9/17/2015 10:23:11,1740378405,9/17/2015 10:21:21,false,clixsense,1,31482589,NLD,11,Gouda,77.167.232.121,[SYMPTOM],[SYMPTOM],found during HYPOGLYCEMIA,n/a,226,189,238,237,197,RO-may_treat,820115-FS1,"To assess the effect of glucagon on renal and hepatic glutamine gluconeogenesis, we infused six normal healthy postabsorptive subjects with glucagon at a rate chosen to produce circulating GLUCAGON concentrations found during HYPOGLYCEMIA and, using a combination of isotopic and net balance techniques, determined the systemic, renal, and hepatic glucose release and renal and hepatic production of glucose from glutamine.",HYPOGLYCEMIA,GLUCAGON
790085295,9/17/2015 11:25:50,1740390446,9/17/2015 11:25:18,false,neodev,1.0,32695853,USA,NV,Las Vegas,192.30.80.172,[PART_OF] [TREATS],"[TREATS]
[PART_OF]",of of treatment of,N/A,118,78,148,147,97,RO-may_prevent,820358-FS1,"From the pharmacological point of view, these studies prove the advantages of PENTAMIDINE AEROSOL in the treatment of PNEUMOCYSTIS CARINII PNEUMONIA (PCP) and provide information on extrarenal excretion mechanisms and deep compartments.",PNEUMOCYSTIS CARINII PNEUMONIA,PENTAMIDINE AEROSOL
790085295,9/17/2015 11:36:24,1740392339,9/17/2015 11:36:01,false,neodev,1.0,30941227,USA,NV,Las Vegas,192.30.80.166,[PART_OF] [TREATS],"[TREATS]
[PART_OF]",of of treatment of,N/A,118,78,148,147,97,RO-may_prevent,820358-FS1,"From the pharmacological point of view, these studies prove the advantages of PENTAMIDINE AEROSOL in the treatment of PNEUMOCYSTIS CARINII PNEUMONIA (PCP) and provide information on extrarenal excretion mechanisms and deep compartments.",PNEUMOCYSTIS CARINII PNEUMONIA,PENTAMIDINE AEROSOL
790085295,9/17/2015 12:11:46,1740399579,9/17/2015 12:11:27,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[TREATS],[TREATS],treatment,N/A,118,78,148,147,97,RO-may_prevent,820358-FS1,"From the pharmacological point of view, these studies prove the advantages of PENTAMIDINE AEROSOL in the treatment of PNEUMOCYSTIS CARINII PNEUMONIA (PCP) and provide information on extrarenal excretion mechanisms and deep compartments.",PNEUMOCYSTIS CARINII PNEUMONIA,PENTAMIDINE AEROSOL
790085295,9/17/2015 12:37:08,1740405400,9/17/2015 12:36:56,false,neodev,1.0,30588889,NLD,07,Amsterdam,77.248.175.222,[TREATS],[TREATS],treatment,N/A,118,78,148,147,97,RO-may_prevent,820358-FS1,"From the pharmacological point of view, these studies prove the advantages of PENTAMIDINE AEROSOL in the treatment of PNEUMOCYSTIS CARINII PNEUMONIA (PCP) and provide information on extrarenal excretion mechanisms and deep compartments.",PNEUMOCYSTIS CARINII PNEUMONIA,PENTAMIDINE AEROSOL
790085295,9/17/2015 12:46:17,1740407968,9/17/2015 12:45:42,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,[TREATS],[TREATS],PENTAMIDINE AEROSOL in treatment of PNEUMOCYSTIS CARINII PNEUMONIA,na,118,78,148,147,97,RO-may_prevent,820358-FS1,"From the pharmacological point of view, these studies prove the advantages of PENTAMIDINE AEROSOL in the treatment of PNEUMOCYSTIS CARINII PNEUMONIA (PCP) and provide information on extrarenal excretion mechanisms and deep compartments.",PNEUMOCYSTIS CARINII PNEUMONIA,PENTAMIDINE AEROSOL
790085295,9/17/2015 12:48:20,1740408568,9/17/2015 12:48:02,false,prodege,1.0,2145087,USA,NY,New York,107.107.57.52,[TREATS],[TREATS],in the treatment of,N/A,118,78,148,147,97,RO-may_prevent,820358-FS1,"From the pharmacological point of view, these studies prove the advantages of PENTAMIDINE AEROSOL in the treatment of PNEUMOCYSTIS CARINII PNEUMONIA (PCP) and provide information on extrarenal excretion mechanisms and deep compartments.",PNEUMOCYSTIS CARINII PNEUMONIA,PENTAMIDINE AEROSOL
790085295,9/17/2015 13:18:10,1740416828,9/17/2015 13:17:57,false,neodev,1.0,33228343,USA,"","",38.95.108.251,[PREVENTS] [TREATS] [CAUSES] [MANIFESTATION] [ASSOCIATED_WITH] [SIDE_EFFECT] [PART_OF] [OTHER] [NONE],"[TREATS]
[PREVENTS]
[CAUSES]
[MANIFESTATION]
[ASSOCIATED_WITH]
[SIDE_EFFECT]
[PART_OF]
[OTHER]
[NONE]",UMONIA (PCP) and provide information on extrarenal excretion mechanisms and deep compartments.,UMONIA (PCP) and provide information on extrarenal excretion mechanisms and deep compartments.,118,78,148,147,97,RO-may_prevent,820358-FS1,"From the pharmacological point of view, these studies prove the advantages of PENTAMIDINE AEROSOL in the treatment of PNEUMOCYSTIS CARINII PNEUMONIA (PCP) and provide information on extrarenal excretion mechanisms and deep compartments.",PNEUMOCYSTIS CARINII PNEUMONIA,PENTAMIDINE AEROSOL
790085295,9/17/2015 13:18:41,1740416966,9/17/2015 13:18:23,false,elite,1.0,31883685,GBR,"","",79.66.244.188,[TREATS],[TREATS],treatment,n/a,118,78,148,147,97,RO-may_prevent,820358-FS1,"From the pharmacological point of view, these studies prove the advantages of PENTAMIDINE AEROSOL in the treatment of PNEUMOCYSTIS CARINII PNEUMONIA (PCP) and provide information on extrarenal excretion mechanisms and deep compartments.",PNEUMOCYSTIS CARINII PNEUMONIA,PENTAMIDINE AEROSOL
790085295,9/17/2015 13:19:47,1740417307,9/17/2015 13:19:20,false,prodege,1.0,33854929,USA,CT,Wallingford,24.2.218.232,[TREATS],[TREATS],treatment,n/a,118,78,148,147,97,RO-may_prevent,820358-FS1,"From the pharmacological point of view, these studies prove the advantages of PENTAMIDINE AEROSOL in the treatment of PNEUMOCYSTIS CARINII PNEUMONIA (PCP) and provide information on extrarenal excretion mechanisms and deep compartments.",PNEUMOCYSTIS CARINII PNEUMONIA,PENTAMIDINE AEROSOL
790085295,9/17/2015 13:26:00,1740419250,9/17/2015 13:25:31,false,neodev,1.0,12115558,USA,OH,Twinsburg,98.27.164.131,[TREATS],[TREATS],advantages in the treatment,N/A,118,78,148,147,97,RO-may_prevent,820358-FS1,"From the pharmacological point of view, these studies prove the advantages of PENTAMIDINE AEROSOL in the treatment of PNEUMOCYSTIS CARINII PNEUMONIA (PCP) and provide information on extrarenal excretion mechanisms and deep compartments.",PNEUMOCYSTIS CARINII PNEUMONIA,PENTAMIDINE AEROSOL
790085295,9/17/2015 13:26:07,1740419258,9/17/2015 13:25:50,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,[TREATS],[TREATS],treatment,n/a,118,78,148,147,97,RO-may_prevent,820358-FS1,"From the pharmacological point of view, these studies prove the advantages of PENTAMIDINE AEROSOL in the treatment of PNEUMOCYSTIS CARINII PNEUMONIA (PCP) and provide information on extrarenal excretion mechanisms and deep compartments.",PNEUMOCYSTIS CARINII PNEUMONIA,PENTAMIDINE AEROSOL
790085295,9/17/2015 13:26:56,1740419573,9/17/2015 13:26:35,false,prodege,1.0,27934334,GBR,C8,Croydon,81.159.60.206,[TREATS],[TREATS],treatment of,N/A,118,78,148,147,97,RO-may_prevent,820358-FS1,"From the pharmacological point of view, these studies prove the advantages of PENTAMIDINE AEROSOL in the treatment of PNEUMOCYSTIS CARINII PNEUMONIA (PCP) and provide information on extrarenal excretion mechanisms and deep compartments.",PNEUMOCYSTIS CARINII PNEUMONIA,PENTAMIDINE AEROSOL
790085295,9/17/2015 13:35:51,1740422480,9/17/2015 13:35:31,false,bitcoinget,1.0,31256687,USA,NY,Poughkeepsie,67.82.252.135,[OTHER] [TREATS],"[TREATS]
[OTHER]",treatment,n/a,118,78,148,147,97,RO-may_prevent,820358-FS1,"From the pharmacological point of view, these studies prove the advantages of PENTAMIDINE AEROSOL in the treatment of PNEUMOCYSTIS CARINII PNEUMONIA (PCP) and provide information on extrarenal excretion mechanisms and deep compartments.",PNEUMOCYSTIS CARINII PNEUMONIA,PENTAMIDINE AEROSOL
790085295,9/17/2015 13:50:30,1740429121,9/17/2015 13:50:05,false,neodev,1.0,31329809,USA,DE,Wilmington,162.223.93.194,[PART_OF] [TREATS],"[TREATS]
[PART_OF]",of of treatment of,N/A,118,78,148,147,97,RO-may_prevent,820358-FS1,"From the pharmacological point of view, these studies prove the advantages of PENTAMIDINE AEROSOL in the treatment of PNEUMOCYSTIS CARINII PNEUMONIA (PCP) and provide information on extrarenal excretion mechanisms and deep compartments.",PNEUMOCYSTIS CARINII PNEUMONIA,PENTAMIDINE AEROSOL
790085295,9/17/2015 14:02:20,1740433192,9/17/2015 14:01:59,false,gifthunterclub,1.0,30901412,GBR,H9,London,77.89.149.62,[TREATS],[TREATS],PENTAMIDINE AEROSOL treatment of PNEUMOCYSTIS CARINII PNEUMONIA (PCP),N/A,118,78,148,147,97,RO-may_prevent,820358-FS1,"From the pharmacological point of view, these studies prove the advantages of PENTAMIDINE AEROSOL in the treatment of PNEUMOCYSTIS CARINII PNEUMONIA (PCP) and provide information on extrarenal excretion mechanisms and deep compartments.",PNEUMOCYSTIS CARINII PNEUMONIA,PENTAMIDINE AEROSOL
790085296,9/17/2015 09:15:24,1740363025,9/17/2015 09:15:07,false,neodev,1.0,32053642,GBR,I7,Newcastle Upon Tyne,92.23.136.205,[TREATS],[TREATS],treated with,N/A,80,60,98,107,69,RO-may_prevent,820359-FS1,The newborns treated with varicella hyperimmunoglobulin and ACYCLOVIR developed ABORTIVE VARICELLA EXANTHEMA without further complications.,ABORTIVE VARICELLA EXANTHEMA,ACYCLOVIR
790085296,9/17/2015 09:16:39,1740363335,9/17/2015 09:16:24,false,elite,1.0,30659754,USA,"","",162.250.145.204,[CAUSES],[CAUSES],developed,N/A,80,60,98,107,69,RO-may_prevent,820359-FS1,The newborns treated with varicella hyperimmunoglobulin and ACYCLOVIR developed ABORTIVE VARICELLA EXANTHEMA without further complications.,ABORTIVE VARICELLA EXANTHEMA,ACYCLOVIR
790085296,9/17/2015 09:22:44,1740364563,9/17/2015 09:22:20,false,instagc,1.0,18960682,GBR,U2,Annan,92.18.213.181,[CAUSES],[CAUSES],newborns treated with ACYCLOVIR developed,N/A,80,60,98,107,69,RO-may_prevent,820359-FS1,The newborns treated with varicella hyperimmunoglobulin and ACYCLOVIR developed ABORTIVE VARICELLA EXANTHEMA without further complications.,ABORTIVE VARICELLA EXANTHEMA,ACYCLOVIR
790085296,9/17/2015 09:24:21,1740364875,9/17/2015 09:23:55,false,neodev,1.0,15848372,AUS,02,Jannali,14.200.59.55,[MANIFESTATION],[MANIFESTATION],developed,n/a,80,60,98,107,69,RO-may_prevent,820359-FS1,The newborns treated with varicella hyperimmunoglobulin and ACYCLOVIR developed ABORTIVE VARICELLA EXANTHEMA without further complications.,ABORTIVE VARICELLA EXANTHEMA,ACYCLOVIR
790085296,9/17/2015 09:24:21,1740364876,9/17/2015 09:23:54,false,neodev,1.0,33644825,USA,FL,Fort Lauderdale,65.111.173.161,[PREVENTS],[PREVENTS],ACYCLOVIR ABORTIVE VARICELLA EXANTHEMA,treats,80,60,98,107,69,RO-may_prevent,820359-FS1,The newborns treated with varicella hyperimmunoglobulin and ACYCLOVIR developed ABORTIVE VARICELLA EXANTHEMA without further complications.,ABORTIVE VARICELLA EXANTHEMA,ACYCLOVIR
790085296,9/17/2015 09:31:56,1740366571,9/17/2015 09:30:42,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[CAUSES],[CAUSES],developed,N/A,80,60,98,107,69,RO-may_prevent,820359-FS1,The newborns treated with varicella hyperimmunoglobulin and ACYCLOVIR developed ABORTIVE VARICELLA EXANTHEMA without further complications.,ABORTIVE VARICELLA EXANTHEMA,ACYCLOVIR
790085296,9/17/2015 09:34:55,1740367296,9/17/2015 09:34:42,false,elite,1.0,30659615,USA,"","",162.250.145.234,[CAUSES],[CAUSES],developed,N/A,80,60,98,107,69,RO-may_prevent,820359-FS1,The newborns treated with varicella hyperimmunoglobulin and ACYCLOVIR developed ABORTIVE VARICELLA EXANTHEMA without further complications.,ABORTIVE VARICELLA EXANTHEMA,ACYCLOVIR
790085296,9/17/2015 09:35:55,1740367476,9/17/2015 09:35:29,false,pocketmoneygpt,1.0,21432964,GBR,F8,Borehamwood,81.159.185.70,[TREATS],[TREATS],treated,N/A,80,60,98,107,69,RO-may_prevent,820359-FS1,The newborns treated with varicella hyperimmunoglobulin and ACYCLOVIR developed ABORTIVE VARICELLA EXANTHEMA without further complications.,ABORTIVE VARICELLA EXANTHEMA,ACYCLOVIR
790085296,9/17/2015 09:40:41,1740368612,9/17/2015 09:40:23,false,neodev,1.0,21515166,NLD,11,Nieuwkoop,83.84.200.25,[TREATS],[TREATS],treated with,n/a,80,60,98,107,69,RO-may_prevent,820359-FS1,The newborns treated with varicella hyperimmunoglobulin and ACYCLOVIR developed ABORTIVE VARICELLA EXANTHEMA without further complications.,ABORTIVE VARICELLA EXANTHEMA,ACYCLOVIR
790085296,9/17/2015 09:50:37,1740370875,9/17/2015 09:50:21,false,elite,1.0,30659677,USA,"","",162.252.172.126,[CAUSES],[CAUSES],developed,N/A,80,60,98,107,69,RO-may_prevent,820359-FS1,The newborns treated with varicella hyperimmunoglobulin and ACYCLOVIR developed ABORTIVE VARICELLA EXANTHEMA without further complications.,ABORTIVE VARICELLA EXANTHEMA,ACYCLOVIR
790085296,9/17/2015 09:59:11,1740373033,9/17/2015 09:57:20,false,neodev,1.0,34081836,USA,CA,San Jose,23.27.248.146,[CAUSES],[CAUSES],ACYCLOVIR developed ABORTIVE VARICELLA EXANTHEMA,N/A,80,60,98,107,69,RO-may_prevent,820359-FS1,The newborns treated with varicella hyperimmunoglobulin and ACYCLOVIR developed ABORTIVE VARICELLA EXANTHEMA without further complications.,ABORTIVE VARICELLA EXANTHEMA,ACYCLOVIR
790085296,9/17/2015 10:00:47,1740373341,9/17/2015 10:00:24,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[CAUSES],[CAUSES],ACYCLOVIR developed ABORTIVE VARICELLA EXANTHEMA,N/A,80,60,98,107,69,RO-may_prevent,820359-FS1,The newborns treated with varicella hyperimmunoglobulin and ACYCLOVIR developed ABORTIVE VARICELLA EXANTHEMA without further complications.,ABORTIVE VARICELLA EXANTHEMA,ACYCLOVIR
790085296,9/17/2015 10:28:38,1740379499,9/17/2015 10:28:14,false,pocketmoneygpt,1.0,28884030,USA,WI,Minocqua,75.143.134.247,[SYMPTOM],[SYMPTOM],developed,n/a,80,60,98,107,69,RO-may_prevent,820359-FS1,The newborns treated with varicella hyperimmunoglobulin and ACYCLOVIR developed ABORTIVE VARICELLA EXANTHEMA without further complications.,ABORTIVE VARICELLA EXANTHEMA,ACYCLOVIR
790085296,9/17/2015 10:34:56,1740380929,9/17/2015 10:33:48,false,clixsense,1.0,17950689,GBR,L9,Sheffield,146.200.192.103,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],hyperimmunoglobulin,NONE,80,60,98,107,69,RO-may_prevent,820359-FS1,The newborns treated with varicella hyperimmunoglobulin and ACYCLOVIR developed ABORTIVE VARICELLA EXANTHEMA without further complications.,ABORTIVE VARICELLA EXANTHEMA,ACYCLOVIR
790085296,9/17/2015 10:51:43,1740384083,9/17/2015 10:51:27,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[CAUSES],[CAUSES],developed,N/A,80,60,98,107,69,RO-may_prevent,820359-FS1,The newborns treated with varicella hyperimmunoglobulin and ACYCLOVIR developed ABORTIVE VARICELLA EXANTHEMA without further complications.,ABORTIVE VARICELLA EXANTHEMA,ACYCLOVIR
790085297,9/17/2015 09:13:40,1740362611,9/17/2015 09:13:15,false,neodev,1.0,32053642,GBR,I7,Newcastle Upon Tyne,92.23.136.205,[PREVENTS] [TREATS],"[TREATS]
[PREVENTS]",reducing pain,N/A,124,0,49,127,8,RO-may_prevent,820315-FS1,NAPROXEN appears to be effective in reducing pain and swelling in acute gout and is an effective analgesic in patients with PAIN following surgery or trauma and in pain of dysmenorrhoea.,PAIN,NAPROXEN
790085297,9/17/2015 09:15:26,1740363028,9/17/2015 09:15:13,false,elite,1.0,30659754,USA,"","",162.250.145.204,[PREVENTS],[PREVENTS],reducing,N/A,124,0,49,127,8,RO-may_prevent,820315-FS1,NAPROXEN appears to be effective in reducing pain and swelling in acute gout and is an effective analgesic in patients with PAIN following surgery or trauma and in pain of dysmenorrhoea.,PAIN,NAPROXEN
790085297,9/17/2015 09:21:00,1740364234,9/17/2015 09:20:43,false,instagc,1.0,18960682,GBR,U2,Annan,92.18.213.181,[TREATS],[TREATS],NAPROXEN appears to be effective in reducing pain,N/A,124,0,49,127,8,RO-may_prevent,820315-FS1,NAPROXEN appears to be effective in reducing pain and swelling in acute gout and is an effective analgesic in patients with PAIN following surgery or trauma and in pain of dysmenorrhoea.,PAIN,NAPROXEN
790085297,9/17/2015 09:22:11,1740364478,9/17/2015 09:21:40,false,neodev,1.0,33644825,USA,FL,Fort Lauderdale,65.111.173.161,[TREATS],[TREATS],NAPROXEN PAIN,heals,124,0,49,127,8,RO-may_prevent,820315-FS1,NAPROXEN appears to be effective in reducing pain and swelling in acute gout and is an effective analgesic in patients with PAIN following surgery or trauma and in pain of dysmenorrhoea.,PAIN,NAPROXEN
790085297,9/17/2015 09:22:25,1740364499,9/17/2015 09:21:58,false,neodev,1.0,15848372,AUS,02,Jannali,14.200.59.55,[MANIFESTATION],[MANIFESTATION],effective analgesic with,n/a,124,0,49,127,8,RO-may_prevent,820315-FS1,NAPROXEN appears to be effective in reducing pain and swelling in acute gout and is an effective analgesic in patients with PAIN following surgery or trauma and in pain of dysmenorrhoea.,PAIN,NAPROXEN
790085297,9/17/2015 09:25:36,1740365129,9/17/2015 09:24:22,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[TREATS],[TREATS],reducing,N/A,124,0,49,127,8,RO-may_prevent,820315-FS1,NAPROXEN appears to be effective in reducing pain and swelling in acute gout and is an effective analgesic in patients with PAIN following surgery or trauma and in pain of dysmenorrhoea.,PAIN,NAPROXEN
790085297,9/17/2015 09:29:45,1740366048,9/17/2015 09:29:29,false,elite,1.0,30659615,USA,"","",162.250.145.234,[PREVENTS],[PREVENTS],effective analgesic,N/A,124,0,49,127,8,RO-may_prevent,820315-FS1,NAPROXEN appears to be effective in reducing pain and swelling in acute gout and is an effective analgesic in patients with PAIN following surgery or trauma and in pain of dysmenorrhoea.,PAIN,NAPROXEN
790085297,9/17/2015 09:33:39,1740367009,9/17/2015 09:32:58,false,pocketmoneygpt,1.0,21432964,GBR,F8,Borehamwood,81.159.185.70,[TREATS],[TREATS],effective in reducing,N/A,124,0,49,127,8,RO-may_prevent,820315-FS1,NAPROXEN appears to be effective in reducing pain and swelling in acute gout and is an effective analgesic in patients with PAIN following surgery or trauma and in pain of dysmenorrhoea.,PAIN,NAPROXEN
790085297,9/17/2015 09:38:02,1740367937,9/17/2015 09:37:31,false,neodev,1.0,21515166,NLD,11,Nieuwkoop,83.84.200.25,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",to be effective in reducing,n/a,124,0,49,127,8,RO-may_prevent,820315-FS1,NAPROXEN appears to be effective in reducing pain and swelling in acute gout and is an effective analgesic in patients with PAIN following surgery or trauma and in pain of dysmenorrhoea.,PAIN,NAPROXEN
790085297,9/17/2015 09:49:25,1740370647,9/17/2015 09:49:13,false,elite,1.0,30659677,USA,"","",162.252.172.126,[SIDE_EFFECT],[SIDE_EFFECT],effective,N/A,124,0,49,127,8,RO-may_prevent,820315-FS1,NAPROXEN appears to be effective in reducing pain and swelling in acute gout and is an effective analgesic in patients with PAIN following surgery or trauma and in pain of dysmenorrhoea.,PAIN,NAPROXEN
790085297,9/17/2015 09:53:04,1740371580,9/17/2015 09:52:18,false,neodev,1.0,34081836,USA,CA,San Jose,23.27.248.146,[TREATS],[TREATS],NAPROXEN appears to be effective in reducing pain,N/A,124,0,49,127,8,RO-may_prevent,820315-FS1,NAPROXEN appears to be effective in reducing pain and swelling in acute gout and is an effective analgesic in patients with PAIN following surgery or trauma and in pain of dysmenorrhoea.,PAIN,NAPROXEN
790085297,9/17/2015 09:56:24,1740372318,9/17/2015 09:56:07,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[TREATS],[TREATS],effective in reducing pain,N/A,124,0,49,127,8,RO-may_prevent,820315-FS1,NAPROXEN appears to be effective in reducing pain and swelling in acute gout and is an effective analgesic in patients with PAIN following surgery or trauma and in pain of dysmenorrhoea.,PAIN,NAPROXEN
790085297,9/17/2015 10:26:13,1740379085,9/17/2015 10:25:57,false,pocketmoneygpt,1.0,28884030,USA,WI,Minocqua,75.143.134.247,[TREATS],[TREATS],effective,n/a,124,0,49,127,8,RO-may_prevent,820315-FS1,NAPROXEN appears to be effective in reducing pain and swelling in acute gout and is an effective analgesic in patients with PAIN following surgery or trauma and in pain of dysmenorrhoea.,PAIN,NAPROXEN
790085297,9/17/2015 10:31:01,1740380020,9/17/2015 10:30:01,false,clixsense,1.0,17950689,GBR,L9,Sheffield,146.200.192.103,[TREATS],[TREATS],pain swelling,NONE,124,0,49,127,8,RO-may_prevent,820315-FS1,NAPROXEN appears to be effective in reducing pain and swelling in acute gout and is an effective analgesic in patients with PAIN following surgery or trauma and in pain of dysmenorrhoea.,PAIN,NAPROXEN
790085297,9/17/2015 10:51:05,1740383940,9/17/2015 10:50:44,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[PREVENTS],[PREVENTS],reducing,N/A,124,0,49,127,8,RO-may_prevent,820315-FS1,NAPROXEN appears to be effective in reducing pain and swelling in acute gout and is an effective analgesic in patients with PAIN following surgery or trauma and in pain of dysmenorrhoea.,PAIN,NAPROXEN
790085298,9/17/2015 13:20:26,1740417613,9/17/2015 13:20:12,false,neodev,1.0,33228343,USA,"","",38.95.108.251,[PREVENTS] [TREATS] [DIAGNOSE_BY_TEST_OR_DRUG] [SYMPTOM] [CONTRAINDICATES] [SIDE_EFFECT] [OTHER] [NONE],"[TREATS]
[PREVENTS]
[DIAGNOSE_BY_TEST_OR_DRUG]
[SYMPTOM]
[CONTRAINDICATES]
[SIDE_EFFECT]
[OTHER]
[NONE]",Effects of platelet glycoprotein IIb/IIIa blockade with TIROFIBAN on adverse cardiac events IN PATIENTS WITH UNSTABLE ANGINA OR ACUTE MYOCARDIAL infarction undergoing coronary angioplasty.,Effects of platelet glycoprotein IIb/IIIa blockade with TIROFIBAN on adverse cardiac events IN PATIENTS WITH UNSTABLE ANGINA OR ACUTE MYOCARDIAL infarction undergoing coronary angioplasty.,92,56,124,143,65,RO-may_treat,820081-FS1,Effects of platelet glycoprotein IIb/IIIa blockade with TIROFIBAN on adverse cardiac events IN PATIENTS WITH UNSTABLE ANGINA OR ACUTE MYOCARDIAL infarction undergoing coronary angioplasty.,UNSTABLE ANGINA,TIROFIBAN
790085298,9/17/2015 13:21:16,1740417892,9/17/2015 13:20:58,false,elite,1.0,31883685,GBR,"","",79.66.244.188,[TREATS],[TREATS],Effects on,n/a,92,56,124,143,65,RO-may_treat,820081-FS1,Effects of platelet glycoprotein IIb/IIIa blockade with TIROFIBAN on adverse cardiac events IN PATIENTS WITH UNSTABLE ANGINA OR ACUTE MYOCARDIAL infarction undergoing coronary angioplasty.,UNSTABLE ANGINA,TIROFIBAN
790085298,9/17/2015 13:22:36,1740418303,9/17/2015 13:22:18,false,prodege,1.0,33854929,USA,CT,Wallingford,24.2.218.232,[CAUSES],[CAUSES],Effects,n/a,92,56,124,143,65,RO-may_treat,820081-FS1,Effects of platelet glycoprotein IIb/IIIa blockade with TIROFIBAN on adverse cardiac events IN PATIENTS WITH UNSTABLE ANGINA OR ACUTE MYOCARDIAL infarction undergoing coronary angioplasty.,UNSTABLE ANGINA,TIROFIBAN
790085298,9/17/2015 13:28:47,1740420112,9/17/2015 13:28:26,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,[TREATS],[TREATS],adverse cardiac events,n/a,92,56,124,143,65,RO-may_treat,820081-FS1,Effects of platelet glycoprotein IIb/IIIa blockade with TIROFIBAN on adverse cardiac events IN PATIENTS WITH UNSTABLE ANGINA OR ACUTE MYOCARDIAL infarction undergoing coronary angioplasty.,UNSTABLE ANGINA,TIROFIBAN
790085298,9/17/2015 13:31:51,1740421094,9/17/2015 13:31:16,false,prodege,1.0,27934334,GBR,C8,Croydon,81.159.60.206,[TREATS],[TREATS],Effects with,N/A,92,56,124,143,65,RO-may_treat,820081-FS1,Effects of platelet glycoprotein IIb/IIIa blockade with TIROFIBAN on adverse cardiac events IN PATIENTS WITH UNSTABLE ANGINA OR ACUTE MYOCARDIAL infarction undergoing coronary angioplasty.,UNSTABLE ANGINA,TIROFIBAN
790085298,9/17/2015 14:03:15,1740433477,9/17/2015 14:01:00,false,neodev,1.0,31329809,USA,DE,Wilmington,162.223.93.194,[SIDE_EFFECT] [PART_OF] [ASSOCIATED_WITH] [DIAGNOSE_BY_TEST_OR_DRUG],"[DIAGNOSE_BY_TEST_OR_DRUG]
[ASSOCIATED_WITH]
[SIDE_EFFECT]
[PART_OF]",Effects of with WITH OR,N/A,92,56,124,143,65,RO-may_treat,820081-FS1,Effects of platelet glycoprotein IIb/IIIa blockade with TIROFIBAN on adverse cardiac events IN PATIENTS WITH UNSTABLE ANGINA OR ACUTE MYOCARDIAL infarction undergoing coronary angioplasty.,UNSTABLE ANGINA,TIROFIBAN
790085298,9/17/2015 14:04:47,1740434053,9/17/2015 14:04:06,false,gifthunterclub,1.0,30901412,GBR,H9,London,77.89.149.62,[MANIFESTATION],[MANIFESTATION],TIROFIBAN adverse cardiac events IN PATIENTS WITH UNSTABLE ANGINA,N/A,92,56,124,143,65,RO-may_treat,820081-FS1,Effects of platelet glycoprotein IIb/IIIa blockade with TIROFIBAN on adverse cardiac events IN PATIENTS WITH UNSTABLE ANGINA OR ACUTE MYOCARDIAL infarction undergoing coronary angioplasty.,UNSTABLE ANGINA,TIROFIBAN
790085298,9/17/2015 14:09:48,1740435921,9/17/2015 14:09:30,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.124.79,[TREATS],[TREATS],Effects on adverse cardiac events,N/A,92,56,124,143,65,RO-may_treat,820081-FS1,Effects of platelet glycoprotein IIb/IIIa blockade with TIROFIBAN on adverse cardiac events IN PATIENTS WITH UNSTABLE ANGINA OR ACUTE MYOCARDIAL infarction undergoing coronary angioplasty.,UNSTABLE ANGINA,TIROFIBAN
790085298,9/17/2015 14:10:09,1740436016,9/17/2015 14:08:49,false,zoombucks,1.0,6744840,CAN,BC,Kelowna,174.4.58.160,[CAUSES],[CAUSES],Effects of,N/A,92,56,124,143,65,RO-may_treat,820081-FS1,Effects of platelet glycoprotein IIb/IIIa blockade with TIROFIBAN on adverse cardiac events IN PATIENTS WITH UNSTABLE ANGINA OR ACUTE MYOCARDIAL infarction undergoing coronary angioplasty.,UNSTABLE ANGINA,TIROFIBAN
790085298,9/17/2015 14:30:23,1740443391,9/17/2015 14:28:56,false,prodege,1.0,34497719,GBR,N5,Haverhill,151.230.78.163,[TREATS] [SYMPTOM],"[TREATS]
[SYMPTOM]",Effects on adverse cardiac events,n/a,92,56,124,143,65,RO-may_treat,820081-FS1,Effects of platelet glycoprotein IIb/IIIa blockade with TIROFIBAN on adverse cardiac events IN PATIENTS WITH UNSTABLE ANGINA OR ACUTE MYOCARDIAL infarction undergoing coronary angioplasty.,UNSTABLE ANGINA,TIROFIBAN
790085298,9/17/2015 14:31:34,1740443892,9/17/2015 14:31:20,false,bitcoinget,1.0,32306192,USA,MA,Amherst,72.19.88.245,[TREATS],[TREATS],TIROFIBAN,N/a,92,56,124,143,65,RO-may_treat,820081-FS1,Effects of platelet glycoprotein IIb/IIIa blockade with TIROFIBAN on adverse cardiac events IN PATIENTS WITH UNSTABLE ANGINA OR ACUTE MYOCARDIAL infarction undergoing coronary angioplasty.,UNSTABLE ANGINA,TIROFIBAN
790085298,9/17/2015 14:37:31,1740446101,9/17/2015 14:36:23,false,clixsense,1.0,32049531,USA,"","",38.95.108.252,[NONE],[NONE],none,none,92,56,124,143,65,RO-may_treat,820081-FS1,Effects of platelet glycoprotein IIb/IIIa blockade with TIROFIBAN on adverse cardiac events IN PATIENTS WITH UNSTABLE ANGINA OR ACUTE MYOCARDIAL infarction undergoing coronary angioplasty.,UNSTABLE ANGINA,TIROFIBAN
790085298,9/17/2015 14:37:47,1740446197,9/17/2015 14:35:16,false,instagc,1.0,22981457,CAN,ON,Ottawa,67.69.8.122,[NONE],[NONE],N/A,It's just a title not a relationship conclusion,92,56,124,143,65,RO-may_treat,820081-FS1,Effects of platelet glycoprotein IIb/IIIa blockade with TIROFIBAN on adverse cardiac events IN PATIENTS WITH UNSTABLE ANGINA OR ACUTE MYOCARDIAL infarction undergoing coronary angioplasty.,UNSTABLE ANGINA,TIROFIBAN
790085298,9/17/2015 14:54:13,1740452810,9/17/2015 14:52:47,false,clixsense,1.0,33115750,GBR,I3,Rochester,90.222.106.192,[TREATS],[TREATS],Effects of,N/A,92,56,124,143,65,RO-may_treat,820081-FS1,Effects of platelet glycoprotein IIb/IIIa blockade with TIROFIBAN on adverse cardiac events IN PATIENTS WITH UNSTABLE ANGINA OR ACUTE MYOCARDIAL infarction undergoing coronary angioplasty.,UNSTABLE ANGINA,TIROFIBAN
790085298,9/17/2015 15:10:38,1740458457,9/17/2015 15:10:23,false,neodev,1.0,34431172,USA,CA,Torrance,66.171.228.183,[CAUSES] [LOCATION] [NONE],"[CAUSES]
[LOCATION]
[NONE]",no,no,92,56,124,143,65,RO-may_treat,820081-FS1,Effects of platelet glycoprotein IIb/IIIa blockade with TIROFIBAN on adverse cardiac events IN PATIENTS WITH UNSTABLE ANGINA OR ACUTE MYOCARDIAL infarction undergoing coronary angioplasty.,UNSTABLE ANGINA,TIROFIBAN
790085299,9/17/2015 09:12:35,1740362380,9/17/2015 09:12:11,false,neodev,1.0,32053642,GBR,I7,Newcastle Upon Tyne,92.23.136.205,[TREATS],[TREATS],mainly to,N/A,73,105,85,84,114,RO-may_prevent,820160-FS1,Binding studies reveal that alpha 1 acid glycoprotein bind mainly to the TUBERCULOSIS drugs: rifampicin; ISONIAZID; pyrazinamide; p aminosalicylic acid; capreomycin; ethionamide; levofloxacin and ofloxacin out with the therapeutic plasma range tested.,TUBERCULOSIS,ISONIAZID
790085299,9/17/2015 09:14:52,1740362929,9/17/2015 09:14:38,false,elite,1.0,30659754,USA,"","",162.250.145.204,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],drugs:,N/A,73,105,85,84,114,RO-may_prevent,820160-FS1,Binding studies reveal that alpha 1 acid glycoprotein bind mainly to the TUBERCULOSIS drugs: rifampicin; ISONIAZID; pyrazinamide; p aminosalicylic acid; capreomycin; ethionamide; levofloxacin and ofloxacin out with the therapeutic plasma range tested.,TUBERCULOSIS,ISONIAZID
790085299,9/17/2015 09:20:08,1740364013,9/17/2015 09:19:40,false,instagc,1.0,18960682,GBR,U2,Annan,92.18.213.181,[TREATS],[TREATS],TUBERCULOSIS drugs:,N/A,73,105,85,84,114,RO-may_prevent,820160-FS1,Binding studies reveal that alpha 1 acid glycoprotein bind mainly to the TUBERCULOSIS drugs: rifampicin; ISONIAZID; pyrazinamide; p aminosalicylic acid; capreomycin; ethionamide; levofloxacin and ofloxacin out with the therapeutic plasma range tested.,TUBERCULOSIS,ISONIAZID
790085299,9/17/2015 09:21:13,1740364301,9/17/2015 09:20:51,false,neodev,1.0,33644825,USA,FL,Fort Lauderdale,65.111.173.161,[TREATS],[TREATS],TUBERCULOSIS ISONIAZID;,heals,73,105,85,84,114,RO-may_prevent,820160-FS1,Binding studies reveal that alpha 1 acid glycoprotein bind mainly to the TUBERCULOSIS drugs: rifampicin; ISONIAZID; pyrazinamide; p aminosalicylic acid; capreomycin; ethionamide; levofloxacin and ofloxacin out with the therapeutic plasma range tested.,TUBERCULOSIS,ISONIAZID
790085299,9/17/2015 09:21:35,1740364358,9/17/2015 09:21:12,false,neodev,1.0,15848372,AUS,02,Jannali,14.200.59.55,[ASSOCIATED_WITH],[ASSOCIATED_WITH],drugs:,n/a,73,105,85,84,114,RO-may_prevent,820160-FS1,Binding studies reveal that alpha 1 acid glycoprotein bind mainly to the TUBERCULOSIS drugs: rifampicin; ISONIAZID; pyrazinamide; p aminosalicylic acid; capreomycin; ethionamide; levofloxacin and ofloxacin out with the therapeutic plasma range tested.,TUBERCULOSIS,ISONIAZID
790085299,9/17/2015 09:22:04,1740364454,9/17/2015 09:20:19,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[IS_A],[IS_A],drugs:,N/A,73,105,85,84,114,RO-may_prevent,820160-FS1,Binding studies reveal that alpha 1 acid glycoprotein bind mainly to the TUBERCULOSIS drugs: rifampicin; ISONIAZID; pyrazinamide; p aminosalicylic acid; capreomycin; ethionamide; levofloxacin and ofloxacin out with the therapeutic plasma range tested.,TUBERCULOSIS,ISONIAZID
790085299,9/17/2015 09:29:12,1740365902,9/17/2015 09:28:59,false,elite,1.0,30659615,USA,"","",162.250.145.234,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],drugs:,N/A,73,105,85,84,114,RO-may_prevent,820160-FS1,Binding studies reveal that alpha 1 acid glycoprotein bind mainly to the TUBERCULOSIS drugs: rifampicin; ISONIAZID; pyrazinamide; p aminosalicylic acid; capreomycin; ethionamide; levofloxacin and ofloxacin out with the therapeutic plasma range tested.,TUBERCULOSIS,ISONIAZID
790085299,9/17/2015 09:31:57,1740366590,9/17/2015 09:30:59,false,pocketmoneygpt,1.0,21432964,GBR,F8,Borehamwood,81.159.185.70,[ASSOCIATED_WITH],[ASSOCIATED_WITH],bind mainly to,N/A,73,105,85,84,114,RO-may_prevent,820160-FS1,Binding studies reveal that alpha 1 acid glycoprotein bind mainly to the TUBERCULOSIS drugs: rifampicin; ISONIAZID; pyrazinamide; p aminosalicylic acid; capreomycin; ethionamide; levofloxacin and ofloxacin out with the therapeutic plasma range tested.,TUBERCULOSIS,ISONIAZID
790085299,9/17/2015 09:36:47,1740367658,9/17/2015 09:36:00,false,neodev,1.0,21515166,NLD,11,Nieuwkoop,83.84.200.25,[TREATS],[TREATS],bind mainly to,n/a,73,105,85,84,114,RO-may_prevent,820160-FS1,Binding studies reveal that alpha 1 acid glycoprotein bind mainly to the TUBERCULOSIS drugs: rifampicin; ISONIAZID; pyrazinamide; p aminosalicylic acid; capreomycin; ethionamide; levofloxacin and ofloxacin out with the therapeutic plasma range tested.,TUBERCULOSIS,ISONIAZID
790085299,9/17/2015 09:48:49,1740370575,9/17/2015 09:48:35,false,elite,1.0,30659677,USA,"","",162.252.172.126,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],drugs:,N/A,73,105,85,84,114,RO-may_prevent,820160-FS1,Binding studies reveal that alpha 1 acid glycoprotein bind mainly to the TUBERCULOSIS drugs: rifampicin; ISONIAZID; pyrazinamide; p aminosalicylic acid; capreomycin; ethionamide; levofloxacin and ofloxacin out with the therapeutic plasma range tested.,TUBERCULOSIS,ISONIAZID
790085299,9/17/2015 09:51:17,1740371094,9/17/2015 09:50:29,false,neodev,1.0,34081836,USA,CA,San Jose,23.27.248.146,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],Binding studies reveal that alpha 1 acid glycoprotein bind mainly to the TUBERCULOSIS drugs: rifampicin; ISONIAZID;,N/A,73,105,85,84,114,RO-may_prevent,820160-FS1,Binding studies reveal that alpha 1 acid glycoprotein bind mainly to the TUBERCULOSIS drugs: rifampicin; ISONIAZID; pyrazinamide; p aminosalicylic acid; capreomycin; ethionamide; levofloxacin and ofloxacin out with the therapeutic plasma range tested.,TUBERCULOSIS,ISONIAZID
790085299,9/17/2015 09:55:07,1740372010,9/17/2015 09:53:47,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[ASSOCIATED_WITH],[ASSOCIATED_WITH],bind mainly to the TUBERCULOSIS drugs: rifampicin; ISONIAZID;,N/A,73,105,85,84,114,RO-may_prevent,820160-FS1,Binding studies reveal that alpha 1 acid glycoprotein bind mainly to the TUBERCULOSIS drugs: rifampicin; ISONIAZID; pyrazinamide; p aminosalicylic acid; capreomycin; ethionamide; levofloxacin and ofloxacin out with the therapeutic plasma range tested.,TUBERCULOSIS,ISONIAZID
790085299,9/17/2015 10:25:33,1740378970,9/17/2015 10:25:13,false,pocketmoneygpt,1.0,28884030,USA,WI,Minocqua,75.143.134.247,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],drugs:,n/a,73,105,85,84,114,RO-may_prevent,820160-FS1,Binding studies reveal that alpha 1 acid glycoprotein bind mainly to the TUBERCULOSIS drugs: rifampicin; ISONIAZID; pyrazinamide; p aminosalicylic acid; capreomycin; ethionamide; levofloxacin and ofloxacin out with the therapeutic plasma range tested.,TUBERCULOSIS,ISONIAZID
790085299,9/17/2015 10:26:28,1740379149,9/17/2015 10:25:02,false,clixsense,1.0,17950689,GBR,L9,Sheffield,146.200.192.103,[LOCATION],[LOCATION],TUBERCULOSIS,NONE,73,105,85,84,114,RO-may_prevent,820160-FS1,Binding studies reveal that alpha 1 acid glycoprotein bind mainly to the TUBERCULOSIS drugs: rifampicin; ISONIAZID; pyrazinamide; p aminosalicylic acid; capreomycin; ethionamide; levofloxacin and ofloxacin out with the therapeutic plasma range tested.,TUBERCULOSIS,ISONIAZID
790085299,9/17/2015 10:44:54,1740382867,9/17/2015 10:43:56,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[OTHER],[OTHER],TUBERCULOSIS drugs:,N/A,73,105,85,84,114,RO-may_prevent,820160-FS1,Binding studies reveal that alpha 1 acid glycoprotein bind mainly to the TUBERCULOSIS drugs: rifampicin; ISONIAZID; pyrazinamide; p aminosalicylic acid; capreomycin; ethionamide; levofloxacin and ofloxacin out with the therapeutic plasma range tested.,TUBERCULOSIS,ISONIAZID
790085300,9/17/2015 11:03:57,1740386252,9/17/2015 11:03:42,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[TREATS],[TREATS],therapy,N/A,122,71,142,140,79,RO-may_treat,820041-FS1,"2010 09 13  Risk of bleeding with single, dual, or triple therapy with WARFARIN aspirin, and clopidogrel in patients with ATRIAL FIBRILLATION",ATRIAL FIBRILLATION,WARFARIN
790085300,9/17/2015 11:10:52,1740387729,9/17/2015 11:09:37,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[OTHER],[OTHER],Risk,N/A,122,71,142,140,79,RO-may_treat,820041-FS1,"2010 09 13  Risk of bleeding with single, dual, or triple therapy with WARFARIN aspirin, and clopidogrel in patients with ATRIAL FIBRILLATION",ATRIAL FIBRILLATION,WARFARIN
790085300,9/17/2015 11:17:31,1740388993,9/17/2015 11:17:12,false,neodev,1.0,32695853,USA,NV,Las Vegas,192.30.80.172,[PART_OF] [DIAGNOSE_BY_TEST_OR_DRUG] [ASSOCIATED_WITH],"[DIAGNOSE_BY_TEST_OR_DRUG]
[ASSOCIATED_WITH]
[PART_OF]",of with or with,N/A,122,71,142,140,79,RO-may_treat,820041-FS1,"2010 09 13  Risk of bleeding with single, dual, or triple therapy with WARFARIN aspirin, and clopidogrel in patients with ATRIAL FIBRILLATION",ATRIAL FIBRILLATION,WARFARIN
790085300,9/17/2015 11:17:39,1740389038,9/17/2015 11:16:17,false,neodev,1.0,30581619,USA,CA,San Jose,50.118.162.56,[NONE],[NONE],good,good,122,71,142,140,79,RO-may_treat,820041-FS1,"2010 09 13  Risk of bleeding with single, dual, or triple therapy with WARFARIN aspirin, and clopidogrel in patients with ATRIAL FIBRILLATION",ATRIAL FIBRILLATION,WARFARIN
790085300,9/17/2015 11:24:49,1740390206,9/17/2015 11:23:53,false,gifthulk,1.0,18666417,USA,PA,Meadville,24.101.32.13,[TREATS] [SIDE_EFFECT],"[TREATS]
[SIDE_EFFECT]",Risk of bleeding with therapy with WARFARIN in patients with ATRIAL FIBRILLATION,n/a,122,71,142,140,79,RO-may_treat,820041-FS1,"2010 09 13  Risk of bleeding with single, dual, or triple therapy with WARFARIN aspirin, and clopidogrel in patients with ATRIAL FIBRILLATION",ATRIAL FIBRILLATION,WARFARIN
790085300,9/17/2015 11:29:41,1740391148,9/17/2015 11:29:24,false,neodev,1.0,30941227,USA,NV,Las Vegas,192.30.80.166,[PART_OF] [ASSOCIATED_WITH] [DIAGNOSE_BY_TEST_OR_DRUG],"[DIAGNOSE_BY_TEST_OR_DRUG]
[ASSOCIATED_WITH]
[PART_OF]",of with or with with,N/A,122,71,142,140,79,RO-may_treat,820041-FS1,"2010 09 13  Risk of bleeding with single, dual, or triple therapy with WARFARIN aspirin, and clopidogrel in patients with ATRIAL FIBRILLATION",ATRIAL FIBRILLATION,WARFARIN
790085300,9/17/2015 11:40:26,1740393239,9/17/2015 11:40:13,false,neodev,1.0,33701549,USA,CA,Torrance,66.171.228.66,[NONE] [ASSOCIATED_WITH],"[ASSOCIATED_WITH]
[NONE]",[IS_A],N/A,122,71,142,140,79,RO-may_treat,820041-FS1,"2010 09 13  Risk of bleeding with single, dual, or triple therapy with WARFARIN aspirin, and clopidogrel in patients with ATRIAL FIBRILLATION",ATRIAL FIBRILLATION,WARFARIN
790085300,9/17/2015 12:00:56,1740397207,9/17/2015 12:00:42,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[TREATS],[TREATS],therapy,N/A,122,71,142,140,79,RO-may_treat,820041-FS1,"2010 09 13  Risk of bleeding with single, dual, or triple therapy with WARFARIN aspirin, and clopidogrel in patients with ATRIAL FIBRILLATION",ATRIAL FIBRILLATION,WARFARIN
790085300,9/17/2015 12:04:01,1740397860,9/17/2015 12:03:39,false,prodege,1.0,14848125,GBR,V8,Airdrie,86.151.77.161,[CONTRAINDICATES],[CONTRAINDICATES],Risk of bleeding,n/a,122,71,142,140,79,RO-may_treat,820041-FS1,"2010 09 13  Risk of bleeding with single, dual, or triple therapy with WARFARIN aspirin, and clopidogrel in patients with ATRIAL FIBRILLATION",ATRIAL FIBRILLATION,WARFARIN
790085300,9/17/2015 12:24:49,1740402407,9/17/2015 12:24:13,false,neodev,1.0,30588889,NLD,07,Amsterdam,77.248.175.222,[ASSOCIATED_WITH],[ASSOCIATED_WITH],in patients with,N/A,122,71,142,140,79,RO-may_treat,820041-FS1,"2010 09 13  Risk of bleeding with single, dual, or triple therapy with WARFARIN aspirin, and clopidogrel in patients with ATRIAL FIBRILLATION",ATRIAL FIBRILLATION,WARFARIN
790085300,9/17/2015 12:35:46,1740405009,9/17/2015 12:35:05,false,prodege,1.0,2145087,USA,NY,New York,107.107.57.52,[TREATS],[TREATS],with,N/A,122,71,142,140,79,RO-may_treat,820041-FS1,"2010 09 13  Risk of bleeding with single, dual, or triple therapy with WARFARIN aspirin, and clopidogrel in patients with ATRIAL FIBRILLATION",ATRIAL FIBRILLATION,WARFARIN
790085300,9/17/2015 12:36:23,1740405187,9/17/2015 12:35:54,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,[TREATS],[TREATS],"therapy with WARFARIN aspirin, in patients with ATRIAL FIBRILLATION",na,122,71,142,140,79,RO-may_treat,820041-FS1,"2010 09 13  Risk of bleeding with single, dual, or triple therapy with WARFARIN aspirin, and clopidogrel in patients with ATRIAL FIBRILLATION",ATRIAL FIBRILLATION,WARFARIN
790085300,9/17/2015 12:38:42,1740405734,9/17/2015 12:38:13,false,instagc,1.0,22981457,CAN,ON,Welland,76.67.127.43,[CAUSES],[CAUSES],Risk bleeding,N/A,122,71,142,140,79,RO-may_treat,820041-FS1,"2010 09 13  Risk of bleeding with single, dual, or triple therapy with WARFARIN aspirin, and clopidogrel in patients with ATRIAL FIBRILLATION",ATRIAL FIBRILLATION,WARFARIN
790085300,9/17/2015 12:42:56,1740406861,9/17/2015 12:41:37,false,neodev,1.0,34215189,GBR,I2,Manchester,82.8.21.5,[TREATS],[TREATS],"WARFARIN aspirin,",N/A,122,71,142,140,79,RO-may_treat,820041-FS1,"2010 09 13  Risk of bleeding with single, dual, or triple therapy with WARFARIN aspirin, and clopidogrel in patients with ATRIAL FIBRILLATION",ATRIAL FIBRILLATION,WARFARIN
790085300,9/17/2015 13:11:19,1740414871,9/17/2015 13:10:23,false,prodege,1.0,33854929,USA,CT,Wallingford,24.2.218.232,[SIDE_EFFECT],[SIDE_EFFECT],Risk,n/a,122,71,142,140,79,RO-may_treat,820041-FS1,"2010 09 13  Risk of bleeding with single, dual, or triple therapy with WARFARIN aspirin, and clopidogrel in patients with ATRIAL FIBRILLATION",ATRIAL FIBRILLATION,WARFARIN
790085301,9/17/2015 13:34:28,1740421913,9/17/2015 13:34:07,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,[TREATS],[TREATS],after acute myocardial infarction,n/a,161,144,182,181,151,RO-may_prevent,820361-FS1,Warfarin alone or with aspirin was superior to aspirin alone after acute myocardial infarction but increased bleeding  Keywords: Anticoagulants ASPIRIN Warfarin MYOCARDIAL INFARCTION  ACP Journal Club.,MYOCARDIAL INFARCTION,ASPIRIN
790085301,9/17/2015 13:41:36,1740426395,9/17/2015 13:40:55,false,prodege,1.0,27934334,GBR,C8,Croydon,81.159.60.206,[PREVENTS],[PREVENTS],after,N/A,161,144,182,181,151,RO-may_prevent,820361-FS1,Warfarin alone or with aspirin was superior to aspirin alone after acute myocardial infarction but increased bleeding  Keywords: Anticoagulants ASPIRIN Warfarin MYOCARDIAL INFARCTION  ACP Journal Club.,MYOCARDIAL INFARCTION,ASPIRIN
790085301,9/17/2015 14:10:29,1740436177,9/17/2015 14:09:49,false,gifthunterclub,1.0,30901412,GBR,H9,London,77.89.149.62,[SIDE_EFFECT],[SIDE_EFFECT],increased bleeding ASPIRIN Warfarin INFARCTION ACP,N/A,161,144,182,181,151,RO-may_prevent,820361-FS1,Warfarin alone or with aspirin was superior to aspirin alone after acute myocardial infarction but increased bleeding  Keywords: Anticoagulants ASPIRIN Warfarin MYOCARDIAL INFARCTION  ACP Journal Club.,MYOCARDIAL INFARCTION,ASPIRIN
790085301,9/17/2015 14:17:37,1740438892,9/17/2015 14:16:11,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.124.79,[TREATS],[TREATS],after acute myocardial infarction,N/A,161,144,182,181,151,RO-may_prevent,820361-FS1,Warfarin alone or with aspirin was superior to aspirin alone after acute myocardial infarction but increased bleeding  Keywords: Anticoagulants ASPIRIN Warfarin MYOCARDIAL INFARCTION  ACP Journal Club.,MYOCARDIAL INFARCTION,ASPIRIN
790085301,9/17/2015 14:27:04,1740442035,9/17/2015 14:25:51,false,zoombucks,1.0,6744840,CAN,BC,Kelowna,174.4.58.160,[TREATS],[TREATS],aspirin alone after,N/A,161,144,182,181,151,RO-may_prevent,820361-FS1,Warfarin alone or with aspirin was superior to aspirin alone after acute myocardial infarction but increased bleeding  Keywords: Anticoagulants ASPIRIN Warfarin MYOCARDIAL INFARCTION  ACP Journal Club.,MYOCARDIAL INFARCTION,ASPIRIN
790085301,9/17/2015 14:35:04,1740445122,9/17/2015 14:34:54,false,bitcoinget,1.0,32306192,USA,MA,Amherst,72.19.88.245,[TREATS],[TREATS],ASPIRIN,N/a,161,144,182,181,151,RO-may_prevent,820361-FS1,Warfarin alone or with aspirin was superior to aspirin alone after acute myocardial infarction but increased bleeding  Keywords: Anticoagulants ASPIRIN Warfarin MYOCARDIAL INFARCTION  ACP Journal Club.,MYOCARDIAL INFARCTION,ASPIRIN
790085301,9/17/2015 14:51:45,1740451920,9/17/2015 14:51:09,false,clixsense,1.0,32049531,USA,"","",38.95.108.252,[NONE],[NONE],none,none,161,144,182,181,151,RO-may_prevent,820361-FS1,Warfarin alone or with aspirin was superior to aspirin alone after acute myocardial infarction but increased bleeding  Keywords: Anticoagulants ASPIRIN Warfarin MYOCARDIAL INFARCTION  ACP Journal Club.,MYOCARDIAL INFARCTION,ASPIRIN
790085301,9/17/2015 14:55:12,1740453131,9/17/2015 14:54:45,false,instagc,1.0,22981457,CAN,ON,Ottawa,67.69.8.122,[CAUSES],[CAUSES],increased bleeding,N/A,161,144,182,181,151,RO-may_prevent,820361-FS1,Warfarin alone or with aspirin was superior to aspirin alone after acute myocardial infarction but increased bleeding  Keywords: Anticoagulants ASPIRIN Warfarin MYOCARDIAL INFARCTION  ACP Journal Club.,MYOCARDIAL INFARCTION,ASPIRIN
790085301,9/17/2015 15:03:43,1740456396,9/17/2015 15:03:25,false,neodev,1.0,31329809,USA,DE,Wilmington,162.223.93.194,[ASSOCIATED_WITH] [DIAGNOSE_BY_TEST_OR_DRUG],"[DIAGNOSE_BY_TEST_OR_DRUG]
[ASSOCIATED_WITH]",or with,N/A,161,144,182,181,151,RO-may_prevent,820361-FS1,Warfarin alone or with aspirin was superior to aspirin alone after acute myocardial infarction but increased bleeding  Keywords: Anticoagulants ASPIRIN Warfarin MYOCARDIAL INFARCTION  ACP Journal Club.,MYOCARDIAL INFARCTION,ASPIRIN
790085301,9/17/2015 15:05:19,1740456903,9/17/2015 15:03:58,false,clixsense,1.0,33115750,GBR,I3,Rochester,90.222.106.192,[TREATS],[TREATS],alone after,N/A,161,144,182,181,151,RO-may_prevent,820361-FS1,Warfarin alone or with aspirin was superior to aspirin alone after acute myocardial infarction but increased bleeding  Keywords: Anticoagulants ASPIRIN Warfarin MYOCARDIAL INFARCTION  ACP Journal Club.,MYOCARDIAL INFARCTION,ASPIRIN
790085301,9/17/2015 15:13:13,1740459243,9/17/2015 15:13:01,false,neodev,1.0,34431172,USA,CA,Torrance,66.171.228.183,[PREVENTS] [NONE],"[PREVENTS]
[NONE]",no,no,161,144,182,181,151,RO-may_prevent,820361-FS1,Warfarin alone or with aspirin was superior to aspirin alone after acute myocardial infarction but increased bleeding  Keywords: Anticoagulants ASPIRIN Warfarin MYOCARDIAL INFARCTION  ACP Journal Club.,MYOCARDIAL INFARCTION,ASPIRIN
790085301,9/17/2015 15:14:50,1740459818,9/17/2015 15:14:36,false,neodev,1.0,30321275,USA,NV,Las Vegas,192.30.80.4,[DIAGNOSE_BY_TEST_OR_DRUG] [ASSOCIATED_WITH],"[DIAGNOSE_BY_TEST_OR_DRUG]
[ASSOCIATED_WITH]",or with,N/A,161,144,182,181,151,RO-may_prevent,820361-FS1,Warfarin alone or with aspirin was superior to aspirin alone after acute myocardial infarction but increased bleeding  Keywords: Anticoagulants ASPIRIN Warfarin MYOCARDIAL INFARCTION  ACP Journal Club.,MYOCARDIAL INFARCTION,ASPIRIN
790085301,9/17/2015 15:20:48,1740462157,9/17/2015 15:20:33,false,neodev,1.0,29363385,USA,DE,Wilmington,162.223.93.162,[DIAGNOSE_BY_TEST_OR_DRUG] [ASSOCIATED_WITH],"[DIAGNOSE_BY_TEST_OR_DRUG]
[ASSOCIATED_WITH]",or with,N/A,161,144,182,181,151,RO-may_prevent,820361-FS1,Warfarin alone or with aspirin was superior to aspirin alone after acute myocardial infarction but increased bleeding  Keywords: Anticoagulants ASPIRIN Warfarin MYOCARDIAL INFARCTION  ACP Journal Club.,MYOCARDIAL INFARCTION,ASPIRIN
790085301,9/17/2015 15:24:50,1740463523,9/17/2015 15:23:49,false,neodev,1.0,12115558,USA,OH,Twinsburg,98.27.164.131,[MANIFESTATION] [TREATS],"[TREATS]
[MANIFESTATION]",increased bleeding,N/A,161,144,182,181,151,RO-may_prevent,820361-FS1,Warfarin alone or with aspirin was superior to aspirin alone after acute myocardial infarction but increased bleeding  Keywords: Anticoagulants ASPIRIN Warfarin MYOCARDIAL INFARCTION  ACP Journal Club.,MYOCARDIAL INFARCTION,ASPIRIN
790085301,9/17/2015 15:30:40,1740465834,9/17/2015 15:30:24,false,neodev,1.0,33018272,USA,DE,Wilmington,162.223.93.180,[DIAGNOSE_BY_TEST_OR_DRUG] [ASSOCIATED_WITH],"[DIAGNOSE_BY_TEST_OR_DRUG]
[ASSOCIATED_WITH]",or with,N/A,161,144,182,181,151,RO-may_prevent,820361-FS1,Warfarin alone or with aspirin was superior to aspirin alone after acute myocardial infarction but increased bleeding  Keywords: Anticoagulants ASPIRIN Warfarin MYOCARDIAL INFARCTION  ACP Journal Club.,MYOCARDIAL INFARCTION,ASPIRIN
790085302,9/17/2015 10:51:39,1740384071,9/17/2015 10:49:40,false,clixsense,1.0,17950689,GBR,L9,Sheffield,146.200.192.103,[TREATS],[TREATS],CAPSAICIN,NONE,45,0,49,48,9,RO-may_prevent,820286-FS1,CAPSAICIN and the lidocaine 5% patch relieve PAIN and decrease allodynia.,PAIN,CAPSAICIN
790085302,9/17/2015 11:02:04,1740385941,9/17/2015 11:01:41,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,45,0,49,48,9,RO-may_prevent,820286-FS1,CAPSAICIN and the lidocaine 5% patch relieve PAIN and decrease allodynia.,PAIN,CAPSAICIN
790085302,9/17/2015 11:05:57,1740386716,9/17/2015 11:05:03,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[TREATS],[TREATS],relieve,N/A,45,0,49,48,9,RO-may_prevent,820286-FS1,CAPSAICIN and the lidocaine 5% patch relieve PAIN and decrease allodynia.,PAIN,CAPSAICIN
790085302,9/17/2015 11:06:43,1740386845,9/17/2015 11:06:13,false,neodev,1.0,30941227,USA,NV,Las Vegas,192.30.80.166,[SYMPTOM],[SYMPTOM],5%,N/A,45,0,49,48,9,RO-may_prevent,820286-FS1,CAPSAICIN and the lidocaine 5% patch relieve PAIN and decrease allodynia.,PAIN,CAPSAICIN
790085302,9/17/2015 11:10:13,1740387626,9/17/2015 11:09:23,false,neodev,1.0,30581619,USA,CA,San Jose,50.118.162.56,[TREATS] [NONE],"[TREATS]
[NONE]",good,good,45,0,49,48,9,RO-may_prevent,820286-FS1,CAPSAICIN and the lidocaine 5% patch relieve PAIN and decrease allodynia.,PAIN,CAPSAICIN
790085302,9/17/2015 11:16:12,1740388797,9/17/2015 11:15:58,false,neodev,1.0,32695853,USA,NV,Las Vegas,192.30.80.172,[OTHER],[OTHER],5%,N/A,45,0,49,48,9,RO-may_prevent,820286-FS1,CAPSAICIN and the lidocaine 5% patch relieve PAIN and decrease allodynia.,PAIN,CAPSAICIN
790085302,9/17/2015 11:19:36,1740389403,9/17/2015 11:18:23,false,gifthulk,1.0,18666417,USA,PA,Meadville,24.101.32.13,[TREATS],[TREATS],CAPSAICIN relieve PAIN,n/a,45,0,49,48,9,RO-may_prevent,820286-FS1,CAPSAICIN and the lidocaine 5% patch relieve PAIN and decrease allodynia.,PAIN,CAPSAICIN
790085302,9/17/2015 11:27:04,1740390681,9/17/2015 11:26:05,false,elite,1.0,33798502,USA,VA,Manassas,207.244.86.212,[TREATS] [PART_OF] [OTHER],"[TREATS]
[PART_OF]
[OTHER]",CAPSAICIN lidocaine,makes sense,45,0,49,48,9,RO-may_prevent,820286-FS1,CAPSAICIN and the lidocaine 5% patch relieve PAIN and decrease allodynia.,PAIN,CAPSAICIN
790085302,9/17/2015 11:39:29,1740393070,9/17/2015 11:39:18,false,neodev,1.0,33701549,USA,CA,Torrance,66.171.228.66,[SYMPTOM] [CAUSES] [PREVENTS] [ASSOCIATED_WITH] [IS_A] [NONE],"[PREVENTS]
[CAUSES]
[SYMPTOM]
[ASSOCIATED_WITH]
[IS_A]
[NONE]",[IS_A],N/A,45,0,49,48,9,RO-may_prevent,820286-FS1,CAPSAICIN and the lidocaine 5% patch relieve PAIN and decrease allodynia.,PAIN,CAPSAICIN
790085302,9/17/2015 11:57:39,1740396593,9/17/2015 11:57:22,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[PREVENTS],[PREVENTS],decrease,N/A,45,0,49,48,9,RO-may_prevent,820286-FS1,CAPSAICIN and the lidocaine 5% patch relieve PAIN and decrease allodynia.,PAIN,CAPSAICIN
790085302,9/17/2015 12:01:33,1740397311,9/17/2015 12:01:16,false,prodege,1.0,14848125,GBR,V8,Airdrie,86.151.77.161,[TREATS],[TREATS],CAPSAICIN relieve PAIN,n/a,45,0,49,48,9,RO-may_prevent,820286-FS1,CAPSAICIN and the lidocaine 5% patch relieve PAIN and decrease allodynia.,PAIN,CAPSAICIN
790085302,9/17/2015 12:22:19,1740401804,9/17/2015 12:21:36,false,neodev,1.0,30588889,NLD,07,Amsterdam,77.248.175.222,[TREATS],[TREATS],relieve,N/A,45,0,49,48,9,RO-may_prevent,820286-FS1,CAPSAICIN and the lidocaine 5% patch relieve PAIN and decrease allodynia.,PAIN,CAPSAICIN
790085302,9/17/2015 12:33:49,1740404533,9/17/2015 12:33:19,false,prodege,1.0,2145087,USA,NY,New York,107.107.57.52,[TREATS],[TREATS],relieve,N/A,45,0,49,48,9,RO-may_prevent,820286-FS1,CAPSAICIN and the lidocaine 5% patch relieve PAIN and decrease allodynia.,PAIN,CAPSAICIN
790085302,9/17/2015 12:34:43,1740404730,9/17/2015 12:34:29,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,[TREATS],[TREATS],CAPSAICIN relieve PAIN,na,45,0,49,48,9,RO-may_prevent,820286-FS1,CAPSAICIN and the lidocaine 5% patch relieve PAIN and decrease allodynia.,PAIN,CAPSAICIN
790085302,9/17/2015 12:35:50,1740405017,9/17/2015 12:35:24,false,instagc,1.0,22981457,CAN,ON,Welland,76.67.127.43,[TREATS],[TREATS],relieve,N/A,45,0,49,48,9,RO-may_prevent,820286-FS1,CAPSAICIN and the lidocaine 5% patch relieve PAIN and decrease allodynia.,PAIN,CAPSAICIN
790085303,9/17/2015 13:20:09,1740417504,9/17/2015 13:19:54,false,neodev,1.0,33228343,USA,"","",38.95.108.251,[TREATS] [DIAGNOSE_BY_TEST_OR_DRUG] [CAUSES] [CONTRAINDICATES] [ASSOCIATED_WITH] [SIDE_EFFECT] [NONE],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]
[CAUSES]
[CONTRAINDICATES]
[ASSOCIATED_WITH]
[SIDE_EFFECT]
[NONE]","FDA approves THALIDOMIDE for HANSEN'S DISEASE side effect, imposes unprecedented restrictions on distribution.","FDA approves THALIDOMIDE for HANSEN'S DISEASE side effect, imposes unprecedented restrictions on distribution.",29,13,45,44,24,RO-may_treat,820088-FS1,"FDA approves THALIDOMIDE for HANSEN'S DISEASE side effect, imposes unprecedented restrictions on distribution.",HANSEN'S DISEASE,THALIDOMIDE
790085303,9/17/2015 13:20:57,1740417790,9/17/2015 13:20:42,false,elite,1.0,31883685,GBR,"","",79.66.244.188,[TREATS],[TREATS],approves for,n/a,29,13,45,44,24,RO-may_treat,820088-FS1,"FDA approves THALIDOMIDE for HANSEN'S DISEASE side effect, imposes unprecedented restrictions on distribution.",HANSEN'S DISEASE,THALIDOMIDE
790085303,9/17/2015 13:22:18,1740418199,9/17/2015 13:22:00,false,prodege,1.0,33854929,USA,CT,Wallingford,24.2.218.232,[CAUSES],[CAUSES],"side effect,",n/a,29,13,45,44,24,RO-may_treat,820088-FS1,"FDA approves THALIDOMIDE for HANSEN'S DISEASE side effect, imposes unprecedented restrictions on distribution.",HANSEN'S DISEASE,THALIDOMIDE
790085303,9/17/2015 13:28:25,1740420023,9/17/2015 13:28:15,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,[TREATS],[TREATS],for,n/a,29,13,45,44,24,RO-may_treat,820088-FS1,"FDA approves THALIDOMIDE for HANSEN'S DISEASE side effect, imposes unprecedented restrictions on distribution.",HANSEN'S DISEASE,THALIDOMIDE
790085303,9/17/2015 13:31:05,1740420812,9/17/2015 13:29:43,false,neodev,1.0,12115558,USA,OH,Twinsburg,98.27.164.131,[TREATS],[TREATS],"THALIDOMIDE for HANSEN'S DISEASE side effect,",n/a,29,13,45,44,24,RO-may_treat,820088-FS1,"FDA approves THALIDOMIDE for HANSEN'S DISEASE side effect, imposes unprecedented restrictions on distribution.",HANSEN'S DISEASE,THALIDOMIDE
790085303,9/17/2015 13:31:16,1740420883,9/17/2015 13:30:51,false,prodege,1.0,27934334,GBR,C8,Croydon,81.159.60.206,[TREATS],[TREATS],approves for,N/A,29,13,45,44,24,RO-may_treat,820088-FS1,"FDA approves THALIDOMIDE for HANSEN'S DISEASE side effect, imposes unprecedented restrictions on distribution.",HANSEN'S DISEASE,THALIDOMIDE
790085303,9/17/2015 14:00:57,1740432620,9/17/2015 14:00:05,false,neodev,1.0,31329809,USA,DE,Wilmington,162.223.93.194,[SIDE_EFFECT],[SIDE_EFFECT],"side effect,",N/A,29,13,45,44,24,RO-may_treat,820088-FS1,"FDA approves THALIDOMIDE for HANSEN'S DISEASE side effect, imposes unprecedented restrictions on distribution.",HANSEN'S DISEASE,THALIDOMIDE
790085303,9/17/2015 14:04:05,1740433833,9/17/2015 14:03:40,false,gifthunterclub,1.0,30901412,GBR,H9,London,77.89.149.62,[SIDE_EFFECT],[SIDE_EFFECT],"THALIDOMIDE for HANSEN'S DISEASE side effect,",N/A,29,13,45,44,24,RO-may_treat,820088-FS1,"FDA approves THALIDOMIDE for HANSEN'S DISEASE side effect, imposes unprecedented restrictions on distribution.",HANSEN'S DISEASE,THALIDOMIDE
790085303,9/17/2015 14:08:49,1740435574,9/17/2015 14:07:38,false,zoombucks,1.0,6744840,CAN,BC,Kelowna,174.4.58.160,[TREATS],[TREATS],approves for,N/A,29,13,45,44,24,RO-may_treat,820088-FS1,"FDA approves THALIDOMIDE for HANSEN'S DISEASE side effect, imposes unprecedented restrictions on distribution.",HANSEN'S DISEASE,THALIDOMIDE
790085303,9/17/2015 14:09:29,1740435819,9/17/2015 14:09:11,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.124.79,[TREATS],[TREATS],approves for,N/A,29,13,45,44,24,RO-may_treat,820088-FS1,"FDA approves THALIDOMIDE for HANSEN'S DISEASE side effect, imposes unprecedented restrictions on distribution.",HANSEN'S DISEASE,THALIDOMIDE
790085303,9/17/2015 14:15:38,1740438008,9/17/2015 14:15:00,false,elite,1.0,33238902,NLD,06,Budel,77.248.148.5,[TREATS],[TREATS],"THALIDOMIDE for HANSEN'S DISEASE side effect,",n/a,29,13,45,44,24,RO-may_treat,820088-FS1,"FDA approves THALIDOMIDE for HANSEN'S DISEASE side effect, imposes unprecedented restrictions on distribution.",HANSEN'S DISEASE,THALIDOMIDE
790085303,9/17/2015 14:28:55,1740442714,9/17/2015 14:28:00,false,prodege,1.0,34497719,GBR,N5,Haverhill,151.230.78.163,[TREATS] [SIDE_EFFECT],"[TREATS]
[SIDE_EFFECT]","for side effect,",n/a,29,13,45,44,24,RO-may_treat,820088-FS1,"FDA approves THALIDOMIDE for HANSEN'S DISEASE side effect, imposes unprecedented restrictions on distribution.",HANSEN'S DISEASE,THALIDOMIDE
790085303,9/17/2015 14:31:18,1740443773,9/17/2015 14:30:58,false,bitcoinget,1.0,32306192,USA,MA,Amherst,72.19.88.245,[TREATS],[TREATS],THALIDOMIDE,N/a,29,13,45,44,24,RO-may_treat,820088-FS1,"FDA approves THALIDOMIDE for HANSEN'S DISEASE side effect, imposes unprecedented restrictions on distribution.",HANSEN'S DISEASE,THALIDOMIDE
790085303,9/17/2015 14:35:11,1740445191,9/17/2015 14:33:57,false,clixsense,1.0,32049531,USA,"","",38.95.108.252,[NONE],[NONE],none,none,29,13,45,44,24,RO-may_treat,820088-FS1,"FDA approves THALIDOMIDE for HANSEN'S DISEASE side effect, imposes unprecedented restrictions on distribution.",HANSEN'S DISEASE,THALIDOMIDE
790085303,9/17/2015 14:35:15,1740445209,9/17/2015 14:34:32,false,instagc,1.0,22981457,CAN,ON,Ottawa,67.69.8.122,[CAUSES],[CAUSES],"side effect,",N/A,29,13,45,44,24,RO-may_treat,820088-FS1,"FDA approves THALIDOMIDE for HANSEN'S DISEASE side effect, imposes unprecedented restrictions on distribution.",HANSEN'S DISEASE,THALIDOMIDE
790085304,9/17/2015 09:21:05,1740364273,9/17/2015 09:20:48,false,elite,1.0,30659754,USA,"","",162.250.145.204,[LOCATION],[LOCATION],in,N/A,56,40,90,89,52,RO-may_treat,820121-FS1,Thirdly the evidence of the efficacy of CLOMIPRAMINE in OCD WITHOUT CONCOMITANT DEPRESSION reported by Montgomery 1980 and supported by other studies suggests that 5 HT uptake inhibitors have a specifically anti obsessional effect.,OCD WITHOUT CONCOMITANT DEPRESSION,CLOMIPRAMINE
790085304,9/17/2015 09:21:11,1740364300,9/17/2015 09:20:51,false,neodev,1.0,32053642,GBR,I7,Newcastle Upon Tyne,92.23.136.205,[SIDE_EFFECT],[SIDE_EFFECT],effect.,N/A,56,40,90,89,52,RO-may_treat,820121-FS1,Thirdly the evidence of the efficacy of CLOMIPRAMINE in OCD WITHOUT CONCOMITANT DEPRESSION reported by Montgomery 1980 and supported by other studies suggests that 5 HT uptake inhibitors have a specifically anti obsessional effect.,OCD WITHOUT CONCOMITANT DEPRESSION,CLOMIPRAMINE
790085304,9/17/2015 09:28:27,1740365730,9/17/2015 09:28:12,false,instagc,1.0,18960682,GBR,U2,Annan,92.18.213.181,[TREATS],[TREATS],efficacy of CLOMIPRAMINE,N/A,56,40,90,89,52,RO-may_treat,820121-FS1,Thirdly the evidence of the efficacy of CLOMIPRAMINE in OCD WITHOUT CONCOMITANT DEPRESSION reported by Montgomery 1980 and supported by other studies suggests that 5 HT uptake inhibitors have a specifically anti obsessional effect.,OCD WITHOUT CONCOMITANT DEPRESSION,CLOMIPRAMINE
790085304,9/17/2015 09:32:29,1740366719,9/17/2015 09:32:03,false,neodev,1.0,15848372,AUS,02,Jannali,14.200.59.55,[PART_OF],[PART_OF],in,n/a,56,40,90,89,52,RO-may_treat,820121-FS1,Thirdly the evidence of the efficacy of CLOMIPRAMINE in OCD WITHOUT CONCOMITANT DEPRESSION reported by Montgomery 1980 and supported by other studies suggests that 5 HT uptake inhibitors have a specifically anti obsessional effect.,OCD WITHOUT CONCOMITANT DEPRESSION,CLOMIPRAMINE
790085304,9/17/2015 09:33:41,1740367011,9/17/2015 09:33:15,false,neodev,1.0,33644825,USA,FL,Fort Lauderdale,65.111.173.161,[TREATS],[TREATS],CLOMIPRAMINE OCD WITHOUT CONCOMITANT,causes,56,40,90,89,52,RO-may_treat,820121-FS1,Thirdly the evidence of the efficacy of CLOMIPRAMINE in OCD WITHOUT CONCOMITANT DEPRESSION reported by Montgomery 1980 and supported by other studies suggests that 5 HT uptake inhibitors have a specifically anti obsessional effect.,OCD WITHOUT CONCOMITANT DEPRESSION,CLOMIPRAMINE
790085304,9/17/2015 09:39:01,1740368217,9/17/2015 09:38:46,false,elite,1.0,30659615,USA,"","",162.250.145.234,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],studies,N/A,56,40,90,89,52,RO-may_treat,820121-FS1,Thirdly the evidence of the efficacy of CLOMIPRAMINE in OCD WITHOUT CONCOMITANT DEPRESSION reported by Montgomery 1980 and supported by other studies suggests that 5 HT uptake inhibitors have a specifically anti obsessional effect.,OCD WITHOUT CONCOMITANT DEPRESSION,CLOMIPRAMINE
790085304,9/17/2015 09:48:51,1740370579,9/17/2015 09:48:18,false,neodev,1.0,21515166,NLD,11,Nieuwkoop,83.84.200.25,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",evidence of the efficacy of,n/a,56,40,90,89,52,RO-may_treat,820121-FS1,Thirdly the evidence of the efficacy of CLOMIPRAMINE in OCD WITHOUT CONCOMITANT DEPRESSION reported by Montgomery 1980 and supported by other studies suggests that 5 HT uptake inhibitors have a specifically anti obsessional effect.,OCD WITHOUT CONCOMITANT DEPRESSION,CLOMIPRAMINE
790085304,9/17/2015 09:49:42,1740370703,9/17/2015 09:49:11,false,pocketmoneygpt,1.0,21432964,GBR,F8,Borehamwood,81.159.185.70,[SYMPTOM],[SYMPTOM],evidence of the efficacy,N/A,56,40,90,89,52,RO-may_treat,820121-FS1,Thirdly the evidence of the efficacy of CLOMIPRAMINE in OCD WITHOUT CONCOMITANT DEPRESSION reported by Montgomery 1980 and supported by other studies suggests that 5 HT uptake inhibitors have a specifically anti obsessional effect.,OCD WITHOUT CONCOMITANT DEPRESSION,CLOMIPRAMINE
790085304,9/17/2015 09:49:50,1740370736,9/17/2015 09:49:24,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[TREATS],[TREATS],efficacy,N/A,56,40,90,89,52,RO-may_treat,820121-FS1,Thirdly the evidence of the efficacy of CLOMIPRAMINE in OCD WITHOUT CONCOMITANT DEPRESSION reported by Montgomery 1980 and supported by other studies suggests that 5 HT uptake inhibitors have a specifically anti obsessional effect.,OCD WITHOUT CONCOMITANT DEPRESSION,CLOMIPRAMINE
790085304,9/17/2015 09:54:51,1740371939,9/17/2015 09:54:37,false,elite,1.0,30659677,USA,"","",162.252.172.126,[LOCATION],[LOCATION],in,N/A,56,40,90,89,52,RO-may_treat,820121-FS1,Thirdly the evidence of the efficacy of CLOMIPRAMINE in OCD WITHOUT CONCOMITANT DEPRESSION reported by Montgomery 1980 and supported by other studies suggests that 5 HT uptake inhibitors have a specifically anti obsessional effect.,OCD WITHOUT CONCOMITANT DEPRESSION,CLOMIPRAMINE
790085304,9/17/2015 10:16:48,1740377312,9/17/2015 10:16:18,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[TREATS],[TREATS],efficacy of CLOMIPRAMINE in OCD WITHOUT CONCOMITANT DEPRESSION,N/A,56,40,90,89,52,RO-may_treat,820121-FS1,Thirdly the evidence of the efficacy of CLOMIPRAMINE in OCD WITHOUT CONCOMITANT DEPRESSION reported by Montgomery 1980 and supported by other studies suggests that 5 HT uptake inhibitors have a specifically anti obsessional effect.,OCD WITHOUT CONCOMITANT DEPRESSION,CLOMIPRAMINE
790085304,9/17/2015 10:33:26,1740380600,9/17/2015 10:33:06,false,pocketmoneygpt,1.0,28884030,USA,WI,Minocqua,75.143.134.247,[TREATS],[TREATS],efficacy,n/a,56,40,90,89,52,RO-may_treat,820121-FS1,Thirdly the evidence of the efficacy of CLOMIPRAMINE in OCD WITHOUT CONCOMITANT DEPRESSION reported by Montgomery 1980 and supported by other studies suggests that 5 HT uptake inhibitors have a specifically anti obsessional effect.,OCD WITHOUT CONCOMITANT DEPRESSION,CLOMIPRAMINE
790085304,9/17/2015 10:44:40,1740382835,9/17/2015 10:44:13,false,clixsense,1.0,17950689,GBR,L9,Sheffield,146.200.192.103,[TREATS],[TREATS],DEPRESSION,NONE,56,40,90,89,52,RO-may_treat,820121-FS1,Thirdly the evidence of the efficacy of CLOMIPRAMINE in OCD WITHOUT CONCOMITANT DEPRESSION reported by Montgomery 1980 and supported by other studies suggests that 5 HT uptake inhibitors have a specifically anti obsessional effect.,OCD WITHOUT CONCOMITANT DEPRESSION,CLOMIPRAMINE
790085304,9/17/2015 10:59:18,1740385422,9/17/2015 10:58:57,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[SYMPTOM],[SYMPTOM],evidence,N/A,56,40,90,89,52,RO-may_treat,820121-FS1,Thirdly the evidence of the efficacy of CLOMIPRAMINE in OCD WITHOUT CONCOMITANT DEPRESSION reported by Montgomery 1980 and supported by other studies suggests that 5 HT uptake inhibitors have a specifically anti obsessional effect.,OCD WITHOUT CONCOMITANT DEPRESSION,CLOMIPRAMINE
790085304,9/17/2015 11:00:32,1740385667,9/17/2015 10:59:57,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",efficacy of in,N/A,56,40,90,89,52,RO-may_treat,820121-FS1,Thirdly the evidence of the efficacy of CLOMIPRAMINE in OCD WITHOUT CONCOMITANT DEPRESSION reported by Montgomery 1980 and supported by other studies suggests that 5 HT uptake inhibitors have a specifically anti obsessional effect.,OCD WITHOUT CONCOMITANT DEPRESSION,CLOMIPRAMINE
790085305,9/17/2015 09:20:24,1740364128,9/17/2015 09:20:10,false,elite,1.0,30659754,USA,"","",162.250.145.204,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],investigate,N/A,205,134,220,219,147,RO-may_treat,820045-FS1,"Similar findings were observed in an interim analysis of fractures in another large, ongoing, long term, controlled clinical trial of ROSIGLITAZONE to investigate cardiovascular endpoints in patients with TYPE 2 DIABETES ( GlaxoSmithKline letter.",TYPE 2 DIABETES,ROSIGLITAZONE
790085305,9/17/2015 09:20:30,1740364153,9/17/2015 09:20:01,false,neodev,1.0,32053642,GBR,I7,Newcastle Upon Tyne,92.23.136.205,[SYMPTOM] [DIAGNOSE_BY_TEST_OR_DRUG],"[DIAGNOSE_BY_TEST_OR_DRUG]
[SYMPTOM]",controlled clinical trial,N/A,205,134,220,219,147,RO-may_treat,820045-FS1,"Similar findings were observed in an interim analysis of fractures in another large, ongoing, long term, controlled clinical trial of ROSIGLITAZONE to investigate cardiovascular endpoints in patients with TYPE 2 DIABETES ( GlaxoSmithKline letter.",TYPE 2 DIABETES,ROSIGLITAZONE
790085305,9/17/2015 09:27:50,1740365562,9/17/2015 09:27:30,false,instagc,1.0,18960682,GBR,U2,Annan,92.18.213.181,[TREATS],[TREATS],clinical trial of,N/A,205,134,220,219,147,RO-may_treat,820045-FS1,"Similar findings were observed in an interim analysis of fractures in another large, ongoing, long term, controlled clinical trial of ROSIGLITAZONE to investigate cardiovascular endpoints in patients with TYPE 2 DIABETES ( GlaxoSmithKline letter.",TYPE 2 DIABETES,ROSIGLITAZONE
790085305,9/17/2015 09:31:32,1740366477,9/17/2015 09:31:15,false,neodev,1.0,15848372,AUS,02,Jannali,14.200.59.55,[MANIFESTATION],[MANIFESTATION],patients with,n/a,205,134,220,219,147,RO-may_treat,820045-FS1,"Similar findings were observed in an interim analysis of fractures in another large, ongoing, long term, controlled clinical trial of ROSIGLITAZONE to investigate cardiovascular endpoints in patients with TYPE 2 DIABETES ( GlaxoSmithKline letter.",TYPE 2 DIABETES,ROSIGLITAZONE
790085305,9/17/2015 09:32:33,1740366753,9/17/2015 09:32:10,false,neodev,1.0,33644825,USA,FL,Fort Lauderdale,65.111.173.161,[TREATS],[TREATS],ROSIGLITAZONE DIABETES,treats,205,134,220,219,147,RO-may_treat,820045-FS1,"Similar findings were observed in an interim analysis of fractures in another large, ongoing, long term, controlled clinical trial of ROSIGLITAZONE to investigate cardiovascular endpoints in patients with TYPE 2 DIABETES ( GlaxoSmithKline letter.",TYPE 2 DIABETES,ROSIGLITAZONE
790085305,9/17/2015 09:38:28,1740368084,9/17/2015 09:38:09,false,elite,1.0,30659615,USA,"","",162.250.145.234,[LOCATION],[LOCATION],"in another large,",N/A,205,134,220,219,147,RO-may_treat,820045-FS1,"Similar findings were observed in an interim analysis of fractures in another large, ongoing, long term, controlled clinical trial of ROSIGLITAZONE to investigate cardiovascular endpoints in patients with TYPE 2 DIABETES ( GlaxoSmithKline letter.",TYPE 2 DIABETES,ROSIGLITAZONE
790085305,9/17/2015 09:47:21,1740370150,9/17/2015 09:47:00,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[TREATS],[TREATS],clinical trial,N/A,205,134,220,219,147,RO-may_treat,820045-FS1,"Similar findings were observed in an interim analysis of fractures in another large, ongoing, long term, controlled clinical trial of ROSIGLITAZONE to investigate cardiovascular endpoints in patients with TYPE 2 DIABETES ( GlaxoSmithKline letter.",TYPE 2 DIABETES,ROSIGLITAZONE
790085305,9/17/2015 09:47:52,1740370260,9/17/2015 09:47:31,false,neodev,1.0,21515166,NLD,11,Nieuwkoop,83.84.200.25,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],were observed in analysis,n/a,205,134,220,219,147,RO-may_treat,820045-FS1,"Similar findings were observed in an interim analysis of fractures in another large, ongoing, long term, controlled clinical trial of ROSIGLITAZONE to investigate cardiovascular endpoints in patients with TYPE 2 DIABETES ( GlaxoSmithKline letter.",TYPE 2 DIABETES,ROSIGLITAZONE
790085305,9/17/2015 09:48:30,1740370444,9/17/2015 09:47:41,false,pocketmoneygpt,1.0,21432964,GBR,F8,Borehamwood,81.159.185.70,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],controlled clinical trial,N/A,205,134,220,219,147,RO-may_treat,820045-FS1,"Similar findings were observed in an interim analysis of fractures in another large, ongoing, long term, controlled clinical trial of ROSIGLITAZONE to investigate cardiovascular endpoints in patients with TYPE 2 DIABETES ( GlaxoSmithKline letter.",TYPE 2 DIABETES,ROSIGLITAZONE
790085305,9/17/2015 09:54:18,1740371838,9/17/2015 09:54:04,false,elite,1.0,30659677,USA,"","",162.252.172.126,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],investigate,N/A,205,134,220,219,147,RO-may_treat,820045-FS1,"Similar findings were observed in an interim analysis of fractures in another large, ongoing, long term, controlled clinical trial of ROSIGLITAZONE to investigate cardiovascular endpoints in patients with TYPE 2 DIABETES ( GlaxoSmithKline letter.",TYPE 2 DIABETES,ROSIGLITAZONE
790085305,9/17/2015 10:15:47,1740377119,9/17/2015 10:14:53,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[ASSOCIATED_WITH],[ASSOCIATED_WITH],ROSIGLITAZONE to investigate cardiovascular endpoints in patients with TYPE 2 DIABETES,N/A,205,134,220,219,147,RO-may_treat,820045-FS1,"Similar findings were observed in an interim analysis of fractures in another large, ongoing, long term, controlled clinical trial of ROSIGLITAZONE to investigate cardiovascular endpoints in patients with TYPE 2 DIABETES ( GlaxoSmithKline letter.",TYPE 2 DIABETES,ROSIGLITAZONE
790085305,9/17/2015 10:32:45,1740380385,9/17/2015 10:32:22,false,pocketmoneygpt,1.0,28884030,USA,WI,Minocqua,75.143.134.247,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],trial,n/a,205,134,220,219,147,RO-may_treat,820045-FS1,"Similar findings were observed in an interim analysis of fractures in another large, ongoing, long term, controlled clinical trial of ROSIGLITAZONE to investigate cardiovascular endpoints in patients with TYPE 2 DIABETES ( GlaxoSmithKline letter.",TYPE 2 DIABETES,ROSIGLITAZONE
790085305,9/17/2015 10:43:47,1740382650,9/17/2015 10:43:26,false,clixsense,1.0,17950689,GBR,L9,Sheffield,146.200.192.103,[TREATS],[TREATS],TYPE 2 DIABETES,NONE,205,134,220,219,147,RO-may_treat,820045-FS1,"Similar findings were observed in an interim analysis of fractures in another large, ongoing, long term, controlled clinical trial of ROSIGLITAZONE to investigate cardiovascular endpoints in patients with TYPE 2 DIABETES ( GlaxoSmithKline letter.",TYPE 2 DIABETES,ROSIGLITAZONE
790085305,9/17/2015 10:57:33,1740385130,9/17/2015 10:56:05,false,neodev,1.0,30581619,USA,CA,San Jose,50.118.162.56,[TREATS] [NONE],"[TREATS]
[NONE]",good,good,205,134,220,219,147,RO-may_treat,820045-FS1,"Similar findings were observed in an interim analysis of fractures in another large, ongoing, long term, controlled clinical trial of ROSIGLITAZONE to investigate cardiovascular endpoints in patients with TYPE 2 DIABETES ( GlaxoSmithKline letter.",TYPE 2 DIABETES,ROSIGLITAZONE
790085305,9/17/2015 10:58:22,1740385276,9/17/2015 10:57:39,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],clinical trial of to investigate,N/A,205,134,220,219,147,RO-may_treat,820045-FS1,"Similar findings were observed in an interim analysis of fractures in another large, ongoing, long term, controlled clinical trial of ROSIGLITAZONE to investigate cardiovascular endpoints in patients with TYPE 2 DIABETES ( GlaxoSmithKline letter.",TYPE 2 DIABETES,ROSIGLITAZONE
790085306,9/17/2015 09:16:30,1740363271,9/17/2015 09:16:05,false,neodev,1.0,32053642,GBR,I7,Newcastle Upon Tyne,92.23.136.205,[PREVENTS],[PREVENTS],related to,N/A,0,48,26,34,102,RO-may_treat,820122-FS1,"IN POORLY CONTROLLED NIDDM SUBJECTS the primary MECHANISM BY WHICH METFORMIN IMPROVES GLYCEMIC CONTROL is related to the suppression of accelerated basal HGP, and this most likely is secondary to an inhibition of hepatic glycogenolysis.",NIDDM,METFORMIN
790085306,9/17/2015 09:17:35,1740363500,9/17/2015 09:17:18,false,elite,1.0,30659754,USA,"","",162.250.145.204,[PREVENTS],[PREVENTS],IMPROVES,N/A,0,48,26,34,102,RO-may_treat,820122-FS1,"IN POORLY CONTROLLED NIDDM SUBJECTS the primary MECHANISM BY WHICH METFORMIN IMPROVES GLYCEMIC CONTROL is related to the suppression of accelerated basal HGP, and this most likely is secondary to an inhibition of hepatic glycogenolysis.",NIDDM,METFORMIN
790085306,9/17/2015 09:24:08,1740364834,9/17/2015 09:23:31,false,instagc,1.0,18960682,GBR,U2,Annan,92.18.213.181,[MANIFESTATION],[MANIFESTATION],IN POORLY CONTROLLED NIDDM SUBJECTS the primary MECHANISM BY WHICH METFORMIN IMPROVES GLYCEMIC CONTROL,N/A,0,48,26,34,102,RO-may_treat,820122-FS1,"IN POORLY CONTROLLED NIDDM SUBJECTS the primary MECHANISM BY WHICH METFORMIN IMPROVES GLYCEMIC CONTROL is related to the suppression of accelerated basal HGP, and this most likely is secondary to an inhibition of hepatic glycogenolysis.",NIDDM,METFORMIN
790085306,9/17/2015 09:26:28,1740365273,9/17/2015 09:25:59,false,neodev,1.0,15848372,AUS,02,Jannali,14.200.59.55,[ASSOCIATED_WITH] [OTHER],"[ASSOCIATED_WITH]
[OTHER]",primary MECHANISM,n/a,0,48,26,34,102,RO-may_treat,820122-FS1,"IN POORLY CONTROLLED NIDDM SUBJECTS the primary MECHANISM BY WHICH METFORMIN IMPROVES GLYCEMIC CONTROL is related to the suppression of accelerated basal HGP, and this most likely is secondary to an inhibition of hepatic glycogenolysis.",NIDDM,METFORMIN
790085306,9/17/2015 09:26:36,1740365285,9/17/2015 09:25:47,false,neodev,1.0,33644825,USA,FL,Fort Lauderdale,65.111.173.161,[CAUSES],[CAUSES],POORLY NIDDM METFORMIN,locate,0,48,26,34,102,RO-may_treat,820122-FS1,"IN POORLY CONTROLLED NIDDM SUBJECTS the primary MECHANISM BY WHICH METFORMIN IMPROVES GLYCEMIC CONTROL is related to the suppression of accelerated basal HGP, and this most likely is secondary to an inhibition of hepatic glycogenolysis.",NIDDM,METFORMIN
790085306,9/17/2015 09:35:43,1740367424,9/17/2015 09:35:30,false,elite,1.0,30659615,USA,"","",162.250.145.234,[SYMPTOM],[SYMPTOM],suppression,N/A,0,48,26,34,102,RO-may_treat,820122-FS1,"IN POORLY CONTROLLED NIDDM SUBJECTS the primary MECHANISM BY WHICH METFORMIN IMPROVES GLYCEMIC CONTROL is related to the suppression of accelerated basal HGP, and this most likely is secondary to an inhibition of hepatic glycogenolysis.",NIDDM,METFORMIN
790085306,9/17/2015 09:38:02,1740367936,9/17/2015 09:35:20,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[NONE],[NONE],N/A,they check metformin in patients with NIDDM,0,48,26,34,102,RO-may_treat,820122-FS1,"IN POORLY CONTROLLED NIDDM SUBJECTS the primary MECHANISM BY WHICH METFORMIN IMPROVES GLYCEMIC CONTROL is related to the suppression of accelerated basal HGP, and this most likely is secondary to an inhibition of hepatic glycogenolysis.",NIDDM,METFORMIN
790085306,9/17/2015 09:38:33,1740368091,9/17/2015 09:37:41,false,pocketmoneygpt,1.0,21432964,GBR,F8,Borehamwood,81.159.185.70,[TREATS],[TREATS],IMPROVES GLYCEMIC CONTROL,N/A,0,48,26,34,102,RO-may_treat,820122-FS1,"IN POORLY CONTROLLED NIDDM SUBJECTS the primary MECHANISM BY WHICH METFORMIN IMPROVES GLYCEMIC CONTROL is related to the suppression of accelerated basal HGP, and this most likely is secondary to an inhibition of hepatic glycogenolysis.",NIDDM,METFORMIN
790085306,9/17/2015 09:43:37,1740369385,9/17/2015 09:41:36,false,neodev,1.0,21515166,NLD,11,Nieuwkoop,83.84.200.25,[OTHER],[OTHER],is related to,n/a,0,48,26,34,102,RO-may_treat,820122-FS1,"IN POORLY CONTROLLED NIDDM SUBJECTS the primary MECHANISM BY WHICH METFORMIN IMPROVES GLYCEMIC CONTROL is related to the suppression of accelerated basal HGP, and this most likely is secondary to an inhibition of hepatic glycogenolysis.",NIDDM,METFORMIN
790085306,9/17/2015 09:51:28,1740371127,9/17/2015 09:51:13,false,elite,1.0,30659677,USA,"","",162.252.172.126,[IS_A],[IS_A],the primary,N/A,0,48,26,34,102,RO-may_treat,820122-FS1,"IN POORLY CONTROLLED NIDDM SUBJECTS the primary MECHANISM BY WHICH METFORMIN IMPROVES GLYCEMIC CONTROL is related to the suppression of accelerated basal HGP, and this most likely is secondary to an inhibition of hepatic glycogenolysis.",NIDDM,METFORMIN
790085306,9/17/2015 10:01:01,1740373379,9/17/2015 10:00:19,false,neodev,1.0,34081836,USA,CA,San Jose,23.27.248.146,[CAUSES] [OTHER],"[CAUSES]
[OTHER]",IN POORLY CONTROLLED NIDDM SUBJECTS the primary MECHANISM BY WHICH METFORMIN IMPROVES GLYCEMIC CONTROL,N/A,0,48,26,34,102,RO-may_treat,820122-FS1,"IN POORLY CONTROLLED NIDDM SUBJECTS the primary MECHANISM BY WHICH METFORMIN IMPROVES GLYCEMIC CONTROL is related to the suppression of accelerated basal HGP, and this most likely is secondary to an inhibition of hepatic glycogenolysis.",NIDDM,METFORMIN
790085306,9/17/2015 10:03:14,1740373945,9/17/2015 10:02:28,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[SIDE_EFFECT],[SIDE_EFFECT],is related,N/A,0,48,26,34,102,RO-may_treat,820122-FS1,"IN POORLY CONTROLLED NIDDM SUBJECTS the primary MECHANISM BY WHICH METFORMIN IMPROVES GLYCEMIC CONTROL is related to the suppression of accelerated basal HGP, and this most likely is secondary to an inhibition of hepatic glycogenolysis.",NIDDM,METFORMIN
790085306,9/17/2015 10:29:28,1740379676,9/17/2015 10:29:14,false,pocketmoneygpt,1.0,28884030,USA,WI,Minocqua,75.143.134.247,[ASSOCIATED_WITH],[ASSOCIATED_WITH],related,n/a,0,48,26,34,102,RO-may_treat,820122-FS1,"IN POORLY CONTROLLED NIDDM SUBJECTS the primary MECHANISM BY WHICH METFORMIN IMPROVES GLYCEMIC CONTROL is related to the suppression of accelerated basal HGP, and this most likely is secondary to an inhibition of hepatic glycogenolysis.",NIDDM,METFORMIN
790085306,9/17/2015 10:38:44,1740381707,9/17/2015 10:36:29,false,clixsense,1.0,17950689,GBR,L9,Sheffield,146.200.192.103,[TREATS],[TREATS],"HGP,",NONE,0,48,26,34,102,RO-may_treat,820122-FS1,"IN POORLY CONTROLLED NIDDM SUBJECTS the primary MECHANISM BY WHICH METFORMIN IMPROVES GLYCEMIC CONTROL is related to the suppression of accelerated basal HGP, and this most likely is secondary to an inhibition of hepatic glycogenolysis.",NIDDM,METFORMIN
790085306,9/17/2015 10:54:54,1740384610,9/17/2015 10:52:11,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[OTHER],[OTHER],IN POORLY CONTROLLED the primary MECHANISM BY WHICH,N/A,0,48,26,34,102,RO-may_treat,820122-FS1,"IN POORLY CONTROLLED NIDDM SUBJECTS the primary MECHANISM BY WHICH METFORMIN IMPROVES GLYCEMIC CONTROL is related to the suppression of accelerated basal HGP, and this most likely is secondary to an inhibition of hepatic glycogenolysis.",NIDDM,METFORMIN
790085307,9/17/2015 09:18:31,1740363687,9/17/2015 09:18:06,false,neodev,1.0,32053642,GBR,I7,Newcastle Upon Tyne,92.23.136.205,[TREATS],[TREATS],treatment of,N/A,123,87,127,126,94,RO-may_prevent,820365-FS1,"Rubin P, Yee JP, Ruoff G. Comparison of long term safety of ketorolac tromethamine and ASPIRIN in the treatment of chronic PAIN",PAIN,ASPIRIN
790085307,9/17/2015 09:18:59,1740363776,9/17/2015 09:18:46,false,elite,1.0,30659754,USA,"","",162.250.145.204,[TREATS],[TREATS],treatment,N/A,123,87,127,126,94,RO-may_prevent,820365-FS1,"Rubin P, Yee JP, Ruoff G. Comparison of long term safety of ketorolac tromethamine and ASPIRIN in the treatment of chronic PAIN",PAIN,ASPIRIN
790085307,9/17/2015 09:26:01,1740365208,9/17/2015 09:25:42,false,instagc,1.0,18960682,GBR,U2,Annan,92.18.213.181,[TREATS],[TREATS],in the treatment of chronic,N/A,123,87,127,126,94,RO-may_prevent,820365-FS1,"Rubin P, Yee JP, Ruoff G. Comparison of long term safety of ketorolac tromethamine and ASPIRIN in the treatment of chronic PAIN",PAIN,ASPIRIN
790085307,9/17/2015 09:29:24,1740365975,9/17/2015 09:29:04,false,neodev,1.0,15848372,AUS,02,Jannali,14.200.59.55,[MANIFESTATION],[MANIFESTATION],treatment of chronic,n/a,123,87,127,126,94,RO-may_prevent,820365-FS1,"Rubin P, Yee JP, Ruoff G. Comparison of long term safety of ketorolac tromethamine and ASPIRIN in the treatment of chronic PAIN",PAIN,ASPIRIN
790085307,9/17/2015 09:29:25,1740365976,9/17/2015 09:29:01,false,neodev,1.0,33644825,USA,FL,Fort Lauderdale,65.111.173.161,[TREATS],[TREATS],ASPIRIN PAIN,prevents,123,87,127,126,94,RO-may_prevent,820365-FS1,"Rubin P, Yee JP, Ruoff G. Comparison of long term safety of ketorolac tromethamine and ASPIRIN in the treatment of chronic PAIN",PAIN,ASPIRIN
790085307,9/17/2015 09:37:04,1740367734,9/17/2015 09:36:49,false,elite,1.0,30659615,USA,"","",162.250.145.234,[TREATS],[TREATS],treatment,N/A,123,87,127,126,94,RO-may_prevent,820365-FS1,"Rubin P, Yee JP, Ruoff G. Comparison of long term safety of ketorolac tromethamine and ASPIRIN in the treatment of chronic PAIN",PAIN,ASPIRIN
790085307,9/17/2015 09:44:14,1740369498,9/17/2015 09:43:41,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[TREATS],[TREATS],treatment,N/A,123,87,127,126,94,RO-may_prevent,820365-FS1,"Rubin P, Yee JP, Ruoff G. Comparison of long term safety of ketorolac tromethamine and ASPIRIN in the treatment of chronic PAIN",PAIN,ASPIRIN
790085307,9/17/2015 09:44:58,1740369659,9/17/2015 09:43:34,false,pocketmoneygpt,1.0,21432964,GBR,F8,Borehamwood,81.159.185.70,[TREATS],[TREATS],treatment,N/A,123,87,127,126,94,RO-may_prevent,820365-FS1,"Rubin P, Yee JP, Ruoff G. Comparison of long term safety of ketorolac tromethamine and ASPIRIN in the treatment of chronic PAIN",PAIN,ASPIRIN
790085307,9/17/2015 09:45:43,1740369837,9/17/2015 09:45:25,false,neodev,1.0,21515166,NLD,11,Nieuwkoop,83.84.200.25,[TREATS],[TREATS],in the treatment of,n/a,123,87,127,126,94,RO-may_prevent,820365-FS1,"Rubin P, Yee JP, Ruoff G. Comparison of long term safety of ketorolac tromethamine and ASPIRIN in the treatment of chronic PAIN",PAIN,ASPIRIN
790085307,9/17/2015 09:52:54,1740371534,9/17/2015 09:52:39,false,elite,1.0,30659677,USA,"","",162.252.172.126,[TREATS],[TREATS],treatment,N/A,123,87,127,126,94,RO-may_prevent,820365-FS1,"Rubin P, Yee JP, Ruoff G. Comparison of long term safety of ketorolac tromethamine and ASPIRIN in the treatment of chronic PAIN",PAIN,ASPIRIN
790085307,9/17/2015 10:04:22,1740374343,9/17/2015 10:04:01,false,neodev,1.0,34081836,USA,CA,San Jose,23.27.248.146,[TREATS],[TREATS],ASPIRIN in the treatment of chronic PAIN,N/A,123,87,127,126,94,RO-may_prevent,820365-FS1,"Rubin P, Yee JP, Ruoff G. Comparison of long term safety of ketorolac tromethamine and ASPIRIN in the treatment of chronic PAIN",PAIN,ASPIRIN
790085307,9/17/2015 10:10:12,1740375910,9/17/2015 10:08:15,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[TREATS],[TREATS],treatment,N/A,123,87,127,126,94,RO-may_prevent,820365-FS1,"Rubin P, Yee JP, Ruoff G. Comparison of long term safety of ketorolac tromethamine and ASPIRIN in the treatment of chronic PAIN",PAIN,ASPIRIN
790085307,9/17/2015 10:31:00,1740380019,9/17/2015 10:30:47,false,pocketmoneygpt,1.0,28884030,USA,WI,Minocqua,75.143.134.247,[TREATS],[TREATS],treatment,n/a,123,87,127,126,94,RO-may_prevent,820365-FS1,"Rubin P, Yee JP, Ruoff G. Comparison of long term safety of ketorolac tromethamine and ASPIRIN in the treatment of chronic PAIN",PAIN,ASPIRIN
790085307,9/17/2015 10:41:03,1740382153,9/17/2015 10:40:42,false,clixsense,1.0,17950689,GBR,L9,Sheffield,146.200.192.103,[TREATS],[TREATS],chronic PAIN,NONE,123,87,127,126,94,RO-may_prevent,820365-FS1,"Rubin P, Yee JP, Ruoff G. Comparison of long term safety of ketorolac tromethamine and ASPIRIN in the treatment of chronic PAIN",PAIN,ASPIRIN
790085307,9/17/2015 10:54:17,1740384427,9/17/2015 10:54:06,false,neodev,1.0,30581619,USA,CA,San Jose,50.118.162.56,[TREATS] [NONE],"[TREATS]
[NONE]",good,good,123,87,127,126,94,RO-may_prevent,820365-FS1,"Rubin P, Yee JP, Ruoff G. Comparison of long term safety of ketorolac tromethamine and ASPIRIN in the treatment of chronic PAIN",PAIN,ASPIRIN
790085308,9/17/2015 12:47:54,1740408475,9/17/2015 12:47:34,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,[TREATS],[TREATS],GOUT administration full course of COLCHICINE,na,33,73,37,36,83,RO-may_prevent,820244-FS1,For control of acute episodes of GOUT administration of a full course of COLCHICINE is the preferred method of therapy.,GOUT,COLCHICINE
790085308,9/17/2015 12:51:58,1740409523,9/17/2015 12:51:31,false,prodege,1.0,2145087,USA,NY,New York,107.107.57.52,[TREATS],[TREATS],For control of,N/A,33,73,37,36,83,RO-may_prevent,820244-FS1,For control of acute episodes of GOUT administration of a full course of COLCHICINE is the preferred method of therapy.,GOUT,COLCHICINE
790085308,9/17/2015 13:19:19,1740417161,9/17/2015 13:19:03,false,neodev,1.0,33228343,USA,"","",38.95.108.251,[DIAGNOSE_BY_TEST_OR_DRUG] [LOCATION] [TREATS] [PART_OF] [NONE] [ASSOCIATED_WITH] [MANIFESTATION],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]
[LOCATION]
[MANIFESTATION]
[ASSOCIATED_WITH]
[PART_OF]
[NONE]",For control of acute episodes of GOUT administration of a full course of COLCHICINE is the preferred method of therapy.,For control of acute episodes of GOUT administration of a full course of COLCHICINE is the preferred method of therapy.,33,73,37,36,83,RO-may_prevent,820244-FS1,For control of acute episodes of GOUT administration of a full course of COLCHICINE is the preferred method of therapy.,GOUT,COLCHICINE
790085308,9/17/2015 13:20:03,1740417450,9/17/2015 13:19:43,false,elite,1.0,31883685,GBR,"","",79.66.244.188,[TREATS],[TREATS],preferred method of therapy.,n/a,33,73,37,36,83,RO-may_prevent,820244-FS1,For control of acute episodes of GOUT administration of a full course of COLCHICINE is the preferred method of therapy.,GOUT,COLCHICINE
790085308,9/17/2015 13:21:15,1740417887,9/17/2015 13:21:01,false,prodege,1.0,33854929,USA,CT,Wallingford,24.2.218.232,[TREATS],[TREATS],administration,n/a,33,73,37,36,83,RO-may_prevent,820244-FS1,For control of acute episodes of GOUT administration of a full course of COLCHICINE is the preferred method of therapy.,GOUT,COLCHICINE
790085308,9/17/2015 13:27:37,1740419762,9/17/2015 13:27:23,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,[TREATS],[TREATS],therapy.,n/a,33,73,37,36,83,RO-may_prevent,820244-FS1,For control of acute episodes of GOUT administration of a full course of COLCHICINE is the preferred method of therapy.,GOUT,COLCHICINE
790085308,9/17/2015 13:28:23,1740420010,9/17/2015 13:28:04,false,neodev,1.0,12115558,USA,OH,Twinsburg,98.27.164.131,[TREATS],[TREATS],preferred method of therapy.,N/A,33,73,37,36,83,RO-may_prevent,820244-FS1,For control of acute episodes of GOUT administration of a full course of COLCHICINE is the preferred method of therapy.,GOUT,COLCHICINE
790085308,9/17/2015 13:29:52,1740420427,9/17/2015 13:29:29,false,prodege,1.0,27934334,GBR,C8,Croydon,81.159.60.206,[TREATS],[TREATS],preferred method of therapy.,N/A,33,73,37,36,83,RO-may_prevent,820244-FS1,For control of acute episodes of GOUT administration of a full course of COLCHICINE is the preferred method of therapy.,GOUT,COLCHICINE
790085308,9/17/2015 13:55:20,1740430699,9/17/2015 13:52:39,false,neodev,1.0,31329809,USA,DE,Wilmington,162.223.93.194,[PART_OF] [IS_A],"[IS_A]
[PART_OF]",of of of a of is of,N/A,33,73,37,36,83,RO-may_prevent,820244-FS1,For control of acute episodes of GOUT administration of a full course of COLCHICINE is the preferred method of therapy.,GOUT,COLCHICINE
790085308,9/17/2015 14:02:40,1740433280,9/17/2015 14:02:21,false,gifthunterclub,1.0,30901412,GBR,H9,London,77.89.149.62,[TREATS],[TREATS],GOUT administration full course of COLCHICINE preferred therapy.,N/A,33,73,37,36,83,RO-may_prevent,820244-FS1,For control of acute episodes of GOUT administration of a full course of COLCHICINE is the preferred method of therapy.,GOUT,COLCHICINE
790085308,9/17/2015 14:05:16,1740434233,9/17/2015 14:03:36,false,zoombucks,1.0,6744840,CAN,BC,Kelowna,174.4.58.160,[TREATS],[TREATS],method of therapy.,N/A,33,73,37,36,83,RO-may_prevent,820244-FS1,For control of acute episodes of GOUT administration of a full course of COLCHICINE is the preferred method of therapy.,GOUT,COLCHICINE
790085308,9/17/2015 14:06:01,1740434472,9/17/2015 14:04:52,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.124.79,[TREATS],[TREATS],control of,N/A,33,73,37,36,83,RO-may_prevent,820244-FS1,For control of acute episodes of GOUT administration of a full course of COLCHICINE is the preferred method of therapy.,GOUT,COLCHICINE
790085308,9/17/2015 14:13:07,1740437071,9/17/2015 14:11:15,false,elite,1,33238902,NLD,06,Budel,77.248.148.5,[TREATS],[TREATS],COLCHICINE is the preferred method of therapy.,n/a,33,73,37,36,83,RO-may_prevent,820244-FS1,For control of acute episodes of GOUT administration of a full course of COLCHICINE is the preferred method of therapy.,GOUT,COLCHICINE
790085308,9/17/2015 14:25:13,1740441376,9/17/2015 14:24:12,false,prodege,1.0,34497719,GBR,N5,Haverhill,151.230.78.163,[TREATS],[TREATS],preferred method of therapy.,I didn't,33,73,37,36,83,RO-may_prevent,820244-FS1,For control of acute episodes of GOUT administration of a full course of COLCHICINE is the preferred method of therapy.,GOUT,COLCHICINE
790085308,9/17/2015 14:26:09,1740441717,9/17/2015 14:25:06,false,instagc,1.0,22981457,CAN,ON,Ottawa,67.69.8.122,[TREATS],[TREATS],control method of therapy.,N/A,33,73,37,36,83,RO-may_prevent,820244-FS1,For control of acute episodes of GOUT administration of a full course of COLCHICINE is the preferred method of therapy.,GOUT,COLCHICINE
790085309,9/17/2015 09:14:35,1740362873,9/17/2015 09:14:01,false,neodev,1.0,32053642,GBR,I7,Newcastle Upon Tyne,92.23.136.205,[TREATS],[TREATS],role in maintaining,N/A,151,105,163,162,112,RO-may_treat,820003-FS1,Cortisol and growth hormone are also secreted in response to hypoglycemia and play a role in maintaining GLUCOSE levels but not in rapid recovery from HYPOGLYCEMIA,HYPOGLYCEMIA,GLUCOSE
790085309,9/17/2015 09:16:04,1740363206,9/17/2015 09:15:45,false,elite,1.0,30659754,USA,"","",162.250.145.204,[TREATS],[TREATS],recovery,N/A,151,105,163,162,112,RO-may_treat,820003-FS1,Cortisol and growth hormone are also secreted in response to hypoglycemia and play a role in maintaining GLUCOSE levels but not in rapid recovery from HYPOGLYCEMIA,HYPOGLYCEMIA,GLUCOSE
790085309,9/17/2015 09:21:46,1740364400,9/17/2015 09:21:23,false,instagc,1.0,18960682,GBR,U2,Annan,92.18.213.181,[MANIFESTATION],[MANIFESTATION],maintaining GLUCOSE levels,N/A,151,105,163,162,112,RO-may_treat,820003-FS1,Cortisol and growth hormone are also secreted in response to hypoglycemia and play a role in maintaining GLUCOSE levels but not in rapid recovery from HYPOGLYCEMIA,HYPOGLYCEMIA,GLUCOSE
790085309,9/17/2015 09:22:44,1740364559,9/17/2015 09:21:48,false,pocketmoneygpt,1.0,21432964,GBR,F8,Borehamwood,81.159.185.70,[TREATS],[TREATS],rapid recovery from,N/A,151,105,163,162,112,RO-may_treat,820003-FS1,Cortisol and growth hormone are also secreted in response to hypoglycemia and play a role in maintaining GLUCOSE levels but not in rapid recovery from HYPOGLYCEMIA,HYPOGLYCEMIA,GLUCOSE
790085309,9/17/2015 09:23:04,1740364627,9/17/2015 09:22:38,false,neodev,1.0,33644825,USA,FL,Fort Lauderdale,65.111.173.161,[TREATS],[TREATS],GLUCOSE HYPOGLYCEMIA,prevents,151,105,163,162,112,RO-may_treat,820003-FS1,Cortisol and growth hormone are also secreted in response to hypoglycemia and play a role in maintaining GLUCOSE levels but not in rapid recovery from HYPOGLYCEMIA,HYPOGLYCEMIA,GLUCOSE
790085309,9/17/2015 09:23:31,1740364715,9/17/2015 09:23:04,false,neodev,1.0,15848372,AUS,02,Jannali,14.200.59.55,[OTHER],[OTHER],play a role but not,n/a,151,105,163,162,112,RO-may_treat,820003-FS1,Cortisol and growth hormone are also secreted in response to hypoglycemia and play a role in maintaining GLUCOSE levels but not in rapid recovery from HYPOGLYCEMIA,HYPOGLYCEMIA,GLUCOSE
790085309,9/17/2015 09:28:43,1740365790,9/17/2015 09:26:54,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[OTHER],[OTHER],role in maintaining,N/A,151,105,163,162,112,RO-may_treat,820003-FS1,Cortisol and growth hormone are also secreted in response to hypoglycemia and play a role in maintaining GLUCOSE levels but not in rapid recovery from HYPOGLYCEMIA,HYPOGLYCEMIA,GLUCOSE
790085309,9/17/2015 09:34:22,1740367150,9/17/2015 09:34:08,false,elite,1.0,30659615,USA,"","",162.250.145.234,[CONTRAINDICATES],[CONTRAINDICATES],rapid recovery,N/A,151,105,163,162,112,RO-may_treat,820003-FS1,Cortisol and growth hormone are also secreted in response to hypoglycemia and play a role in maintaining GLUCOSE levels but not in rapid recovery from HYPOGLYCEMIA,HYPOGLYCEMIA,GLUCOSE
790085309,9/17/2015 09:39:25,1740368309,9/17/2015 09:38:28,false,neodev,1.0,21515166,NLD,11,Nieuwkoop,83.84.200.25,[CAUSES],[CAUSES],in response to,n/a,151,105,163,162,112,RO-may_treat,820003-FS1,Cortisol and growth hormone are also secreted in response to hypoglycemia and play a role in maintaining GLUCOSE levels but not in rapid recovery from HYPOGLYCEMIA,HYPOGLYCEMIA,GLUCOSE
790085309,9/17/2015 09:50:02,1740370774,9/17/2015 09:49:48,false,elite,1.0,30659677,USA,"","",162.252.172.126,[MANIFESTATION],[MANIFESTATION],recovery,N/A,151,105,163,162,112,RO-may_treat,820003-FS1,Cortisol and growth hormone are also secreted in response to hypoglycemia and play a role in maintaining GLUCOSE levels but not in rapid recovery from HYPOGLYCEMIA,HYPOGLYCEMIA,GLUCOSE
790085309,9/17/2015 09:56:10,1740372254,9/17/2015 09:55:14,false,neodev,1.0,34081836,USA,CA,San Jose,23.27.248.146,[OTHER] [CAUSES],"[CAUSES]
[OTHER]",maintaining GLUCOSE levels but not in rapid recovery from HYPOGLYCEMIA,N/A,151,105,163,162,112,RO-may_treat,820003-FS1,Cortisol and growth hormone are also secreted in response to hypoglycemia and play a role in maintaining GLUCOSE levels but not in rapid recovery from HYPOGLYCEMIA,HYPOGLYCEMIA,GLUCOSE
790085309,9/17/2015 09:59:03,1740372993,9/17/2015 09:57:53,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[NONE],[NONE],N/A,It states that glucose does not help the medical condition,151,105,163,162,112,RO-may_treat,820003-FS1,Cortisol and growth hormone are also secreted in response to hypoglycemia and play a role in maintaining GLUCOSE levels but not in rapid recovery from HYPOGLYCEMIA,HYPOGLYCEMIA,GLUCOSE
790085309,9/17/2015 10:27:59,1740379399,9/17/2015 10:26:35,false,pocketmoneygpt,1.0,28884030,USA,WI,Minocqua,75.143.134.247,[TREATS],[TREATS],maintaining,n/a,151,105,163,162,112,RO-may_treat,820003-FS1,Cortisol and growth hormone are also secreted in response to hypoglycemia and play a role in maintaining GLUCOSE levels but not in rapid recovery from HYPOGLYCEMIA,HYPOGLYCEMIA,GLUCOSE
790085309,9/17/2015 10:32:35,1740380358,9/17/2015 10:32:18,false,clixsense,1.0,17950689,GBR,L9,Sheffield,146.200.192.103,[TREATS],[TREATS],HYPOGLYCEMIA,NONE,151,105,163,162,112,RO-may_treat,820003-FS1,Cortisol and growth hormone are also secreted in response to hypoglycemia and play a role in maintaining GLUCOSE levels but not in rapid recovery from HYPOGLYCEMIA,HYPOGLYCEMIA,GLUCOSE
790085309,9/17/2015 10:54:20,1740384449,9/17/2015 10:54:01,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[MANIFESTATION],[MANIFESTATION],rapid recovery,N/A,151,105,163,162,112,RO-may_treat,820003-FS1,Cortisol and growth hormone are also secreted in response to hypoglycemia and play a role in maintaining GLUCOSE levels but not in rapid recovery from HYPOGLYCEMIA,HYPOGLYCEMIA,GLUCOSE
790085310,9/17/2015 09:18:05,1740363619,9/17/2015 09:17:49,false,neodev,1.0,32053642,GBR,I7,Newcastle Upon Tyne,92.23.136.205,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],drug studies,N/A,73,52,84,82,72,RO-may_prevent,820323-FS1,"In over 1,287 noninvasive drug studies involving 11 ANTIARRHYTHMIC DRUGS ARRHYTHMIA aggravation occurred in 117 tests (9%.",ARRHYTHMIA,ANTIARRHYTHMIC DRUGS
790085310,9/17/2015 09:18:44,1740363727,9/17/2015 09:18:28,false,elite,1.0,30659754,USA,"","",162.250.145.204,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],drug,N/A,73,52,84,82,72,RO-may_prevent,820323-FS1,"In over 1,287 noninvasive drug studies involving 11 ANTIARRHYTHMIC DRUGS ARRHYTHMIA aggravation occurred in 117 tests (9%.",ARRHYTHMIA,ANTIARRHYTHMIC DRUGS
790085310,9/17/2015 09:25:40,1740365145,9/17/2015 09:25:11,false,instagc,1.0,18960682,GBR,U2,Annan,92.18.213.181,[CAUSES],[CAUSES],ANTIARRHYTHMIC DRUGS ARRHYTHMIA aggravation occurred,N/A,73,52,84,82,72,RO-may_prevent,820323-FS1,"In over 1,287 noninvasive drug studies involving 11 ANTIARRHYTHMIC DRUGS ARRHYTHMIA aggravation occurred in 117 tests (9%.",ARRHYTHMIA,ANTIARRHYTHMIC DRUGS
790085310,9/17/2015 09:29:00,1740365861,9/17/2015 09:28:28,false,neodev,1.0,33644825,USA,FL,Fort Lauderdale,65.111.173.161,[PREVENTS],[PREVENTS],ANTIARRHYTHMIC DRUGS ARRHYTHMIA,prevents,73,52,84,82,72,RO-may_prevent,820323-FS1,"In over 1,287 noninvasive drug studies involving 11 ANTIARRHYTHMIC DRUGS ARRHYTHMIA aggravation occurred in 117 tests (9%.",ARRHYTHMIA,ANTIARRHYTHMIC DRUGS
790085310,9/17/2015 09:29:02,1740365878,9/17/2015 09:28:20,false,neodev,1.0,15848372,AUS,02,Jannali,14.200.59.55,[NONE],[NONE],n/a,one complete medical term,73,52,84,82,72,RO-may_prevent,820323-FS1,"In over 1,287 noninvasive drug studies involving 11 ANTIARRHYTHMIC DRUGS ARRHYTHMIA aggravation occurred in 117 tests (9%.",ARRHYTHMIA,ANTIARRHYTHMIC DRUGS
790085310,9/17/2015 09:36:48,1740367666,9/17/2015 09:36:33,false,elite,1.0,30659615,USA,"","",162.250.145.234,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],drug,N/A,73,52,84,82,72,RO-may_prevent,820323-FS1,"In over 1,287 noninvasive drug studies involving 11 ANTIARRHYTHMIC DRUGS ARRHYTHMIA aggravation occurred in 117 tests (9%.",ARRHYTHMIA,ANTIARRHYTHMIC DRUGS
790085310,9/17/2015 09:43:34,1740369370,9/17/2015 09:41:59,false,pocketmoneygpt,1.0,21432964,GBR,F8,Borehamwood,81.159.185.70,[ASSOCIATED_WITH],[ASSOCIATED_WITH],studies involving,N/A,73,52,84,82,72,RO-may_prevent,820323-FS1,"In over 1,287 noninvasive drug studies involving 11 ANTIARRHYTHMIC DRUGS ARRHYTHMIA aggravation occurred in 117 tests (9%.",ARRHYTHMIA,ANTIARRHYTHMIC DRUGS
790085310,9/17/2015 09:43:39,1740369402,9/17/2015 09:41:52,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[TREATS],[TREATS],drug studies involving,N/A,73,52,84,82,72,RO-may_prevent,820323-FS1,"In over 1,287 noninvasive drug studies involving 11 ANTIARRHYTHMIC DRUGS ARRHYTHMIA aggravation occurred in 117 tests (9%.",ARRHYTHMIA,ANTIARRHYTHMIC DRUGS
790085310,9/17/2015 09:45:24,1740369769,9/17/2015 09:45:03,false,neodev,1.0,21515166,NLD,11,Nieuwkoop,83.84.200.25,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],occurred in,n/a,73,52,84,82,72,RO-may_prevent,820323-FS1,"In over 1,287 noninvasive drug studies involving 11 ANTIARRHYTHMIC DRUGS ARRHYTHMIA aggravation occurred in 117 tests (9%.",ARRHYTHMIA,ANTIARRHYTHMIC DRUGS
790085310,9/17/2015 09:52:37,1740371479,9/17/2015 09:52:22,false,elite,1.0,30659677,USA,"","",162.252.172.126,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],drug studies,N/A,73,52,84,82,72,RO-may_prevent,820323-FS1,"In over 1,287 noninvasive drug studies involving 11 ANTIARRHYTHMIC DRUGS ARRHYTHMIA aggravation occurred in 117 tests (9%.",ARRHYTHMIA,ANTIARRHYTHMIC DRUGS
790085310,9/17/2015 10:04:00,1740374232,9/17/2015 10:03:41,false,neodev,1.0,34081836,USA,CA,San Jose,23.27.248.146,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],ANTIARRHYTHMIC DRUGS ARRHYTHMIA,N/A,73,52,84,82,72,RO-may_prevent,820323-FS1,"In over 1,287 noninvasive drug studies involving 11 ANTIARRHYTHMIC DRUGS ARRHYTHMIA aggravation occurred in 117 tests (9%.",ARRHYTHMIA,ANTIARRHYTHMIC DRUGS
790085310,9/17/2015 10:08:14,1740375320,9/17/2015 10:05:34,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[CAUSES],[CAUSES],aggravation,N/A,73,52,84,82,72,RO-may_prevent,820323-FS1,"In over 1,287 noninvasive drug studies involving 11 ANTIARRHYTHMIC DRUGS ARRHYTHMIA aggravation occurred in 117 tests (9%.",ARRHYTHMIA,ANTIARRHYTHMIC DRUGS
790085310,9/17/2015 10:30:46,1740379975,9/17/2015 10:30:26,false,pocketmoneygpt,1.0,28884030,USA,WI,Minocqua,75.143.134.247,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],studies,n/a,73,52,84,82,72,RO-may_prevent,820323-FS1,"In over 1,287 noninvasive drug studies involving 11 ANTIARRHYTHMIC DRUGS ARRHYTHMIA aggravation occurred in 117 tests (9%.",ARRHYTHMIA,ANTIARRHYTHMIC DRUGS
790085310,9/17/2015 10:40:41,1740382108,9/17/2015 10:40:26,false,clixsense,1.0,17950689,GBR,L9,Sheffield,146.200.192.103,[SIDE_EFFECT],[SIDE_EFFECT],aggravation occurred,NONE,73,52,84,82,72,RO-may_prevent,820323-FS1,"In over 1,287 noninvasive drug studies involving 11 ANTIARRHYTHMIC DRUGS ARRHYTHMIA aggravation occurred in 117 tests (9%.",ARRHYTHMIA,ANTIARRHYTHMIC DRUGS
790085310,9/17/2015 10:54:00,1740384390,9/17/2015 10:53:44,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],drug studies,N/A,73,52,84,82,72,RO-may_prevent,820323-FS1,"In over 1,287 noninvasive drug studies involving 11 ANTIARRHYTHMIC DRUGS ARRHYTHMIA aggravation occurred in 117 tests (9%.",ARRHYTHMIA,ANTIARRHYTHMIC DRUGS
790085311,9/17/2015 13:20:43,1740417728,9/17/2015 13:20:28,false,neodev,1.0,33228343,USA,"","",38.95.108.251,[LOCATION] [DIAGNOSE_BY_TEST_OR_DRUG] [TREATS] [IS_A] [PART_OF] [ASSOCIATED_WITH] [CONTRAINDICATES] [NONE],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]
[LOCATION]
[CONTRAINDICATES]
[ASSOCIATED_WITH]
[IS_A]
[PART_OF]
[NONE]","munization of toddlers New England Journal of Medicine An outbreak of HEPATITIS A associated with green onions Vaccine A prospective, randomized, comparative US trial of a combination hepa","munization of toddlers New England Journal of Medicine An outbreak of HEPATITIS A associated with green onions Vaccine A prospective, randomized, comparative US trial of a combination hepa",189,384,206,207,395,RO-may_prevent,820368-FS1,"Infectious Diseases  Preventing hepatitis A and hepatitis B virus infections among men who have sex with men  Hepatology  The cost effectiveness of hepatitis A vaccination in patients with CHRONIC HEPATITIS C  Journal of the American Medical Association  Incidence of hepatitis A in Israel following universal immunization of toddlers  New England Journal of Medicine  An outbreak of HEPATITIS A associated with green onions  Vaccine  A prospective, randomized, comparative US trial of a combination hepatitis A and B vaccine (Twinrix) with corresponding monovalent vaccines (Havrix and Engerix B) in adults  Review  Clinical Microbiology Reviews  Hepatitis A:.",CHRONIC HEPATITIS C,HEPATITIS A
790085311,9/17/2015 13:21:34,1740417975,9/17/2015 13:21:17,false,elite,1.0,31883685,GBR,"","",79.66.244.188,[ASSOCIATED_WITH],[ASSOCIATED_WITH],HEPATITIS,n/a,189,384,206,207,395,RO-may_prevent,820368-FS1,"Infectious Diseases  Preventing hepatitis A and hepatitis B virus infections among men who have sex with men  Hepatology  The cost effectiveness of hepatitis A vaccination in patients with CHRONIC HEPATITIS C  Journal of the American Medical Association  Incidence of hepatitis A in Israel following universal immunization of toddlers  New England Journal of Medicine  An outbreak of HEPATITIS A associated with green onions  Vaccine  A prospective, randomized, comparative US trial of a combination hepatitis A and B vaccine (Twinrix) with corresponding monovalent vaccines (Havrix and Engerix B) in adults  Review  Clinical Microbiology Reviews  Hepatitis A:.",CHRONIC HEPATITIS C,HEPATITIS A
790085311,9/17/2015 13:23:11,1740418441,9/17/2015 13:22:37,false,prodege,1.0,33854929,USA,CT,Wallingford,24.2.218.232,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",effectiveness,n/a,189,384,206,207,395,RO-may_prevent,820368-FS1,"Infectious Diseases  Preventing hepatitis A and hepatitis B virus infections among men who have sex with men  Hepatology  The cost effectiveness of hepatitis A vaccination in patients with CHRONIC HEPATITIS C  Journal of the American Medical Association  Incidence of hepatitis A in Israel following universal immunization of toddlers  New England Journal of Medicine  An outbreak of HEPATITIS A associated with green onions  Vaccine  A prospective, randomized, comparative US trial of a combination hepatitis A and B vaccine (Twinrix) with corresponding monovalent vaccines (Havrix and Engerix B) in adults  Review  Clinical Microbiology Reviews  Hepatitis A:.",CHRONIC HEPATITIS C,HEPATITIS A
790085311,9/17/2015 13:30:12,1740420541,9/17/2015 13:28:48,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,[ASSOCIATED_WITH] [TREATS],"[TREATS]
[ASSOCIATED_WITH]",vaccination,n/a,189,384,206,207,395,RO-may_prevent,820368-FS1,"Infectious Diseases  Preventing hepatitis A and hepatitis B virus infections among men who have sex with men  Hepatology  The cost effectiveness of hepatitis A vaccination in patients with CHRONIC HEPATITIS C  Journal of the American Medical Association  Incidence of hepatitis A in Israel following universal immunization of toddlers  New England Journal of Medicine  An outbreak of HEPATITIS A associated with green onions  Vaccine  A prospective, randomized, comparative US trial of a combination hepatitis A and B vaccine (Twinrix) with corresponding monovalent vaccines (Havrix and Engerix B) in adults  Review  Clinical Microbiology Reviews  Hepatitis A:.",CHRONIC HEPATITIS C,HEPATITIS A
790085311,9/17/2015 13:32:59,1740421502,9/17/2015 13:31:52,false,prodege,1.0,27934334,GBR,C8,Croydon,81.159.60.206,[OTHER],[OTHER],HEPATITIS,N/A,189,384,206,207,395,RO-may_prevent,820368-FS1,"Infectious Diseases  Preventing hepatitis A and hepatitis B virus infections among men who have sex with men  Hepatology  The cost effectiveness of hepatitis A vaccination in patients with CHRONIC HEPATITIS C  Journal of the American Medical Association  Incidence of hepatitis A in Israel following universal immunization of toddlers  New England Journal of Medicine  An outbreak of HEPATITIS A associated with green onions  Vaccine  A prospective, randomized, comparative US trial of a combination hepatitis A and B vaccine (Twinrix) with corresponding monovalent vaccines (Havrix and Engerix B) in adults  Review  Clinical Microbiology Reviews  Hepatitis A:.",CHRONIC HEPATITIS C,HEPATITIS A
790085311,9/17/2015 14:04:16,1740433910,9/17/2015 14:03:18,false,neodev,1.0,31329809,USA,DE,Wilmington,162.223.93.194,[IS_A] [ASSOCIATED_WITH] [PART_OF],"[ASSOCIATED_WITH]
[IS_A]
[PART_OF]",A with of A with A of An of of a A,N/A,189,384,206,207,395,RO-may_prevent,820368-FS1,"Infectious Diseases  Preventing hepatitis A and hepatitis B virus infections among men who have sex with men  Hepatology  The cost effectiveness of hepatitis A vaccination in patients with CHRONIC HEPATITIS C  Journal of the American Medical Association  Incidence of hepatitis A in Israel following universal immunization of toddlers  New England Journal of Medicine  An outbreak of HEPATITIS A associated with green onions  Vaccine  A prospective, randomized, comparative US trial of a combination hepatitis A and B vaccine (Twinrix) with corresponding monovalent vaccines (Havrix and Engerix B) in adults  Review  Clinical Microbiology Reviews  Hepatitis A:.",CHRONIC HEPATITIS C,HEPATITIS A
790085311,9/17/2015 14:05:16,1740434234,9/17/2015 14:04:48,false,gifthunterclub,1.0,30901412,GBR,H9,London,77.89.149.62,[PART_OF],[PART_OF],CHRONIC HEPATITIS C outbreak of HEPATITIS A,N/A,189,384,206,207,395,RO-may_prevent,820368-FS1,"Infectious Diseases  Preventing hepatitis A and hepatitis B virus infections among men who have sex with men  Hepatology  The cost effectiveness of hepatitis A vaccination in patients with CHRONIC HEPATITIS C  Journal of the American Medical Association  Incidence of hepatitis A in Israel following universal immunization of toddlers  New England Journal of Medicine  An outbreak of HEPATITIS A associated with green onions  Vaccine  A prospective, randomized, comparative US trial of a combination hepatitis A and B vaccine (Twinrix) with corresponding monovalent vaccines (Havrix and Engerix B) in adults  Review  Clinical Microbiology Reviews  Hepatitis A:.",CHRONIC HEPATITIS C,HEPATITIS A
790085311,9/17/2015 14:11:45,1740436640,9/17/2015 14:09:48,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.124.79,[IS_A],[IS_A],hepatitis A and hepatitis B virus infections,N/A,189,384,206,207,395,RO-may_prevent,820368-FS1,"Infectious Diseases  Preventing hepatitis A and hepatitis B virus infections among men who have sex with men  Hepatology  The cost effectiveness of hepatitis A vaccination in patients with CHRONIC HEPATITIS C  Journal of the American Medical Association  Incidence of hepatitis A in Israel following universal immunization of toddlers  New England Journal of Medicine  An outbreak of HEPATITIS A associated with green onions  Vaccine  A prospective, randomized, comparative US trial of a combination hepatitis A and B vaccine (Twinrix) with corresponding monovalent vaccines (Havrix and Engerix B) in adults  Review  Clinical Microbiology Reviews  Hepatitis A:.",CHRONIC HEPATITIS C,HEPATITIS A
790085311,9/17/2015 14:12:19,1740436789,9/17/2015 14:10:10,false,zoombucks,1.0,6744840,CAN,BC,Kelowna,174.4.58.160,[ASSOCIATED_WITH],[ASSOCIATED_WITH],in patients with,N/A,189,384,206,207,395,RO-may_prevent,820368-FS1,"Infectious Diseases  Preventing hepatitis A and hepatitis B virus infections among men who have sex with men  Hepatology  The cost effectiveness of hepatitis A vaccination in patients with CHRONIC HEPATITIS C  Journal of the American Medical Association  Incidence of hepatitis A in Israel following universal immunization of toddlers  New England Journal of Medicine  An outbreak of HEPATITIS A associated with green onions  Vaccine  A prospective, randomized, comparative US trial of a combination hepatitis A and B vaccine (Twinrix) with corresponding monovalent vaccines (Havrix and Engerix B) in adults  Review  Clinical Microbiology Reviews  Hepatitis A:.",CHRONIC HEPATITIS C,HEPATITIS A
790085311,9/17/2015 14:31:53,1740443997,9/17/2015 14:30:24,false,prodege,1.0,34497719,GBR,N5,Haverhill,151.230.78.163,[NONE],[NONE],n/a,"Appears to be a listing of different articles in journals, the two highlighted words are from different articles",189,384,206,207,395,RO-may_prevent,820368-FS1,"Infectious Diseases  Preventing hepatitis A and hepatitis B virus infections among men who have sex with men  Hepatology  The cost effectiveness of hepatitis A vaccination in patients with CHRONIC HEPATITIS C  Journal of the American Medical Association  Incidence of hepatitis A in Israel following universal immunization of toddlers  New England Journal of Medicine  An outbreak of HEPATITIS A associated with green onions  Vaccine  A prospective, randomized, comparative US trial of a combination hepatitis A and B vaccine (Twinrix) with corresponding monovalent vaccines (Havrix and Engerix B) in adults  Review  Clinical Microbiology Reviews  Hepatitis A:.",CHRONIC HEPATITIS C,HEPATITIS A
790085311,9/17/2015 14:31:59,1740444049,9/17/2015 14:31:36,false,bitcoinget,1.0,32306192,USA,MA,Amherst,72.19.88.245,[TREATS],[TREATS],CHRONIC HEPATITIS,N/a,189,384,206,207,395,RO-may_prevent,820368-FS1,"Infectious Diseases  Preventing hepatitis A and hepatitis B virus infections among men who have sex with men  Hepatology  The cost effectiveness of hepatitis A vaccination in patients with CHRONIC HEPATITIS C  Journal of the American Medical Association  Incidence of hepatitis A in Israel following universal immunization of toddlers  New England Journal of Medicine  An outbreak of HEPATITIS A associated with green onions  Vaccine  A prospective, randomized, comparative US trial of a combination hepatitis A and B vaccine (Twinrix) with corresponding monovalent vaccines (Havrix and Engerix B) in adults  Review  Clinical Microbiology Reviews  Hepatitis A:.",CHRONIC HEPATITIS C,HEPATITIS A
790085311,9/17/2015 14:38:46,1740446569,9/17/2015 14:37:35,false,clixsense,1.0,32049531,USA,"","",38.95.108.252,[NONE],[NONE],none,none,189,384,206,207,395,RO-may_prevent,820368-FS1,"Infectious Diseases  Preventing hepatitis A and hepatitis B virus infections among men who have sex with men  Hepatology  The cost effectiveness of hepatitis A vaccination in patients with CHRONIC HEPATITIS C  Journal of the American Medical Association  Incidence of hepatitis A in Israel following universal immunization of toddlers  New England Journal of Medicine  An outbreak of HEPATITIS A associated with green onions  Vaccine  A prospective, randomized, comparative US trial of a combination hepatitis A and B vaccine (Twinrix) with corresponding monovalent vaccines (Havrix and Engerix B) in adults  Review  Clinical Microbiology Reviews  Hepatitis A:.",CHRONIC HEPATITIS C,HEPATITIS A
790085311,9/17/2015 14:45:15,1740449412,9/17/2015 14:44:05,false,instagc,1.0,22981457,CAN,ON,Ottawa,67.69.8.122,[PREVENTS],[PREVENTS],effectiveness hepatitis A vaccination,N/A,189,384,206,207,395,RO-may_prevent,820368-FS1,"Infectious Diseases  Preventing hepatitis A and hepatitis B virus infections among men who have sex with men  Hepatology  The cost effectiveness of hepatitis A vaccination in patients with CHRONIC HEPATITIS C  Journal of the American Medical Association  Incidence of hepatitis A in Israel following universal immunization of toddlers  New England Journal of Medicine  An outbreak of HEPATITIS A associated with green onions  Vaccine  A prospective, randomized, comparative US trial of a combination hepatitis A and B vaccine (Twinrix) with corresponding monovalent vaccines (Havrix and Engerix B) in adults  Review  Clinical Microbiology Reviews  Hepatitis A:.",CHRONIC HEPATITIS C,HEPATITIS A
790085311,9/17/2015 14:54:37,1740452930,9/17/2015 14:53:19,false,instagc,1,29411108,USA,OH,Eaton,24.210.181.92,[NONE],[NONE],N/A,Its talking about the hep A vaccination in relation to Hep C,189,384,206,207,395,RO-may_prevent,820368-FS1,"Infectious Diseases  Preventing hepatitis A and hepatitis B virus infections among men who have sex with men  Hepatology  The cost effectiveness of hepatitis A vaccination in patients with CHRONIC HEPATITIS C  Journal of the American Medical Association  Incidence of hepatitis A in Israel following universal immunization of toddlers  New England Journal of Medicine  An outbreak of HEPATITIS A associated with green onions  Vaccine  A prospective, randomized, comparative US trial of a combination hepatitis A and B vaccine (Twinrix) with corresponding monovalent vaccines (Havrix and Engerix B) in adults  Review  Clinical Microbiology Reviews  Hepatitis A:.",CHRONIC HEPATITIS C,HEPATITIS A
790085311,9/17/2015 14:54:59,1740453051,9/17/2015 14:54:13,false,clixsense,1.0,33115750,GBR,I3,Rochester,90.222.106.192,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",effectiveness,N/A,189,384,206,207,395,RO-may_prevent,820368-FS1,"Infectious Diseases  Preventing hepatitis A and hepatitis B virus infections among men who have sex with men  Hepatology  The cost effectiveness of hepatitis A vaccination in patients with CHRONIC HEPATITIS C  Journal of the American Medical Association  Incidence of hepatitis A in Israel following universal immunization of toddlers  New England Journal of Medicine  An outbreak of HEPATITIS A associated with green onions  Vaccine  A prospective, randomized, comparative US trial of a combination hepatitis A and B vaccine (Twinrix) with corresponding monovalent vaccines (Havrix and Engerix B) in adults  Review  Clinical Microbiology Reviews  Hepatitis A:.",CHRONIC HEPATITIS C,HEPATITIS A
